The Role of Proteomics in Colorectal Cancer Biomarker Discovery by Goodbrand, Sarah A.
University of Dundee
DOCTOR OF MEDICINE
The Role of Proteomics in Colorectal Cancer Biomarker Discovery
Goodbrand, Sarah A.
Award date:
2015
Awarding institution:
University of Dundee
Link to publication
General rights
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners
and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.
            • Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
            • You may not further distribute the material or use it for any profit-making activity or commercial gain
            • You may freely distribute the URL identifying the publication in the public portal
Take down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Download date: 17. Feb. 2017
 1 
Declaration 
I   hereby   declare   that   this   thesis   is   my   own   work   and   that   it   hasn’t   been   submitted  
anywhere, and for any other degree or professional qualification except as specified. 
 
 
 
 
 
Signed  
 
Date  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 2 
Acknowledgements 
 
I would firstly like to thank my supervisors Professor Robert Steele and Professor Mike 
Ferguson for the huge amount of time, effort, support and encouragement they gave me 
throughout my period of research and to the point of submission of this MD thesis.  I 
am indeed indebted for all they have done for me. 
 
I would also like to pay a special thanks to my sponsor Tenovus for providing funding 
to allow me to undertake this research.  Without their generosity, support and resources 
this research would not have been in anyway possible. 
 
I would also like to say a huge and special thanks to those within the Proteomics 
Facility, especially Douglas Lamont and Kenny Beattie.  Without their help this 
research would not have been possible.  They helped me through the thick and thin of 
this MD project, and are an absolute credit to the University.  I am also indebted to them 
for the enormous amount of help, support and general encouragement they gave me  (as 
well as the endless amounts of cups of coffee and biscuits they provided!) 
 
I would also like to thank my partner Hemal, and also my family and friends, whose 
love and support (and of course understanding!) eventually guided me to the end of this 
MD. 
 
 
 
 
 
 
 3 
Abbreviations 
 
CRC    Colorectal Cancer 
FAP    Familial Adenomatous Polyposis 
HNPCC   Hereditary Non-Polyposis Colorectal Cancer 
CIN    Chromosomal Instability  
MSI    Microsatellite Instability  
FOBT    Faecal Occult Blood Testing 
CT    Computerised Tomography 
GI    Gastrointestinal 
RCT    Randomized Controlled Trial 
CI    Confidence Interval 
GP    General Practioner 
NORCCAP   Norwegian Colorectal Cancer Prevention Study 
ACRIN   American College of Radiology Imaging trial 
CSF    Cerebrospinal Fluid 
ROC    Receiver Operating Curve 
MS    Mass Spectrometer 
EDTA    Ethylenediamine Tetraacetic Acid 
EDRN    Early Detection Research Network 
DNA    Deoxyribonucleic acid 
L-DNA   Intact genomic DNA 
RNA    Ribonucleic acid 
MCR    Mutation Clustering Region 
ACF    Aberrant Crypt Foci 
CIMP    CpG Island Methylator Phenotype 
MCM2   Minichromosome Maintenance protein 2 
CEA    Carcinoembyronic antigen 
PSA    Prostate Specific Antigen 
TIMP-1   Tissue inhibitor of metalloprotineases Type 1 
SELDI    Surface-enhanced laser desorption/ionization 
CRMP-2   Collapsin response mediator protein-2 
MIF    Macrophage migration inhibitory factor 
M-CSF   Macrophage colony stimulating factor 
M2-PK   M2-pyruvate kinase 
IL-8    Interleukin-8 
CRP    C-reactive protein 
VEGF    Vascular endothelial growth factor 
mg    Milligrams 
ml    Milliliters 
CE    Capillary electrophoresis 
HPLC    High Performance Liquid Chromatography 
DIGE    Difference in gel electrophoresis 
iTRAQ Isobaric Tagging for Relative and Absolute Quantitation 
ICAT    Isotope Coded Affintity Tag 
SILAC    Stable isotope labelling by amino acids in cell culture 
MuDPIT   Multidimensional protein identification technology 
PMF    Peptide Mass Fingerprinting 
 4 
MS1 scan   Survey Scan 
MS2    Tandem mass spectra  
PTM    Post-translational modification  
ID    Identification 
RP-HPLC Reverse phase High Performance Liquid Chromatography 
LC Liquid Chromatography  
m/z Mass to Charge ratio 
ESI Electrospray Ionisation 
MALDI Matrix Assisted Laser Desorption Ionisation 
UV Ultraviolet 
TOF Time of Flight 
Δm    Mass difference between the peaks 
amu    Atomic mass units 
DC    Direct current 
RF    Radiofrequency 
CID    Collision Induced Dissociation 
ppm    Parts per million 
ETD    Electron Transfer Dissociation 
FTICR    Fourier Transform Ion Cyclotron 
CA    Collisional Activation 
HCD    High energy Collision Induced Dissociation 
ECD    Electron Capture Dissociation 
PQD    Pulsed Q Dissociation 
Q-ToF    Quadrapole Time of Flight 
TIC    Total Ion Chromatogram 
G-test    Likelihood ratio/chi squared distribution 
LPE test   Local pooled error test    
t-test    Students t-test 
MARS    Multiple Affinity Removal Systems 
SCX    Strong Cation Exchange 
MOWSE   MOlecular Weight Search 
E-value   Expectation value 
FDR    False Discovery Rate 
FP    False positives 
TP    True positives 
CI     Confidence Intervals 
MUC    Mucins 
PNA    Arachis hypogea 
SNA    Sambucus nigra 
HPA    Helix pomatia 
F1    Flow through 1 
F2    Flow through 2 
TEAB    Triethylammonium bicarbonate buffer 
PBS    Phosphate Buffered Solution 
MWCO   Molecular weight cut off marker 
BCA    Bicinchoninic acid 
BSA    Bovine serum albumin 
IAA    Iodoacetamide 
 5 
ACN    Acetonitrile 
CE    Collision Energy 
NCE    Normalised Collision Energy 
TFA    Trifluroacetic acid 
ANOVA   Analysis of variance 
.mgf    Mascot generic file     
DTT    Dithitothreitol 
JAC    Jacalin 
Con A    Concanavalin A 
WGA    What Germ Agglutinin 
EPI    Enhanced Product Ion Scan 
rsd    Relative standard deviation 
IPA    Ingenuity Pathway Analysis 
COL1A1   Collagen alpha-1(1) chain 
COL1A2   Collagen alpha-2(1) chain 
HBA    Haemoglobin subunit alpha 
AZGP1   Alpha 2 glycoprotein 1, zinc 
PCA    Principal component analysis 
Apo    Apolipoprotein 
LRG    Leucine rich glycoprotein 
AAT    Alpha 1 antitrypsin 
AHSG    Alpha 2HS glycoprotein 
PSME3   Proteasome activator complex subunit 3 
MAF    Macrophage activating factor  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 6 
Abstract 
Colorectal cancer is one of the most prevalent cancers within the UK and has a steadily 
rising incidence.  If detected early Colorectal Cancer (CRC) is highly curable, but 
currently only 9% of patients present when the cancer is in the earliest stages (Dukes 
Stage A).  The unique characteristics of the disease render CRC a suitable model for 
population screening.  Current screening modalities have proven utility but they lack 
sensitivity and specificity, and thus there is a need to develop non-invasive tests to 
detect and stage the disease.  Biomarkers are gaining popularity as they provide a 
unique biological signature for the disease, and thus there has been increased expansion 
in the use of Proteomic technologies to undertake such research.  The primary aim of 
this thesis was to apply proteomic techniques to analyze serum of patients with CRC, 
and thus develop novel biomarkers to aid in the diagnosis of CRC within a screening 
population.    Prior to undertaking this, I firstly developed a reproducible and 
standardized pathway for biomarker verification using 2 proteomic platforms – iTRAQ 
and label free.  I identified that the use of depletion methods along with iTRAQ and 
orbitrap analysis of the generated peptides yielded the best data.  Using these 
technologies I was able to investigate the relative abundance of proteins secreted into 
the serum of 17 controls and 53 patients with CRC.  This study identified 12 potential 
proteins from iTRAQ analysis and 10 from from the label free platform, that were either 
up or down regulated in the serum of patients with CRC compared to controls. 
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INTRODUCTION  
1.0 Background to Colorectal Cancer 
In 2010 40,695 cases of CRC were diagnosed in the UK, 22,834 (56%) in men and 
17,861 (44%) in women, making it the 3rd commonest cancer in both males and 
females (1-4). The majority of CRCs originate in the elderly population, with 73% of 
cases occurring in those aged 65 and over (1-4).  Around 26% of CRCs occur in those 
aged between 60-69 years (1-4).  Up to the age of 50 the incidence is similar for men 
and women, over this threshold, colorectal cancers predominantly occur in males (a-d). 
The lifetime risk for men developing colorectal cancer is 1 in 14, and for women 1 in 19 
(5).  The incidence of CRC in males has increased by 29% and for females by 6% since 
1975 (1-4).  66% of all CRCs originate in the colon and the remainder in the rectum 
(including the anus) (1-4).   A significant proportion of colon cancers originate in the 
left/distal colon (rectosigmoid, sigmoid, descending colon and splenic flexure), they 
account for approximately over 60% of cases according to site (1-4).  63% of rectal 
cancers occur in men, whilst colon cancers occur equally between men and women (1-
4).  Colorectal cancer is a leading cause of morbidity and mortality in the western 
world, and is the second commonest cause of cancer related death in the UK, after lung 
cancer (6). In 2010 there were 15,708 (8574 males and 7134 females) deaths from CRC 
in the UK, predominantly in those aged 65 and over (7-9).  The outcome of patients 
with colorectal cancer (CRC) depends to a large extent upon the stage of the disease at 
the time of diagnosis, but 90% of symptomatic cases are not diagnosed until the cancer 
has penetrated through the bowel wall or spread to local or distant regions (Dukes 
stages B-D) (10).  The 5-year survival of patients with Dukes stage A CRC is 93.2%, 
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compared to 6.6% with Dukes stage D, and around 10% of patients will present with 
disseminated disease (Dukes stage D) at diagnosis (See Table 1) (11,12). 
Table 1: % of cases and 5-year survival according to Dukes Stage 
DUKES Stage at diagnosis % of cases 5 year survival 
A 8.7% 93.2% 
B 24.2% 77.0% 
C 23.6% 47.7% 
D 9.2% 6.6% 
Unknown 34.3% 35.4% 
 
The overall 5-year survival rates for men and women have however improved over the 
past 30 years, rising from 22% to 54%  in males and from 23% to 56%  in females (6).  
This does however still mean approximately 50% of the population diagnosed with 
CRC are not alive at 5 years, so there is scope for improving the detection and 
therapeutic options for CRC. 
Colorectal cancer has a long pre-clinical phase.  The progression of normal colonic 
mucosa to a carcinoma can take several decades to occur through the accumulation of 
numerous genetic and epigenetic events.  It is also well documented that the majority of 
colorectal cancers originate from adenomas meaning that the early detection of such 
surrogate markers is paramount, especially as several studies have shown that the 
removal of colonic adenomas can lead to a reduction in CRC (13-16).  The initiation 
and progression of adenoma to CRC was first postulated by Fearson and Vogelstein 
(17,18), who identified that through an accumulation of genetic mutations of APC gene, 
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18q gene, K-ras and P53 sporadic CRC will develop (17,18).  85% of CRCs develop 
sporadically, the remainder develop as part of a hereditary cancer syndrome such as 
FAP or HNPCC, or on the background of inflammatory bowel disease.   
There are principally 3 genetic pathways (See Figure 1) that underpin the adenoma 
carcinoma sequence.  Approximately 85% of CRCs will develop sporadically as a result 
of genetic instability, which can be the result of 1 of the 3 pathways. 
1.  The most common pathway is characterized by chromosomal losses and gains, 
along with loss of heterozygosity, resulting in mutations predominantly of APC, 
P53 and KRAS.  It is referred to as the chromosomal instability pathway (CIN) 
or microsatellite-stability pathway (MSS) or  (19,20).  CIN pathway tumours 
tend be left sided or distal, highly differentiated and more often node positive or 
metastatic (21-24).  
2. The second pathway termed the microsatellite instability (MSI) pathway is 
described by the loss of the expression of mismatch-repair genes, which results 
in the formation of microsatellites (19,25).  MSI pathway tumours tend to right 
sided or proximal in origin, poorly differentiated, T3 tumours, but are less likely 
to have nodal or distal organ involvement. (21-24) 
3. The third pathway is explained by epigenetic gene silencing (26).  This refers to 
changes in gene expression that are not the result of changes in the DNA 
sequence.  It is typified by losses or gains in DNA methylation (26). One such 
example  is  at  CpG  islands  where  methylation  doesn’t  normally  occur  (26). 
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Figure 1: CRC genetic pathways 
Reproduced from Sonja Hrasovec and Damjan Glavac.  MicroRNAs as novel 
biomarkers in colorectal cancer.  Frontiers in Genetics. 2012;3(180):1-9. 
Clearly the adenoma-carcinoma sequence is a well-documented model that explicitly 
describes the natural progression of normal to adenomatous tissue and finally 
carcinoma.  Patients with pre-cancerous lesions such as adenomas are however 
generally asymptomatic.  Symptomatic patients often present when the disease is 
advanced, and the stage of the disease at presentation is closely related to survival.  In 
fact 40% of cancers will present as a surgical emergency with perforation or 
obstruction, which is associated with a much poorer prognosis.  To reduce such adverse 
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clinical outcomes the screening of asymptomatic patients has been advocated, which 
has and will undoubtedly lead to substantial clinical benefits.   Although current CRC 
screening modalities have had a positive impact on both the incidence and mortality 
related to CRC, the performance of these tests are still limited in terms of both cost 
effectiveness and/or diagnostic accuracy.  Thus new screening tests require to be 
developed, and one potential is the use of molecular diagnostic markers and in 
particular protein biomarkers in biological fluids or tissue.  This thesis will introduce 
and discuss the subject of screening for colorectal cancer as well as appraising current 
colorectal screening modalities.  It will further evaluate newer screening options, which 
include molecular biomarkers in both stool and serum, and the role of proteomics within 
this area, which largely forms the foundations of this thesis project. 
1.1  Population Screening 
The purpose of screening is to investigate asymptomatic individuals within a population 
to detect the disease when it is most amenable to treatment. CRC screening is applied to 
populations limited only by age or high-risk groups. 
According to the criteria of Wilson and Jungner (27), the justification for CRC 
screening stems from the fact that: 
1. CRC is a common health problem, with clinically important morbidity and 
mortality. 
2. There is evidence that early recognition leads to better outcomes compared to 
disease detected at a later stage. 
3. There is a clearly defined target population and agreed modes of further 
diagnostic investigation. 
4. There are simple, safe, acceptable and validated screening tools. 
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5. The benefits associated with screening surpass potential risks  
1.2  Options for Colorectal Cancer Screening 
There are a number of screening tests that can be employed for detecting the earliest 
stages of CRC, indicating that one screening tool is not unequivocally superior. The 
strategies are not equal in terms of the evidence of their effectiveness, risk and also their 
financial and psychological implications.   
The tests that have been considered for population based screening programs for 
detecting adenomas and early colorectal cancer include: 
1. Faecal Occult Blood Testing – FOBT 
2. Sigmoidoscopy 
3. Colonoscopy 
4. CT Colonography. 
5. Molecular markers including biomarkers in stool and serum 
1.2.1  Faecal Occult Blood Testing (FOBT) 
FOBT was first proposed for screening in the 1970s when there was a sharp rise in the 
number of colorectal cancer cases being diagnosed (28). FOBT is a non-specific test 
that will detect colonic blood losses greater than 1.5 mls per day, which is regarded as 
being more than just normal physiological losses (29).  The problem with utilizing 
FOBT is that most adenomas and some colorectal cancers bleed intermittently if at all 
and therefore elude detection using this method.  Only adenomas greater than 2cm will 
bleed habitually (30). 
Two broad categories of FOBT are available: 
1. Guaiac – (Rehydrated and Non-rehydrated).  They are based upon pseudo 
peroxidase activity of haem in haemoglobin so that in the presence of haem, 
 13 
oxygen is released from peroxide, facilitating oxygenation of a chromogen, 
guaiac, into a blue product (29).  Guaiac based tests do, however, react to the 
presence of any peroxidase activity, not only that of human haem (29).  Dietary 
restriction to exclude vegetable and animal peroxidase activity is therefore often 
implemented.  Results from a cohort of healthy volunteers consuming a diet rich 
in red meat and vegetables, demonstrated that the effect can last for up to 3 days 
(31). 
2. Immunochemical – These tests exploit monoclonal antibodies against the globin 
portion of human haemoglobin, which are conjugated to a dye or enzyme 
indicator system (29).  By employing this test the number of false positives are 
reduced, firstly because its activity is not influenced by dietary factors and 
secondly upper GI lesions do not skew the results as the globin moiety is 
degraded as it passes through the GI tract (32). 
There are many commercially available FOBTs for instance guaiac FOBTs includes – 
Hemoccult II and the Hemoccult Sensa and Immunochemical FOBTs comprise of the 
HemeSelect for instance.  Currently there are no specific recommendations or guidance 
as to which test should be employed.  Important characteristics that it should possess 
however are sensitivity, specificity, cost effectiveness, acceptability and it should  lastly 
show a reduction in both morbidity and mortality.  The sensitivity, specificity and 
positive predictivity are measures of the FOBTs performance.  Most studies have 
suggested that a two tier approach is adopted in that initial samples are tested using a 
guaiac based assay and then positive samples are re-tested using an immunochemical 
based strategy (33) 
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The sensitivity and specificity of FOBT depends upon the type of test employed, and in 
the case of the guaiac based test whether it is re-hydrated or not; sensitivity is higher 
and specificity is lower with the rehydrated test (34). The Hemoccult II guaiac test is 
one of the most commonly used and studied FOBT for detecting CRC in average risk 
individuals. The sensitivity of this test for detecting colorectal cancer has been shown to 
vary between 21-81% (35,36).  For polyps greater than 1cm, its sensitivity ranges 
between 13 to 31% (35,37).  The specificity of Hemoccult II is 98-99% (37-40).  The 
predictive value for this test varies from 7-12% for CRCs and 17-27% for adenomas 
>1cm (37). The Hemoccult II sensa test is a newer guaiac based test.  It differs form the 
Hemoccult II test as it incorporates an enhancer to detect lower levels of peroxidase 
activity.  This test has been shown to have improved sensitivity; in one study the 
combined sensitivity for cancer, increased from 38% using the older Hemoccult II 
guaiac test to 79% with the Hemoccult II sensa test (37).  Both guaiac tests were also 
compared with the immunochemical FOBT Hemeselect that demonstrated a sensitivity 
of 69%.  Specificity was in reverse order, for the Hemoccult II it was 98%, the 
Hemeslecet was 94% and the Haemoccult II Sensa was 87% (37).  Other studies have 
also reported similar or higher sensitivities but the failure of this test lies with its poor 
specificity, which is attributable to its predilection for peroxidase activity. The problems 
of poor specificity that are correlated with the guaiac tests are obviated through the use 
of immunochemical FOBTs such as the Hemeselect.  There are few reported studies of 
its efficacy but those that have evaluated its performance suggest sensitivities of 69%-
97% for colorectal cancer and 58%-67% for polyps (37,41,42). Specificity was 94%-
98% (37,41,42). This suggests that the HemeSelect is superior in terms of its 
performance characteristics but this is to the detriment of the cost and the complexity 
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involved analyzing it.  On the basis of these studies a combination test was assessed 
utilizing 3 Hemeoccult Sensa tests initially, and then 3 Hemeslect test secondly if the 
initial tests were positive. The reported sensitivity for CRC for this combination test 
was 66%, specificity was 97% and the predictive value was 9% (37).  For adenomas 
>1cm sensitivity was 50%, specificity 98% and the predictive value was 22% (37). 
Reported sensitivity and specificity for the detection of cancer and polyps therefore 
depends upon the analytical capabilities of the FOBT test, with variations in these 
parameters being dependant upon the assay that is adopted and the interpretation of the 
results of the various studies that included heterogeneous populations. The results do 
however suggest that up to 60% of individuals who undergo an FOBT may have a false 
positive result (40). FOBT should therefore not be regarded as a diagnostic test but as a 
means of selecting individuals that may require further investigation. 
Evidence for the effectiveness of FOBT screening at reducing CRC mortality has been 
derived from four well designed randomized control trials (RCTs) in the US, Denmark, 
UK and Sweden (43-47), as well as seven case control studies (48-54).   The RCTs have 
demonstrated a decline in disease specific mortality ranging from 11-33% using annual 
or biennial screening.  Combining the RCTS in a Meta analysis, results in a statistically 
significant reduction in CRC mortality of 16% (Confidence interval 0.78-0.90) (43).  
This series of trial data has also clearly established that yearly screening is more 
effective than biennial screening.  Offering yearly screening leads to a 16-33% 
reduction in CRC mortality, whilst biennial screening leads to a 11-21% reduction in 
colorectal cancer mortality (43-47).   As would be expected all four randomized 
controlled trials also demonstrated a favorable shift in disease stage with more Dukes 
Stage A cancers than Dukes Stage C or D cancers being discovered (43-47).  As a result 
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of the findings from these trials the UK National Screening Committee recommended 
that colorectal cancer screening should be piloted, to ascertain if a national screening 
programme in the UK would be both practical and cost effective.  In April 2000 a bowel 
screening pilot commenced inviting all individuals aged between 50-74 years registered 
with a GP practice in Fife, Grampian and Tayside in Scotland and Coventry and 
Warwick in England to participate.  The results to date have demonstrated that a 
national screening programme would be both feasible and valuable, and should bring 
about a reduction in colorectal cancer mortality comparable to the aforementioned trials 
(55).  The above projections are however dependent upon subject acquiescence both in 
terms of the initial uptake and subsequent conformity   Compliance collectively in the 
randomized controlled trials ranged from 60% to 78% and for the UK screening pilot 
57% (34,43). Adherence to screening programs has shown been to be related to 
increasing age, being female and physician recommendation (56); reasons for non-
compliance are multifactorial and can be related to social factors such as depravation or 
psychological implications of a positive test for instance. Other disadvantages of FOBT 
relate to over diagnosis and the risks of subsequent endoscopic tests that follow a 
positive result, which include colonic perforation, haemorrhage and even death.  
However the risk of complications appears to be insignificant as none of the 4 trials 
encountered any excess deaths related to the screening process (43-47).   
FOBT is currently the safest and most cost effective screening modality. More 
significantly it has led to a reduction in CRC mortality that cannot currently be attained 
by any other preventative measure.  
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1.2.2  Flexible Sigmoidoscopy 
In recent years there has been increasing interest in the use of endoscopic screening 
methods, which include flexible sigmoidoscopy and colonoscopy.  The most recent 
publication relating to the use of flexible sigmoidoscopy for screening for CRC has 
been from a multi center randomized trial in the UK in 2010.  The trial randomly 
assigned participants aged between 55 and 64 to either a once off flexible 
sigmoidoscopy or no screening.  The trial demonstrated that a once off flexible 
sigmoidoscopy could reduce colorectal cancer by 33% and disease specific mortality by 
43% (57-59). On the basis of these results NHS England is now offering patients aged 
55 flexible sigmoidsocopy screening until the age of 60, when they will then be 
screened using FOBT. There are 3 other randomized control trials that are currently 
being undertaken to provide further evidence of the effectiveness of flexible 
sigmoidocsopy in screening for CRC.  The preliminary results from one of the trials – 
the Norwegian Colorectal Cancer Prevention (NORCCAP) study have so far 
corroborated the findings from the UK trial (60). A randomized Dutch study also 
compared guaiac and immunochemical FOBT with flexible sigmoidoscopy and 
demonstrated slightly lower participation rates for flexible sigmoidoscopy (32% versus 
50% and 62% respectively for the subtypes of FOBT) but a higher diagnostic yield in 
the flexible sigmoidoscopy arm (8% versus 1.1% and 2.4% respectively) (61).   A 35cm 
flexible sigmoidscope will detect 30% to 40% of adenomas and CRCs, a 60cm scope 
will detect 40% to 60% of adenomas and cancers (62).  Sensitivity for flexible 
sigmoidoscopy is 97% for CRC and large adenomas and specificity is 94% for cancers 
and 93% for polyps (61).  Clearly an important limitation of flexible sigmoidoscopy is 
an inability to visualize the proximal colon. Several studies have addressed the 
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importance if any, of finding distal polyps and the prevalence of proximal polyps if 
small polyps are identified at flexible sigmoidoscopy with conflicting results.  One such 
study demonstrated that if a tubular adenoma <1cm in size is identified on flexible 
sigmoidocopy there is a less than 1% occurrence of a proximal lesion (63).  Patients 
with more aggressive distal lesions, had a greater than 10% frequency of advanced 
proximal lesions (63).  Another study suggested that proximal adenomas were identified 
in 29% of patients with small distal adenomas, and 57% of patients if they had larger 
distal adenomas (64). The removal of distal adenomas via flexible sigmoidoscopy has 
however shown to contribute to an overall decline in CRC incidence. 
Flexible sigmoidoscopy is highly sensitive, of moderate cost and has a low risk of 
complications, approximately 1 perforation per 10,000 examinations (34). 
1.2.3  Colonoscopy 
Currently no randomized controlled trials have validated the use of colonoscopy in a 
screening population.  It is unique when compared to all other CRC screening 
modalities in that it allows direct visualization of the entire colon.  Two cohort studies 
have demonstrated that colonoscopy can lead to a reduction in CRC mortality via the 
removal of adenomas, with few clinically important adenomas being missed (65-67). 
The sensitivity of colonoscopy for CRC detection is 95%, and specificity of course must 
be 100% (68). Colonoscopy is however invasive, it has the highest risk of perforation (1 
in 1000), so that 1 to 3 per 10,000 patients will die of complications from the procedure 
(69).    
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1.2.4  CT Colonography 
In 1994 Vinning and Gelfand reported the use of CT to simulate virtual endoluminal 
images   of   a   patient’s   colon,   which   is   now   known   as   CT   colonography   (70). 3D 
endoluminal images are generated within a single breath hold in a fully prepped and 
distended colon.  Early studies looking at CT colonography demonstrated variable 
results with regard to its sensitivity and specificity, with sensitivity ranging from 64% to 
94%, and  specificity of 95% to 100%  for adenomas greater than 1cm, for cancers these 
parameters approach 100% (71-73).  The most recent studies are from the American 
College of Radiology Imaging (ACRIN) trial (74,75) which produced two papers on the 
efficacy of CT colonography in a screening population and the effectiveness of this 
modality in patients aged 65 and over.   The original trial data demonstrated that CT 
colonography was a useful adjunct in detecting asymptomatic large colorectal adenomas 
or cancers in 90% of patients (74). Of the adenomatous polyps 6 mm or larger, 78% 
were detected. Specificity estimates ranged from 86% to 89% among lesions 6 mm or 
larger. The data therefore suggests that CT colonoscopy is comparable to conventional 
colonoscopy.  Further analysis of the data according to age illustrated that for most 
measures of diagnostic performance there were no differences in those aged over or 
under 65 (75).  For the detection of small or flat lesions adenomas CT colonoscopy 
performs poorly (76). For the case of size this may however prove insignificant as it is 
widely acknowledged that adenomas less than 1cm will rarely progress into invasive 
cancer. 
CT colonography confers a number of advantages over other screening modalities 
1. It has the ability to visualize the entire colon and can negotiate and visualize the 
colon proximal to an obstructive tumour or redundant loops.   
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2. It is a useful alternative in those who cannot tolerate or undergo conventional 
colonoscopy 
3. It identifies not only intraluminal lesions but also extra colonic pathology, in 
particular metastases. 
Important limitations of CT colonography are  
1. False positives can occur due to the misinterpretation of retained stool, or the 
colon distending poorly because of diverticular disease  
2. It is not therapeutic and therefore patients have to undergo a further procedure if 
any significant pathology is identified.   
3. Exposure to radiation albeit a smaller dose compared to conventional CT. 
4. The cost of the procedure may also render it unsuitable as a primary test in 
population screening  
1.2.5  Biomarkers 
1.2.5.1  Overview of Biomarkers 
A biomarker is a quantifiable biological molecule that is representative of, or directly 
involved in the physiological and pathological mechanisms that underlie a particular 
disease.  A cancer biomarker maybe a molecule produced directly by the tumour itself 
or by the host in response to the presence of the tumour.  Ideally a cancer biomarker 
should be assayed in biological fluids such as blood, urine, CSF or faeces and thus be 
obtained non-invasively.   Biomarkers are detectable and quantifiable at all stages in the 
evolution of the disease including the earliest stages.  Genetic, proteomic, glycomic or 
epigenetic biomarkers could therefore be used throughout the progression of the disease 
to determine  
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1. Risk 
2. Diagnosis 
3. Treatment options 
4. Response to treatment  
5. The risk or presence of recurrence 
Essentially biomarkers can therefore be classified as markers of risk, disease or 
intermediate points within the evolution of the disease, for example establishing the 
effects of treatments.  A risk biomarker establishes those individuals who are at 
increased risk of developing a certain disease, who are likely to be asymptomatic. 
Identifying individuals that are at higher risk of developing a disease when compared to 
the general population, allows targeting of invasive investigations.  With reference to 
CRC, an adenoma can be regarded as a risk biomarker. In contrast biomarkers of 
disease indicate the presence of disease or the likehood that an individual will develop 
disease within a specified interval.  Lastly Intermediate biomarkers maybe  
1. Predictive – It could identify patients who will benefit or who maybe susceptible 
to the harmful effects of a particular treatment. 
2. Pharmacodynamics – It could be used to assess biological response and also the 
extent of the response 
3. Prognostic – Signifies the predictive utility of the treatment regime undertaken 
1.2.5.2  What makes a good biomarker? 
An ideal biomarker should enable an unbiased diagnosis of a specific disease, 
principally in patients who are without symptoms.  It should therefore fulfill a number 
of requirements (77,78) 
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1. It must be directly involved in the development of the disease it is intended to 
indicate. 
2. It should be able to differentiate between normal and disease states 
3.  It must be differentially expressed at various stages of the disease.  Thus the 
measured level of the biomarker should generally reflect the stage. 
3. The correlation between individuals must be reproducible and the variance 
between individuals and laboratory tests must be known. 
4. Detection of the molecular marker should have a positive impact on mortality. 
5. It should be quantifiable in tissues that are easily collected and available for 
repeated assay. 
6. The levels of the biomarker should be modified by subsequent interventions 
7. It should have predictive accuracy  
With reference to the last requirement a number of basic statistical considerations 
should be probed during a biomarker study.  2 such inherent features are sensitivity, 
which refers to the ability of test to demonstrate a disease when it is present, and 
specificity, which is the ability of a test to predict the absence of disease when it truly is 
not present.  Although both are integral statistical features of a biomarker they do not 
take into account or reflect the population being tested.  The positive and negative 
predictive values, which signify the number of tests that truly are positive and negative 
respectively, should therefore also be considered/calculated.    Comparing the mean 
biomarker values to determine statistical significance is also not recommended, as this 
would involve determining a single cut off value, which would separate both groups.  It 
is generally advocated that a range of values are determined and the sensitivity and 
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specificity for each are calculated and plotted in a receiver operating characteristic 
(ROC) curve (79). 
1.2.5.3  Sources of biomarkers 
The nature and quality of the biological sample that is used for analysis in any 
proteomic biomarker discovery study will determine the eventual outcome.  The sample 
that is chosen must have characteristics that are favorable for both the clinician and the 
patient.   For instance it must be  
1. Easily accessible  
2. Demonstrate high sensitivity and specificity for a given disease 
3. Reproducible 
4. Cost effective  
5. Easy to process.   
The sample maybe a tissue specimen, blood or a proximal fluid such as urine, saliva or 
stool.   
1.2.5.3.1 Tissue 
Tissue is an important sample format for making a histological diagnosis, its routine use 
as biomarker is not ideal however.  Tissue has to be obtained through invasive 
techniques such a biopsy or surgery, and therefore presents an element of risk to the 
patient.  Other inherent problems include the heterogeneity of tumour tissue leading to 
problems with reproducibility, and also the processing of tissue which can be time 
consuming and costly. Tissue is however most likely to closely represent the 
constituents of the tumour and its surrounding environment.  A number of studies have 
identified candidate biomarkers through the use of tissue in breast (80), lung (81), 
prostate (82) and pancreatic cancer (83). 
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1.2.5.3.2 Blood 
To overcome the problems associated with obtaining and processing tissue, minimally 
invasive body fluids such as blood are now being utilized in protein biomarker studies.  
A major advantage of utilizing blood is its close proximity with all cells in the host 
organism.  The changes in the hosts circulating proteins, is due to either the primary 
effects of the pathological cells, which are released into the circulation by either 
secretion or shredding, angiogenesis, or direct invasion or destruction of the tumour 
(84). Or the secondary effects facilitated by the host in response to the presence of these 
abnormal cells. For instance changes in the immune system in response to the disease 
state is another means by which circulating blood proteins are altered. Many other 
factors can also lead to changes in the protein profile, and therefore elements such as 
age, medication and the presence of other pathology must be accounted for. Analytical 
methods must therefore also be standardized and controlled when using blood in 
biomarker studies (85) to prevent imposing any processing errors that may lead to false 
positive results. 
For a serological biomarker to be considered as a potential biomarker it must be 
1. Absent or present in low levels in healthy individuals as well as those with 
benign disease 
2. Tissue specific 
3. Produced by either the tumour or its microenvironment, and thus be present at 
high enough levels in the circulation 
Although blood is useful as a biomarker due to its proximity to tumour tissue and it 
generally reflects the host environment, it is a complex medium thus making its analysis 
difficult for a number of reasons.  These include 
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1. Proteins from other organisms such as bacteria are present 
2. The dynamic range of proteins within blood is >1010.  The capability of the most 
sensitive MS is >106 (86).  There are a number of fractionation or enrichment 
strategies that will be discussed later in the introduction (Section 1.8), which can 
overcome this difficulty however.   
3. >95% of blood is composed of 22 highly abundant proteins, which effectively 
hampers the detection of lower abundance proteins of biological interest such as 
cytokines. (87) Although the depletion of these using antibody affinity columns 
can facilitate the detection of lower abundance proteins, other proteins of 
diagnostic importance can be lost during this process.  One study demonstrated 
that the depletion of albumin can lead to significant losses of low abundance 
proteins such as cytokines. (88) 
Blood can be analyzed whole, or as serum or plasma. Plasma and serum differ by the 
absence of certain proteins such as fibrinogen, and the presence of cellular products that 
are the result of the coagulation process.  By combining blood with an anticoagulant 
such as EDTA (ethylenediamine tetraacetic acid) or sodium citrate and heparin, plasma 
is generated.  If blood is withdrawn into a container without an anticoagulant and either 
centrifuged immediately or allowed to stand until clot retraction occurs, serum is 
created.  Factors, which can affect the quality of plasma, are the type of anticoagulant 
used, processing and also sample storage.  Factors influencing serum quality are the 
type of container used to collect the sample and the time allowed for clot retraction (89).  
The recommendations are that serum should be used over plasma, it should be collected 
in a glass container and then frozen in a uniform time interval (89).  If plasma is used, 
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EDTA is the recommended anticoagulant and an absolutely uniform process should be 
established for obtaining plasma each time. 
1.5.2.3.3  Other proximal fluids 
Due to the complexity of blood and the concentration range present, a number of other 
proximal fluids such as urine, saliva, and stool are being analyzed as potential sources 
of biomarkers.   
Urine as a source of biomarkers to aid in the detection of kidney disease is attractive as 
urine can be obtained non-invasively and in sufficiently large quantities. The amount 
and composition of the urinary proteome directly reflects changes in the function of the 
kidneys and is generally considered less complex than blood to analyze. Protein 
concentrations can vary widely in urine however, but this can be compensated by 
standardization based on urinary creatinine (90) or urinary housekeeping peptides, 
which are present almost ubiquitously in human urine independent of age, sex, health, 
and drugs (91).  To date MS based urinary proteomics has been utilized to identify 
protein biomarkers in prostate cancer (92), bladder cancer (93) and even non-kidney 
disease (94). 
Saliva is a hypotonic fluid which contains an abundant source of organic molecules  
including proteins. Salivary proteins originate from the local vasculature and therefore a 
similar, if not identical, composition of proteins can be identified in saliva and serum.    
Saliva can therefore be regarded as a potential source of biomarkers for a number of 
systemic diseases.  Saliva would be an excellent source of biomarkers as it is easy to 
collect,  and  doesn’t  require  specialized or invasive techniques to obtain it.  Saliva can 
be obtained by stimulatory i.e. through mastication or non-stimulatory methods.  
Generally the latter is preferred to prevent modulation and dilution of the proteins of 
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interest.  Saliva as a biomarker medium does have some disadvantages such as the 
circudian variation in the composition, and also the concentration of salivary proteins is 
1000 times less than serum (95).  A number of salivary biomarkers have been 
discovered and validated in breast caner (96), oral caner (97), lung cancer (98), 
pancreatic cancer (99) and oral disease (100).   
The use of stool as a source of biomarkers in colorectal cancer has been discussed in 
section 1.2.6.1.1. 
1.5.2.3.4  Cell lines 
Analysis of cancer cell lines presents a simpler alternative when compared to blood or 
proximal fluids for biomarker discovery.  The secretomic analysis of cancer cell lines is 
especially important in biomarker discovery.  The term secretome was first proposed by 
Tjalsma et all in 2000 after studying the bacteria B.subtilis (101). This study defined 
Secretomics as all of the proteins secreted by an organism, cell or tissue into the 
extracellular matrix.  The proteins that make up the secretome are either shed or 
secreted from the cell surface or the intracellular compartment by lysis, apoptosis or 
necrosis.  These cancer-secreted proteins are then likely to end up within the circulation 
and can thus be measured.  The identification of such proteins in vitro, would mean a 
targeted approach can then be used to verify and validate corresponding proteins in 
vivo.  One of the main biological sources of secreted proteins in vitro is the supernatant 
of cancer cell lines.  Secretomic analysis of several cancer cell lines has been reported 
including breast cancer (102-105) lung cancer (106,107) prostate cancer, (104,108) 
cervical cancer (109) ovarian cancer (110) and bladder cancer (111) cell lines. In most 
studies, the number of identified proteins per cell line secretome ranges from 250 to 700 
(102-104, 111).  Although sceretome cancer cell line analysis does seem promising, a 
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few   studies   have   shown   that   changes   in   vitro   don’t   correlate   in   vivo,   and   very   few  
actual differences exist between normal and cancerous tissue cell lines (112) 
Advantages of analyzing cell lines 
1. Cell lines are readily available and are generally easily propagated 
2. Allows for high-throughput and cost effective analysis 
3. Easily modified to reflect pathological processes in vivo 
4. Enables secretome analysis. 
5. The analysis of blood is complex as the complete set of proteins expressed by the 
host is analyzed.  By analyzing the secretome, specific proteins that are easily liberated 
are assayed thereby reducing such complexities. 
6. Permits detection of low abundance proteins, as the dynamic range that exists when 
analyzing blood is not an issue. Allows for reproducibility as growth and other 
conditions can be standardized. 
Disadvantages   
1. Cancer is a heterogeneous disease and thus no cancer cell line can reflect this.  
2. Variations within a single cell line exist. 
3. The interplay of the host stromal/microenvironment and immune response both of 
which influence tumour development and progression is absent.  Cell line analysis does 
therefore not take into account the complex interplay between the host and the tissue 
microenvironment 
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4.  Cell  lines  can’t  parallel  the  complexity  of tumour tissue 
5. The genomic and proteomic alterations that underpin the transformation of benign 
tissue into a malignancy cannot be defined. 
1.2.5.3   Phases of Biomarker Discovery 
Biomarker discovery is subject to a multitude of biases ranging from the heterogeneous 
nature of the samples being used, to the way in which samples are collected, stored and 
finally prepared for downstream analysis and finally to the methodology employed.  A 
systematic and reproducible approach is therefore central to any biomarker discovery 
study.      In   2002   therefore   the   National   Cancer   Institute’s   ‘Early   Detection   Research  
Network’   developed   a   five-phase approach to biomarker discovery in an attempt to 
standardize and negate the biases encountered during biomarker discovery projects 
(113) 
Phase I: 
This is defined as the pre-clinical exploratory phase.  It involves the comparison of 
specimens from control individuals and patients with the disease of interest.  The 
objective is to identify proteins, which are under or over expressed in the pathological 
specimen, which could then be used in a clinical assay.   A lot of consideration should 
be given to the specimen type used in this phase (which should be obtained prior to the 
commencement  of  a  patient’s  treatment),  a  spectrum  of  specimens  (i.e.  different  stages)  
should be analyzed and ideally it should come from a well-defined cohort or tissue bank 
(114).   Control specimens should be matched as closely as possible to the disease 
specimens so that any differences between the 2 are because of the presence of the 
tumour rather than other biological factors such as age, sex or presence of other 
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diseases.  The number of specimens used, is determined by ascertaining what the 
eventual outcome of the study is and the variability that exists.  A number of factors can 
lead to variability within a biomarker study group (113) such as 
1. The range of disease stages and the prevalence of each 
2. The number of biomarkers under appraisal 
3. The ability of each biomarker to distinguish between normal and disease 
subjects 
4. The statistics used to validate the efficacy of the biomarker 
Because of the aforementioned reasons, it is recommended that computer programs 
rather than simple calculations are used to determine sample size. 
Each identified biomarker is then assessed to determine how well it differentiates 
between normal and disease, which in turn is measured by sensitivity and specificity 
and also by summary statistics such as a receiver operating characteristic (ROC) curve.   
Phase II: 
The objective of phase II is to develop a non-invasive clinical assay based on the 
findings from phase I.  The case subjects in phase II will all have established disease.  
All the biomarkers selected in phase I will be preferentially expressed in the specimens 
derived from the subjects and all the cases are generally representative of the screening 
population that will be eventually targeted.  The performance of the biomarker(s) is 
determined firstly by its ability to distinguish between the presence of disease in the 
case subjects and the absence in the control subjects, and secondly by determining the 
sensitivity and specificity and finally by the establishment of a ROC curve.  Other aims 
of this phase are to ensure reproducibility, to assess how factors such as tumour stage, 
age, sex, smoking etc. might impact on the assay and also to set thresholds for the assay. 
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Phase III: 
During phase III the biomarker(s) are assessed in subjects who have yet to develop 
symptoms and are compared with levels in control subjects.  If the levels differ only 
marginally between controls and subjects, there is probably little utility in developing 
the biomarker assay for screening purposes, as its unlikely to have the capacity to 
differentiate between patients who have pre-clinical disease and those who have not 
developed the disease.  If the opposite outcome is proven, standards are set for 
developing the biomarker panel for clinical utilization. This will include (113) 
1. Determining the exact time at which the biomarker can detect pre-clinical 
disease, meaning longitudinal data will required to be collected. 
2. Selecting the biomarkers which show greatest potential 
3. Determining the interval at which the assay should be employed 
4. Clarifying if the biomarker is more likely to project the presence of pre-clinical 
disease in certain populations. 
Three sample components need to be considered when structuring this phase: 
      1.  The number of case and control subjects 
      2.  The number of samples that should be evaluated for each subject. 
      3.  The timing of the samples 
Phase IV: 
Compared to Phases I-III, samples in phase IV are collected and analyzed prospectively.  
This will lead to positive subjects undergoing a definitive procedure to confirm or refute 
the presence of a particular disease.  The detection and false recommendation rate or the 
type I/II errors are thus calculated and disclosed in this phase.  This phase also sets out 
to outline the characteristics of the disease at the time of detection, such as the stage. 
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Phase V: 
The final phase determines the impact of the screening modality on end points of health 
such as mortality or the cost per life saved, and also the risks associated with 
undergoing the test.  Reasons that the biomarker(s) may not have a positive impact 
include (113) 
1. Poor compliance 
2. Successive treatment algorithms maybe ineffectual 
3. Overdiagnosis 
4. Lead time or length time biases 
1.2.6  CRC BIOMARKERS 
The ideal candidate biomarker for CRC would be easily detectable in bodily fluids such 
as blood or stool, and would reflect not only the presence of the disease but the stage in 
a given individual. The genetic events that underlie CRC carcinogenesis are well 
documented and with advances in technology it has therefore enabled researchers to 
postulate and verify some candidate biomarkers.   The multi-step nature of colorectal 
tumourogenesis, has, however meant that the identification of a single biomarker is 
unlikely.  To a certain extent researchers have overcome this by choosing pivotal 
genetic aberrations that occur as normal mucosa progresses to a carcinoma.  The ability 
of a marker to determine risk or suggest the presence of disease is therefore reflected in 
its relative importance in this cascade, for example, 60% of sporadic CRCs have a 
mutation in the APC gene, thus making it an ideal candidate (115).   
The progression of normal tissue to an adenoma and then finally to a carcinoma is the 
result of an accumulation of genetic alterations.  The genetic aberrations that occur 
therefore offer an opportunity to detect stage specific changes in DNA, RNA and 
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protein expression.  A number of DNA mutations and proteins are being evaluated in 
both stool and serum that could serve as biomarkers to either indicate the presence of 
adenoma(s) or early CRC. The proximity of the tumour to stool, and the likehood 
therefore of an altered spectrum of proteins being released into stool that could be easily 
detected, makes stool an excellent paradigm.  The fact that it is also a non-invasive test, 
its measurement requires no bowel preparation and it screens the entire colon are other 
reasons that make it an excellent medium to search for potential biomarkers.  It has been 
shown that approximately 1010 colonocytes are continuously shed from the mucosa into 
the stool on a daily basis (116-118).  The entire colonic epithelium is renewed every 3 
to 4 days, compared to blood, which is shed intermittently (116-118).  The exfoliation 
of cells in colonic tumours is 4-5 times greater than normal epithelium, and therefore 
potential biomarkers should be more abundant and present in all samples compared to 
blood (119,120).  Unlike faecal occult blood screening, molecular based screening 
techniques detects cancer specific markers or changes such as DNA mutations (which 
are stable in stool), epigenetic changes such as microsatellite instability and 
unfragmented L-DNA.   
1.2.6.1.1            Stool biomarkers of CRC – DNA based 
Faecal DNA tests detect abnormal or mutant DNA in stool.  No single genetic 
identification has been consistently found in colorectal tumours, therefore, a panel of 
DNA markers is normally assayed.  Haug and Brenner in 2005 (121) systematically 
reviewed the literature on DNA based stool testing and concluded that such DNA panels 
detected CRC with a specificity of 95%, with sensitivity varying between 60% - 90% 
(121,122).  Imperiale et al compared faecal DNA screening with FOBT in detecting 
CRC.  Of the invasive cancers discovered during this study, the DNA panel detected 
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52% and FOBT 13%. (122,123). Whilst for the invasive cancers plus adenomas the 
DNA panel detected 41% and FOBT 14% (122,123).  Specificity was 94% for the 
faecal DNA test and 95% for FOBT (122,123).  The results for the main studies looking 
at multi-panel DNA stool testing are shown in Table 2 below. 
Table 2:  Overview of the literature for multi panel faceal DNA testing 
Reference DNA markers Number 
of CRCs 
detected 
CRC 
sensitivity 
Number of 
adenomas 
detected 
Adenoma 
sensitivity 
Specificity 
Imperiale 
2004 (123) 
21 mutations in APC, 
P53, KRAS, MSI and L-
DNA 
16/31 52%) 110/1051 10.5% 94.4% 
Alqhuist 
2000 (124) 
15 mutations in APC, 
TP53, KRAS  and L-
DNA 
20/22 81.8% 9/11 81.8% 93% 
Tagore 
2003 (125) 
21 mutations in APC, 
TP53 and K-RAS and 
DNA integrity 
33/52 63.5% 16/28 57.1% 96% 
Rengucci 
2001 (126) 
7 mutations in TP53, K-
RAS  and 5 MSI markers 
31/46 67.4% N/A N/A 100% 
Dong 
2001 (127) 
3 mutations in TP53, K-
RAS and BAT26 
36/51 70.6% N/A N/A N/A 
Koshji 
2002 (128) 
Loss of heterozygosity at 
the microsatellite loci 
APC, P53, DCC, MLH1 
30/30 100% N/A N/A 86.7% 
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The DNA stool biomarkers that have been identified in colonocytes correlate well to the 
genetic events that underpin the adenoma-carcinoma sequence.  They include 
1. APC – The  APC  gene  encodes  a  tumour  suppressor  protein  that  regulates  β-catenin 
signaling and thus cellular proliferation and adhesion (129,130).  Inactivation of the 
APC protein occurs early in the Vogelstein model and is responsible for both sporadic 
and inherited CRCs (129).  60-80% of sporadic CRCs will harbor a mutation in the 
APC gene (116,129).  The main disadvantage with APC testing is that it is technically 
difficult and extremely time consuming, as the mutations can be distributed throughout 
the entire coding region (129,131,132).  The majority of APC mutations do however 
occur in a region referred to as the Mutation Clustering Region (MCR), and thus testing 
can be restricted to this area with only a modest loss in sensitivity (133).   
2. K-ras – The K-ras proto-oncogene encodes a Ras family protein that is involved in 
signal transduction (129).  40-50% of sporadic CRCs and adenomas > 1cm will have a 
K-ras mutation (129).  Mutations in K-ras evolve early in the CRC pathway as 
corroborated by the fact that 13-95% of K-ras mutations are found in the earliest 
identifiable changes in the transition of normal mucosa to carcinoma, the aberrant crypt 
foci (ACF) (129, 134-136).  Distal tumours are more likely to have undergone a 
mutation in the K-ras gene (133).  
3. P53 – Is a tumour suppressor gene that encodes a protein, which regulates apoptosis, 
angiogenesis and the cell cycle (129).  30-60% of colorectal cancers contain mutated 
p53 genes depending on the stage, grade and location of the tumour. (129).  Mutations 
in the p53 gene occurs late in CRC carcinogenesis (129).  
4. BRAF – Plays a pivotal role in growth and inhibition of apoptosis through its activity 
as a serine/threonine kinase (133).  Mutations in BRAF are found in all stages of CRC 
 36 
and are thus likely to represent an early event in the CRC pathway.  K-ras and BRAF 
mutations appear never to occur synchronously in a colonic tumour (137).  BRAF 
mutations are associated with a poor prognosis (138). 
5. Microsatellite instability (MSI) – Microsatellites occur throughout the genome and 
are essentially short stretches of DNA in which 1-5 nucleotides are tandemnly repeated 
(129,133). Microsatellite instability occurs secondary to defects in the mismatch repair 
system, resulting in a change in the DNA length because of gained or lost units (133).  
MSI in sporadic CRCs is the consequence of aberrant DNA methylation of the CpG 
motifs of the MLH1 gene which results in it becoming epigenetically silenced (133).  
This hypermethylation phenotype is referred to as CpG island methylator phenotype – 
CIMP.  CIMP positive tumours are more likely to be proximally located, have K-ras, 
BRAF and p53 mutations, occur in older patients and are more likely to be associated 
with CRCs occurring in females.  This phenomenon arises early in CRC, in apparently 
normal mucosa, in 15-30% of sporadic CRCs (116) and is associated with a better 
prognosis compared to stage matched microsatellite stable tumours. 
6. L-DNA – Colonocytes shed from normal colonic mucosa undergo apoptosis, 
resulting in DNA fragmentation, and thus a reduction in intact genomic DNA.  
Conversely malignant colonocytes have a reduced rate of apoptosis and thus it is 
possible to detect intact genomic DNA – L-DNA, which could function as a potential 
biomarker.  Boynton et al (139) using faecal samples from 25 patients with CRC and 77 
controls looked at amplified L-DNA of differing length from 4 different genetic loci 
(APC, p53, BRCA1 & BRCA2) to determine the predictive value of L-DNA as a 
diagnostic marker of CRC.  When L-DNA was detected from >18 bands from a 
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possible 24 bands, specificity for CRC detection was 97% and sensitivity was 57%.  
(139) 
The single DNA mutation tests described above are highly specific but are not sensitive 
due to the heterogenuous nature of CRC.  The detection of these biomarkers is also 
highly dependent upon retrieving the colonocytes with the abnormality.  Therefore 
multi-target strategies to increase sensitivity whilst maintaining specificity should be 
adopted.  The results also show that multi-target faecal DNA panels confer greater 
sensitivity and similar specificity when compared to FOBT (See also Table 2).  DNA 
stool testing has other inherent advantages for example faecal DNA from patients with 
CRC has higher integrity compared to healthy controls, multiple specimens are not 
required and lastly dietary restrictions are not necessary.   The challenge for DNA stool 
testing lies in separating abnormal colonocyte DNA from normal human DNA and  also 
animal/bacterial  DNA,  and  then  it’s  subsequent  amplification  prior  to  its  degradation. 
1.2.6.2   Stool biomarkers of CRC – Non-DNA based  
Non-DNA based stool screening has also identified a number of proteins as potential 
screening markers.  These include Transferrin, Albumin, Calprotectin, 
Minichromosome  Maintenance  protein  2  (MCM2)  and  α1-antitrypsin (140-144).   
1.Transferrin – Is an iron binding glycoprotein that is stable in stool (116).   One study 
demonstrated that the measurement of Transferrin in stool in combination with FOBT 
achieves sensitivity of 85% and specificity of 100% (140)  
2. Albumin – Is not stable in stool due to bacterial and enzymatic degradation. Increased 
levels have however been identified in patients with all types of colorectal pathology, 
therefore it lacks overall sensitivity (141) 
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3. Calprotectin – Is a calcium binding protein that has both an anti-proliferative and 
anti-microbial action (116).  It is raised in both inflammatory and neoplastic pathology 
of the colon. One study compared faceal calprotectin levels with FOBT for the detection 
of CRC.  It showed that the sensitivity of faecal calprotectin was 79% for CRC and 
adenomas, and the specificity 72%, whilst the sensitivity for FOBT for this combined 
group was 43% and the specificity 92% (142).  Another study demonstrated a 
sensitivity of 68% and specificity of 91% for calprotectin revealing CRC (145). 
4. MCM2 – Is a protein that is necessary for DNA replication during mitosis in the 
colonic epithelium (116).  In normal crypt architecture MCM2 is present at the bottom 
of it.  In colorectal cancer or in adenomas it is present throughout the crypt (143).  In the 
same study, which described the above findings, MCM2 proteins were found in 90% of 
the colonocytes in patients with CRC, compared to none of the colonocytes retrieved 
from healthy controls (143). 
5. Alpha-1 anti trypsin – Is stable in stool rendering it a potentially suitable biomarker 
for detecting CRC.  The mechanism of alpha-1 anti trypsin is to avert the actions of 
proteolytic enzymes that are produced in response to colonic pathology.  It has been 
shown to have a specificity of 63% for CRC and 33% for adenomas >1cm (144). 
Although most of these proteins are stable in stool, their lack of specificity and 
sensitivity for colorectal cancer will likely render them unsuitable for colorectal cancer 
screening. 
1.2.6.3.1                     Current serum biomarkers of CRC 
To date only 10 serum proteins have been described in the literature that can be 
effectively used as cancer biomarkers, e.g. PSA, CA 125 etc.  The most widely used 
marker for CRC, Carcinoembyronic antigen (CEA) is poorly sensitive (30-40%) and 
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specific (90%) for early CRC, and thus measuring CEA is not recommended for 
screening (122).  Up to 60% of early CRCs would not be detected using it as a 
screening tool (122).  As with using CEA for screening, the low sensitivity and 
specificity of CEA has rendered it also unsuitable for the diagnosis of CRC.  The only 
proven clinical utility of CEA is in prognosis and as a surveillance marker after surgical 
resection.   Several studies have demonstrated that patients with high pre-operative 
levels of CEA have a worse prognosis compared to those with low levels, which also 
appears to be independent of stage. (146). The levels of CEA should also fall after 
surgery, but unchanged levels post-operatively are indicative of a risk of early 
recurrence (147). 50% of patients who undergo surgical resection will develop 
metastasis within the first 2-3 years of their procedure.  Serial monitoring of CEA can 
detect recurrent or metastatic disease with a sensitivity of 80% and specificity of 70% 
(148).  Arnoud et al (149) demonstrated that for diagnosing liver metastasis CEA 
measurements had a sensitivity of 94% and specificity of 96%.  Another evaluation of 
CEA in diagnosing liver metastasis determined it had a 100% sensitivity (150).  It does 
however exhibit low sensitivity for the detection of locoregional recurrences (151)  
Several other candidate serum candidates have been identified but in some cases the 
differences that were detected in the serum of CRC patients were in acute phase 
proteins and thus represent an immune response rather than a cancer specific response. 
Consequently these proteins would not demonstrate high sensitivity towards CRC.  
Some of the proteins found to be upregulated in the sera of patients with CRC are 
discussed below: 
1. Tissue inhibitor of metalloprotineases Type 1 (TIMP-1) – Is a glycoprotein that 
inhibits most matrix metalloprotineases and therefore governs cellular activities 
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such as apoptosis and proliferation (129,133).  TIMP-1 is significantly elevated 
in those with CRC, even in the earliest stages of the disease (152,153).   Those 
with more advanced disease (Dukes stage D) have been shown to have higher 
levels as compared to those with Dukes stage A CRC (152,153).  In the same 
study they also found that combining TIMP-1 levels with CEA levels increased 
sensitivity for CRC from 65% to 75%, and for rectal cancer from 42% to 54%, 
with 95% specificity (152,153).  Patients with adenomas, inflammatory bowel 
disease or primary breast cancer do not show high levels of TIMP-1 (154).  
Univariate and multivariate statistical analysis has also demonstrated that there 
is an increased incidence of mortality in those patients with CRCs that express 
high levels TIMP-1(155).  
2. α  – defensins – Using SELDI-TOF techniques both Albrethsen et al (156) and 
Melle et al (157) independently analyzed the protein profiles in colonic tissue 
and sera in patients with CRC and normal controls.  They   identified   that   α   – 
defensin 1-3 were significantly upregulated in the sera and tissue of patients 
with CRC. Albrethsen demonstrated that the levels of these proteins could 
predict CRC with a sensitivity of 69% and a specificity of 100%.  (156). 
3. Collapsin response mediator protein-2 (CRMP-2) – Using CRC cell lines Wu et 
al identified Collapsin response mediator protein-2 as a potential biomarker for 
CRC and subsequently evaluated this protein in the sera of 201 CRC patients 
and 210 normal controls (158).  CIMP-2 levels demonstrated better sensitivity 
but poorer specificity in detecting CRC as compared to CEA.  When measured 
in conjunction with CEA sensitivity rose to 77% and specificity to 95% for CRC 
 41 
(158).  Yoneda et al (159) suggested CRMP-2 might regulate a key aspect of 
tumor progression. 
4. C3a-anaphylatoxin –Habermann et al (160) found that serum levels of C3a-
anaphylatoxin were significantly higher in those patients with CRC compared to 
normal controls.  They found that the levels of C3a-anaphylatoxin could predict 
CRC with 96.8% sensitivity and 96.2% specificity (160).  In the same study it 
was also established 86.1% of adenomas have elevated levels of C3a-
anaphylatoxin confirming its utility as a diagnostic marker (160) 
5. Macrophage migration inhibitory factor (MIF) – Based on the observation that 
the MIF gene is significantly upregulated in CRC Kim et al (161) evaluated the 
protein it encodes in sera as a potential biomarker of CRC. MIF levels were 
measured in the serum of 129 patients with CRC and 53 normal controls, and 
were found to be significantly elevated in patients with CRC with a specificity 
of 90.6% (vs. 100% for CEA) and sensitivity of 47.3% (vs. 29.5% for CEA).  
(161) 
6. Macrophage colony stimulating factor (M-CSF) – Both macrophage colony 
stimulating factor and granulocyte colony stimulating factor are elevated in the 
sera of patients with CRC (162,163).  The presence of elevated serum levels of 
M-CSF was also found to be predictive of lymph node metastasis (162,163). 
7. Prolactin – A study conducted by Soroush et al (164) tested prolactin levels in 
47 patients with CRC and 51 healthy controls.  They found that elevated levels 
of prolactin could predict CRC with a sensitivity of 77% and specificity of 98%. 
8. M2-pyruvate kinase – Is a cytosolic enzyme that is released into the circulation 
by cancer cells that have undergone apoptosis.  Zhang et al (165) demonstrated 
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that its expression was upregulated in CRC, and amplified levels were 
associated with a more advanced stage and lymph node metastasis. Another 
study conducted by the same group demonstrated a diagnostic sensitivity of 
serum M2-PK to be 100% for CRC, 95% for advanced adenomas, 82% for 
adenomas, and 83% for non-adenomatous polyps. There were no CRC cases 
missed and 40.51% of unnecessary colonoscopies were avoided when the cut-off 
value was 2.00 U/m (166) 
Protein microarrays offer a combination of high sensitivity and multiplexing 
possibilities for identifying potential biomarkers from a single sample. Recent published 
data from Haberman et al (167), utilizing such techniques demonstrated a specific 
signature for CRC at the protein level. They developed a biochip containing 9 proteins: 
CEA, IL-8, VEGF, S100A11, MCSF, C3adesArg, CD26, and CRP.  The sensitivities of 
different combinations of proteins ranged from 17%-47%, with specificities ranging 
from 81%-90%.  Although it is an innovative approach further studies need to be 
conducted to find a protein signature that will yield more promising results. 
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1.3 Role of proteomics in Colorectal Cancer Biomarker   
discovery 
1.3.1  Introduction to proteomics 
Genomic analysis has played an important role in understanding many diseases but 
advances in technology and completion of the human genome project has meant that the 
next level of molecular enquiry, the proteome can now be studied. 
As of yet the multiple molecular alterations that occur at the genome level during the 
transition of normal colonic mucosa to invasive carcinoma, have not been translated 
into serum protein biomarkers that would have sufficient sensitivity and specificity for 
use in a colorectal screening programme. It likely relates to the fact that the proteome is 
far more complex than the genome.  The human genome contains 33,000 genes but 
these encode for more than 200,000 proteins, which excludes those proteins, which 
undergo post translational modifications (168). Delineating tumoral protein markers is 
therefore often difficult, expensive and extremely time consuming.  Some other reasons 
for the failure to identify colorectal cancer specific serum protein biomarkers relate to 
the tremendous range of protein levels in plasma, ranging from <1ng/ml to 10s of 
mgs/ml, which is 12 orders of magnitude (168) Other reasons relate to the fact that over 
99% of serum is composed of 22 highly abundant proteins and thus obscure the lower 
abundant proteins of biological interest.  Even following the immunodepletion of such 
proteins, there are still 8-10 orders of magnitude of plasma to analyze which far exceeds 
the capabilities of current proteomic technologies, which cover 4 orders of magnitude 
(168).  Adding an immunodepletion step can however lead to the loss of less abundant 
proteins, resulting in the decline of reliable information and discrepancies between 
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samples.  Lastly proteins are dynamic and can be modified by cleavage or by the 
addition of new functional groups that may affect their detection (168).   
It appears that there are many challenges to overcome when studying proteomics.  To 
overcome these issues, effective sample preparation is required to reduce complexity 
and to enrich lower abundance proteins of biological interest whilst depleting the most 
abundant ones along with state-of-the-art instrumentation, extensive data processing and 
data analysis.  The theory behind all of the aforementioned tools will be reviewed and 
appraised within the following sections of this thesis.  
Proteomic analysis does however have a number of inherent advantages over genomic 
analysis (169): 
1. The identified protein is the biological endpoint 
2. It provides complete information on all cellular functions, as proteins not genes 
govern these. 
3. The proteome is dynamic and is in constant flux because of a combination of 
factors, including post-translational modifications. 
4. mRNA expression does not always correlate with protein concentration.   Many 
factors aside from mRNA abundance determine protein expression and it is 
therefore necessary to study proteins (170,171) 
5. Proteomics is the study of the complete proteome complement, which includes 
protein expression patterns, protein interactions within cells and functional states 
including post-translational modifications.   
Studies of protein expression using proteomic platforms, especially in the field of 
biomarker discovery are therefore gaining popularity as they identify proteins 
modified or unmodified, which are involved in disease progression, and are 
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therefore allowing researchers to understand the mechanisms that underpin many 
diseases. 
1.3.2  Proteomic analysis  
1.3.2.1  Introduction to quantitative proteomics 
Proteomic analysis can be classified into 3 main categories (See Figure 2) 
1. Expression proteomics including quantitative proteomics 
2. Functional proteomics 
3. Structural proteomics  
Expression proteomics identifies proteins in different states and differentially 
expressed proteins in related samples for instance healthy versus disease. It includes 
quantitative proteomics, which can determine differential protein abundance.  
Expression proteomics does not provide information on the proteins cellular 
function, which includes the analysis of post-translational modifications for 
instance. This is within the remit of functional proteomics. Structural proteomics 
can determine not only the structure of proteins but also how proteins interact.  This 
thesis involves predominantly quantitative proteomics.  A small section is included 
on functional proteomics, in particular looking at glycosylation as a post-
translational modification (Section 2.0). 
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Figure 2: Proteomic categories 
Reproduced from Kondethimmanahalli Chandramouli. Proteomics: Challenges, 
Techniques and Possibilities to Overcome Biological Sample Complexity. Hum 
Genomics Proteomics January - December 2009 vol. 1 no. 1 239204 
1.3.2.2  Separation step of quantitative proteomics 
Quantitative proteomics involves a separation and sometimes a fractionation step, 
followed by an identification step.  Separation and fractionation steps are initially 
undertaken to reduce the complexity of the biological sample under investigation and 
therefore allow identification of a larger number of lower abundance proteins of 
interest. 
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The separation step can be undertaken at the protein or peptide level, and usually 
involves a gel such as 2D OR 2D DIGE, or non-gel based method such as Capillary 
electrophoresis (CE) or High Performance Liquid Chromatography (HPLC).   The 
quantitative platform can be label free or label based, where the latter can be further 
divided into chemical (ITRAQ and ICAT) or metabolic (SILAC) labelling mass 
spectrometry based strategies.  All of the above strategies will be discussed in detail 
later. 
1.3.2.3   Protein identification step of quantitative proteomics 
Regardless of the method of separation, protein identification is performed by Mass 
spectrometry (MS).   There are a number of strategies to identify proteins by mass 
spectrometry (See Figure 3) 
1. Top down mass spectrometry – Analyses the intact protein by MS following 
separation. 
2. Bottom up mass spectrometry or shotgun proteomics – Is an MS approach 
which, analyses peptides following the proteolytic digestion of proteins. 
3. MuDPIT – Is a further strategy utilized in shotgun proteomics whereby the 
resultant peptide mixture is fractionated in one- or two-dimensions. This will be 
discussed further in the fractionation section (Section 1.8). 
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Figure 3: Bottom Up and Top Down proteomics 
 Reproduced from G.Scherperel.  Emerging methods in proteomics: top-down protein 
characterization by multistage mass spectrometry.  Analyst 2007,132,500-506 
1.3.2.3.1  Top down mass spectrometry 
As previously alluded to, top down proteomics is a technology which measures the 
molecular masses of intact proteins.  This approach is well suited to the analysis of 
protein modifications, in particular post-translational modifications, as the structural 
characteristics  of  the  protein  are  preserved,  as  it  obviates  the  proteolytic  step.      The  “top  
part”   involves  measuring   the  molecular  weight   of   the   intact   protein   and   comparing   it  
with a value predicted by the genomic sequence, which will reveal any modifications in 
the  protein.    The  “down  part”  involves  selecting  the  modified  section  of  protein  through  
gas phase separation, inducing fragmentation of it, and then mapping of the 
modification site.   The determination of intact protein masses, and also the generation 
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of multiply charged ions through such methods, is often difficult and time consuming to 
analyze, therefore variants of this method have been developed, using fractionation, 
dissociation techniques or instruments with high mass accuracy to circumvent these 
problems.  Other limitations of this approach are (172): 
1. Difficult to analyze intact proteins larger than 50kDa 
2. Difficult to couple separation techniques with this approach  
3. Protein dissociation mechanisms are poorly understood 
4. Poorly developed bioinformatics tools 
1.3.2.3.2  Bottom up mass spectrometry/Shotgun proteomics 
Proteomics depends upon identifying the sequence of a protein normally with MS.  MS 
is much better at analyzing peptides compared with proteins. The basis of the bottom up 
approach is therefore to digest proteins in gel or in solution, normally with trypsin, to 
generate peptides suitable for MS analysis.   
Trypsin is a serine protease, which cleaves protein chains mainly at the carboxyl side of 
arginine and lysine residues, except if either is followed by prolene (173).  Trypsin is 
preferentially used in MS based proteomics as it cleaves proteins into a size which is 
acceptable for MS analysis, its specific, the cleavage products are charged making MS 
analysis possible, and lastly its tolerant of many of the additives used in MS 
methodology (173).   Other proteases such as Lys-C and Asp-N produce larger 
fragments and are also less biologically active when compared to trypsin.  A major 
drawback of trypsin is however its inability to properly cleave hydrophobic proteins 
especially membrane proteins, which are often identified at low levels or not at all in 
many MS proteomic studies (173). 
Bottom up MS experiments can be performed using either of 2 methodologies (174) 
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1. Peptide Mass Fingerprinting (PMF) – This analytical method measures the exact 
molecular masses of the peptides that are generated from cleavage of the protein 
mixture.  MS analysis of the peptides generates a peak list of molecular masses, 
which is then compared against a protein sequence database, which has 
translated the genome of a certain species into a list of proteins.   The database 
also theoretically cleaves the translated proteins with the same enzyme used in 
the experiment.  This theoretical mass is then compared with the peak list of 
masses and the unknown sample proteins are identified.   An ID will only be 
made if the protein sequence is present in the database, which is 1 of the 
drawbacks of this approach 
2. Shotgun proteomics – Compared to PMF, this approach achieves protein 
identification by 2 stages of data acquisition.  Firstly by measuring the 
molecular mass of the peptides, and secondly by partially sequencing selected 
peptides using tandem MS. In the first stage an m/z value is obtained for all the 
peptides contained within the analyte.  The spectrum containing this data is 
called the survey or MS1 scan.  The ions generated during this stage are known 
as precursor ions.  The second stage involves selecting certain precursor ions 
based on their relative abundance or within a certain mass range, fragmenting 
these pre-selected ions to generate product ions, which are then displayed in an 
MS2 or tandem mass spectra.  Product ions are the result of the fragmentation of 
peptide bonds within the precursor ions, to generate ions that differ in mass by 
the mass of an amino acid.  Product ions containing the N-terminus are called b 
ions, whilst those containing only the C-terminus are termed y ions.  
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Fragmentation methods are discussed later within the introduction (Section 
1.6.5). 
A further element of shotgun proteomics, which can maximize protein 
identification, is fractionation.  Fractionation can be employed to overcome 
complexity of the sample being analyzed and also the dynamic abundance range 
that can be encountered for example in serum. Fractionation can be performed at 
the protein or the peptide level.  MUDPIT (175,176) is a specific form of 
peptide fractionation, which uses 2 dimensions of fractionation such as strong 
cation exchange as the initial phase then reverse phase chromatography as the 
subsequent phase.  Fractionation will be discussed in detail later in the 
introduction (Section 1.8). 
Advantages  of  the  “bottom up”  approach  are  (174);; 
1. It’s  a  well  developed and recognized methodology 
2. Good bioinformatics tools are readily available 
3. It can be easily coupled with separation methods 
4. It can analyze complex mixtures such as serum 
5. The digestion of proteins to peptides overcomes problems with instability and 
solubility that present when analyzing intact proteins.   
6. Shotgun proteomics is well suited to chemical modifications that aid 
quantification such as ITRAQ 
Limitations of the “bottom  up” approach are (174): 
1. Peptides that are shared by 2 or more proteins maybe difficult to identify 
2. Identification is possible but whole sequence coverage and complete protein 
characterization is not always possible however. 
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3. The sample requires to be relatively pure and in large enough quantities to 
enable subsequent analysis 
4. Dynamic range of some analytes such as serum is difficult to overcome.  
Sampling of lower abundance proteins is therefore often difficult 
5. Protein ID may not be possible if PTMs are not accounted for during database 
searching  
1.4 Sample collection and storage in quantitative 
proteomics 
Proteomics involves studying and characterizing proteins in all physiological and 
pathological conditions as previously alluded to.  To investigate such a complex 
environment a number of important steps must be undertaken to ensure that accurate 
and reproducible results are obtained.  The methodology is obviously an integral part of 
such, but even simple measures such as the handling and storage of the biological fluid 
being investigated can affect protein profiling via mass spectrometry.  Sample 
collection, handling and storage have been shown to have significant effects on the 
proteome (177,178).  This is further supported by the fact that despite different research 
groups using similar MS analytical platforms disease biomarker reproducibility is low 
(177,178).  Factors that have the greatest effect include the type of anticoagulant used 
during sample collection, time between phlebotomy and centrifugation and the time 
taken between separation of plasma and serum from whole blood (177,178). 
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1.5  Quantitative proteomics – Separation techniques 
The characterization and quantification of proteins and peptides within a multifaceted 
mixture by mass spectrometry is often difficult, largely due to the dynamic range of 
proteins in body fluids.  To reduce the complexity of such mixtures a separation step is 
often undertaken prior the identification process by mass spectrometry to ensure that all 
the polypeptides within the sample are analyzed.  Both gel and non-gel based separation 
steps, can be coupled with mass spectrometry in proteomic studies and will be 
introduced below. High performance liquid chromatography (HPLC) and in particular 
RP-HPLC was the separation method of choice for this proteomic study for the reasons 
outlined below. 
1.5.1   Gel based  
Gel electrophoresis is one of the most widespread separation strategies used and it 
involves using two different properties of the protein for separation - the isoelectric 
point and molecular mass. There are however several limitations of this methodology: 
1. It has low detection and linearity 
2. Membrane proteins are poorly soluble in such media 
3. Limited loading capacity 
4. Labor intensive so relatively low throughput 
5. Total proteome coverage is limited to proteins with molecular weights in 10-
200KDa ranges with neutral or acidic isoelectric points.   
6. Proteins with a pH>9.5 are difficult to focus. 
7. Low abundance proteins difficult to detect (179,180). 
 54 
Some of these limitations have been circumvented by the development of multiplexing 
methods such as fluorescent 2D difference in gel electrophoresis (2D DIGE).  The dyes 
label  the  ε-amine groups of lysines, specifically to form an amide (179).  Different dyes 
are independently introduced into control and disease mixtures, after such the samples 
are resolved on a 2D gel.  The dyes have the same molecular weight and charge and 
therefore similar proteins in different samples have the same relative 2D mobility (179).  
The protein patterns are visualized by illuminating the gel at different excitation 
wavelengths (179).  The gels are then analyzed using specific software and selected 
spots of interest are then excised and finally analyzed via mass spectrometry.  
Advantages of this 2D DIGE approach include 
1. A reduction in variability through its ability to display more than 2 protein 
mixtures 
2. It is quantitative 
3. It has a much lower range of sensitivity 
4. It has a linear range of 4-5 orders of magnitude compared to other colorimetric 
methods which have 1-2 (179-181) 
2D DIGE has been used in the search for protein biomarkers in both oesophageal and 
breast cancer, however some of the limitations presented by conventional 2DGE has 
also been encountered using 2D DIGE in such studies (182,183) 
Because of the low resolution of 2D DIGE, bias against membrane proteins and its 
ability to visualize only high abundance proteins has meant that non-gel approaches are 
gaining popularity.   
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1.5.2   Non gel based separation techniques 
1.5.2.1   Capillary Electrophoresis (CE) 
In essence all electrophoretic techniques separate peptide ions based on their migration 
rate within an electric field.  By applying an electric field to an electrolyte fluid filled 
capillary, sample ions will migrate, as an electro-osmotic flow is generated.    The 
migration of these ions is based upon the differences in charge and radius of the ion as 
well as the viscosity, a relationship that can be explained by the electrophoretic mobility 
(184).  The rate at which the ions move is directly proportional to the strength of the 
applied electric field, charge state and size of the ion.   Therefore the greater the voltage, 
the higher the charge state or the smaller the size the faster the ions will travel.  CE 
methods can be separated into whether they have a continuous or discontinuous 
electrolyte system, the former can be further subdivided into whether a kinetic or steady 
state process is accomplished (185).  The continuous CE system has an unchanged 
electrolyte buffer throughout the capillary, which can be constant (steady state) or 
varying (kinetic) in composition (185).  In a discontinuous system the analyte will move 
between a number of different electrolytes (185). 
Advantages of CE (186) 
1. Fast separation 
2. Optimum separation of small sample volumes 
3. High resolution 
4. No gradient is required therefore the ideal parameters can be achieved 
throughout the whole separation process 
5. Compatible with all buffers 
6. Relatively inexpensive to perform 
 56 
Disadvantages of CE (186) 
1. Difficult to interface with downstream MS analysis 
2. Only small volumes can be loaded and therefore sensitive detection can be 
difficult 
1.5.2.2   Liquid Chromatography (LC) 
Chromatography involves the separation of a complex mixture through the interaction 
of the sample constituents with a mobile and stationary phase.  The mobile phase is 
normally a liquid or gas (Liquid or Gas chromatography respectively), the solid phase 
silica or alumni column.  The sample is dissolved with the mobile phase and then flows 
through the solid phase relaying the sample with it.   Separation occurs thereafter 
because of the equilibrium distribution of molecules between the stationary phase and 
the mobile phase, allowing molecules to therefore differentially migrate.  The speed at 
which a molecule migrates through the column is therefore dependent upon the number 
of molecules in the stationary phase and its predilection for the stationary phase.  
Components are preferentially attracted to the stationary phase depending upon their 
polarity, structure and solubility.  Molecules, which are predominantly found in the 
mobile phase, will move through the column fastest, whilst those found in the stationary 
phase principally, will move slowest.  The time taken for an analyte to move through 
the stationary phase is termed the retention time. In summary the migration of analytes 
is therefore dependent upon the distribution of molecules between the stationary and 
mobile phases which is determined by 
1. The composition of the mobile and stationary phases 
2. The polarity of the mobile phase 
3. Separation temperature 
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4. Column pressure 
Separation is represented diagrammatically by a chromatogram where the x-axis is the 
retention time and the y-axis corresponds to the detector signal.  The resultant peaks 
depicted on the chromatogram are Gaussian shaped.  Optimal separation is depicted by 
sharp narrow symmetrical peaks, and also by large separation between peaks.  
Resolution is the ability to separate 2 chromatographic peaks, selectivity is the distance 
between the 2 peaks or a ratio of 2 analytes retention times.   
Optimal chromatographic separation can be explained by 2 theories - the plate theory 
(187) and the rate theory (188).  The Plate theory views the column as being separated 
into a number of theoretical plates.  A theoretical plate is a sector within the column 
where the solid and mobile phase can establish equilibrium with each other.  Separation 
of the analyte occurs because the mobile phase moves from 1 plate to the next. The 
efficiency of separation proposed by this theory is dependent upon the number of plates 
and also the height (Height equivalent of the theoretical plate) of the plates.  Proficiency 
improves with a greater number of plates and also a smaller plate height.  The factors 
which determine plate number, include (189) 
1. Column length 
2. Stationary phase particle size – This is perhaps the most important factor.  The 
smaller the particle size, the greater the plate number thus the greater the 
separation efficiency. 
3. Packing quality 
4. Flow 
5. Instrument quality 
6. Retention factor 
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The rate theory explains the relationship between the plate height and the flow of the 
mobile phase.  The rate theory takes into account the time taken for the analyte to 
equilibrate between the stationary and mobile phase as opposed to the plate theory, 
which does not. The resultant shape of chromatogram is therefore dependent on the rate 
of elution and also by the mechanisms, which can lead to peak broadening.  The 
mechanisms by which peak broadening can occur is explained by the Van Deemter  
Equation (188): 
H = A + B / u + C u 
H = Height of the theoretical plate 
A = Eddy diffusion 
B = Longitudinal diffusion 
C = Resistance to mass transfer 
U = Average velocity of the mobile phase 
1. Eddy Diffusion – The flow of analytes through the stationary phase is not 
straight and thus different paths are taken by each solute.   The paths are of 
different lengths, meaning differences in retention time will occur.  Factors 
which affect the Eddy diffusion include (189): 
1. Particle size 
2. Particle shape 
3. Particle structure 
4. Quality of the column packing 
2. Longitudinal diffusion – Explains the diffusion of analytes through the mobile 
phase along the longitudinal axis of the solid phase.  The concentration of the 
analyte is less at the periphery compared to the center of the mobile phase 
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therefore a concentration gradient exists along which diffusion can occur.    If 
the velocity of the mobile phase is high, the analyte spends less time on the 
column and thus the longitudinal diffusion is less. 
Factors that affect longitudinal diffusion are: (189) 
1. Velocity of the mobile phase 
2. Viscosity of the mobile phase 
3. Temperature 
4. Analyte type 
3. Resistance to mass transfer – The transfer of analytes between the mobile and 
solid phase occurs constantly throughout separation to maintain equilibrium.  
The time taken for analytes to pass between phases is dependent upon their 
location within the solid phase at time X and the distance they have to travel to 
maintain equipoise.  If the velocity of the mobile phase is high, and the analyte 
has a preference for the solid phase, the analyte in the mobile phase will move 
ahead of that in the stationary phase leading to broadening of the peak. 
Factors that can affect this parameter include (189) 
1. Particle size 
2. Viscosity and velocity of the mobile phase 
3. Diffusion coefficient  
4. Porosity of the packing 
5. Temperature 
There are a number of different types of liquid chromatography.  The type of 
chromatography that I have concentrated on in this proteomic project, for the reasons 
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outlined below, is Reverse Phase High performance Liquid Chromatography (RP-
HPLC).   
Standard LC has a number of shortcomings, namely 
1. Operational pressures are low thus separation is time consuming 
2. Larger columns are required  
3. Larger sample volumes are necessary 
Normal phase chromatography uses a non-polar mobile phase and a polar solid phase, 
as opposed to RP-LC, which has a non-polar/hydrophobic solid phase and a 
polar/hydrophilic mobile phase.  In RP-LC therefore the retention times for polar 
molecules are shorter, and for non-polar they are longer.  The advantages of RP-LC are 
1. Allows the analysis of highly charge ions 
2. Good resolving power 
The introduction of HPLC which uses high pressure, smaller column dimensions, 
smaller column particle sizes and shorter columns has circumvented many of the 
drawbacks associated with standard LC making it the most popular chromatographic 
separation technique. 
1.6 Protein identification in quantitative proteomics – 
Mass Spectrometry 
1.6.1   Introduction to mass spectrometry 
Mass spectrometry has become an integral part of biomarker discovery, largely because 
advances in MS proteomics has meant that the search for protein markers over or under 
expressed in various disease processes is now possible.  MS analysis of biological fluids 
has been shown to be fast, reproducible and can record an expression pattern associated 
with the disease rather than just single proteins.  For example by analyzing the serum of 
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patients with prostate cancer, specific and sensitive identification of a protein 
expression pattern was possible in >80% of individuals (190,191).   
Mass spectrometry is essentially a technique for determining the mass, composition and 
structure of an analyte by ionizing the compound and then measuring the mass to charge 
ratio (m/z) of the charged particles that are generated.  When applied to proteomics 
research mass spectrometry has the capability to not only identify but also quantify 
proteins within the given analyte. 
A mass spectrometer can be divided into 3 fundamental parts: 
1. Ion source 
2. Mass analyzer 
3. Detector 
All of which will be discussed in the sections below. 
1.6.2   Ion source 
Ionization is the process by which molecules are converted into ions by the addition or 
removal of electrons.  Whilst desorption is the process by which ions are converted 
from a liquid into a gas phase.  The purpose of the ionization source is to therefore 
generate negatively or positively charged ions in the gas phase that can then be 
separated in the mass analyzer.  Molecules are ionized as they are easier to manipulate 
through the mass spectrometer as compared to neutral molecules.  If the sample has a 
functional group that accepts protons, positive ionization is used.  Protonation is 
achieved by the addition of formic acid to the sample and the buffers.   Proteins and 
peptides are normally analyzed in this way.   Carbohydrates or DNA are normally 
analyzed under negative ionization conditions, as they have a functional group that loses 
protons.  Deprotonation is achieved through the addition of a volatile amine or ammonia 
 62 
solution.  The sample can then be either directly injected into the ionization source or 
can be coupled to a separation method such as HPLC or CE.  The complexity of the 
sample and the type of ionization source used dictates this.  There are many different 
types of ionization source depending upon whether the sample being analyzed is 
volatile, thermally labile, the complexity of the sample and also the molecular masses of 
the analytes.  Some ionization methods can also cause extensive fragmentation and are 
therefore not suitable as is the case for  proteins  and  peptides.    Two  “softer”   ionization 
methods commonly used in MS proteomics are 
1. Electrospray Ionization (ESI) – Fenn 1998 
2. Matrix Assisted Laser Desorption Ionization (MALDI) – Karas 1987 
Both will be discussed further. 
1.6.2.1   ESI 
J.Fenn first coupled ESI with MS (192) in the 1980s, for which he later received the 
Nobel Prize in Chemistry in 2002.  In ESI the sample is initially dissolved in a polar and 
highly volatile solution.  The resultant sample is then passed through a steel capillary at 
atmospheric pressure, with a strong voltage applied to the tip of it.  The actual voltage 
that requires to be applied depends upon the capillary diameter and the solvent being 
used.  The effect of the electric field generates an aerosol of highly singly or multiply 
charged particles.  Depending on the polarity of the electric field, resultant particles 
(protons if a positive potential) will accumulate.  Once the force from the electric field 
equates to the surface tension of the liquid a Taylor Cone is formed.  A droplet is 
formed when the force from the electric field exceeds the surface tension.  Solvent 
 63 
evaporation from the charged droplet is facilitated by the capillary needle being heated, 
or by use of a nebulizing gas such as nitrogen.  Evaporation of the solvent leads to a 
reduction in a diameter of the droplet to a point where the magnitude of the droplets 
charge can overcome the surface tension holding it together, this is known as the 
Rayleigh limit.  When this is exceeded Coulomb explosion will occur, leading to 
dispersion of the droplets into smaller entities.  This fission process continues until the 
charge state of the droplet becomes too low.  During each fission the droplet will lose 1-
2.3% of it mass and 10-18% of its charge (193,194).   The process by which these 
smaller droplets finally become gas phase ions can be explained by 1of 2 theories (See 
Figure 4) 
1. Charge residue model – Dole et al (195) suggested that gas phase ions are 
generated when enough fission cycles have been performed so that each droplet 
contains only 1 ion. 
2. Ion evaporation model – Iribrane and Thomson (196) suggested that upon the 
droplet reaching a certain size, the droplets can undergo desorption directly 
emitting the ions. 
The ions, which result from either of these 2 processes, can then pass into the mass 
analyzer by virtue of the potential and pressure gradient that exists. 
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Figure 4: Processes by which gas phase ions are generated 
Reproduced from http://www.jic.ac.uk/services/proteomics/electrospray.htm 
A low flow rate version of ESI was developed by Wilm et al in 1996 (197), and was 
termed Nano-spray ionization.  It uses silica capillaries that are 20um in diameter 
instead of steel capillaries, which have an internal diameter of 100um, as used in 
conventional ESI.  Using the aforementioned features has meant less of the sample is 
consumed and smaller droplets are initially formed, enhancing the overall ionization 
process.  A common application of Nano-spray ionization is in the study of peptides.   
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The advantages of ESI are numerous 
1. The intact analyte is measured compared to other ionization process which can 
cause extensive fragmentation of the sample  
2. Can be coupled with separation techniques 
3. Can analyze large molecules 
4. Can produce multiply charged ions, which can allow for the analysis of heavy 
molecular weight species.   
5. Using ESI a mass accuracy within 0.01% can be achieved (198) 
The disadvantages of ESI are  
1. Strongly affected by detergents and salts 
2. Susceptible to suppression effects.  When using ESI to analyze a complex 
mixture, ion formation of lower concentration analytes can be hampered. 
3. Requires manual tuning  
4. The resultant spectra are often difficult to analyze 
ESI is used within the scope of this thesis for the reasons stated above. 
16.2.2  MALDI 
Karas and Hillenkamp developed MALDI in 1988 (199).   MALDI is especially useful 
in the analysis of compounds, which are thermo labile, volatile and contain anlaytes 
with large molecular masses.   MALDI essentially generates ions from a solid state by 
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bombarding the sample with laser light.   Initially the sample is combined with a 
volatile solvent then with a UV absorbent matrix.  An excess of matrix is added to 
ensure absorption of the laser energy and also prevent fragmentation of the sample.  The 
sample is spotted onto a MALDI target plate, air-dried, resulting in a crystal lattice 
which encompass the analyte.  There are a number of matrices available, for example 
sinapinic acid which is commonly used for protein analysis or alpha-cyano-4-
hydroxycinnamic for peptide analysis.   Properties of the matrix include its ability to 
absorb energy generated at the laser wavelength, vacuum stability, it must be able to 
crystalize with the sample but at the same time have low chemical reactivity and it must 
be a source of protons.    Upon crystallization, ionization and desorption of the sample 
is induced by short intense pulses of a laser.  The matrix converts this energy into 
excitation energy, which leads to vaporization of the matrix and the generation of singly 
charged ions.  The exact mechanism by which ionization occurs is unknown. 
 
Figure 5 : MALDI-TOF MS sample ionization.   
Reproduced from www.http://ba333.free.fr/khira/Mauritz%20-%20Maldi-
Tof%20Mass%20Spectrometry.pdf 
 67 
Advantages of MALDI (200) 
1. Ionization occurs as discrete events due to the pulsed nature of the lasers, 
therefore subsequent MS analysis can be synchronized, leading to very little 
sample loss 
2. High throughput 
3. Tolerant of salts and buffers 
4. Spectra are relatively easy to interpret as only singly charged ions are generated, 
regardless of molecular mass. 
5. Fragmentation tends not to occur 
6. Easier to use and maintain than ESI 
7. Can generate gas phase ions from large biomolecules 
Disadvantages of MALDI (200) 
1. Only certain MS instruments can be coupled with MALDI 
2. Presence of matrix produces some noise at the lower end of the mass spectrum 
and can therefore prevent the identity of lower molecular weight species 
3. Not quantitative 
4. Majority of the energy is used to excite the matrix rather than ions 
5. Difficult to find suitable matrices 
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6. Although tolerant of salts, it can be sensitive to trace amounts of buffer salts that 
can interfere with resultant spectra 
1.6.3   Mass Analyzer 
Following production of the ions the mass analyzer separates the ions using an 
electromagnetic field.  According to Newton’s 2nd law of motion and The Lorentz force 
law, ion motion through generation of this force, is dependent upon both the mass and 
charge of the ion.  A mass spectrometer therefore doesn’t  directly  measure  mass  but  a  
combination of these 2 parameters, the charge state (z) and the mass (m) or the m/z 
ratio. 
Mass analyzers can be grouped according to their properties, with the underlying basic 
function to separate ions based on the m/z.  Analyzers can also be classified according 
to the scanning mode i.e. whether ions are scanned dependent on their m/z or not, the 
beam type, if it is a trapping instrument, if it is a continuous or pulsed analyzer and 
finally if the induced fragmentation is high or low energy.  Often 2 mass analyzers are 
coupled together to achieve the best results. 
 There are a number of important characteristics of a mass analyzer  
1. Its upper mass limit – This is the highest mass (m/z ratio) that can be analyzed 
2. Transmission – which is the ratio between the number of ions generated and the 
number reaching the source.  It is expressed in atomic mass units (amu) 
3. Resolution – The ability of the mass analyzer to resolve 2 adjacent peaks. It is 
defined as m/Δm,  where  m  is  the  mass  of  the  peaks  being  resolved  and  Δm  is  the  
mass difference between the peaks.  The resolving power of the mass analyzer is 
its ability to yield 2 distinct signals for 2 ions that have a similar or a small 
molecular mass difference. 
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4. Mass accuracy – Is the error between the m/z measurement and the theoretical 
m/z value.  It is measured in ppm. 
There are 4 types of mass analyzer commonly used in MS proteomics today and each 
will be discussed further below.   All differ considerably in in their resolution, mass 
accuracy and sensitivity.   
1.6.3.1   Time of Flight (TOF) 
In a TOF analyzer (see Figure 6) ions are separated according to velocity.  Ion velocities 
are inversely related to the square root of the m/z value.  Thus ions with a lower m/z 
will achieve a higher velocity, whilst those with a higher m/z value achieve lower 
velocities.  Using a set amount of kinetic energy ions are accelerated over a fixed 
distance to the detector at a known time.  The m/z value can then derived by calculating 
the length of time taken for the ion to move from the source to the detector, since the 
ions all have the same energy.  This describes a linear TOF.  A more sophisticated TOF 
analyzer has a reflectron added. The purpose of the reflectron is to compensate for ions 
with similar m/z values having slightly different velocities and also having different 
starting times, in essence it enhances resolution.  Typically TOF analyzers are coupled 
with MALDI. 
Advantages of TOF mass analyzers (201,202) 
1. Easy to understand 
2. High m/z range 
3. High transmission, therefore high sensitivity 
4. Fast 
Disadvantages of TOF mass analyzers (201,202) 
1. Require a pulse of ions rather than a continuous flux  
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2. Limited MS/MS ability  
3. Poorest mass resolution 
 
Figure 6: TOF mass analyzer 
Reproduced from http://what-when-how.com/proteomics/time-of-flight-mass-
spectrometry-proteomics. 
Basic configurations of time-of-flight mass spectrometers: (a) a simple linear TOF mass 
analyzer with a single-stage ionization source, (b) a reflectron TOF mass analyzer with 
a dual-stage ion extraction source, and (c) an orthogonal acceleration mass analyzer 
with a quadrupole ion guide and a dual-stage reflectron 
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1.6.3.2   Quadrapole 
Ion motion in a quadrapole mass analyzer is the result of a radiofrequency electric field 
(See Figure 7).  4 cylindrical rods that are set parallel to each other generate the field. A 
radiofrequency voltage is then applied between a pair of rods with a dc voltage 
superimposed.  For a given DC voltage and RF value only ions with a certain m/z will 
have a stable trajectory through the quadrapoles whilst all the others will collide with 
the rods and never reach the detector.   The movement of ions in a quadrapole mass 
analyzer is therefore not dependent on kinetic energy but on the m/z value.  Altering the 
magnitude of the RF and dc voltage produces a mass spectrum. 
Advantages of a quadrapole mass analyzer (201,202) 
1. Uses much lower voltages to accelerate the ions 
2. Smaller instrument 
3. Excels in quantification 
Disadvantages of the quadrapole mass analyzer 
1. Lower resolution 
2. Not suitable for pulsed ionization methods 
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Figure 7: Quadrapole mass analyzer 
Reproduced from http://www.doping.chuv.ch/en/lad_home/lad-prestations-
laboratoire/lad-prestations-laboratoire-appareils/lad-prestations-laboratoire-appareils-
ms.htm. 
1.6.3.3   Ion Trap 
1.6.3.3.1  Quadrapole Ion Trap 
The quadrapole ion trap was invented by Wolfgang Paul, for which he won the Nobel 
Prize in Physics in 1989 (203).  The quadrapole ion trap can be of a linear or 3D type, 
with the former having the ability to store more ions.  Ion traps work on the basis of 
Paul’s  principles  so  they  are  often  referred  to  as  Paul’s  traps. 
The quadrapole ion trap is conceptually similar to the quadrapole mass analyzer but 
instead the quadraploes are bent to form a closed loop.  Unlike quardapole instruments 
where the movement and detection of ions is achieved by altering the potential so that 
only certain ions are selected, in the quadrapole ion trap, the ions are trapped and 
expelled according to their m/z.  Ions are trapped through the generation of an electric 
field in 3 dimensions x,y and z.  This is in contrast to the quadrapole mass analyzer 
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where an electric field is generated in 2 dimensions, x and y, and ions move 
perpendicular to this field in the z direction.  The trapping efficiency is enhanced by a 
constant flow of gas, usually nitrogen or helium, meaning that this type of analyzer 
operates at high pressure.  The constant flux of gas also helps to improve resolution and 
also in the fragmentation of ions in collision induced dissociation (CID), which is the 
technology employed in the linear ion trap, the Orbitrap.  
To generate a mass spectrum the movement of ions in a quadrapole ion trap is unstable, 
whilst the trajectory of ions in a quadrapole mass analyzer requires being stable.  Ions 
become unstable in a mass dependent manner by altering the Rf voltage.   The motion 
of ions in the field generated by a quadrapole ion trap can be explained by the Mathieu 
stability equation.   
Ion traps have a similar m/z range and resolution to a quadrapole mass analyzer.  The 
resolution can however be improved by reducing the Rf voltage scan rates without 
losing any sensitivity (204,205).  The mass accuracy is hundreds of ppm. 
Advantages (201,202) 
1. High sensitivity 
2. Compressed mass analyzer 
3. Can perform multiple stages of MS 
Disadvantages 
1. Operate at high pressure.  
2. Quality of the mass spectrum is affected by parameters such as excitation, 
trapping etc. 
 74 
 
Figure 8: Quadrapole Ion trap.   
Reproduced from  
http://www.fpiinc.com:8599/web/en/mars6100;jsessionid=54DD29BE34B03626AB97
A86528847DB5 
1.6.3.3.2  Kingdon Ion Trap  
The Kingdon ion trap was described in the 1920s by K.H.Kingdon (206).  The Orbitrap 
mass analyzer invented by Makarov (which is predominantly utilized in this thesis 
project) descends from the principles of the Kingdon trap.  Trapping in a Kingdon trap 
is achieved through the generation of an electrostatic field without the need for either 
magnetic or dynamic electric fields. In the Kingdon trap, applying a DC voltage 
between an outer cylindrical electrode and a central thin wire electrode generates a 
radial electric potential.   Stable movement of ions within this, is achieved if the ions are 
created within the trap or if the velocity of the ions introduced is perpendicular to the 
wire electrode (207). The electrodes in the Orbitrap mass analyzer are specifically 
configured so that the outer electrode is barrel shaped and the inner spindle shaped, the 
resultant effect is the generation of an electrostatic field with quadra-logarithmic 
potential distribution (208).  Ions are trapped because both centrifugal and centripetal 
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forces balance their electrostatic attraction to the inner electrode.  Ion motion in an 
Orbitrap mass analyzer is both circular and oscillatory along the z-axis.  The ion 
trajectory is circular because of the interaction of the two aforementioned forces and the 
electrostatic field, and oscillatory because firstly the field strength varies along the z-
axis  and  secondly  the  direction  of  the  electric  field  isn’t  parallel  at  different  points  along  
the z-axis (208).  The outer electrode detects the oscillating frequency of the ions as an 
image current, which is a direct measure of the mass of the ions.  The high resolving 
power of the Orbitrap can be attributed to the fact that the oscillating frequency is 
directly representative of the mass of the ions and is independent of other factors such 
as the spread of the ions or their kinetic energy.    Other advantages include (209) 
1. Low mass deviation, < 3 ppm 
2.  Higher ion trapping capacity compared to traditional quadrapole mass analyzer 
3. High sensitivity 
4. High resolution 
5. Fast scan speeds 
A special or unique feature of the Orbitrap mass analyzer is the C trap (as depicted 
in Figure 9), which essentially stores and then injects ions.  The C trap or curved 
linear trap device allows for efficient injection of ions into the Orbitrap. The C trap 
presses the ions according to time and space and then moves them into the trap 
through the Z lens. 
Thermo Fisher Scientific makes the Orbitrap analyzer commercially available.  It is 
a hybrid instrument as it contains more than 1 type of mass analyzer – Orbitrap and 
ion trap.  The Orbitrap acquires the full scans whilst the ion trap simultaneously 
selects, isolates and fragments the most abundant peptides.  It is constructed in this 
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manner to increase the duty cycle and to allow the Orbitrap to acquire an MS 
spectrum whilst the linear ion trap induces a number of CID fragmentations.  The 
latest instrument the LTQ Orbitrap Velos (See Figure 9) has 2 modifications that 
have led to superior MS data acquisition. Firstly it consists of 2 ion traps at 
differential pressures – 1 is operated at low pressure the other at a high pressure.  
Secondly it has the added addition of an S-lens, which enables superior transmission 
of ions, faster scan times and increased sensitivity.  The benefits of the LTQ velos 
include 
1. Ion traps are typically operated at a single pressure.  The ion traps in the LTQ 
velos are operated at different pressures.  By operating 1 at a higher pressure 
trapping and fragmentation efficiency is improved.  Whilst the other lower 
pressure trap increases scan speed. 
2. Improved identification of low level analytes 
3. It has ETD capabilities 
 
 
Figure 9: Orbitrap Mass Spectrometer  
Reproduced from www.thermo.com 
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1.6.3.3.3   Fourier Transform Ion Cyclotron (FTIC)  
FTICR (See Figure 10) utilizes a magnetic field to determine the m/z.  FITCR unlike 
the ion trap analyzer is referred to as a static trap.  The ions trajectory within a magnetic 
field is circular, by generating an intense magnetic field ion velocity becomes slower 
and  they  become  “trapped”  within  this  field.    The  mass  is  determined  by  measuring  the  
cyclotron frequency of the ions circular motion.  By applying an excitation pulse that 
encompasses many cyclotron frequencies different masses can be calculated using the 
Fourier transformation equation.  Advantages of the FITCR (201, 202) 
1. It has the highest mass resolution of any mass analyzer 
2. Well suited for ion chemistry and some MS/MS experiments 
3. Can be coupled to MALDI 
4. Minimal ion destruction 
5. Stable mass calibration 
Limitations of the FITCR mass analyzer 
1. Expensive to buy and run 
2. Limited dynamic range 
3. Operated at low pressures 
4. Not suitable for quantitation as it only has low energy CID capabilities 
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Figure 10: FITCR Mass Analyzer 
Reproduced from http://jlab.chem.yale.edu/research/techniques/fourier-transform-icr 
1.6.4  Detector 
The detector monitors the flux of ions, which pass by or hit it, and records either the 
current or charge induced by such.  The signal is amplified and transmitted to the data 
system to produce a mass spectrum.  The mass spectrum produced is a function of the 
relative intensity of all the ions measured within a defined time versus the m/z value. 
There are a number of detectors that exist and they can be classified as either 
1. Photographic plates and faraday cylinders – Both of which directly measure the 
charge that reaches them 
2. Electron or photon multipliers – Amplify the intensity of the signal that is 
transmitted to it.  The electron multiplier is the commonest detector used. 
1.6.5    Tandem MS/MS 
To identify peptides mass alone will not suffice, therefore peptide ions need to be 
activated and fragmented (211).  Tandem or MS2 mass spectrometry is a method of 
achieving such through the analysis of specific or individual ions within a complex 
mixture, as well as high mass accuracy measurements (212). It nominally involves 2 
stages of MS, combined with a process that causes a change in mass or charge of the 
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selected ion.  A precursor ion is an ion, which has undergone some form of 
transformation or decomposition, the product ion is the ion resulting from this reaction.  
The first stage of MS2 isolates the ion, which is subsequently activated and fragmented, 
and then the second stage separates the fragmented ions according to mass.  The 2 mass 
analyzers are separated by a collision cell, into which an inert gas flows.  The gas 
collides in a process either known as collisional activation (CA) or collision induced 
dissociation (CID) with the selected ions to induce their fragmentation.  The mass 
analyzers can be of the same or different types, and the multiple stages of mass analysis 
can be achieved by separating the former in time or the latter in space.  Tandem Mass 
Spectrometers can therefore be conceived in either of 2ways  -  
1. Tandem Mass Spectrometer in space – The mass analyzers are physically 
separated and distinct but remain connected to maintain the vacuum.  Thus the 
isolation, activation and detection of the peptide ions are all done in different 
analyzers.  Typically TOF or triple quadrapole analyzers are used in such 
configurations.  Drawbacks of this include a limit on the number of MS/MS 
episodes that can be performed as each event requires a further mass analyzer 
with loss of efficiency. 
2. Tandem Mass Spectrometer in time – The isolation, activation, separation and 
detection is achieved by performing a sequence of events over a specified time 
in the same mass analyzer, usually in an ion trap or FT ICR instrument.  The 
number of MS/MS events is not restricted in this way but with increasing 
MS/MS the resultant fragments become smaller with each cycle and hence more 
difficult to analyze.   
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 There are a number of different data acquisition modes that a tandem mass 
spectrometer can operate in to acquire MS2 data.  These include -  
1. Precursor ion scan 
The first analyzer transmits all the sample ions whilst the second monitors specific 
fragment ions.  This is useful for analyzing glycosylated peptides.   
2. Product ion scan 
The first analyzer selects specific precursor ions and then the second analyzer detects all 
the resultant product ions.  This experiment is particularly useful for generating peptide 
sequence information 
3. Neutral loss ion scan 
Consists of selecting a neutral product fragment and detecting all the fragmentation ions 
that result in the loss of the particular fragment. The first analyzer scans all the masses 
and then the second scans for the ions that result from the loss of the fragment. 
Fragmentation of the gas phase ions generated during the 1st and 2nd stages of an MS2 
experiment is essential.  Fragmentation requires being undertaken as the mass of the 
peptide alone will not determine identity.  Fragmentation occurs as a result of an 
increase in the internal energy of the ions, which leads to the breakage of the peptides 
chemical bonds and finally the dissociation of the ions.  The types of fragment ions that 
are detected during an MS/MS experiment is determined by 
1. Instrumentation employed 
2. Amount of energy utilized  
3. How the energy is transferred 
4. Peptide sequence 
5. Charge state 
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The peptides can be fragmented anywhere along their sequence.  Fragments will only be 
detected if they carry at least 1 charge.   If the charge is retained at the N-terminus of 
the fragment, the ions is classified as a, b or c.  If its held on the C terminus its an x, y 
or z ion.  Low energy CID (Collision Induced Dissociation) will generally generate b 
and y ions, HCD (High energy Collision Induced Dissociation) will generate all of the 
aforementioned ions, and ECD (Electron Capture Dissociation)/ETD (Electron Transfer 
Dissociation) will produce c, y and z ions.   
1.6.5.1  CID 
CID is one of the commonest methods of ion dissociation in Tandem Mass 
Spectrometry.  CID involves accelerating the ions to increase their kinetic energy.  
These ions then collide with neutral molecules usually helium, nitrogen or argon.  This 
results in the conversion of the kinetic energy into internal energy, whereby if the latter 
exceeds the former, fissuring of the chemical bonds will occur and the ions will 
fragment.  Fragmentation by CID typically cleaves the peptides at the CO=NH bonds 
thus the resultant spectra are predominantly formed by b and y ions.  The energy 
imparted during CID collisions can be high or low energy.  TOF and magnetic sector 
instruments are capable of high energy CID, whilst quadrapole and trap instruments 
generally employ low energy CID.  High energy CID is generally more reproducible 
than low energy CID.  Although CID is widely utilized there are a number of potential 
drawbacks (213) 
1. Difficulty in fragmenting peptides that are long, have a high charge state and 
comprise of specific amino acid components. 
2. Basic residues can hamper the dissociation process in CID 
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3. Not suitable for the fragmentation of intact proteins or peptides with 
posttranslational modifications such as phosphorylation. 
4. Low mass ion fragments are not retained in the ion trap.  This has therefore 
meant it has limited use in quantitative proteomics especially those that utilize 
iTRAQ. 
1.6.5.2   HCD 
Higher energy collisional dissociation (HCD) is frequently used in conjunction with the 
Orbitrap mass analyzer and circumvents a number of the problems associated with CID.  
The activation times in HCD are shorter and the activation energies higher compared to 
CID.  In this arrangement the ions are stored in the C-trap, fragmented in the HCD cell 
then delivered back into the C-trap before detection in the Orbitrap analyzer.  
Advantages of HCD are 
1. The collision energy used is higher than that used in the CID ion trap meaning 
there is no loss of low mass ion fragments.  It is therefore suitable for iTRAQ 
analysis. 
2. Mass accuracy is at the ppm level 
3. High resolution scanning 
4. Increased ion fragments 
5. Wider range of fragmentation pathways 
One of the main drawbacks of HCD is the requirement for more ions to be evaluated to 
provide comprehensive analysis, when compared to CID fragmentation, thus spectral 
acquisition times are much longer. 
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1.6.5.3   PQD 
Ion fragmentation in an ion trap has been predominantly been undertaken by CID.  As 
previously alluded to, the use of CID fragmentation means that ions with a lower mass 
are not sequenced, as only ions over a certain m/z with a stable trajectory are trapped 
(214).  PQD was therefore developed by Thermofisher Scientific and exclusively used 
in their linear ion trap to overcome such difficulties.  It is a 3-stage process (214) 
1. Short precursor ion activation at a high activation level (Q) using a brief 
excitation pulse 
2. The conversion of kinetic energy to internal energy at a high Q for a short period 
3. The dissociation of the ions as Q is pulsed down by rapidly dropping the RF 
amplitude 
This is in contrast to CID where the activation and dissociation of ions is performed at a 
constant Q.   The main advantage of PQD is that it covers the low mass range and 
therefore can be used for iTRAQ quantitation.  iTRAQ quantitation, which forms the 
basis of this thesis, can be performed in a broad range of instruments including Q-ToF 
and ToF-ToF instruments.  It cannot however be performed in ion traps including 
hybrid machines such as the Orbitrap because of the low mass cut off limitation without 
the use of HCD or PQD.  The use of PQD is however is at the expense of a loss of 
subsequent signal intensity 
1.6.5.4   ETD 
ETD induces fragmentation through the transfer of reagent/radical anions to cations.   
The peptides are cleaved along the backbone and not at side chains or modifications, 
thus producing c and z ions.  Because it relies on radical induced fragmentation along 
the peptide backbone it cannot be used for iTRAQ experiments.  ETD is therefore 
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especially useful for sequencing peptides with post-translational modifications as well 
as for higher charge state ions and longer peptides or even intact proteins, and it doesn’t  
suffer from the low mass cut off that is encountered with CID.  The number of 
subsequent identifications can be however be smaller when compared with CID or HCD 
because of the slower scan rates 
1.6.5.5   ECD 
Induces fragmentation of gas phase ions through their collision with low energy 
electrons.  It is a relatively new technique primarily used in conjunction with FI TCR 
mass analyzers, and its role in tandem MS has therefore not been fully elucidated.  The 
fact that it uses low energy electrons will most likely limit its use in mass spectrometers 
that lack magnetic fields. 
It appears however that it will be particularly useful for sequencing peptides with PTMs 
and fragmenting whole macromolecules.  The mechanism of using low energy electrons 
will however limit its use in mass spectrometers that lack magnetic fields. 
1.7   QUANTITATIVE PROTEOMICS 
Although MS identifies proteins, by omitting the gel visualization step protein 
abundance cannot be determined.  Quantitative data, relative (i.e. the amount of a 
protein in 1 biological state in relation to another) or absolute (i.e. the amount of the 
protein in question) can now easily be obtained by utilizing metabolic i.e. SILAC or 
chemical i.e. ICAT/ITRAQ labelling techniques or now even by non-labelling 
techniques using label free platforms which directly compare 2 proteomes. 
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1.7.1   Metabolic labelling strategies 
1.7.1.1   SILAC  
Stable isotope labelling by amino acids in cell culture (SILAC) has proven to be a 
simple but very powerful tool in quantitative proteomics.  It was first described using 
Saccharomyces Cerevisia grown in media with amino acids containing stable isotopes 
(215,216).  The use of a specific isotopic amino acid rather than a pool of amino acids 
was termed SILAC.  It simply consists of growing 2 cell populations in enriched media, 
with either a light or heavy chain form of an amino acid.  Every peptide that is then 
subsequently generated down stream is separated by the mass difference introduced by 
the label (215).  Utilizing only a single amino acid means that the MS/MS spectra are 
easier to interpret than if a pool of amino acids is incorporated (216).  Recently SILAC 
was applied to a clinical study on prostate cancer, where 60 proteins were found to be 
over expressed and 22 under expressed in highly metastatic prostatic cancer cells, the 
results were subsequently confirmed by western blot analysis (217).  A major drawback 
of SILAC is that only proteins extracted from growing cells can be analyzed and 
therefore it is not practical for any kind of biological sample (215,216).  The advantage 
of SILAC when compared to chemical labelling however is that it does not require any 
special sample processing techniques, and is lower in cost. 
1.7.2   Chemical labelling strategies 
1.7.2.1   ICAT  
A popular method of chemical tagging is the use of an Isotope Coded Affinity Tag 
(ICAT).  It makes use of a chemical label in different isotopic forms, heavy and light 
(218,219).  The reagent consists of a reactive group, which is cysteine directed, a linker 
region, and a biotin group that allows for recovery of the labelled peptide (220).  1 of 
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the isotopes is added to the control sample the other to the test sample, which is then 
combined, digested and analyzed in a mass spectrometer.  The isotopic substitutions do 
not affect the behaviour of the peptides during separation and therefore the same 
peptides from 2 different biological samples are co-eluted and quantified at the same 
time (220).  The mass spectrometer measures the relative abundance of each isotopic 
form and subsequently generates a peptide fingerprint (220).  In this manner a global 
view of protein abundance in 2 different samples can be determined (219).  Another 
advantage of this method is that by labelling only cysteine residues the complexity of 
the sample mixture is substantially reduced (219).  Few studies have however utilized 
this chemical modification method for a number of reasons 
1.  It’s expensive 
2.  Low throughput, due to purification steps required etc. 
3.  Can only compare a limited number of samples, maximum is 8. 
4. Non-specificity and incomplete labelling secondary to protein 
modifications can occur (217-219) 
1.7.2.2   ITRAQ 
iTRAQ is another chemical tagging method that uses the same chemistry, but adds a tag 
that generates a reporter ion in the low-end region of the fragmentation spectrum.  The 
iTRAQ reagent consists of 3 moieties (See Figure 11) (215) 
a. An N-hydroxysuccinimide (NHS) ester group, which links the iTRAQ 
reagent to peptides by reacting with free primary amines at the amini-
termini and lysine side chains. 
b. A balance group 
c. A reporter group 
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Figure 11: Schematic of iTRAQ reagent 
Reproduced from http://proteomique.crchul.ulaval.ca/en/services.html 
The last 2 groups constitute an isobaric tag.  There are 4 tags which produce fragment 
ions of mass 114, 115, 116 or 117 and through the balance group add up to the same 
mass (215, 221).  During MS/MS the reporter group is released and generates an ion 
signal with a distinct mass/charge ratio for each form of iTRAQ label, and thus the 
relative intensities of these ion signals can determine the abundance of the protein 
subsequently.  A standard iTRAQ workflow would involve initially an 
immunodepeltion step, followed by tryptic digestion, labelling, and a pre-fractionation 
step such as strong cation exchange and finally LC with tandem MS/MS analysis.  It has 
a number of advantages over the other quantitation methods previously described: 
1. There is increased analytical throughput as the multiplexing strategy allows for 4 
separately labelled pools of protein to be analyzed 
2. The mass spectrum is simplified due to the isobaric nature of the reagent 
3. It does not rely on the reconstruction of chromatograms as quantification is 
based on reporter ions that fragment during MS/MS. 
4. There are fewer chromatographic steps as compared to ICAT 
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5. It allows for the quantitation of more peptides as amine groups are more 
abundant than cysteinyl sulfhydryl groups. (215, 221) 
This approach is however complex, expensive and often requires being repeated using 
reverse labelling to distinguish between peptides from the 2 states.  iTRAQ has been 
used in a number of different cancer biomarker discovery studies including head and 
neck cancer (222), breast cancer (223), hepatocellular cancer (224), lung cancer (225), 
bladder cancer (226), pancreatic cancer (227) and prostate cancer (228). 
1.7.3   Label free 
Quantitative proteomics can be divided into label and label free approaches.  The use of 
chemical labels such as ITRAQ and ICAT are expensive, require specialized software 
and expertise for subsequent data analysis, only a limited number of samples can be 
assayed at one time and finally not all analytes are suitable for chemical labelling.  
Label free quantitative proteomics is an alternative approach that obviates a number of 
these problems.  More importantly label free proteomics has been shown to provide 
greater coverage of the proteome and its dynamic range (229).  It relies on the principals 
that corresponding peptides from 2 dis-similar biological samples will elute at the same 
time, and that there is a direct association between the subsequent MS signal and the 
relative abundance of the peptide (230).  Label free quantitative proteomics can be 
performed 2 ways 
1. Spectral counting analysis at the MS/MS level 
2. Intensity based analysis at the MS level 
Regardless of the method employed for quantitation in label free proteomics the general 
workflow is similar.  Initially the proteins of interest are digested, the composite 
mixture is then separated by LC or LC/LC, MS analysis is then performed finally 
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followed by a data assessment step which includes peptide identification, quantification 
and statistical analysis. 
Spectral counting entails computing the total number of MS/MS spectra for a given 
peptide.   The basis of spectral counting arises from the direct observation that the 
number of times a peptide is selected for fragmentation diametrically correlates with its 
relative abundance (231).  In this approach a survey MS scan is initially performed and 
then the top peptides from such analysis are selected for an MS/MS scan, and then the 
spectral counts for each peptide are aggregated.   Subsequent data analysis is relatively 
straightforward and unlike TIC analysis it does not require specific programs.  Data 
generated this way does however have to undergo normalization and statistical analysis 
to ensure that the data generated is both accurate and reliable.   
Normalization is undertaken in label free proteomics to correct for any systematic 
biases that can result in changes in the observed peptide signal intensities.  Such biases 
maybe introduced at the sample preparation, chromatography or MS analysis stages and 
thus the deviations detected may not be due to biological variation but experimental 
variation.  Callister et al (232) evaluated 4 normalization techniques - global 
normalization, linear regression, local regression and quantile.  They concluded that the 
normalization technique applied should be tailored to the data set, but nominally linear 
regression performed best if biological variation is present (232) 
Zhang et al (233) appraised 5 statistical tools with reference to spectral counting  - t-
test, fishers exact test, G-test, AC test and LPE test.  They concluded  
1. If 1 or 2 replicates are used the G-test, AC test and Fishers exact test should be 
exploited 
2. If  ≥  3  replicates  the  t-test is most suitable 
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3. G-test is the most sensitive for detecting differential protein expression 
Spectral counting has been applied in many biomarker discovery projects to date 
including lung cancer (234), breast cancer (235, 236), prostate cancer (237), gastric 
cancer (238) and inflammatory bowel disease (239). 
Although spectral counting is both straight forward to perform and relatively sensitive 
at detecting changes in protein abundance, its ability to quantitate lower abundance 
proteins due to statistical limitations is restricted. 
Intensity based label free proteomics is centered on evaluating changes in ion intensity 
by analyzing the peak height or area under the peak of ions of a particular m/z at a 
particular time.  To identify peptides accurate m/z values and elution times are captured, 
and then the peptides are formally ascertained by comparing these values with those in a 
database.  Accurately aligning these features, and then paralleling the Ion 
chromatograms can then evaluate relative peptide abundance in different samples.  
Intensity based label free proteomics therefore must be free from any variability that can 
occur in sample preparation, ionization, and with the LC platform i.e. drifting of elution 
times etc.  The efficacy of this method was first demonstrated using myoglobin.  In this 
study using myoglobin they observed that the peak area of the peptides increased with 
increasing concentrations, and that the peak area correlated linearly with abundance, 
and significantly improved with normalization (240, 241).  Applying such a 
methodology to complex biological samples can be problematic for the following 
reasons (240) 
1. Experimental variation can lead to perceived differences in intensity 
2. Drifts in retention time secondary to chromatographic shifts will complicate the 
eventual outcome 
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3. Large data sets are collected and therefore specific computer programs are 
required for the data analysis 
1.8  FRACTIONATION TECHNOLOGIES 
As previously alluded to the investigation of biological fluids and in particular plasma 
or serum is often difficult due to the dynamic range of its constituents, the proteins of 
biological interest being present in low abundance and then the added complexity that 
tryptic digestion imposes.  Not only does separation allow for the aforementioned but it 
also minimizes ion suppression by enhancing the resolution of ions that vary by charge 
and hydrophobicity. A number of effective strategies can therefore be applied during 
sample preparation and subsequent data analysis to facilitate and enhance proteomic 
biomarker discovery.  For instance 
1. Sample preparation strategies – Immunoaffinity depletion columns 
2. Peptide/Protein strategies  - Multidimensional LC separation techniques. 
Serum contains 60-80mg of protein/ml, over 90% of which is composed of a number of 
high abundance proteins including albumin which constitutes 55% of it (242). The low 
abundant proteins of biological interest contribute to only 1% of the total protein 
content of serum (243).  This complexity along with the substantial dynamic range (See 
Figure 12) of proteins and their physical properties makes serum and plasma the hardest 
biological fluid to mine.   
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Figure 12: Dynamic range of serum.   
Reproduced from Genway website 
1.8.1  Immunoaffinity depletion 
Immunoaffinity depletion is 1 of the strategies that can be incorporated early into a 
biomarker discovery study to reduce the difficulties described above.  It involves the 
depletion of the predominant proteins within serum or plasma to allow the assay of 
lower abundance proteins of biological interest. There are a number of commercially 
available depletion kits, a few of which have been evaluated to determine their binding 
specificity and efficiency, reproducibility, their necessity, the subsequent proficiency of 
MS to assess for low abundance proteins and whether depletion is detrimental, as it may 
lead to the loss of relevant protein biomarkers.  The 3 systems I looked at were the 
Multiple Affinity Removal Systems (MARS) 6, MARS 14 and IgY 12/Supermix 
systems.  
Several studies have been described in the literature comparing some high abundant 
protein depletions (244-247).  To my knowledge there are however no studies that have 
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extensively compared several depletion studies and in particular the Agilent MARS 
depletion system with the Seppro IgY/Supermix system in a similar data set and then 
subsequently used MS analysis.  The studies which have been performed do however 
demonstrate that upstream depletion strategies leads to a greater number of medium or 
low abundance proteins being identified (244-247).  As previously alluded to however 
the depletion of such proteins may lead to the loss of proteins that may function as 
disease biomarkers. 
1.8.2 Multi-dimensional separation – Strong Cation Exchange and 
Reverse Phase Chromatography 
Giddings first proposed multidimensional separation in 1984 (248).  It involves at least 
2 methods, which fractionate peptides according to their physical properties such as 
size, charge or hydrophobicity.  The separation methods are considered orthogonal if 
the disjunction is based on different physical properties.  The peak capacity is defined as 
the amount of peaks/components that are formally resolved in such an experiment, and 
if the separation is orthogonal the total peak capacity is the product of the peak 
capacities for each separation step (249).  The peak capacity is an indicator of the 
resolving power of the separation method.  By selecting methods, which separate in 
different ways, the peak capacity is augmented.  There are a number of techniques that 
can be implemented in multidimensional separation.  The choice depends on the amount 
of time required for separation, the buffers being consumed during the separation and 
MS phases subsequently and lastly if the different techniques can conjoin.  The first 
dimension of this approach can be Strong Cation Exchange (SCX), SDS-PAGE, Size 
exclusion Chromatography or even RP-LC.  Requirements for the first stage are it 
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should have a large loading capacity and it and the corresponding buffers should be 
congruent with the second dimension.  The second dimension of this approach is 
interfaced with the mass spectrometer and is usually RP-LC because of its high 
resolution, compatibility with ESI and its desalting capabilities (249).  The commonest 
combination of interfaces is SCX with RP.  This combination has been shown to help 
identify large sets of low abundance proteins (250).  The configuration of 
multidimensional separations can be off or on line.  Off line separation refers to the 
collection of analyte fractions prior to the second dimension of separation.  This is often 
the preferred option for large-scale analysis and for increasing the depth of coverage. 
Other advantages include better separation because of the presence of a linear gradient, 
increasing amounts or organic solvent can be utilized, and both separation procedures 
can be optimized. On line refers to the continuous flow of analyte between both modes 
of separation and the mass spectrometer.  It has the advantage of minimizing sample 
loss and the possible contravention of contaminants, as well as ease of operation. 
1.9 BIOINFORMATICS - PROCESSING AND 
ANALYSIS OF PROTEOMIC DATA FOR 
BIOMARKER DISCOVERY 
The discovery of biomarkers is based on the comparison of 2 physiological states – 
disease versus control with the objective to detect early disease or monitor the response 
or disease at specific stages of treatment. They will only be of clinical value if they have 
predictive performance, the difference reflects changes in pathology and it has 
measurable impact. Single variations between groups are unlikely and most likely there 
will hundreds or thousands of deviations many of which will be of no significance and 
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even those of significance may actually be false positives.  Analyzing proteomic data 
can therefore often be difficult and time consuming for those reasons but also because 
of the complexity and heterogeneity of the samples being analyzed, the diversity of the 
methods that can be utilized for analysis and the multiple stages of methodology that 
can lead to sample losses or alterations, as well as the interaction or interference of 
biological contaminants.  The retrieval, organization and analysis of large raw and 
processed mass data sets therefore requires automated bioinformatic tools such as 
databases, and statistical models to make the data meaningful 
1.9.1  Factors that affect proteomic profiling 
As previously alluded to the technological aspects of a proteomic study can be 
challenging in numerous ways.  There are however other sources of variability that that 
are not associated with the disease state being investigated, and should be taken into 
account during the experimental design.  These include 
1. Sample collection and storage which has been previously discussed 
2. Non-standardization of case subjects and controls in terms of physiological 
states or age and sex. 
3. Differences in genetics 
4. Changes in metabolic states 
5. Changes in cell cycle phases 
6. Changes in the inflammatory response to the presence of disease 
7. Changes relating to presence of other underlying chronic diseases 
1.9.2  Overview of protein identification 
The identification of proteins is achieved through the assessment of MS2 data generated 
from the analysis of peptides.   MS2 data is composed of large numbers of peptide ions, 
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which are denoted by letters depending upon whether the charge is retained at the C, or 
N terminus, which are formed during the fragmentation process.  From these ion spectra 
the amino acid composition can be derived and thus the parent peptide can be 
ascertained.  Sophisticated search programs are the method of choice to perform such 
tasks with the ultimate aim to assign the experimental data to a protein.  These engines 
will firstly assign the experimental spectrum to a database sequence, they will then 
determine the probability and significance of the match, and then finally validate the 
result. 
1.9.3  Data analysis methods 
Several algorithms are available for analyzing or assigning MS or MS/MS spectra to 
peptide identifications.  There are 3 approaches or searches that can be undertaken: 
1. Peptide mass fingerprint  - Can only be used for analyzing a simple mixture of a 
pure protein.  A list of peptide molecular masses generated from a protein digest 
are used as the experimental data set for this type of database search 
2. Sequence query  - 1 or more peptide masses data are combined with specific 
amino acid data 
3. MS/MS data – uses uninterpreted MS/MS data from 1 or more peptides or an 
LC-MS/MS run. 
The last approach is relevant to this thesis project and will therefore be discussed in 
detail further. 
The approach of all 3 methods is analogous in that the experimental data is compared 
with calculated fragment ion or peptide mass values in a sequence database along with 
the application of appropriate cleavage rules. 
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1.9.3.1   Database searching - MASCOT 
MASCOT is a search engine that can decode MS2 data into peptide and subsequently 
protein IDs.  MASCOT can interrogate and decode mass spectrometry data from one or  
all three of the search types detailed overleaf, but as previously alluded to the MS/MS 
search method is pertinent to this project.  MASCOT will use uninterpreted MS/MS 
data form 1 or more peptides to identify peptides and thus proteins. MS/MS ion data 
was used initially for peptide ID by Yates et al in 1995 (251) and formed the basis of 
the SEQUEST program.  It was further developed and adapted to form the core of 
protein ID in MASCOT a few years later. 
The first requirement for database searching is the generation of a peak list.  Peak lists 
are lists of centroided mass values, with or without associated intensity values.  In the 
case of MS/MS data peak detection in the chromatographic dimension is also required.  
Raw MS data is converted into a peak list by a process called peak picking or detection.  
There are 3 main peak detection algorithms 
1. Signal to noise ratio 
2. Template based peak detection e.g. Gaussian function 
3. Continuous Wavelet Transform  
Within this spectral pre-processing phase signal filtering, baseline subtraction, 
normalization, noise reduction, peak extraction, dimensionality reduction and 
transformation, and data exploration will also occur (252) 
Upon completion of this stage the database search matches the unknown spectrum to an 
archive of known organism specific peptides.  Similarities between the experimental 
and known database spectra are then gauged using a number of factors such as peak 
intensities etc.  The association is however dependent upon the presence of the sequence 
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within the database. PTMs, complex mixtures of proteins and the presence of novel 
proteins can however also alter the performance of the search engine.  Upon completion 
of matching the unknown peptides to stored known sequences in a database, the data is 
subjected to a number of scoring metrics. 
1.9.3.1.1  Ion scoring systems 
Many different ways of scoring peptide matches between an experimental spectrum and 
a known sequence have been developed.  The most accepted method of ion scoring of 
an MS/MS match is based on calculating probabilities. 
1.9.3.1.1.1  MOWSE 
MOlecular Weight Search (MOWSE) is a scoring system first described by Pappin in 
1993 (253).  Initially experimental MS/MS data is compared with the calculated peptide 
masses within the database.  A match is confirmed if the calculated database value falls 
within a certain mass tolerance of the experimental data.  Taking into account a number 
of weighting factors and not merely taking into account the relative abundance of 
matching peptides a final score is formulated.  The factors, which the final score is 
dependent upon, are the size of the protein and peptide.  Thus a large peptide from a 
small protein generates the highest score whilst a small peptide from a large protein the 
lowest score.  Setting a weight range for the intact protein can help filter the data.   
Other advantages of MOWSE include (254) 
1. The fact that protein size is compensated for. 
2. The model consists of numerous spaces separated by 100 Da (the average aa 
mass). 
3. Models the behavior of a proteolytic enzyme 
MOWSE does not however provide a measure of confidence for the prediction. 
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1.9.3.1.1.2  Probability based scoring    
Mascot uses a 'probability-based MOWSE' algorithm to assess whether the observed 
match assigned to a certain peptide ion sequence is a random event or not.  The real 
match, which is therefore not a random event, has the lowest probability and is reported 
as the best match. 
This method has several advantages over MOWSE and simple cut-off scoring 
techniques (255):  
1. A simple rule can be used to judge whether a result is significant or not and 
statistical tests of significance can be applied. 
2. Both MS/MS and MALDI-TOF data can be scored in the same way  
3. MS/MS data can be matched 
4. No prebuilt indexes 
5. Scores from different searches and from different databases can be compared 
6. Search parameters can be optimized more readily by iteration.  
7. Different types of matching can be performed  
8. Less likely to be liable to false positives 
Whether the best match is the most significant match depends upon the database size 
and the quality of the data set.  The larger the database the smaller the probability 
calculation which can be difficult or inconvenient. To overcome the small probability 
numbers that can be encountered therefore, the total MASCOT score is given as         S 
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= -10*Log(P) where P is the absolute probability that the observed match is a random 
event.  Reporting the score in such a way means that the best match is the one with the 
highest score. Knowing the absolute probability score (which is also referred to as the 
MASCOT or identity threshold score) and the size of the sequence database a 
quantitative measure of significance (p-value) can be ascertained.  A result is considered 
significant if it occurs at random with an incidence of less than 5%.  Setting the 
significance at this level suggests that there is 1 in 20 chance of being a false positive, 
which equates to a p-value of 0.05 or 95% confidence in the observed result.  A further 
assessment of the strength of the data generated is the expectation value and the 
homology threshold.  The expectation value (E value) is derived from the absolute 
probability score and the significance threshold.  It is essentially describes the number 
of times that you would expect the MASCOT score to be generated because of chance.  
The smaller the E value the better the match.  If the data quality is poor the threshold 
score may not be achieved even although the match is correct indicating that the match 
is an outlier from the distribution of scores.  The Homology threshold score essentially 
signifies therefore that the match is an outlier.  It nominally is a lower value than the 
identity threshold score.  The 3 parameters (identity threshold score, homology 
threshold score and the e-value) outlined above are essentially applicable to the 
assessment of peptide and not protein identifications.  The main focus of MASCOT is 
to assign matches and statistical scores to peptides.  Protein ID is however an important 
element and possibly considered to be the endpoint of any biomarker discovery study.  
Protein IDs are generated in MASCOT from the total ion scores.  For each protein that 
is reported MASCOT will calculate an overall protein score.  The protein score is a 
reflection of all the scores of all the spectra assigned to that protein.  Those ion scores 
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that exceed 1 or both thresholds are only included in the calculation. The proteins that 
are identified are essentially the best representation of the peptide sequences described.   
The most likely assigned peptide match is displayed in bold and red within the protein 
list in MASCOT.  Although the protein score is a derivative of the peptide ion scores it 
is not probability based and is statistically insignificant.   
1.9.3.1.2  MASCOT search parameters 
The use of MASCOT for mass based database searching also means that search 
parameters can be optimized.  This is particularly relevant as the successful assignment 
of matches can be altered by proteolysis or the presence of peptide modifications for 
instance that must be accounted for prior to performing the search.  Knowledge of the 
enzyme used in the experiment is essential.  Proteolysis using trypsin must be stipulated 
in the database settings prior to commencing a search to allow for any missed cleavages 
that can occur.  These can occur because the cleavage site is not accessible to trypsin. 
Trypsin will also not cleave a peptide if there is a basic residue adjacent to the cleavage 
site, the ratio of enzyme to substrate to enzyme is too low or the environment to enable 
proteolysis  isn’t  correct.  Peptide modifications also add to the complexity of database 
searching.  The presence or absence of these modifications is generally unknown and 
they must be accounted for during any high throughput proteomics study. Modifications 
can be described as ether fixed/quantitative or variable/non-quantitative.   
The fixed modifications were 
1. Carbamidomethyl – During the iTRAQ process alkylation with Iodoacetamide 
to prevent the formation of dilsuphide bonds is undertaken.  This process leads 
to the addition of a carbamidomethyl group. 
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The variable modifications selected in this thesis project are 
1. Oxidation (M) 
2. Dioxidation (M) 
3. Acetyl (N terminus) 
4. Gln-pyro-glu 
A maximum of number of variable modifications should be selected, as the greater the 
number of variable modifications selected the longer the time taken to perform the 
search and the more random matches generated.  The final consideration for any 
database search is defining the error window on the measured mass values – the peptide 
tolerance, which can be expressed as ppm, Da or %.  Too large a window increases the 
number of false positives, too small a window results in loss of authentic matches.  
Most search engines will also allow mass tolerances for both the precursor and fragment 
data to be considered.  This is especially important for hybrid instruments such as the 
Orbitrap, which has different precision for MS and MS/MS. 
1.9.3.1.3  Validation of MS/MS searches in MASCOT  
1.9.3.1.3.1 Decoy database and estimation of the false discovery 
   rate (FDR) 
Although MASCOT assigns statistical values to the probability of a random match 
occurring with a 95% confidence or p<0.05, false positive results can occur.  
Confidence in the allocations that MASCOT makes has to be ascertained by calculating 
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the FDR.  The FDR is an estimation of the number of falsely positive results within the 
assignments made by MASCOT.  It can be accurately computed by means of decoy 
database strategies.  A decoy database is essentially a database of amino acid sequences 
derived from the target database that are either reversed, shuffled or randomized.  
Matches to the decoy database are considered false discoveries, and the numbers of 
matches in the decoy database above a certain threshold score are reported.  The number 
of decoy matches is essentially a measure of the number of false positives. If FP is false 
positives (generated from the decoy database) and TP true positives (derived from the 
true) database, the FDR (which is expressed as a %) is therefore essentially FP/(FP + 
TP).   
1.9.3.1.3.2  Receiver Operating Curve (ROC) 
Reporting the FDR rather the false positive or true positive rate is generally more 
widely accepted for conveying error rates in MS database searches.  A ROC is another 
way of graphically illustrating the quality of a database search.  It is created by plotting 
2 types of errors - the true positive rate (sensitivity) against the false positive rate as a 
function of 1 of the MASCOT threshold parameters  (1 - specificity) (See Figure 13 for 
ROC). 
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Figure 13: ROC curve.  Reproduced from matrix science help pages www. 
The red curve is a good example of the axes that the data should follow; the yellow line 
is a bad example.  There are 2 main problems with the use of ROC curves in validating 
database data 
1. MASCOT or any other database search cannot directly estimate the number of 
true positives and false positives, thus a ROC curve will simply represent the 
number of identifications in the true database search versus those generated in 
the decoy database search. 
2. In large proteomic database searches there are usually a large number of 
sequences that remain unmatched and any further matches may originate from 
the decoy database search, which leads to a poorly shaped curve.   
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1.9.3.2   Data analysis for quantitative proteomics 
Label free data analysis in the form of spectral counting and spectral peak intensity 
based analysis has already been discussed in the label free section above.  Many 
approaches can be utilized to analyze quantitative chemical/metabolic labelled 
proteomic data including reporter protocol, precursor protocol or complex protocol 
based on whether the quantification is performed by calculating the number of peaks, 
peak intensity, peak area or the area of the extracted ion chromatogram.  No matter what 
quantification process is applied to the data it is performed at the peptide level but 
reported at the protein level.  Data analysis of iTRAQ data within MASCOT is based on 
the reporter protocol.  The reporter protocol is centered on measuring the relative 
intensities of fragment peaks of specific m/z values within the MS2 spectra to ascertain 
peptide quantification.  The peptide abundances are then combined to calculate the 
protein abundance.   
MASCOT will initially generate a centroided peak list from the raw MS2 data for 
the database searching and quantification.  During this process it will  
1. Remove peaks that are below a certain signal to noise ratio. 
2. It will remove the peaks that are below a certain resolution 
3. It will set a threshold for the number of peaks within a certain mass range 
4. Assign a charge state to the ions 
5. Merge the MS2 spectra that have the same precursor mass 
MASCOT will then identify and quantify the peptide data to generate peptide ratios.  
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Peptide ratios are only produced if certain criteria are fulfilled, namely 
1. Minimum precursor charge of 1 
2. Peptide modification state is delineated 
3. Strength of the peptide ratio – the score must be above the identity or homology 
threshold 
4. Minimum number of fragment ions 
A protein ratio is then only derived from the summation of the peptide ratios if the 
minimum number of peptide matches is reached, nominally 2.  There are 3 methods for 
calculating the protein ratio value in MASCOT from a set of peptide ratios 
1. Average – The protein ratio is the average of the peptide ratios.  Calculating the 
average means that confidence intervals (CI) can be computed in combination 
with the standard deviation.  By multiplying and dividing the average with the 
standard deviation, the CI is obtained. 
2. Median – The median peptide ratio is selected to represent the protein ratio 
3. Weighted – The peptide values are summed and the protein  ratio is derived 
from this computation. 
The standard deviation is measure of the uncertainty of the protein ratio that is 
generated.  A standard deviation will only be derived if the peptide matches are 
consistent with a normal distribution.  If normality is confirmed by the Shapiro Wilk 
test, then outliers within the data can also be identified.  There are a number of methods 
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that can be selected within MASCOT to test and remove outliers, namely 
1. Grubbs 
2. Dixons 
3. Auto 
4. Rosners 
2.0  Post translational modifications - Glycosylation 
2.0.1  Overview of Glycosylation 
Glycosylation is the commonest but most complex post-translational modification, and 
more than 50% of proteins within a cell are in fact glycosylated (257).  Glycosylation 
involves the covalent addition of a sugar/glycan moiety such as a mono- or 
oligosaccharide to specific amino acids (257).  A glycoprotein is therefore a protein 
with one or more glycan’s covalently bonded to it.  The enzymes that are responsible 
for the attachment of the glycan’s are referred to as glycosyltransferases, and with more 
than 200 known glycosyltransferases this process can be complex to assay.  
There are several different types of glycosylation depending upon the type of  glycan 
attached and the substrate-glycan bond.  There are 2 main types of glycosylation N- and 
O linked.  Both involve the attachment of a sugar moiety to a specific amino acid that is 
extended to form large branched glycan structures.  
1. N-linked glycosylation (258) – Is a co-translational event, which occurs in the 
endoplasmic reticulum. The glycan’s are therefore attached as the proteins are 
being translated.  The attachment of the glycan is to the nitrogen group of an 
asparagine residue within the endoplasmic reticulum 
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2. O-linked glycosylation (258) – Occurs as a post-translational event in the Golgi 
apparatus, whereby the O linked glycan’s are attached once the proteins are 
translated.  Typically an N-acetylgalactosamine residue binds to the oxygen 
molecule of either a serine or threonine within the nucleus, cytosol, endoplasmic 
reticulum and Golgi apparatus 
Proteins can undergo any form of glycosylation, and can have different types of 
glycosylation at multiple sites.  The glycosylation of proteins is however largely 
dependent on the availability of glycosyltransferases, amino acid sequence and protein 
accessibility.  
Glycosylation is an important cellular event especially for mechanisms such as protein 
folding, cell-to-cell communication, protein stability and cell protection 
2.0.2  Glycosylation and Cancer 
Aberrant glycosylation is a predominant or universal feature in the development and 
progression of tumours especially during specific processes such as differentiation, 
angiogenesis, invasion, metastasis and apoptosis (259-265).  During tumourigenesis 
changes in the profiles of glycoproteins and the glycan’s they present, occur either 
through transformation of the glycosylation sites they encompass, the glycan’s they 
present or because of changes in the levels of glycosyltransferases for instance, meaning 
they are an ideal target for biomarker discovery studies.  Some of the most widely 
measured biomarkers in current clinical practice are glycoproteins namely PSA, CA 19-
9, CEA and CA-125.  Interest in the use of glycoproteomics in biomarker studies over 
recent years has gained popularity as both glycan or glycoprotein profiling has a number 
of advantages over peptide or protein biomarker studies (266) 
1. More than 50% of secreted proteins are glycoproteins 
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2. Focusing on the analysis of a subset of proteins reduces sample complexity 
3. Aberrant glycosylation is a pathognomonic event that underlies many disease 
states 
4. Changes in the patterns of glycosylation are more readily apparent than 
differences in protein expression in many diseases 
5. Modifications in glycosylation occur early and in many proteins, during the 
transition of normal to disease states, thus increasing the likehood of detecting 
abnormalities early 
6. Glycosylated proteins are stable 
7. Alterations of protein glycosylation can be diagnostic because glycosylation is 
an important cellular event that controls many cellular functions 
To date there have been a few studies that have studied glycosylation differences as 
potential biomarkers.  Thaysen-Anderson (267) researched a known colorectal cancer 
biomarker – Tissue Inhibitor of Metalloproteinase-1 (TIMP-1).  They identified a 
number of glycosylated isoforms of TIMP-1 that were unique to colorectal cancer cell 
lines (267).  Nakano et al (268) identified specific glycoforms of haptoglobin that 
differentiated patients with chronic pancreatitis, pancreatic carcinoma and control 
subjects.  Aberrant glycosylation in colorectal cancer has been associated with increased 
levels of the enzymes that control glycosylation – glycosyltransferases (269).  Much of 
the insight of aberrant glycosylation in colorectal cancer has been derived from studying 
glycoproteins called Mucins. Mucins can be categorized as either secretory or trans 
membrane, with their predominant role being the transport of fibre in the colon.  There 
are currently 17 known Mucins.  A well-known Mucin, which becomes elevated in 
metastatic colorectal cancer, and is used in current clinical practice is CEA.  Elevated 
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levels of MUC 1, is predictive of metastatic potential (269).  Aberrant mucin 
glycosylation is therefore an important step of a colorectal cancers ability to 
metastasize, which can be corroborated by the fact that colorectal cancer cells treated 
with molecules that avert the attachment of O-linked glycan’s results in the dissolution 
of mucin glycosylation and their attachment to endothelial cells (269). MUC5, which is 
not normally expressed in normal colonic mucosa, can be detected in patients with CRC 
(269).  
Changes in the composition of the sugars can also be demonstrated in colorectal cancer 
through the use of lectin affinity enrichment.  Using the lectin from pea, Arachis 
hypogea (PNA) it has been disclosed that the Thomas Fridenreich   “T-antigen”   is  
elevated in patients with CRC (269).  In contrast to the sialyl-Tn Antigen, detected by 
Sambucus nigra (SNA), which is under-expressed in CRC (269).  The over-expression 
of sialyl-lewis X in CRC cells is associated with a poor prognosis especially if 
identified in Dukes B tumours, and can be determined using the Helix pomatia (HPA) 
lectin (269).  
Glycosyltransferases themselves can serve as cancer biomarkers.  Elevated levels of 
specific enzymes involved in glycan synthesis and catabolism have been identified in 
ovarian, pancreatic, gastric and colorectal cancer (270). 
2.0.3  Glycomic analysis of glycans, glycopeptides and glycoproteins 
Glycoproteomic approaches can be divided into glycan, glycoprotein (top down 
workflow) or glycopepetide (bottom up workflow) based.  The glycomic analysis of 
glycoproteins can be complex firstly because glycoproteins are a combination of both 
protein and mono- or oligosaccharides, secondly they are a diverse group of proteins 
both in their structure and composition and lastly 82 of the top 100 proteins in serum are 
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glycoproteins.   Equally glycan analysis can be difficult due to the synthetic pathways 
involved, heterogeneity of glycan’s in that there are many different glycan isomers, 
branching, linkages and variable lengths, as well as the differences in their underlying 
biology.   There is also only a limited amount of substrate to analyze as glycan’s and 
glycoproteins cannot be replicated.  A truly glycoproteomic approach would integrate 
both glycan and glycoprotein analysis, such an approach is however still being 
established.  At present the data generated from glycomic studies has generally been 
qualitative rather than quantitative, merely therefore ascertaining the presence or 
absence of glycosylated proteins between disease states rather than differential levels. 
2.0.3.1  Glycan analysis 
The search for glycan biomarkers begins with harvesting of the glycan moiety from the 
glycoprotein from a biological source such as serum.  The glycan moiety is separated 
from   the   protein   either   enzymatically   using   glycases   or   chemically   by   β-elimination.  
The glycan’s are finally enriched and analyzed using either compositional mass 
profiling or structure specific chromatographic profiling.  Although this approach 
potentially reduces sample complexity and is a high throughput option, valuable 
information regarding, the actual glycoproteins and the glycosylation sites from which 
the glycan motifs are covalently bonded to are lost during such analysis. 
2.0.3.2  Glycoprotein and Glycopeptide analysis 
Glycoprotein and glycopeptide analysis will both involve steps to enrich the substrate, 
chromatographically separate it, and then analyze it using mass spectrometry and 
bioinformatics.  The difference between the 2 strategies is dependent upon the stage at 
which enrichment occurs.  In the glycoprotein approach enrichment is performed prior 
to digestion, whilst in glycopeptide techniques enrichment is executed after digestion.  
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The later workflow is often more commonly followed as it provides more information 
of the glycoprotein profile and glycosylation sites can be more readily mapped.  
However it is time consuming, there is less sequence coverage compared to the top 
down approach and current technology does not presently allow for the mapping of 
multiple glycan sites (266).  An advantage of performing the affinity selection at the 
protein level is that sequence information can be imparted upon, therefore leading to 
glycoprotein identification (271) A drawback of this method is overcoming non-specific 
protein interactions, which is of particular concern when using lectin enrichment (271). 
There are several enrichment techniques available to enhance glycan’s, glycopetides 
and glycoproteins such as 
1. Hydrophilic interaction liquid chromatography 
2. Size exclusion chromatography 
3. Hydrazide chemistry based solid phase extraction methods 
4. Lectin based affinity methods 
The later method was utilized within the domain of this thesis project as it was the only 
technology readily available to us within the time constraints of this project. 
Lectins are naturally occurring carbohydrate-binding proteins that demonstrate high 
specificity for certain glycan moieties. Their principal role is to provide cellular defense 
against pathogenic bacteria.  Lectins that can be used in glycomic studies are available 
in recombinant form, produced from either bacteria or yeast.  They can be used 
individually or multiply, with the later being labelled multi lectin affinity 
chromatography. They are available conjugated with either agarose in an HPLC, 
centrifugal or low pressure format or magnetic beads. 
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The elution of lectins is achieved using using mono- or disaccharide solutions, or high 
salt acidic solutions.  Finally it can be coupled with mass spectrometry to identify 
proteins.  
Advantages 
1. Lectins are highly sensitive to glycosylation changes, due to their unique 
binding specificity 
2. Can be coupled with various platforms 
3. Less variation is introduced using lectin affinity enrichment as there is less 
disparity between phases 
Disadvantages 
1. Will enrich only a certain subset of glycan’s 
2. Overall glycoprotein expression cannot be ascertained 
3. The enrichment efficiency is not as good as other techniques as exemplified in a 
membrane protein study of breast cancer cells where only between 18-26% of 
proteins were identified as glycoproteins using lectin enrichment (272).  This 
can however be increased by introducing immunoaffinity depletion and/or 
separation stages. 
4. Non-specific binding of abundant proteins can also occur 
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Aims and Objectives 
The main aim of my research presented here was to develop proteomic research 
techniques for their use in biomarker discovery and identification of serum biormakers 
for use in detecting CRC in asymptomatic individuals.  This was broken into 2 main 
chapters 
1. A proteomic development phase – During this phase particular emphasis was 
placed on sample attainment and preparation, the assessment of label and label 
free protemic platfroms, the importance of experimental design and the 
application of relevant statistical methods to enable mining of the datasets 
generated. 
2. Discovery and Identification phase – The workflow, which was tested and 
appraised in the development phase, was then used to discover potential 
biomarkers in the serum of patients with CRC and controls.   
 
 
 
 
 
 
 
 
 115 
Materials and Methods 
2.1  Methods employed for whole serum analysis utilizing 
iTRAQ and label free platforms 
2.1.1 Serum collection 
Serum samples were collected from patients at the time of their attendance for a 
screening colonoscopy following a positive guaiac and immunochemical FOBT 
between 2005 and 2009.  Following informed consent blood samples were obtained 
prior to the patient’s colonoscopy via venepuncture into a citrated tube and immediately 
spun for 10 minutes at 5000-x g to separate the serum and plasma components.  
Following this the serum samples were transferred into Lo-Bind eppendorf tubes and 
stored at -80°C in the Tayside Tissue Bank until analysis could be performed.  Suitable 
controls were identified by a colonoscopic examination that was free from any colonic 
pathology.  The sera from patients with colorectal cancer were selected on pathological 
criteria and were separated and analysed according to their Dukes Staging (A-C).  The 
serum from controls and those with colorectal cancer were age and sex matched.  A 
diagnostic set of 53 cancer samples and 17 controls were subsequently defined (See 
Table 3 & 4) 
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Table 3: Characteristics of Cancer patients included in this study 
Patient Sex Age Dukes stage Primary 
tumour site 
A1 M 62 A Rectum 
A2 M 81 A Sigmoid 
A3 M 74 A Sigmoid 
A4 M 74 A Rectum 
A5 M 76 A Rectum 
A6 F 71 A  
A7 F 63 A Rectum 
A8 M 77 A Right colon 
A9 F 71 A Caecum 
A10 F 59 A Rectum 
A11 M 83 A Rectum 
A12 M 75 A Rectum 
A13 M 73 A Rectum 
A14 M 75 A Sigmoid 
A15 M 86 A Rectum 
A16 M 82 A Descending 
colon 
B1 M 72 B Sigmoid 
B2 M 93 B Sigmoid 
B3 M 94 B Transverse 
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Patient Sex Age Dukes stage Primary 
tumour site 
B4 F 63 B Sigmoid 
B5 F 85 B Sigmoid 
B6 F 62 B Rectum 
B7 F 58 B Rectum 
B8 F 67 B Right colon 
B9 M 70 B Right colon 
B10 M 83 B Right colon 
B11 M 69 B Rectum 
B12 M 79 B Transverse 
B13 M 55 B Sigmoid 
B14 F 83 B Sigmoid 
C1 M 65 C Rectum 
C2 M 57 C Sigmoid 
C3 F 66 C Rectum 
C4 F 76 C Rectum 
C5 F 85 C Rectum 
C6 F 75 C Sigmoid 
C7 M 65 C Sigmoid 
C8 M 57 C Rectum 
C9 M 79 C Transverse 
C10 F 63 C Rectum 
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Patient Sex Age Dukes stage Primary 
tumour site 
C11 M 78 C Rectum 
C12 F 71 C  
C13 F 76 C Sigmoid 
C14 M 87 C Rectum 
C15 M 77 C Splenic flexure 
C16 F 86 C Right colon 
C17 F 71 C Sigmoid 
C18 M 66 C Sigmoid 
C19 M 55 C Sigmoid 
C20 M 84 C  
C21 M 54 C Rectum 
C22 M 65 C Rectum 
C23 F 69 C Rectum 
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Table 4: Characteristics of Control individuals included in this study 
Patient Sex Age 
A1 F 66 
B1 M 74 
C1 F 74 
D1 M 76 
E1 M 71 
F1 M 72 
G1 M 59 
H1 M 64 
I1 M 63 
J1 M 64 
K1 M 57 
L1 M 56 
M1 M 58 
N1 F 73 
O1 F 65 
P1 M 86 
Q1 F 68 
 
 
 
 
 
 120 
2.1.2  Depletion of highly abundant serum proteins  
Initially control serum samples were used to test the reproducibility, selectivity and 
analytical variation of the antibody depletion columns from both Agilent (MARS Hu6 
and MARS Hu14) and Seppro Genway (IgY 12 and Supermix system).  Upon testing it 
was evident that the Genway LC columns were the most efficacious and thus the 
remainder of this research to identify potential biomarkers was conducted using these 
columns. 
2.1.2.1  MARS Hu6, Agilent antibody depletion spin column 
 A pooled control human serum sample was spun for 10 minutes at 5000-x g, to separate 
the   lipids.      15μl   of   the   lipid free pool was then diluted   with   185μl   of   buffer   A   and  
filtered through an Agilent spin filter to remove any particulates for 5mins at 5000-x g.  
4mls of buffer A was dispensed and pushed through the antibody column to equilibrate.  
The diluted serum sample was loaded onto the antibody column, and spun for 1.5 
minutes at 100-x g.    A  further  400μl  of  buffer  A  was  loaded  into  the  column,  and  spun  
for 2.5 minutes at 100-x g.  This  was  labelled  as  “Flow  through  fraction  1”  (F1).    The  
cartridge   was   placed   in   a   fresh   collection   tube   and   a   further   400μl   of   buffer   A   was  
added.    This  was  labelled  as  “Flow  through  fraction  2”  (F2).    Loading 4mls of buffer B 
onto the depletion column eluted the bound proteins.  The column was then re-
equilibrated with 4mls of buffer A and stored at 4°C until its subsequent use. Fractions 
F1 and F2 were finally combined, primed for the downstream analysis of the low 
abundance proteins contained within these 2 eluents. 
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2.1.2.2  MARS Hu6, Agilent antibody depletion using 20Mm TEAB as the 
   Depletion buffer 
 The proprietary buffer A contained a high molarity of Sodium Chloride, which 
interferes with both the ITRAQ analysis but also Strong Cation Exchange Fractionation.  
Using TEAB would also omit the need for a protein precipitation step, which could 
result in protein losses.  A depletion step substituting buffer A with 20Mm TEAB was 
therefore undertaken.  To test the efficacy of this approach, a 1D Gel was run as 
outlined in the following sections.  The TEAB buffer did however prove not to be as 
effective  as  buffer  A  and  wasn’t  pursued  further  as  the  MARS  system  was  replaced  with  
the IgY/Supermix column detailed below. 
2.1.2.3  MARS Hu14, Agilent antibody depletion spin cartridge 
 A pooled human serum sample was spun for 10 minutes at 5000-x g, to separate the 
lipids.  7 – 10μl  of  the  serum  pool  was  diluted  to  200μl  with  buffer  A.     The  antibody  
column was initially equilibrated with 4mls of buffer A.  200μl  of  dilute  serum  sample  
was added to the column and centrifuged for 1.5mins at 100-x g.     A   further  400μl  of  
buffer A was added and spun for 2.5 minutes at 100 x g, where the unbound material 
was  collected  as  “Flow  through  fraction  1”  (F1).        The  cartridge was placed in a fresh 
collection  tube  and  a  further  400μl  of  buffer  A  was  added.    This  was  labelled  as  “Flow  
through  fraction  2”   (F2).     Loading 4mls of buffer B onto the depletion column eluted 
the bound high abundance proteins.  The column was then re-equilibrated with 4mls of 
buffer A and stored at 4°C until required. Fractions F1 and F2 were combined at this 
stage. 
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 2.1.2.4 Genway IgY14 LC10 and Supermix LC2 antibody depletion 
columns 
Dilution/equilibration buffer (1x PBS, 150mM NaCl, pH 7.4), Stripping buffer (100mM 
Glycine, pH2.5) and Neutralisation buffer (100mM Tris-HCl, pH8.0) were set up as the 
mobile phases for both the IgY14 LC10 and Supermix LC2 depletion columns on a 
Hitachi LC system.  The lines were primed at a flow rate of 2.0ml/minute for 10 
minutes.  Prior to processing any samples both columns were subjected to 2 buffer runs.  
The LC timetable for the IgY14 LC 10 column consisted of a wash segment for 25 
minutes with 100% 1x PBS, an elution period of 18 minutes with 100% of 100mM 
Glycine, a 10 minute neutralisation step with 100% 100mM Tris-Hcl and finally a re-
equilibration phase with 100% 1x PBS for 12 minutes.  All of the aforementioned steps 
of the cycle were run at a flow rate of 2mls/min. The LC timetable for the Supermix 
column commenced with a 5 minute wash phase with 100% 1x PBS, an elution period 
of 11 minutes with 100% 0.1M Glycine, a 7 minute neutralisation step with 100% 0.1M 
Tris-HCl and finally a re-equilibration period of 7 minutes with 100% 1x PBS.  All of 
the aforementioned steps of the cycle were set at a flow rate of 1ml/minute.  After 
baseline checking with the columns coupled, whilst running 100% 1x PBS at a flow rate 
of 0.5mls/minute the columns were subjected to a blank run, using the following 
conditions, 100% 1x PBS for 25 minutes at 0.5mls/minute followed by 100% 1x PBS 
for 15 minutes at 1.0mls/minute.  The flow through from both columns was monitored 
at 280nm and collected.  200µl of a crude pooled serum sample was diluted with 800µl 
of 1x PBS and filtered through a 0.22µm Agilent spin filter for 5 minutes at 13.1rpm.  
1000µl of the diluted and filtered serum was injected and the method previously 
described for the blank run was initiated.  Once again the flow through was monitored 
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at 280nm and collected.  The flow through was stored at -80ºC if not analysed 
immediately.  The bound proteins were subsequently eluted and the columns neutralised 
and re-equilibrated as per the LC timetables for the IgY14 LC 10 and Supermix LC2 
previously delineated.  To ensure complete removal of the bound proteins, the flow 
through from the columns during the LC timetables was monitored at 280nm.  The 
columns were stored at 4ºC between runs.  The HPLC system was thoroughly cleaned 
with 30% methanol between runs to prevent aggregation of salts, and also 
contamination between disease and control serum samples. 
After prolonged use the peak height of the unbound fraction became much greater than 
that of the bound fraction, suggesting loss of column capacity from improper 
regeneration.  To correct this, an additional 2 column volumes were added to the elution 
phase of the LC timetable for both columns.  Buffers were also routinely replenished to 
prevent biological overgrowth and thus optimise column performance. 
2.1.3  Protein precipitation/desalting methods 
2.1.3.1  Acetone precipitation 
Using control MARS depleted serum samples this method of precipitation was assessed 
to determine both its efficiency at removing interfering non-proteinacious substances 
from a protein preparation and also the amount of sample lost during this precipitation 
method.  6 volumes of ice cold 100% acetone were added to the depleted serum sample 
and vortexed vigorously.  The mixture was subsequently left at -20ºC overnight.   The 
following day the protein was pelleted by centrifuging the sample for 10 minutes at 
13.1rpm at 4ºC.  The supernatant was decanted following this and the pellet washed 
twice with 1 precipitation volume of 50% acetone.  The sample was spun at 4ºC for 
10minutes between washes and the resultant supernatant discarded each time.  After the 
 124 
final wash the pellet was air dried for 20 minutes in preparation for the next step of the 
proteomics workflow. 
2.1.3.2 Buffer exchange with Agilent 5KDa molecular cut off weight 
markers 
The eluent from the depletion step was exchanged with 50mM TEAB x5 using the 
Agilent 5KDa MWCO markers.  The markers were spun at 5000xg for 20mins in a 
Beckmann Coulter centrifuge.  Between spins further volumes of elute and TEAB were 
decanted into the MWCO marker.  Each elute was exchanged with a total volume of 
12mls of 50mM TEAB.  The resultant protein concentrate was transferred into Lo-Bind 
Eppendorf tubes and lyophilized overnight. 
2.1.4  Protein reduction 
To  each  of  the  dried  samples  25μl  of  sample  buffer,  1μl  of  2%  SDS  and  2μl  of  reducing  
agent (all provided in the iTRAQ kit) were added in sequence.  The samples were 
vortexed to mix and spun for 2 minutes at 13.2rpm.  Finally the tubes were incubated 
for 60ºC for 1 hour.   Following incubation the samples were briefly spun in preparation 
for the protein quantitation step. 
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2.1.5  iTRAQ Labelling 
A   volume   which   equated   to   50μg   of   protein   was   decanted   into   a   fresh   Lo-bind 
eppendorf tube and made up to a total volume of 28µl with the sample buffer provided 
in   the   iTRAQ   kit.      To   each   sample   1μl   of   freshly   prepared   84mM   iodoacetamide  
solution was added.  The sample was once again vortexed to mix and spun.  The 
samples were then incubated in the dark for 30 minutes.  25mg of Roche trypsin was re-
constituted with 25µl of Milli-Q,  with  10μl  of   this  stock  being  added   to  each  sample.    
The samples were digested overnight at 37ºC on a shaking platform.  The following 
morning the samples were labelled with the iTRAQ reagents in the following manner.  
Following equilibration of the ITRAQ reagent with room temperature, each vial was 
spun to bring the solution to the bottom.  Following this 70µl of 100% ethanol 
(provided in the kit) was added to each vial.  The contents of the ITRAQ reagent vial 
were subsequently transferred to one of the sample tubes.  Each sample was labelled 
independently with a different tag, with a maximum of 4 tags being utilised per sample 
set.  For the labelling reaction to achieve optimal efficiency the pH was ascertained and 
ensured to be above pH 8.0.  If the pH was incorrect and it appeared to be too acidic, a 
further volume of sample buffer  was  added  up  to  10μl.    The  samples  were  incubated  for  
1 hour at room temperature.  Following this period of incubation the reaction was 
quenched with 100µl of Milli-Q and incubated for a further 30 minutes at room 
temperature.  Each individually labelled sample was combined into a single Lo-bind 
eppendorf tube and placed in a speed vac until dry.  To remove volatile salts that had 
previously been introduced into the sample, it was lyophilized x 3 over a 24 hour period 
following the speed vac step, reconstituting the peptide mixture in-between  with  500μl  
of Milli-Q each time.   
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2.1.6  Peptide separation methods 
A number of peptide separation methods were employed to ascertain which led to the 
greatest number of proteins identified and also the largest number of low abundance 
proteins. 
2.1.6.1  C18 Zip tips 
The dried samples were re-suspended in 50µl of a mixture of 25% Acetonitrile and 
0.1% Formic acid.  The sample was vortexed to mix and spun briefly.  The C18 zip tip 
was  prepared  by  adding  10μl  PorosHS resin to the zip tip, as the capacity of the resin 
was 20µg/µl.  The resin was composed of 10% slurry in 50% methanol.  The zip tip was 
subsequently  washed  x3  with  25μl  of  a  mixture  of  25%  Acetonitrile  and  0.1%  Formic  
acid.  The sample was loaded and the flow through stored in case subsequent mass spec 
analysis did not yield data.  The tip with the loaded sample was further washed with 
25μl  of  a  mixture  of  25%  Acetonitrile  and  0.1%  Formic  acid  for  a  total  of  3  times.    The  
digested sample mixture was separated using 25µl sequential sodium chloride cuts – 
5mM, 15mM, 20mM, 100mM, 200mM, 300mM, 400mM, and 800mM, repeating this 
process twice.  The sodium chloride solutions were prepared in 25% Acetonitrile and 
0.1% Formic acid.  The fractions were dried in a speed vac and finally re-suspended in a 
volume   of   1%   formic   acid   that   would   equate   to   2.5μg   of   peptide   per   10μl   or   15µl  
injection depending on the chromatographic/mass spectrometry interface employed.  
 
 
 
 
 
 127 
2.1.6.2  Off-line SCX: Thermo BioBasic SCX column and Polysulfoethyl A 
  SCX Column 
Offline SCX separation of peptides from the desalted samples was performed on a 
Dionex UV3000 HPLC system at a flow rate of 0.2mls/min. The HPLC configuration 
consisted of a 250µl sample loop.  A pre-determined temperature of 37ºC was used to 
improve the chromatography. 
 I  compared  2  SCX  (Thermo  Biobasic  150  x  1.0mm,  5μm,  300Å  and  Polysulfoethyl  A  
200  x  2.1,  5μm,  300Å)  columns  both  with  similar  loading  capacities  of  1mg  of  peptide  
mixture, to ascertain which column separated the peptide mixture more efficiently and 
thus lead to more identified proteins and also proteins considered to be of low 
abundance.    I  loaded  200μg  of  protein  onto  each  column, which equated with the 4-plex 
iTRAQ experiment requirements.  Initial buffer compositions and running conditions 
for both columns were as follows: 
Mobile phase A – 5mM KH2PO4 in 25% Acetonitrile, pH 3.0. 
Mobile phase B – 1M KCl, 5mM KH2PO4 in 25% Acetonitrile, pH 3.0. 
The column was equilibrated for 35 minutes with 100% A at a rate of 0.2mls/min.  
Whilst doing this the dried pooled iTRAQ samples were prepared for injection onto the 
column  by  addition  of  buffer  A  and  pH’d  to  2.7  with  1M  phosphoric  acid,  to  ensure  that  
all the peptides had a net positive charge and were thus retained on the SCX column, to 
a   total  volume  of  200μl.     The  peptide  mixture  was   loaded  and  washed  for  14  minutes  
with 100% A.  A linear multi-step 60 minute gradient was then instituted, with a 
gradual elution for 48minutes with 0-150mM B, followed by a quick elution for 12 
minutes with 150-400mM B, with this molarity being held for 18 minutes, with a final 
change in molarity to 100% B over 18 minutes.  The chromatographic sequence was 
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completed with an equilibration phase of 35 minutes with 100% A.  Peptide elution was 
monitored at 215nm and fractions were collected at minute intervals over the entire 
length of the gradient, i.e. for a total of 85 fractions.  The UV trace was then used to 
combine fractions according to their absorbance so in most instances a total of 50-60 
fractions underwent LC-MS/MS analysis.   
The chromatographic separation using this gradient appeared to be suboptimal and thus 
the protein yield and identification of low abundance proteins was relatively low.  
Therefore a number of changes were introduced.  Firstly the molarity of Mobile phase B 
was changed to 600mM KCl instead of 1M KCl due to the presence of 2 different 
phases in the reservoir, most likely secondary to the fact that the 1M KCl was not 
dissolving uniformly in the Acetonitrile.  The viscosity of the mobile phase B was very 
much higher than that of A, and it was therefore likely that mixing of the 2 mobile 
phases at the beginning of the gradient was also inaccurate.  I also concurrently changed 
the gradient schedule to ensure we were collecting equal amounts of peptides in each 
fraction.  The previous gradient was not long enough meaning a large percentage of 
peptides were eluting at a similar time, thus defeating the purpose of performing a 
second dimension of chromatography.  The following buffer compositions and gradient 
timetable were therefore subsequently instigated. 
Mobile phase A - 5mM KH2PO4 in 25% Acetonitrile, pH 3.0. 
Mobile phase B – 600mM KCl, 5mM KH2PO4 in 25% Acetonitrile, pH 3.0. 
The sample was injected at time 0 and washed for 25 minutes with 100% A, at a flow 
rate of 0.2mls/min.  Over a 13 minute window the molarity of buffer B was changed 
from 0 to 50mM.  A multi-step linear gradient then followed with a gradual elution 
period of 50mM to 250mM B over 130 minutes, with a quick elution interval of 30 
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minutes with a change in molarity from 250mM to 400Mm.  This was followed by a 
change in molarity of Buffer B from 400mM to 600Mm over 20minutes, with 100% of 
B being held for 22 minutes.  A final equilibration step of 43 minutes at 100% A 
concluded the separation.  The UV monitoring, flow rates and collection of the eluted 
peptides were as previously described.  The samples were finally lyophilized, re-
constituted in 15µl 1% Formic acid, centrifuged for 10mins at 100rpm and then 
separated into vials ready for LC-MS analysis. 
Prior to separation of the iTRAQ samples the columns were tested with both blanks and 
VSG/Cytochrome C digests.   
2.1.6.3  Phenomenex Gemini 3µm C18 150 x 2.0mm reverse phase column  
Either 100µg or 200µg protein digest, depending upon whether a 2-plex or 4-plex 
ITRAQ experiment was being carried out, was reconstituted in 200µl of 200mM 
Ammonium Formate pH 10, Mobile phase A.  The pH of the sample was adjusted to 
pH10 with 1M ammonium hydroxide.  Mobile phase B was 100% Acetonitrile.  A 
Dionex UV3000 HPLC (see SCX section for a description) was used to deliver the 
reconstituted digest to the Gemini C18 RP column.   
The initial set up conditions for the HPLC are as described for the SCX column in 
section 2.2.6.2. 
The column was initially equilibrated for 35mins with Buffer A at a flow rate of 
0.2mls/min.   
The sample was then loaded onto the column and washed for 25mins with Buffer A at a 
flow rate of 0.2mls/min.  A multi-step linear gradient then followed with varying 
concentrations of Buffer B to elute the peptides from the column at a flow rate of 
0.2mls/min 
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0-60 mins – 0-35% Buffer B 
60-70mins – 35%-50% Buffer B 
2mins – 50%-90% Buffer B 
The column was then re-equilibrated with Buffer A for 43 minutes. 
The UV monitoring, collection and pooling of the peptide fractions are as described in 
the SCX section.   
2.1.7 Serum preparation for label free analysis 
Serum samples (Control, CRC pool and Dukes stage pools) were depleted as previously 
alluded to.  Upon depletion the flow through fractions were buffer exchanged into 
20mM TEAB with the 5MWCO markers (Agilent).  The fractions were buffer 
exchanged a total of x 5 with 12mls of 20mM TEAB.  The centrifugal speed and time 
for this step were 5000 x g and 20 minutes respectively.  The protein concentrate was 
finally lyophilized over night.  Following this the samples were reduced as in the 
manner for the ITRAQ serum samples, using a combination of 28µl of 1M TEAB, 1 µl 
2% SDS and 2µl of TCEP and incubated for 1 hour at 60°C.  A Bradford assay was 
prepared as previously described and a volume, which equated to 50μg, was decanted to 
a fresh eppendorf tube for up-stream  analysis.    If  the  volume  was  <28μl,  1M  TEAB  was  
used to inflate the volume.  The protein mixture was then alkylated and digested as 
described in previous sections and finally dried in a speed vac and stored at -80ºC until 
LC-MS analysis could be performed. 
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2.1.8  Second dimension: Liquid chromatography-electrospray 
  Ionization tandem mass spectrometry analysis of ITRAQ samples 
Nano-scale micro capillary reversed-phase chromatography coupled with electro spray 
tandem mass spectrometry experiments were either performed on a QSTAR XL hybrid 
quadrapole time of flight mass spectrometer (Applied Bio systems), and an LTQ 
Orbitrap mass spectrometer (Thermo fisher Scientific).  The methods applied for both 
are described in the following sections 
2.1.8.1  LC  Packing’s  nanoflow  HPLC  system  interfaced  with  an  Applied 
  Biosystems QSTAR XL QqTOF mass spectrometer  
An  LC  Packing’s  Ultimate  HPLC  was   used   for   second  dimension   separation   prior   to  
MS/MS analysis, with the HPLC being driven by Chromeleon.   Mobile phase A 
consisted of 0.1% Formic acid (FA) and 2% Acetonitrile (ACN), whilst mobile phase B 
comprised of 0.08% FA and 90% ACN.  The dried sample was initially reconstituted in 
20μl   of   Buffer   A.   The   samples   were   then   injected   using   the   Famos   Autosampler,  
equipped  with  a  20μl  sample   loop  onto  an  LC  Packing’s pre-column at a flow rate of 
200nl/min.  Peptide mixtures were subsequently separated on a PepMap 100 RP column 
(LC  Packings,  C18,  3μm,  100Å,  length  15cm,  ID  75  μm)  using  a  linear  gradient  of  5%  
to 90% Buffer B over 180 minutes, with a 10 minute wash at 5% Buffer B in the case of 
the 180 minute run, and for the 60 minute run a gradient of 5% to 90% Buffer B over 60 
minutes, with a 10 minute wash being applied.  
The ionisation process was pneumatically supported by nebulised nitrogen, which along 
with the electrospray voltage and interface temperature was determined and manually 
adjusted at the time of calibration. 
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The QSTAR mass spectrometer was initially manually tuned in the following manner 
using 1 GFP. 
The QSTAR XL was operated in positive ion mode using a standard IDA protocol.  The 
MS survey scan range was 400-2000m/z operating over a 1 second window.  This was 
followed by 3 MS/MS scans per cycle (cycle time 9.9996 seconds), therefore each 
product ion scan was accumulated over approximately 3 seconds, on the 3 most 
abundant ions determined in the survey scan, if above the threshold of 10 counts.  The 
effect of using a 2 second EPI scan was also determined in the method development 
phase.  Each precursor ion was selected twice and then excluded for 180 seconds (mass 
tolerance 50mmu).  The m/z interval for the MS/MS scans was 100 to 1800, with a 2+ 
and 3+ charge state selection.  The collision energy (CE) used to promote fragmentation 
of the reporter ions was determined using the following equation and Table 5: 
CE = Slope x (m/z) + (intercept) 
Table 5: CE parameters 
Charge Intercept Slope 
Unknown +1 0.0575 
2+ +2 0.0625 
3+ 0 0.0625 
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2.1.8.2  Dionex UV3000 HPLC coupled with an LTQ Orbitrap XL 
  Using Higher Collisional Dissociation (HCD) fragmentation 
An ultimate 3000 nLC (Dionex) HPLC was linked to an LTQ Orbitrap XL mass 
spectrometer (Thermoscientific). Dried SCX peptide ITRAQ labelled samples which 
had  been  reconstituted  20μl  0f  1%  Formic  acid  were  loaded  onto  an  Acclaim  PepMap  
100 C18 pre-column   (300μm x   5mm)   at   a   flow   rate   of   20μl/min   using   the   Dionex  
autosampler, and washed for 18 minutes with Buffer C.  The sample was subsequently 
separated using the following buffer conditions and elution gradient (See Table 6).  The 
gradient was formed using Buffers A and B. 
Buffer A – 2% Acetonitrile (ACN) in 0.01% Formic acid (FA) 
Buffer B - 98% Acetonitrile in 0.08% Formic acid 
Buffer C – 0.05% Trifluoracetic acid (TFA). 
Table 6: LC conditions for iTRAQ experiments on Orbitrap mass spectrometer 
Time (mins) Flow (μl/min) % B 
0 0.3 5 
3 0.3 5 
68 0.3 35 
70 0.3 90 
80 0.3 90 
81 0.3 5 
100 0.3 5 
 
Internal calibration was performed using the ion signal at m/z 445.120025 as a lock 
mass.  The electrospray voltage, nitrogen gas and interface temperature were optimised 
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at  the  time  of  manual  calibration  of  the  LTQ  and  FT,  using  GFP  1μm  in  methanol  and  
0.1%  formic  acid  at  a  infusion  rate  of  0.3μl/min.    Nominally  the  capillary  voltage  was  
set at 1.3kV and the source temperature at 200°C in most instances following 
calibration. 
The LTQ Orbitrap XL was operated using XCalibur in a positive ion mode utilising 
HCD data dependent acquisition.  Intact peptides (MS range 335-1800 m/z) were 
initially measured at 60000 FWHM resolution with a full FT-MS scan cycle in profile 
mode.   Automatic gain control was also used to prevent over-filling of the ion trap. 
This was followed by 3 MS/MS HCD experiments of the 5 most abundant ions in 
centroid mode. The maximal ion accumulation time allowed for each MS/MS scan 
mode was 1 microsecond.  Fragment ions were detected at 7500 resolution with a 
greater than 2+ charge state selection, with the MS2 scan ranging from 100 up to 1800 
m/z.  A number of normalized collision energies were tested (35%, 45% and 55%) to 
ascertain which CE would generate good signals for both the ITRAQ reporter ions and 
the peptide fragments ions in profile mode. 
2.1.8.3  Dionex UV3000 HPLC coupled with an LTQ Orbitrap XL using 
  Pulsed Q Collision Induced Dissociation (PQD) 
The LC conditions for PQD data acquisition are as described for the HCD mode.  MS 
Data was acquired in data-dependent acquisition conditions, with the MS data being 
generated under similar operating conditions as for HCD.  Each MS scan was 
followed by 6 PQD MS/MS scans on the 5 top most intense peaks.  The MS2 scan 
ranged from 50 to 1800 m/z.  PQD parameters were set as isolation width 3 m/z, 
normalised CE 35%, activation Q 0.7, and activation time (T) 0.1ms. 
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2.1.9  Second dimension: Liquid chromatography-electrospray ionization 
tandem mass spectrometry label free analysis 
Label free analysis was performed using the LTQ Orbitrap XL.  The LC gradient and 
buffer conditions are identical to those communicated in section 2.2.7.1.   
Internal calibration was performed in a similar manner as for the iTRAQ experiments 
with the lock mass 445.120025.  The source voltage was 1.3kV, the capillary 
temperature was set at 200°C and the CE was set at 35 v.   In the first instance only an 
MS scan was performed.  This was performed in a data dependent manner in positive 
ion mode, with 60000 resolution and a mass range of 335 – 1800 m/z. The data was 
acquired as a profile scan.  The raw MS data was then input into Progenesis and 
analysed as described in section 2.2.11.1.  The features identified from the Progenesis 
software were exported into an excel spreadsheet to generate an inclusion list.  The 
inclusion lists included features up-regulated in CRC or Dukes, the retention time for 
the feature, the normalised abundance for the feature and the features charge state.  A 4-
minute retention time window (+/- 2 minutes) was added to the retention time for a 
particular feature generated in Progenesis to allow for any differences in the LC 
operating conditions.  Only up regulated features in the disease group were included for 
further analysis, as we initially hypothesized that this aberration would be more likely 
than down regulation.  This feature list was subsequently included in the initial MS 
method (Global parent masses) and re run using the same samples to generate MS2 data 
on the features within the inclusion list only.  The IT-MS/MS was performed with 
centroided data, with a default charge state of > +2, using CID activation and a 
normalised CE of 35 v. 
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2.1.10  Quantitation and Identification of mass spectrometry derived 
iTRAQ and label free data 
2.1.10.1  iTRAQ quantitation using Mascot 
Raw data was processed and filtered via Mascot Distiller/Daemon (Versions 
2.2.2/2.2.1.0, Matrix Science) in the case of data generated from the Orbitrap, whilst 
data generated from the QSTAR was processed via Mascot Daemon using .WIFF files.  
The ITRAQ quantitation method was configured in Mascot, a description of which is 
found in Table 7 overleaf 
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Table 7: MASCOT iTRAQ quantitation method 
METHOD 
Constrain Search No 
Protein Ratio type Median 
Require bold red Yes 
Minimum peptides 2 
MODIFICATION GROUPS FIXED 
Carbamidomethyl (C) 
ITRAQ (N term) 
ITRAQ (K) 
MODIFICATION GROUPS VARIABLE:  ITRAQ (Y) 
PROTOCOL: Reporter 
COMPONENTS: 
 114 115 116 117 
Monoisotopic 114.11123 115.10826 116.11162 117.11497 
Average 114.17347 115.16688 116.15954 117.15219 
CORRECTIONS/SHIFTS: 
 114 115 116 117 
-2 0.0 0.0 0.0 0.1 
-1 1.0 2.0 3.0 4.0 
1 5.9 5.6 4.5 3.5 
2 0.2 0.1 0.1 0.1 
RATIOS: 
Numerator: 114, 115, 116, 117 Coefficient: 1.0 
Denominator: 114 Coefficient: 1.0 
QUALITY: 
Minimum precursor charge 1 
Isolated precursor No 
Min. a(1) 0.0 
Peptide Threshold Type At least homology 
Peptide Threshold Value 0.05 
Exclusion ITRAQ_Variable 
OUTLIER: Auto 
NORMALISATION: Median 
 
The following parameters (See Table 8) were then set in Mascot for Protein 
Identification for QSTAR and Orbitrap iTRAQ data 
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Table 8: MASCOT parameters for iTRAQ Protein ID analysis 
 QSTAR ORBITRAP 
Database IPI Human 
Taxonomy All entries 
Enzyme Trypsin 
Report top Auto 
Max missed cleavages 1 
Fixed modifications All in template 
Variable modifications Dioxidation,  Acetyl  (N  term),  Gln  →  pyro-Glu (N term Q), Oxidation 
(M) 
Peptide tolerance ± 0.5 Da 10ppm 
#13C 2 peaks after 1st carbon 12 
Monoisotopic Yes 
Fragment mass tolerance ± 0.8 Da ± 0.6 Da 
Quantitation method  Applied 
Data import filter ABI MDS Sciex analyst. WIFF file MGF files generated from raw 
data in distiller 
 
Protein identification and quantitation acceptance criteria were 
1. Ion score > threshold for Mascot i.e. scores within the confidence range of 95% 
probability, p < 0.05 
2. Bold red 
3. Fold change in expression < 0.5 or > 1.5 
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2.1.10.2  Label free quantitation utilising Progenesis LC-MS 
6 replicate runs per sample (CRC, Dukes and control) were analysed via the Progenesis 
LC-MS workflow.  Raw data files (MS only) generated from the Orbitrap were 
imported into the software in profile mode.  Each data file appeared as a 2-D 
representation of the run and at this point any problems with the data import including if 
the data had been centroided during the acquisition and subsequent conversion were 
highlighted.  Following the data import stage a reference LC-MS data file was selected, 
to which all the runs would be aligned to.  The reference run was usually the 3rd 
replicate generated from the control sample, as it demonstrated a clear and 
representative feature pattern and had minimum distortion.  The next step was to align 
the LC-MS data from each replicate run to the reference to correct for the variable 
elution of peptides during the chromatographic separation and was therefore performed 
in the retention time direction.  For each run a total of 5 manually placed alignment 
vectors were placed, evenly distributed from top to bottom of the whole run.  The 
features from the reference run were highlighted in green whilst the run being analysed 
in green, therefore any manually placed vectors were deemed correct when a particular 
feature turned black.  Upon addition of the manual vectors, between 200-400 automatic 
vectors was also generated by the software.  This process was repeated for all the runs.  
Alignment was manually verified for each run and corroborated by ensuring a similar 
number of vectors being added for each replicate run.  Any replicate run, which clearly 
had a disparity between the total vectors numbers as compared to the other 
corresponding replicate runs within the sample set, was excluded from subsequent 
analysis.  Upon completion of the alignment stage the data was filtered according to 
either position, charge state, number of isotopes or combinations of these parameters.  I 
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refined the sample set by including only those features (peptides) that had a charge state 
of 2+, 3+ or 4+ and at least 2 isotopes, features  that  didn’t  possess  these  properties  were  
not included.  Upon filtering the runs were grouped biologically for comparative 
purposes, allowing the software to generate a list of statistically ranked features, with 
accompanying fold changes.  At this point the feature list was edited to include only 
those features with an Anova value of p < 0.05 and a fold change greater than 2.  A 
value of infinity indicated presence/absence.  The review stage had 3 display modes: 
1D, 2D and 3D expression profiles which allowed for comparative exploration of the 
detected features.  The information was displayed as an aggregate for the feature across 
all the aligned runs, however details of individual runs could be displayed to ascertain if 
there was any missing data.  If a feature had data missing from more than 2 of the 
replicate runs it was not included for further analysis.   
Peptide abundance was calculated from the sum of the peak areas within the isotope 
boundaries, therefore peptide ions and isotope boundaries were manually verified and 
edited if required for each feature during this stage, by 
1. Splitting, merging or deleting peptide ions. 
2. Adding, removing or adjusting isotope boundaries. 
Any editing of a particular feature was again performed on the aggregate run and thus 
propagated across all runs.  
The ranked list was further refined using the 3 statistical tools in the next part of the 
Progenesis LC-MS workflow.  Firstly using principal component analysis.  I could 
identify if there were any outliers in my data and how well the samples grouped, any 
run   which   didn’t   cluster   according   to   the   original   groupings   was   disregarded.         The  
second option you can explore within Progenesis LC-MS is the relationship between 
 141 
features expression profiles using correlation analysis, this is graphically displayed as a 
dendogram, as well as all the features which were analogous being highlighted in the 
adjacent table, allowing me to select those features that were differentially upregulated 
in the CRC pool and Dukes samples. The final statistical test applied to the data set was 
power analysis.  A graphical representation showing the percentage of features which 
have a power of 80% or more and how this relates to the number of replicates per 
sample is provided for each experiment.  Only those features with a power value greater 
than 80% were included for further analysis.  So in summary a feature was included for 
subsequent analysis if: 
1. P value < 0.05 
2. Fold change at the peptide level of > 2 
3.  There  were  no  missing  values  for  ≥ 2 of the replicates 
4. Clustered within the original groupings 
5. It was upregulated in CRC pool or Dukes stage 
6. Power > 0.8 
Using the above parameters to filter the data a list of features was generated for 
inclusion and thus generation of MS2 spectra for protein identification.  The MS2 data 
was generated for each inclusion list using the Orbitrap mass spectrometer as described 
in the aforementioned section.  Upon generation of the LC-MS data containing MS2 
spectra, the raw files were loaded into the software and aligned to the original reference 
run   and   subsequently   assigned   to   one   of   the   defined   original   groups.      In   the   “view  
results”   tabset   any   feature   with   MS2   data   was   highlighted   in   the   features   table   and  
selected  for  inclusion  in  the  “query  set.”   Using RAW2MSM (Version 1.7.2007.04.11) 
the Orbitrap XL .RAW MS2 data were extracted to generate mascot generic files 
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(.mgf).  The extracted data was then searched in Mascot using the parameters outlined 
in Table 9. 
Table 9: MASCOT parameters for Label free Protein ID analysis 
Type of Search MS/MS ion search 
Instrument ESI-TRAP 
Database IPI Human 
Taxonomy All entries 
Enzyme Trypsin/P 
Report top Auto 
Max missed cleavages 1 
Fixed modifications Carbamidomethyl (C) 
Variable modifications Dioxidation,  Acetyl  (N  term),  Gln  →  pyro-Glu (N term Q), Oxidation 
(M) 
Peptide tolerance ± 10ppm 
#13C 2 peaks after 1st carbon 12 
Monoisotopic Yes 
Fragment mass tolerance ± 0.6 Da 
Data import filter MGF files generated from raw data in distiller 
 
Upon completion the search was saved as a .DAT file and imported back into the 
Progenesis software.  The protein IDs were then coupled with the original MS data to 
construct a list of not only proteins IDs but also associated fold changes.  The fold 
change was derived from the original MS data by initially measuring the sum of all the 
peak areas to generate the peptide abundance.  The protein abundance was then 
computed from the sum of all the peptide ion abundances, which have been identified as 
coming from a particular protein.   In the final two sections of the software the protein 
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IDs and their associated quantitation and statistics could be reviewed and any 
conflicting results scrutinised and omitted to produce a final report. 
2.2  SDS-PAGE analysis of serum profile 
2.2.1  1D gel preparation 
Serum from the CRC pool and control pool were depleted, TEAB buffer exchanged and 
lyophilized.  The dried sample was re-suspended in 20µl of 50mM TEAB in preparation 
for Bradford quantitation, which was prepared as described previously.  A volume 
equivalent  to  3,  5  and  10μg  of  protein  were  removed  from  each  sample,  as  determined  
by the Bradford assay and dried in a speedvac.  The dried samples were re-suspended in 
10μl  of  x4  sample  buffer,  10μl  MilliQ  and  finally  5μl  of  50mM  DTT,  and  incubated  at  
70°C  for  10  minutes.    Subsequently  5μl  of  300mM  IAA  and  10μl  of  MilliQ  were  added  
and left to incubate in   the   dark   at   room   temperature   for   30   minutes.      40μl   of   each  
sample was loaded into the wells of a 4-12% bis-tris gel, the 1st well being occupied by 
5μl   of   the   benchmark   protein   ladder.      The   MOPS   running   buffer   was   prepared   by  
adding 30mls of MOPS to 575mls of MilliQ and then poured  into the gel running 
chamber.    50μl  of  antioxidant  was  added  to  the  buffer  and  then  gel  was  set  off  to  run  at  
200V for approximately 45 minutes or until the samples had reached the bottom of the 
gel.  The gel was stained with coomassie stain for 1 hour and then de-stained for 30 
minutes with MilliQ.  Prior to excising the gel bands an image was obtained.  Gel bands 
from  the  wells  loaded  with  5μg  of  protein  from  the  both  the  control  and  CRC  pool  were  
excised and further bands of interest, i.e. those that differed from the 2 sample sets were 
also  excised  from  the  lanes  loaded  with  3μg  of  protein.     
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2.2.2  Gel band clean up 
To  each  gel  slice  200μl  of  MilliQ  and 200μl  of  100%  Acetonitrile  was added and left at 
room temperature for 15  minutes.      The   solvent   was   discarded   and   200μl   of   100mM  
ammonium bicarbonate was added to the residual gel pieces and again left at room 
temperature   for   15   minutes.      The   solvent   was   once   discarded   and   200μl   of   100Mm  
ammonium bicarbonate in 50% Acetonitrile was added and left at room temperature for 
15   minutes.      The   solvent   was   discarded   and   a   final   volume   of   100μl   of   100%  
Acetonitrile was added and left at room temperature for 10 minutes.  The solvent was 
discarded and the gel pieces were dried in the speed vac for 30 minutes 
2.2.3  In-gel reduction/Alkylation  
10mM DTT in 100mM ammonium bicarbonate was added to each gel band and 
incubated at 56°C for 60 minutes, discarding the buffer after this time had elapsed.  
50mM IAA in 100mM ammonium bicarbonate was then added to the gel bands and 
incubated at room temperature in the dark for 30 minutes, once again discarding the 
buffer after use.  The gel bands were finally washed in 50:50 20mM ammonium 
bicarbonate:ACN, and then 100% ACN for 15 minutes each.  The gel bands were once 
again  speedvac’d  to  dryness.  
2.2.4 Tryptic digestion of gel band slices  
Trypsin   (Roche   modified   sequencing   grade)   was   prepared   by   adding   25μl   of   1mM  
Hydrochloride   acid   to   a   vial   of  Roche   trypsin,   2.5μl  was   removed   from   the   vial   and  
decanted   into   200μl   of   20mM   ammonium   bicarbonate   to   a   final   concentration   of  
12.5μg/ml.     A  volume  was  decanted  onto   the  dry  gel   bands,   just   enough   to   rehydrate  
and  cover,  which  usually  equated  to  a  volume  of  5μl.    The  digests  were  then  incubated  
overnight at 30°C on a shaking platform. 
 145 
2.2.5  Gel band extraction 
The following day an equal volume of 100% Acetonitrile was added to the above and 
left at room temperature for 10 minutes to extract the peptides.  This volume was 
removed and decanted into a fresh lo-bind tube and dried in the speed vac.  To the gel 
pieces  50μl  of  5%  formic  acid  was  added  and  left  at  room  temperature  for  10  minutes.    
Following   this   period   50μl   of   100%   Acetonitrile   was   added   and   the   samples   left   to  
incubate for 45 minutes at room temperature.  This volume was removed and 
transferred into the same fresh lo-bind eppendorf tube and placed into the speed vac.  
To  the  gel  pieces  40μl  of  100%  Acetonitrile  was  added  and  left  at  room  temperature  for  
10 minutes.  This volume was transferred into the fresh lo-bind eppendorf tube and 
dried in the speed vac in preparation for LC-MS/MS analysis on the Applied 
Biosystems QTRAP. 
2.2.6  LC-MS/MS analysis of gel pieces 
An ultimate 3000 nLC (Dionex) HPLC was linked to a 4000 QTRAP. Essentially it 
consists of 2 HPLCs attached to a linear trap.  The Dionex 3000 buffers were as follows 
Gradient pump:   Buffer A – 2% ACN) in 0.1% FA 
    Buffer B - 90% ACN in 0.08% FA 
Loading pump:  0.1% FA in 2% ACN 
Post column addiction: 80% 2-propanol 
The dried gel pieces were  reconstituted  in  5μl  of  5%  formic  acid,  vortexed  and  then  40  
μl  of  milliQ  water  was  added  to  bring  the  formic  acid  concentration  to  1%.     
The extracted digest was initially loaded onto the trapping column (Pep-Map C-18 1mm 
x  5mm)  at  a  rate  of  20μl/min.    The trapping column was then turned into the gradient 
pump pathway flowing at 200nl/min in line with the Nano column (Pep-Map  C18  75μm  
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x 150mm).  Peptides were eluted from this column using a gradient of 5% to 90% 
Buffer B over 30 minutes and mixed with post column buffer into the MS system.  The 
MS system was controlled by Analyst 1.4.1.  All spectra were acquired in data 
acquisition mode (positive ion) with an MS survey scan and 8 IDAs for MS/MS.  
Meaning that the MS system would scan for 1 second then choose 8 peptides from the 
MS 1 scan to MS/MS (0.5 sec x 8), so that the duty cycle was 9 seconds, which was the 
repeated over the whole gradient length i.e. 30 minutes. 
2.2.7  Fingerprint identification of gel slice extractions 
The MS/MS data was extracted into a Peak list file (*.tmp) using a script in Analyst 
1.4.1.  This PKL file was then used to perform the database search. 
The extracted data was then searched in Mascot using the parameters outlined in Table 
10. 
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Table 10: MASCOT parameters for Gel QTRAP analysis 
Type of Search MS/MS ion search 
Database IPI Human 
Taxonomy All entries 
Enzyme Trypsin/P 
Report top Auto 
Max missed cleavages 1 
Fixed modifications Carbamidomethyl (C) 
Variable modifications Dioxidation, Acetyl  (N  term),  Gln  →  pyro-Glu (N term Q), Oxidation 
(M) 
Peptide tolerance ± 10ppm 
#13C 2 peaks after 1st carbon 12 
Monoisotopic Yes 
Fragment mass tolerance ± 0.6 Da 
Data import filter Peak list file 
 
2.3 Sub-proteome analysis – Glycosylation analysis using 
multi-lection affinity chromatography 
2.3.1 Preparation of buffers and multi-lectin affinity PD-10 disposable 
column 
The agarose bound lectins listed in Table 14 were used to prepare the multi-lectin 
affinity column.  The table also includes the corresponding elution buffer, used to 
fractionate the sample.  A multi-lectin equilibration buffer (20mM Tris, 150mM NaCl, 
1mM Mn2+, 1mM Ca2+, pH 7.4) was used to equilibrate the column, prepare the 
samples and also remove any non-specifically bound proteins. 
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Table 11: Lectins and their corresponding elution buffer 
LECTIN ELUTION BUFFER ELUTION 
ORDER 
Jacalin (Jac) 0.8M Galactose, 20mM Tris, 0.15M NaCl,  
pH 7.4 
1 
Concanavalin A (Con A) 0.5M methyl-α-D-mannopyranoside, 20mM Tris, 
0.15M NaCl, pH 7.4 
2 
Wheat Germ Agglutinin 
(WGA) 
0.5M N-acetyl-glucosamine, 20mM Tris, 0.15M Nacl, 
pH 7.4 
3 
 
The multi-lection affinity columns were prepared with 0.5mls of each of the following 
lectins Jac, Con A and WGA in a PD-10 disposable column.  A separate column was 
prepared for each sample in the experimental set up.  The lectins were both loaded onto 
and eluted from the PD-10 disposable column in the order depicted in the above table.  
Prior to loading of the agarose bound lectins 10µl of equilibration buffer was added to 
the bottom of the PD-10 column.  
2.3.2  Elution of captured proteins 
Control and CRC samples were primarily depleted using the IgY/Supermix depletion 
column previously described.  Following this the depleted samples underwent 
diafiltration using the 5KDa MWCO markers as outlined in section xx.  After the 
diafiltration step the samples were lyophilized and stored at -20ºC until further analysis.  
The thawed samples were subsequently re-suspended in 50µl of the lectin equilibration 
buffer.  Bradford quantitation was carried out in the manner as described in previous 
sections, and a volume which equated to 50µg of protein was removed from each 
sample and loaded onto the columns.  The columns were left at room temperature for 15 
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minutes.  10mls of elution buffer was subsequently added to displace the bound 
glycoproteins form the lectin affinity media and collected for further analysis. 
2.3.3 Concentration, reduction, alkylation and digestion of the generated 
glycoproteins 
Each fraction was concentrated using a 10kDa Amicon filter and buffer exchanged with 
50mm TEAB for a total of 3 times with a total volume of 12mls of TEAB for 20 
minutes at 5000g.  Following this the fractions were dried in the speed vac overnight.  
Dried samples were re-suspended in 20µl of 50Mm TEAB and the amount of protein 
recovered in each fraction as well as the unbound fraction was measured by Bradford 
quantitation.  The recovery from the columns was calculated using the following 
equation: 
Recovery (%) = (Flow through + eluted protein) / (Total amount of protein loaded) x 
100 
Similar amounts of protein were decanted into fresh Lo-Bind eppendorf tubes and 
reduced with 5µl of 50mm DTT and incubated for 30 minutes at 56°C.  Fractions were 
then alkylated with 5µl of 300mm IAA and left for 30 minutes in the dark.  Finally the 
fractions were digested overnight with 1µg of Roche trypsin and dried in a speedvac the 
following morning.  The fractions were stored at -20ºC until LC-MS/MS analysis. 
2.3.4  LC-MS/MS analysis of glycoproteins isolated using the multi-lectin 
affinity column 
The enriched glycopeptide fractions were reconstituted   in   5μl   of   5%   formic   acid,  
vortexed   and   then   40   μl   of   milliQ   water   was   added   to   bring   the   formic   acid  
concentration to 1%.   They were subsequently separated on the ultimate 3000 nLC 
(Dionex) HPLC and finally analysed on the QTRAP 4000 as described in section 2.3.  
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2.3.5  Fingerprint identification of glycoproteins following lectin 
immunoaffinity analysis 
The MS/MS data was extracted into a Peak list file (*.tmp) using a script in Analyst 
1.4.1.  This PKL file was then used to perform the database search. 
The extracted data was then searched in Mascot applying the search parameters detailed 
in Table 12.  For identification of the glycosylation sites the variable modifications were 
extended to deamination of asparagine (N). 
Table 12: MASCOT parameters for ID of glycoproteins 
Type of Search MS/MS ion search 
Database IPI Human 
Taxonomy All entries 
Enzyme Trypsin/P 
Report top Auto 
Max missed cleavages 1 
Fixed modifications Carbamidomethyl (C) 
Variable modifications Dioxidation,  Acetyl  (N  term),  Gln  →  pyro-Glu (N term Q), Oxidation 
(M), deamination of asparagine (N) 
Peptide tolerance ± 10ppm 
#13C 2 peaks after 1st carbon 12 
Monoisotopic Yes 
Fragment mass tolerance ± 0.6 Da 
Data import filter Peak list file 
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RESULTS 
3.1  Comparison of serum depletion methods 
The optimal antibody depletion method/column for depleting crude serum was 
established by looking at 3 different depletion columns, namely Agilent Human MARS 
6 and MARS 14 columns, which deplete serum of the top 6 and top 14 most abundant 
proteins respectively, and lastly the IgY LC-14 /Supermix system from Seppro Genway 
which depletes serum of the 14 most abundant proteins and then 50 of the moderately 
abundant proteins or tissue leakage proteins.  The MARS columns are both centrifugal 
spin   down   columns,   which   have   a   capacity   of   10μl   and   15μl   of   crude   serum  
respectively.  The IgY/Supermix system is an LC column, with a loading capacity of 
200µl of crude serum.  All of the aforementioned columns contain polyclonal antibodies 
but with different binding specificities.  Using a pool of control serum the aim was to 
comprehensively evaluate and compare the 3 different columns with regard to not only 
corroborating if their use would improve the eventual serum protein profiles through the 
detection of low abundant proteins of biological interest, but also if they were 
reproducible, sensitive and efficient.  The columns were thus assessed by determining 
the  
1. Total number of proteins identified. 
2. Total number of low abundant proteins present in the unbound fraction. 
3. Number of high abundant or medium abundant proteins present in the 
unbound fraction which should effectively have been removed by the 
antibody columns (depletion efficiency)  
4. Number of unique and cross over proteins identified by each system.  
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High abundant proteins were defined as those that should have been removed by any of 
the depletion systems.  Medium abundant proteins were described as those that should 
have been removed by the supermix system, whilst low abundant proteins were 
specified as those not expected to be removed by depletion.   
We initially tested the columns without using any peptide separation methods, followed 
by the analysis of the fractions using HPLC coupled with both the QSTAR and 
Orbitrap-XL mass spectrometers. All analyses of the columns were performed in at least 
2 replicate experiments.  
Table 13:  Comparison of Serum depletion methods using the QSTAR mass 
spectrometer.  
 DEPLETION COLUMN 
MARS Hu6 MARS Hu14 IgY/Supermix 
No. of proteins above 
significance threshold 
39  34  35 
No. of high abundant 
proteins (%) 
13 (33%) 
 
8 (24%) 4 (11%) 
No. of medium abundant 
proteins (%) 
15 (39%) 10 (29%) 7 (20%) 
No. of low abundant 
proteins (%) 
11 (28%) 
 
16 (47%) 24 (69%) 
No. of unique proteins (%) 16  (41%) 11 (32%) 23 (67%) 
No. of cross over proteins 
(%) 
23 
(59%) 
23 
(68%) 
12 
(33%) 
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Figure 14: Comparison of antibody depletion columns using the QSTAR mass 
spectrometer 
 
When comparing the columns using the QSTAR mass spectrometer, it was 
demonstrated firstly that the total number of proteins analysed did not differ hugely 
between the columns (39 for MARS Hu6, 34 for MARS Hu14 and 35 for 
IgY/Supermix) using the QSTAR mass spectrometer (See Table 16 and Figure 14).  
However a higher percentage of high and medium abundance proteins were reported 
using the MARS Hu6 column (33%) compared to the MARS Hu14 (24%) and 
IgY/Supermix (11%) system (See Table 16 and Figure 14).  The IgY/Supermix system 
generated a larger percentage of both low abundance (69%) and unique proteins (67%) 
(See Table 16 and Figure 14).  Overall from this analysis it therefore appears that the 
IgY/Supermix system gives a more unique and in depth proteome coverage in terms of 
the number of both distinctive and low abundance proteins identified. 
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Table 14:  Comparison of Serum depletion methods using Orbitrap-XL mass 
spectrometer.  
 DEPLETION COLUMN 
MARS Hu6 MARS Hu14 IgY/Supermix 
No. of proteins above the 
significance threshold 
74 81 98 
No. of  high abundant 
proteins (%) 
12 (16%) 9 (11%) 6 (7%)  
No. of medium abundant 
proteins (%) 
36 (49%) 46 (57%) 19 (19%) 
No. of low abundant proteins 
(%) 
26 (35%) 26 (32%) 73 (74%) 
No. of unique proteins (%) 28 (38%) 33 (41%) 69 (70%) 
No. of cross over proteins 
(%) 
46 (62%) 48 (59%) 29 (30%) 
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Figure 15: Comparison of antibody columns using the Orbitrap-XL mass spectrometer 
 
A number of conclusions can be inferred upon from the above Table 17 and Figure 15. 
Firstly, as corroborated by the results generated from the QSTAR and Orbitrap mass 
spectrometers the use of the IGY/Supermix antibody depletion system improves the 
resolution of serum proteomic analysis, in that a larger number of both low abundance 
proteins (69%) and unique proteins (70%) were quantitatively determined following 
serum depletion utilising the IgY/Supermix system as compared to the MARS depletion 
kit.  Secondly use of the Orbitrap mass spectrometer, greatly increased the yield of 
proteins for which were above the significance threshold and also the overall numbers 
of low abundance proteins for all the depletion columns as compared the results 
generated from the QSTAR. In conclusion use of the IgY/Supermix antibody depletion 
serum depletion system in conjunction with subsequent mass spectrometer analysis 
utilising an Orbitrap augments the detection of low abundance proteins. 
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3.2 Comparison of protein precipitation/desalting methods 
The ability of Acetone precipitation and also diafiltration using 5kDa molecular weight 
cut off markers (MWCOs) to concentrate dilute peptide mixtures and remove low 
molecular weight materials was directly compared.  The MWCO markers had the added 
ability of being able to desalt and buffer exchange (diafiltration), separate the effluent 
from other bound molecules, and rapidly change the ionic and/or pH environment.  
Control crude serum was depleted via the MARS Hu6 antibody depletion columns and 
subjected to either acetone precipitation or diafiltration.  Quantifying the residual 
protein mass by Bradford protein estimation pre- and post precipitation/diafiltration 
ascertained the effectiveness of the 2 methods.  Application of acetone precipitation 
resulted in only a 36% protein yield, whilst use of the 5kDa MWCO markers resulted in 
a yield of 68% (See Table 15).   
Table 15: Comparison of protein precipitation/desalting methods 
 Average 
absorbance value 
pre procedure 
Protein 
estimation pre 
procedure (ug/ul) 
Average 
absorbance value 
post procedure 
Protein 
estimation post 
procedure (ug/ul) 
Acetone precipitation 0.308 6.1 0.119 2.2 
5kDa MWCO 
markers 
0.454 
 
9.3 0.317 6.3 
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3.3  Comparison of peptide separation methods 
Four peptide level separation methods were tested to determine their efficiency at 
separating a complex biological sample such as those utilised in this research, and in 
particular their ability to lead to the eventual sequencing of low abundant species.  The 
4 separation methods namely C18 zip tips, Strong Cation Exchange using a 
Thermofisher scientific column and Polysulfoethyl A column and lastly a high pH 
reverse phase column, the latter 3 being LC columns. All of the separation methods 
described above were tested with control serum digest that had previously been depleted 
using the IgY/Supermix depletion system and subsequently labelled with 4 ITRAQ 
reagents, so that 200µg of total protein was digested and subsequently analysed.  
Peptides were eluted from the columns with gradients as described in the materials and 
methods section, which in turn had been calculated according to the dimensions of the 
column, where 1 column volume was equivalent to 3.5 minutes.  Fractions were 
collected every minute and combined according to their abundance as ascertained from 
a UV trace at 215nm.  A total of 50-60 fractions for each LC separation method were 
subsequently analysed via the Orbitrap mass spectrometer, in the case of C18 zip tips a 
total of 8 fractions were analysed.  Resultant MS/MS data was filtered via Mascot 
Distiller and identified and quantified using Mascot Daemon.  From the Mascot report 
the parameters defined in Table 5 were determined, and along with a representative 
chromatogram of each column the effectiveness of each column was proven. 
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Table 16: Comparison of peptide separation methods 
 C18 Zip tips Thermo SCX PolySulfoethyl A 
SCX 
High pH-RP 
Total no. of 
proteins (%) 
39 82 96 82 
No. of high abundance 
proteins (%) 
13 (33%) 7 (9%) 3 (3%) 8 (10%) 
No. of medium 
abundance proteins (%) 
15 (38%) 28 (34%) 34 (35%) 31 (38%) 
No. of low abundance 
proteins (%) 
11 (28%) 47 (57%) 59 (61%) 43 (52%) 
No. of unique proteins 
(%) 
18 (46%) 29 (35%) 33 (34%) 25 (30%) 
No. of cross over 
proteins (%) 
21 (54%) 53 (65%) 63 (66%) 57 (70%) 
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Figure 16:  Venn diagram representing the overlap of identified proteins in the 4-
peptide separation methods tested 
 
 
   
The total number of proteins identified by each peptide separation method differed (See 
Table 20 and Figure 16).  The C18 zip tips reported the least with 39, whilst the others 
identified similar numbers (Thermo SCX 82, Poly LC 96 and High pH-RP 82) (See 
Table 20).  The C18 zip tips performed least well in terms of the numbers/% of low 
abundance proteins (See Table 20).  There was little variation in the numbers/% of high; 
medium and low abundance proteins identified between the LC columns (See table 20).  
The Poly LC column did however report the largest % of low abundance proteins (See 
table 20).  There was a larger % of unique proteins identified by the C18 zip tips but this 
is likely to be the case because a larger % of high abundance proteins were still present 
in the unbound fraction.  Similar numbers of unique and thus cross over proteins were 
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identified by the 3 LC columns.  This is demonstrated graphically within the Venn 
diagram above. 
The effectiveness of the columns at peptide separation was lastly assessed by comparing 
the chromatograms that were generated from each of the columns (Figures 17 - 19).  
The chromatograms differ between columns, but it appears that the Poly-LC SCX 
column generates both more well-defined, obvious peaks, and peaks that attain a higher 
intensity.   
It can therefore be inferred from the above results that the Poly-LC SCX column 
appears to be best at separating complex peptide mixtures. 
Figure 17:  UV chromatogram for Poly LC SCX column measured at 215nm.  The Y-
axis shows the UV absorbance, the X-axis the time in minutes. 
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Figure 18:  UV chromatogram for Thermo SCX column measured at 215nm.  The Y-
axis shows the UV absorbance, the X-axis the time in minutes. 
 
Figure 19:  UV chromatogram for RP column measured at 215nm.  The Y-axis shows 
the UV absorbance, the X-axis the time in minutes. 
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3.4  Optimisation of HPLC gradient 
3.4.1   HPLC gradient length optimisation 
Using a single depleted serum fraction generated from a C18 zip tip (10µl injection, 
total protein analysed 2.5ug) the effect of the length of the HPLC gradient on the 
number of peptides eluted and also the number of proteins yielded above the 
significance threshold was determined using the LC Packing’s HPLC interfaced with 
the QSTAR XL mass spectrometer.   From the single fraction we generated a total of 
1069 peptides and 1330 peptides for subsequent electrospray analysis using a 60min 
and 180 minute elution gradient respectively, although neither sample generated any 
significant protein hits when analysed in Mascot (Matrix Science) (See Table 17).   
Table 17: Comparison of HPLC gradient length for electrospray analysis 
 60 minute 180 minutes 
Total number of peptides 
analysed 
1069 1330 
Number of protein hits No significant hits No significant hits 
 
3.5  Optimisation of QSTAR parameters 
3.5.1     Effect of Enhanced Product Ion Scan duration on subsequent 
   Protein identification 
The length of the acquisition period of the MS2 scan was altered to ascertain the effect 
of this duration on the accumulated data.  A 1 second, 2 second and 3 second Enhanced 
Product Ion Scan (EPI) was tested using a simple peptide mixture and then finally a 
complex serum digest labelled with ITRAQ reagents at varying dilutions, with a 2 
second and 3 second EPI scan (See Tables 18 & 19).  Both experiments demonstrated 
 163 
that a 2 second EPI gave more peptide identifications and thus protein identifications, as 
well as more ITRAQ quantitation in the case of the latter experiment. 
Table 18:  Effect of EPI length on the number of peptides and proteins derived from a 
simple digest 
 EPI DURATION 
1 second 2 second 3 second 
No. of peptides 1778 1094 821 
No. of proteins > significance 
threshold 
6 7 6 
 
Table 19: Effect of EPI length on the number of peptides derived from an ITRAQ 
labelled serum digest 
 2 second EPI 3 second EPI 
Dilution No of peptides No of proteins No of peptides No of proteins 
1:1 3187 49 2296 46 
1:2 3057 53 2263 54 
1:5 2904    46 2065 40 
1:10 2890 43 2166 45 
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3.6  Optimisation of Orbitrap settings 
3.6.1        Optimal HCD collision energy for generation of ITRAQ reporter 
        ions/fragmentation data 
3 settings of normalised collision energy for HCD fragmentation were tested, 35%, 45% 
and 55% using 2 SCX fractions from a control ITRAQ experiment.  The normalized 
collision energy of 35% gave poor ITRAQ reporter intensities (See Table 24 and Figure 
24, and thus quantitation but good ms/ms fragments for identity, whilst the 55% 
generated good ITRAQ reporters for quantitation but poor ms/ms fragments for identity 
(See Table 20 and Figure 22).  The normalized collision energy of 45% gave both 
reasonable ms/ms fragments and ITRAQ reporter ion intensities (See Table 20 and 
Figure 21).  PQD fragmentation was also tested on this occasion and although it 
generated good reporter ion data, the ms/ms data was very poor (See Table 20 and 
Figure 23). 
Table 20:  Comparison of normalised collision energy HCD parameters 
 No. of peptides No. of proteins No. of proteins with ITRAQ 
ratios (%) 
HCD 35% 1467 26 4 (15%) 
HCD 45% 1481 31 11 (35%) 
HCD 55% 1329 22 13 (59%) 
PQD 1290 16 7 (44%) 
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Figure 20: HCD 35%.  MS/MS Fragmentation of ATEHLSTLSEK 
 
Figure 21: HCD 45%.  MS/MS Fragmentation of ATEHLSTLSEK 
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Figure 22: HCD 55%.  MS/MS Fragmentation of ATEHLSTLSEK 
 
Figure 23: PQD.  MS/MS Fragmentation of ATEHLSTLSEK 
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3.6.2  Comparison of QSTAR and Orbitrap for iTRAQ quantitation 
Using depleted but non-fractionated iTRAQ labelled control serum, and with the 
optimised settings described above for each Mass spectrometer, I compared the 
performance of each at iTRAQ quantitation against the parameters set out in Table 21 
below.   
Table 21: Comparison of Orbitrap-XL and QSTAR mass spectrometers at iTRAQ 
quantitation 
 MASS SPECTROMETER 
Orbitrap-XL QSTAR 
No. of proteins above 
significance threshold 
115 31 
No. of high abundant 
proteins (%) 
8 (7%) 6 (19%) 
No. of medium abundant 
proteins (%) 
21 (18%) 12 (39%) 
No. of low abundant 
proteins (%) 
86 (75%) 13 (42%) 
No. of unique proteins (%) 107 (83%) 28 (74%) 
No. of cross over proteins 
(%) 
8 (7%) 8 (26%) 
No of proteins without 
iTRAQ data (%) 
26 (22%) 26 (84%) 
 
In all of the parameters assessed, as expected the Orbitrap mass spectrometer out 
performed the QSTAR in all aspects.  It must however be noted that 84% of the proteins 
didn’t  have  a  label  attached  for   the  QSTAR  data.     This  seems  unexpectedly  high,  and  
rather than this representing poor instrumentation it may have been a difficulty with the 
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pre-analytical steps.  I did however look at the raw MS data to see if the iTRAQ labels 
were present and this was the case. 
3.7  Assessment of iTRAQ labelling error 
The error associated with iTRAQ labelling in my experiments was assessed using the 
proven methodologies described above.  2 replicate experiments were performed.  2 
tags were used 117 and 114, with 114 being used as the denominator in one of the 
Mascot searches, and 117 in the other.  A total of 78 proteins above the significance 
threshold were identified in the first experiment, 105 in the second, 96 of which were 
unique.    In  the  first  experiment  7  proteins  didn’t  have  any  iTRAQ  tags  attached  to  them.    
The remainder had both tags ascribed to them.  In the second experiment 40 proteins 
had no tags, the remainder had 2 tags appended.  The mean, standard deviation and % 
relative standard deviation (rsd) were then calculated.  Table 22 below summarises the 
findings. 
Table 22: Error associated with iTRAQ experiments 
Label 114 117 
Range 0.601 – 1.37 0.569 – 1.141 
Mean 0.938 0.984 
Standard deviation 0.074748 0.082229 
rsd (%) 8.0% 8.4% 
 
Both the sample and amount of sample were similar therefore if there was no error 
introduced the ratios would be 1.  The above demonstrates that the range of error 
associated with iTRAQ labelling in my experiments was 0.94 (+/- 0.07) – 0.98 (+/- 
0.08). 
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3.8  Final iTRAQ experiments  
3.8.1  CRC pool results 
Equal volumes of serum from all the cancer samples in this research were initially 
pooled and analysed using iTRAQ.  Serum protein expression profiles were evaluated 
by comparing the results from four biological replicates of the 4-plex iTRAQ 
experiment.  Within each experiment there were also duplicates of both the CRC pool 
and control samples.  The whole list of proteins and the reporter ion ratios relative to the 
controls generated from these experiments are presented in the appendix.  In total 251 
unique proteins amid all 4 experiments were identified and quantified by MASCOT, 
with 70, 145, 88 and 105 proteins in the first, second, third and fourth replicates 
respectively (See Table 66, appendix).  A total of 154 proteins across all 4 experiments 
had no reporter data appointed to the identified protein.  A subset of 12 (See Table 23) 
proteins were selected for possible bioinformatic analysis using IPA, based on certain 
selection criteria: 
1. Above significance threshold and p < 0.05 
2. Significant alteration i.e. iTRAQ ratio > 1.5 or < 0.5 
3. Consistent shift in both the duplicate samples in the same experiment and 
also, at least two of the biological replicates. 
The boxes shaded in red represent upregulated proteins (See Appendix and Table 23).  
There were no down-regulated proteins identified in any of the four experiments (See 
Table 67, Appendix and Table 23).  Where iTRAQ ratios have not been reported a 
dashed line illustrates this.  A blank box simply means that the protein was not 
classified in that particular replicate. 
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Table 23:  Deregulated proteins and their ratios in CRC serum identified in the 4 biological replicates 
 
PROTEIN IPI 
CRC 
(1) 
CRC 
(1) CON. 
CRC 
(2) 
CRC 
(2) CON. 
CRC 
(3) 
CRC 
(3) CON. 
CRC 
(4) 
CRC 
(4) CON. 
Av. Ratio Log2 
Isoform 1 of Alpha-1-
antitrypsin  IPI00553177 5.72 5.117 0.929 4.984 4.64 1.009 6.416 6.064 1.221 3.706 1.423 0.464 3.9806 1.992985906 
SERPINA3 cDNA 
FLJ35730 fis, clone 
TESTI2003131, highly 
similar to ALPHA-1-
Antichymotrypsin  IPI00550991 2.352 3.073 1.127 2.356 3.134 1.222 2.617 3.568 1.401 1.063 0.623 0.664 2.431125 1.281624074 
Leucine-rich alpha-2-
glycoprotein  IPI00022417 3.688 3.54 1.238 3.924 3.92 1.088 4.76 4.317 1.1 0.977 0.775 0.609 3.309375 1.726558779 
Serum amyloid P-
component  IPI00022391 1.738 2.024 1.027 1.738 --- 1.027 1.897 1.926 1.513 1.766 1.501 0.805 1.6157 0.692159346 
COL1A1 Collagen 
alpha-1 (I) chain  IPI00297646 8.299 8.243 2.557 6.35 6.266 2.436 --- --- 2.008 
   
6.343 2.665165342 
COL1A2 Collagen 
alpha-2 (I) chain  IPI00304962 12.94 8.243 2.557 4.99 6.827 0.514 --- 4.659 --- 
   
5.8198571
43 2.54098374 
HBA2;HBA1 
Haemoglobin subunit 
alpha  IPI00410714 5.725 3.33 1.974 5.894 3.287 1.945 --- --- --- 
   
4.042 2.015069322 
HPR 47 kDa protein  IPI00641737 7.613 6.202 0.886 6.575 5.746 0.893 --- --- --- 
   
5.4044 2.434134458 
Inter-alpha-trypsin 
inhibitor heavy chain 
H1  IPI00292530 2.787 --- --- 2.997 --- 1.144 1.244 1.171 1.193 3.309 2.003 1.542 2.774 1.471967788 
C9 Complement 
component C9  IPI00022395 2.232 2.571 1.23 2.306 2.574 1.229 2.595 2.863 1.567 --- --- --- 2.5235 1.335426087 
AZGP1 alpha-2-
glycoprotein 1, zinc  IPI00166729 2.007 2.234 0.978 1.923 2.222 1.028 2.081 2.526 1.214 1.269 1.167 0.761 2.1655 1.114700172 
S100A9 Protein IPI00027462 1.972 1.827 1.201 1.925 1.834 1.179 1.943 2.073 1.253    1.929 0.947853143 
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Functional analysis of the identified proteins was also performed in Panther 
(http://www.pantherdb.org) and also Uniprot (http://www.uniprot.org) and is 
displayed in Table 24. 
Table 24: Functional analysis of CRC pool identified proteins using iTRAQ 
Protein Protein Class 
 
Molecular 
function 
 
Biological function 
Isoform 1 of Alpha-1-
antitrypsin 
Peptidase inhibitor Peptidase activity Proteolysis 
Immunity 
SERPINA3 cDNA FLJ35730 
fis, clone TESTI2003131, 
highly similar to ALPHA-1-
ANTICHYMOTRYPSIN 
Peptidase inhibitor Peptidase activity Proteolysis 
Immunity 
Leucine-rich alpha-2-
glycoprotein 
Immunological Receptor activity Immunity 
Serum amyloid P-component  Metal ion binding Acute phase 
Protein folding 
COL1A1 Collagen alpha-1(I) 
chain 
Transporter Receptor activity Cell to cell adhesion and 
communication 
COL1A2 Collagen alpha-2(I) 
chain 
Transporter Receptor activity Cell to cell adhesion and 
communication 
HBA2;HBA1 Haemoglobin 
subunit alpha 
Transporter Ion binding and 
transport 
Oxygen transport, 
metabolism 
HPR 47 kDa protein - - - 
Inter-alpha-trypsin inhibitor 
heavy chain H1 
Peptidase inhibitor Peptidase activity 
Calcium ion 
binding 
Proteolysis 
S100A9 Protein S100-A9 Immunological Antimicrobial 
Antioxidant 
Apoptosis, immunity, 
chemotaxis 
C9 Complement component 
C9 
Immunological MAC constituent Immunity 
AZGP1 alpha-2-glycoprotein 
1, zinc 
Immunological Antigen binding 
Transporter 
activity 
Cell adhesion, antigen 
processing, immune 
response 
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The proteins appear to belong predominantly to the transporter, peptidase inhibitor or 
immunological protein families.  Thereby their primary roles appear to be involved in 
aspects of cellular immunity, transportation of molecules or receptor activities. 
3.8.2  Dukes A-C iTRAQ results 
Using the verified methodology described above the serum from patients with Dukes 
A-C were combined according to stage and analysed using three technical replicates 
per stage.  A total of 446 unique proteins (See Table 67, Appendix), were identified in 
the 3 Dukes iTRAQ experiments, with 425 proteins being identified in both 
experiments 1 and 3, and 429 in experiment 2.  56 proteins had no reporter data.  The 
whole list of proteins and the reporter ion ratios relative to the controls generated 
from these experiments are presented in the appendix (Table 67). 191 of these 
proteins were selected for possible bioinformatic analysis using IPA (See Table 25), 
based on certain selection criteria: 
1. Above significance threshold and p < 0.05 
2. Significant alteration i.e. iTRAQ ratio > 1.5 or < 0.5 
3. Consistent variation in the ratios in at least two of the biological replicates. 
The iTRAQ ratios from each replicate were used to derive an average ratio for each of 
these 191 specified proteins identified in a particular Dukes stage.  The average 
iTRAQ (Relative) ratio data was finally transformed to logarithmic scale using log 2 
transformation to make it easier to compare fold changes between up-regulated and 
down-regulated proteins. Red shaded boxes signify up-regulation and blue down-
regulation (See Table 29). All of the shaded boxes imply the degree of fold change is 
large enough for further study.  The numbers in bold in the Log2 columns refer to the 
stronger trend of fold change from Dukes A to C.   
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Table 25: Significant dys-regulated proteins in iTRAQ Dukes stages A-C (Average values produced 3 biological replicates) 
 
PROTEIN IPI 
DUKES A 
(Average) 
DUKES A 
(Log2) DUKES B (Average) 
Dukes B 
(Log2) 
DUKES C 
(Average) 
DUKES C 
(Log2) 
Isoform 1 of Alpha-1-antitrypsin  IPI00553177.1 0.572333333 -0.805072461 2.818 1.494671612 1.458666667 0.544650237 
A2M Alpha-2-macroglobulin  IPI00478003.1 0.762 -0.392137097 1.691 0.75787666 1.293666667 0.371465932 
AZGP1 alpha-2-glycoprotein 1, zinc  IPI00166729.4 0.728333333 -0.457329221 1.569333333 0.65015182 1.038666667 0.054732733 
Putative uncharacterized protein PZP  IPI00748437.2 0.64 -0.64385619 1.7105 0.774418104 0.9865 -0.019609044 
SERPING1 cDNA FLJ58826, highly similar to 
Plasma protease C1 inhibitor  IPI00879931.1 --- --- 2.736333333 1.452243986 1.364 0.447843644 
AMBP Protein AMBP  IPI00022426.1 --- --- 1.883 0.913033 1.433333333 0.519374159 
HPX Hemopexin  IPI00022488.1 --- --- 2.367 1.243059706 0.909 -0.1376478 
PRAME family member 11  IPI00867556.2 --- --- 3.624666667 1.857848327 1.564333333 0.64554796 
Neural cell adhesion molecule 2  IPI00376427.4 0.528 -0.921390165 2.107666667 1.075646719 1.348333333 0.431177202 
Probable E3 ubiquitin-protein ligase HERC2  IPI00005826.1 --- --- 1.582 0.6617496 1.207333333 0.271824046 
Isoform 3 of Ankyrin repeat domain-containing 
protein 26  IPI00793360.1 --- --- 1.582 0.6617496 1.207333333 0.271824046 
tudor domain containing 9  IPI00384419.4 --- 
 
1.61 0.687060688 1.1555 0.20851726 
SRGAP1 Isoform 2 of SLIT-ROBO Rho GTPase-
activating protein 1  IPI00414827.1 --- --- 1.582 0.6617496 1.207333333 0.271824046 
SLIT-ROBO Rho GTPase-activating protein 2  IPI00479125.3 --- --- 1.61 0.687060688 1.1555 0.20851726 
Putative uncharacterized protein ENSP00000373129  IPI00642121.2 --- --- 1.61 0.687060688 1.1555 0.20851726 
Putative uncharacterized protein TTN  IPI00412307.8 0.7525 -0.410236513 2.0215 1.015426204 
  APOA4 Apolipoprotein A-IV  IPI00304273.2 0.985666667 -0.020828257 1.357666667 0.441129314 1.999333333 0.999519021 
APOA4 apolipoprotein A-IV precursor  IPI00847179.1 0.99 -0.01449957 1.346666667 0.429392792 1.989 0.992043276 
CLU Clusterin  IPI00291262.3 0.626666667 -0.674229839 1.401 0.486456956 1.708666667 0.772870978 
55 kDa protein  IPI00029863.4 0.638666667 -0.64686494 1.267666667 0.342175438 1.644 0.717210299 
Serum amyloid P-component  IPI00022391.1 0.926 -0.110915901 1.512666667 0.597094108 2.407333333 1.26743592 
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ORM1 Alpha-1-acid glycoprotein 1  IPI00022429.3 --- --- --- --- 1.724666667 0.786317553 
IGFALS insulin-like growth factor binding protein, 
acid labile subunit isoform 1 precursor  IPI00925635.1 --- --- --- --- 2.231666667 1.158121555 
C2 Complement C2 (Fragment)  IPI00303963.1 --- --- 1.333666667 0.415398128 1.727666667 0.788824893 
CNDP1 Beta-Ala-His dipeptidase  IPI00064667.4 --- --- 1.479666667 0.565272208 1.928666667 0.947603823 
C8A Complement component C8 alpha chain  IPI00011252.1 --- --- 1.448 0.534061602 1.660333333 0.73147291 
Coagulation factor IX  IPI00296176.2 0.825666667 -0.276368632 1.144 0.194087052 1.622 0.69777382 
Corticosteroid-binding globulin  IPI00027482.1 0.677333333 -0.562062099 1.331666667 0.413233002 1.549 0.631337144 
Complement component C8 beta chain  IPI00294395.1 --- --- --- --- 1.652333333 0.724504758 
Isoform 1 of Ficolin-3  IPI00293925.2 0.746666667 -0.421463768 1.473666667 0.559410234 1.832666667 0.873944406 
SART1 U4/U6.U5 tri-snRNP-associated protein 1  IPI00021417.3 --- --- 1.009666667 0.013879077 1.768333333 0.82239025 
Kinesin-like protein KIF21B variant  IPI00397809.4 --- --- 1.009666667 0.013879077 1.768333333 0.82239025 
Isoform 2 of Uncharacterized protein C20orf117  IPI00797771.1 --- --- 1.009666667 0.013879077 1.768333333 0.82239025 
Isoform 2 of Nuclear mitotic apparatus protein 1  IPI00006196.3 --- --- 1.009666667 0.013879077 1.768333333 0.82239025 
Isoform 1 of Squamous cell carcinoma antigen 
recognized by T-cells 3  IPI00006025.1 --- --- 1.009666667 0.013879077 1.768333333 0.82239025 
Zinc finger CCCH domain-containing protein 6  IPI00410656.1 --- --- 1.009666667 0.013879077 1.768333333 0.82239025 
cDNA FLJ16404 fis, clone UTERU2008019, highly 
similar to Serine/threonine-protein kinase 3  IPI00411984.5 --- --- 1.009666667 0.013879077 1.768333333 0.82239025 
C19orf61 59 kDa protein  IPI00005189.1 0.626333333 -0.674997434 1.156333333 0.20955734 1.647666667 0.720424406 
Isoform 1 of Rab GTPase-binding effector protein 1  IPI00293009.4 0.7205 -0.472929664 1.475 0.560714954 1.863 0.897627674 
Isoform 1 of Sarcolemmal membrane-associated 
protein  IPI00791574.1 0.679 -0.55851652 1.110666667 0.1514259 1.506333333 0.591041056 
Isoform 7 of Sarcolemmal membrane-associated 
protein  IPI00432472.2 0.679 -0.55851652 1.110666667 0.1514259 1.506333333 0.591041056 
E3 ubiquitin-protein ligase RAD18  IPI00024579.1 --- --- 1.459666667 0.545638949 1.859666667 0.895044051 
Isoform 2 of Neuroepithelial cell-transforming gene 1 
protein  IPI00180559.3 --- --- 1.459666667 0.545638949 1.859666667 0.895044051 
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CP Ceruloplasmin  IPI00017601.1 0.636 -0.652901329 1.957333333 0.968889467 2.000333333 1.000240429 
GC vitamin D-binding protein precursor  IPI00742696.2 0.699 -0.516635639 2.001333333 1.000961476 1.772666667 0.825921276 
HBB Hemoglobin subunit beta  IPI00654755.3 0.662333333 -0.594370628 3.421333333 1.77455867 2.898 1.535057595 
GC Vitamin D-binding protein  IPI00555812.4 0.696333333 -0.522150008 1.913333333 0.936088236 1.747 0.804879608 
HBA2;HBA1 Hemoglobin subunit alpha  IPI00410714.5 0.774666667 -0.368352432 4.008666667 2.003122458 3.518 1.814755483 
ITIH1 Inter-alpha-trypsin inhibitor heavy chain H1  IPI00292530.1 0.603666667 -0.728175954 2.093 1.065572312 1.760666667 0.816121801 
SERPINF1 Pigment epithelium-derived factor  IPI00006114.4 0.945333333 -0.081104968 1.855666667 0.891937582 1.875333333 0.907147052 
GSN Isoform 1 of Gelsolin  IPI00026314.1 0.895333333 -0.159503196 1.538666667 0.621680723 1.950333333 0.963720717 
C9 Complement component C9  IPI00022395.1 0.587 -0.768567592 2.129 1.09017595 2.549 1.349931373 
AGT Angiotensinogen  IPI00032220.3 0.719 -0.475936324 1.925 0.944858446 2.014333333 1.010302441 
LRG1 Leucine-rich alpha-2-glycoprotein  IPI00022417.4 0.904333333 -0.145073453 3.469666667 1.794797069 3.019666667 1.594389303 
Serpin peptidase inhibitor, clade D (Heparin 
cofactor), member 1  IPI00292950.4 0.613 -0.706041021 1.661666667 0.732631004 2.313666667 1.210181028 
APOE Apolipoprotein E  IPI00021842.1 1.221333333 0.288457003 2.441 1.287472295 4.523666667 2.177492626 
COL1A1 Collagen alpha-1(I) chain  IPI00297646.4 --- --- 2.666 1.41467678 2.5 1.321928095 
APOE MRNA for apolipoprotein E  IPI00878953.1 1.2675 0.341985747 2.4905 1.316435411 4.4905 2.166876092 
ITIH3 Isoform 1 of Inter-alpha-trypsin inhibitor 
heavy chain H3  IPI00028413.8 0.906666667 -0.141355849 2.490666667 1.316531954 2.555 1.353323291 
ITIH2 Inter-alpha-trypsin inhibitor heavy chain H2  IPI00305461.2 0.661 -0.597277823 1.974666667 0.98160914 1.642333333 0.715746971 
cDNA FLJ60769, highly similar to Inter-alpha-
trypsin inhibitor heavy chain H3  IPI00909807.1 0.957666667 -0.062404508 2.51 1.327687364 2.582666667 1.368861453 
FN1 Isoform 1 of Fibronectin  IPI00022418.1 0.660666667 -0.598005538 2.283 1.19093086 3.984 1.994217647 
COL1A2 Collagen alpha-2(I) chain  IPI00304962.3 1.655333333 0.727121761 2.889 1.530570204 2.410666667 1.269432177 
C1RL Complement C1r subcomponent-like protein  IPI00009793.4 0.941 -0.087733372 1.702 0.767231037 2.463666667 1.300807073 
ACTG1 Actin, cytoplasmic 2  IPI00021440.1 0.607666667 -0.718647939 1.963666667 0.973550052 1.775333333 0.828089928 
SERPINA7 Thyroxine-binding globulin  IPI00292946.1 --- --- 1.894666667 0.921944054 2.015666667 1.011257078 
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APOC2 Apolipoprotein C-II  IPI00021856.3 1.796666667 0.845322772 2.595666667 1.376105126 4.606333333 2.203618814 
C1R cDNA FLJ54471, highly similar to Complement 
C1r subcomponent  IPI00296165.6 1.103666667 0.14230451 1.799333333 0.847462476 2.533333333 1.341036918 
C1S Complement C1s subcomponent  IPI00017696.1 0.524 -0.932361283 1.666 0.736388401 1.930666667 0.949099102 
ACTA2 ACTA2 protein (Fragment)  IPI00927545.1 0.607666667 -0.718647939 1.963666667 0.973550052 1.775333333 0.828089928 
C1RL 48 kDa protein  IPI00872573.1 0.939666667 -0.089779023 1.722666667 0.784643569 2.504333333 1.324426602 
POTEF ANKRD26-like family C member 1B  IPI00739539.6 0.607666667 -0.718647939 1.963666667 0.973550052 1.775333333 0.828089928 
CPN2 Carboxypeptidase N subunit 2  IPI00479116.1 --- --- 1.643333333 0.716625146 2.186 1.128293401 
Complement C1q subcomponent subunit C  IPI00022394.2 0.809 -0.305788392 1.717333333 0.780170093 1.823 0.866314561 
Coagulation factor X  IPI00019576.1 0.766666667 -0.38332864 1.818666667 0.862881144 1.821 0.864730922 
Mannosyl-oligosaccharide 1,2-alpha-mannosidase IC  IPI00745251.2 0.564666667 -0.824528626 2.145333333 1.101201825 1.883666667 0.913543688 
Isoform A of Zinc finger protein 268  IPI00031595.1 0.715666667 -0.48264031 2.554 1.352758525 2.125 1.087462841 
FABP1 protein (Fragment)  IPI00010290.2 0.6635 -0.591831629 2.5355 1.342270274 1.946 0.96051171 
sorting nexin 6 isoform b  IPI00298111.7 0.735 -0.444183845 2.489666667 1.315952597 2.214 1.146655222 
IGKV1-5 IGKV1-5 protein  IPI00419424.3 0.154666667 -2.69276579 0.627666667 -0.671929501 0.230333333 -2.118204885 
Putative uncharacterized protein  IPI00550731.2 0.16 -2.64385619 0.9135 -0.130523366 0.1945 -2.36215794 
IGKC IGKC protein  IPI00472961.2 0.189666667 -2.398461943 0.647 -0.628162383 0.296666667 -1.75308526 
IGKV2-24 IGKV2-24 protein  IPI00440577.3 0.188666667 -2.406088543 0.830666667 -0.267658432 0.245333333 -2.027184829 
IGK@ IGK@ protein  IPI00784865.1 0.188666667 -2.406088543 0.830666667 -0.267658432 0.245333333 -2.027184829 
IGKV3-20 IGK@ protein  IPI00889156.1 0.188666667 -2.406088543 0.830666667 -0.267658432 0.245333333 -2.027184829 
ALB Isoform 1 of Serum albumin  IPI00745872.2 0.074 -3.756330919 0.453333333 -1.141355849 0.223 -2.164884385 
ALB Putative uncharacterized protein ALB  IPI00022434.4 0.074 -3.756330919 0.452333333 -1.14454178 0.223333333 -2.1627295 
IGKC IGKC protein  IPI00845354.1 0.188666667 -2.406088543 0.880333333 -0.183878199 0.256333333 -1.963906997 
IGHM IGHM protein  IPI00472610.2 0.16 -2.64385619 0.615666667 -0.699778634 0.261666667 -1.934197942 
IGHV4-31 Immunoglobulin heavy variable 4-31  IPI00785084.1 0.161666667 -2.628905848 0.613 -0.706041021 0.261 -1.937878288 
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IGHG1 IGHG1 protein  IPI00448938.1 0.161666667 -2.628905848 0.613333333 -0.705256734 0.265 -1.915935735 
cDNA FLJ78387  IPI00876888.1 0.161666667 -2.628905848 0.613 -0.706041021 0.261333333 -1.936036941 
IGHG1 Putative uncharacterized protein 
DKFZp686O01196  IPI00423463.1 0.161666667 -2.628905848 0.613 -0.706041021 0.261 -1.937878288 
IGHG1 Putative uncharacterized protein 
DKFZp686K03196  IPI00423464.1 0.161666667 -2.628905848 0.615333333 -0.700559948 0.267666667 -1.901490608 
F7 Factor VII active site mutant immunoconjugate  IPI00382606.1 0.161666667 -2.628905848 0.617666667 -0.695099619 0.266333333 -1.908695092 
 HCG2010697  IPI00642632.1 0.166 -2.590744853 0.568333333 -0.815190761 0.426 -1.231074664 
IGLV3-21 IGLV3-21 protein  IPI00815938.1 0.162 -2.625934282 0.5745 -0.799621202 0.424 -1.23786383 
Putative uncharacterized protein ENSP00000374988 
(Fragment)  IPI00736860.3 0.111 -3.171368418 0.593333333 -0.75308526 0.226333333 -2.143479021 
IGHM Putative uncharacterized protein 
DKFZp686I15212  IPI00418153.1 0.163666667 -2.611167571 0.638 -0.648371671 0.274333333 -1.865998165 
IGHG3 IGHG3 protein  IPI00472345.1 0.163666667 -2.611167571 0.636333333 -0.652145398 0.271666667 -1.880090536 
Putative uncharacterized protein DKFZp686C15213  IPI00426051.3 0.098333333 -3.346175641 0.604333333 -0.726583576 0.226333333 -2.143479021 
IGHG2 Protein  IPI00829767.1 0.098333333 -3.346175641 0.604333333 -0.726583576 0.226333333 -2.143479021 
IGHG4 Putative uncharacterized protein IGHG4 
(Fragment)  IPI00830132.1 0.113 -3.145605322 0.590333333 -0.760398289 0.234333333 -2.093365906 
Ig kappa chain V-III region WOL  IPI00387118.1 0.195666667 -2.353530092 0.561 -0.833927324 0.405333333 -1.302819272 
IGJ immunoglobulin J chain  IPI00178926.2 0.35 -1.514573173 0.290666667 -1.782562461 0.487 -1.038006323 
Rheumatoid factor D5 light chain (Fragment)  IPI00816799.1 
  
0.685666667 -0.544420707 0.328666667 -1.605302949 
Myosin-reactive immunoglobulin kappa chain 
variable region (Fragment)  IPI00384401.1 0.126 -2.988504361 0.672333333 -0.572751417 0.367333333 -1.444838277 
Single-chain Fv (Fragment)  IPI00470652.1 0.113333333 -3.141355849 0.476333333 -1.069956584 0.367 -1.446148032 
IGKV2-40 Ig kappa chain V-II region Cum  IPI00387107.3 0.134333333 -2.896110757 0.549 -0.865121946 0.290666667 -1.782562461 
Putative uncharacterized protein ENSP00000374799 
(Fragment)  IPI00854709.1 0.134333333 -2.896110757 0.549 -0.865121946 0.290666667 -1.782562461 
LOC440786 Ig kappa chain V-II region TEW  IPI00736885.1 0.134333333 -2.896110757 0.549 -0.865121946 0.290666667 -1.782562461 
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ASCC3 cDNA FLJ56882, highly similar to 
Activating signal cointegrator 1 complex subunit 3  IPI00787562.3 0.082666667 -3.596550475 0.562 -0.831357964 0.205666667 -2.281620106 
Isoform 1 of Kinase suppressor of Ras 2  IPI00414043.2 0.301666667 -1.728972803 0.322333333 -1.633374706 0.497 -1.008682243 
Dystonin  IPI00642259.2 0.146666667 -2.769387072 0.462333333 -1.112994713 0.666666667 -0.584962501 
dystonin isoform 3  IPI00008756.7 0.146666667 -2.769387072 0.462333333 -1.112994713 0.666666667 -0.584962501 
Isoform 1 of Dynein heavy chain 17, axonemal  IPI00888430.1 0.146666667 -2.769387072 0.462333333 -1.112994713 0.666666667 -0.584962501 
Centrosome-associated protein 350  IPI00103595.2 0.146666667 -2.769387072 0.462333333 -1.112994713 0.666666667 -0.584962501 
Isoform 4 of Transforming acidic coiled-coil-
containing protein 2  IPI00643465.2 0.146666667 -2.769387072 0.462333333 -1.112994713 0.666666667 -0.584962501 
Isoform 1 of Melanophilin  IPI00012201.1 0.146666667 -2.769387072 0.462333333 -1.112994713 0.666666667 -0.584962501 
Isoform 1 of Exportin-5  IPI00640703.3 0.146666667 -2.769387072 0.462333333 -1.112994713 0.666666667 -0.584962501 
Isoform A of Uncharacterized protein C21orf70  IPI00027898.3 0.146666667 -2.769387072 0.462333333 -1.112994713 0.666666667 -0.584962501 
Isoform 1 of Engulfment and cell motility protein 1  IPI00219532.1 0.146666667 -2.769387072 0.462333333 -1.112994713 0.666666667 -0.584962501 
Putative uncharacterized protein C14orf53  IPI00924472.1 0.146666667 -2.769387072 0.462333333 -1.112994713 0.666666667 -0.584962501 
APOA1 Apolipoprotein A-I  IPI00021841.1 0.438333333 -1.189899701 0.571333333 -0.807595391 0.892333333 -0.164345362 
PPBP Platelet basic protein  IPI00022445.1 0.321333333 -1.637857449 0.722 -0.469929258 0.724666667 -0.46461056 
Lambda-chain  IPI00827875.1 0.232333333 -2.10573194 0.616 -0.698997744 0.535 -0.902389203 
IGL@ IGL@ protein  IPI00154742.6 0.23 -2.120294234 0.607 -0.720231578 0.537 -0.897006007 
IGL@ IGL@ protein  IPI00658130.1 0.237333333 -2.075013354 0.621666667 -0.68578687 0.535666667 -0.900592572 
IGLV2-14;IGLC2;IGLC1;IGLC3 IGLV2-14 protein  IPI00816555.1 0.232333333 -2.10573194 0.616 -0.698997744 0.535 -0.902389203 
IGL@ IGL@ protein  IPI00744476.6 0.232333333 -2.10573194 0.616 -0.698997744 0.535 -0.902389203 
Putative uncharacterized protein  IPI00807428.1 0.190333333 -2.39339985 0.618666667 -0.69276579 0.532 -0.910501849 
IGL@ IGL@ protein  IPI00555945.1 0.198333333 -2.334000927 0.620333333 -0.688884445 0.522666667 -0.936036941 
 IGLV4-3 IGLV4-3 protein  IPI00382938.3 0.182 -2.457989644 0.618666667 -0.69276579 0.523666667 -0.93327932 
IGHV3OR16-13;IGHA1 IGHA1 protein  IPI00430842.3 0.201 -2.314732593 0.582 -0.780908942 0.696 -0.522840789 
IGHV3OR16-13;IGHA1 IGHA1 protein  IPI00719233.1 0.201 -2.314732593 0.582 -0.780908942 0.696 -0.522840789 
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IGHV3OR16-13;IGHA1 Putative uncharacterized 
protein DKFZp686K18196 (Fragment)  IPI00423462.5 0.21 -2.251538767 0.595 -0.749038426 0.646 -0.63039393 
IGHV3OR16-13;IGHA1 SNC66 protein  IPI00383164.1 0.115 -3.120294234 0.615666667 -0.699778634 0.603666667 -0.728175954 
IGL@ IGL@ protein  IPI00745660.2 0.246333333 -2.021316231 0.646333333 -0.629649697 0.515 -0.957355663 
LOC100126583 cDNA FLJ41981 fis, clone 
SMINT2011888, highly similar to Protein Tro alpha1 
H,myeloma  IPI00784830.1 0.115 -3.120294234 0.607333333 -0.719439542 0.584333333 -0.775136505 
IGHA2 IGHA2 protein  IPI00783993.1 0.115 -3.120294234 0.607333333 -0.719439542 0.584333333 -0.775136505 
IGL@ IGL@ protein  IPI00829877.1 0.19 -2.395928676 0.618 -0.694321257 0.526666667 -0.925037942 
PRSS1 Trypsin-1  IPI00011694.1 0.119666667 -3.062906752 0.676666667 -0.563482773 1.079 0.109694865 
TF Serotransferrin  IPI00022463.1 0.323333333 -1.628905848 1.001666667 0.00240249 0.970666667 -0.042952145 
IGHA2 Putative uncharacterized protein 
DKFZp686O16217 (Fragment)  IPI00894384.1 0.1055 -3.244685096 0.65 -0.621488377 0.6035 -0.728574324 
APOA2 Apolipoprotein A-II  IPI00021854.1 0.198666667 -2.331578265 0.688666667 -0.538122247 0.760666667 -0.394663709 
IGHM IGHM protein  IPI00477090.6 0.279 -1.841662973 0.664 -0.590744853 0.62 -0.689659879 
IGHM IGHM protein  IPI00479708.5 0.279 -1.841662973 0.671 -0.575615328 0.621666667 -0.68578687 
CFI Complement factor I  IPI00291867.3 0.473333333 -1.079071571 1.138 0.186500558 1.314 0.393965276 
CFI 43 kDa protein  IPI00795153.2 0.465 -1.104697379 1.15 0.201633861 1.3165 0.396707521 
TMSL3 Thymosin beta-4-like protein 3  IPI00180240.2 0.082666667 -3.596550475 0.527333333 -0.923212901 0.602333333 -0.731365995 
V1-17 protein  IPI00887169.1 0.252 -1.988504361 0.672 -0.573466862 0.529333333 -0.917751588 
Ig lambda chain V-I region HA  IPI00382420.1 0.276666667 -1.853779259 0.719 -0.475936324 0.534333333 -0.904188075 
TPM4 Isoform 1 of Tropomyosin alpha-4 chain  IPI00010779.4 0.213333333 -2.22881869 0.751666667 -0.411835067 0.896666667 -0.157356328 
Amyloid lambda 6 light chain variable region SAR 
(Fragment)  IPI00386839.1 0.286 -1.805912948 0.606 -0.722610301 0.568666667 -0.814344854 
 Tetranectin  IPI00009028.1 0.496 -1.011587974 1.271333333 0.346342343 1.396 0.481298942 
Cryocrystalglobulin CC2 lambda light chain variable 
region (Fragment)  IPI00890733.1 0.252 -1.988504361 0.672 -0.573466862 0.529333333 -0.917751588 
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PROTEIN IPI 
DUKES A 
(Average) 
DUKES A 
(Log2) DUKES B (Average) 
Dukes B 
(Log2) 
DUKES C 
(Average) 
DUKES C 
(Log2) 
 PRG4 Isoform A of Proteoglycan 4  IPI00024825.2 0.396 -1.336427665 0.507 -0.979942348 0.694666667 -0.525607223 
IGLV4-69 V5-6 protein  IPI00478997.3 0.266333333 -1.908695092 0.807666667 -0.308168096 0.591666667 -0.757143476 
IGLV1-36 V1-11 protein  IPI00552943.3 0.252 -1.988504361 0.672 -0.573466862 0.529333333 -0.917751588 
PHKG1 PHKG1 protein  IPI00220396.19 0.4035 -1.309359421 0.9485 -0.076280321 1.1805 0.239398042 
IGLV1-40 V1-13 protein (Fragment)  IPI00789259.1 0.252 -1.988504361 0.672 -0.573466862 0.529333333 -0.917751588 
Ig lambda chain V-II region BUR  IPI00003947.1 0.252 -1.988504361 0.672 -0.573466862 0.529333333 -0.917751588 
IGLV2-18 V1-5 protein  IPI00553215.3 0.244 -2.035046947 0.6815 -0.553214438 0.513 -0.962969269 
Ig gamma lambda chain V-II region DOT  IPI00385686.1 0.252 -1.988504361 0.672 -0.573466862 0.529333333 -0.917751588 
Ig lambda chain V-II region NEI  IPI00382424.1 0.252 -1.988504361 0.672 -0.573466862 0.529333333 -0.917751588 
LOC651536 similar to hCG96018  IPI00742233.2 0.244 -2.035046947 0.6815 -0.553214438 0.513 -0.962969269 
Ig lambda chain V-II region VIL  IPI00382433.1 0.252 -1.988504361 0.672 -0.573466862 0.529333333 -0.917751588 
Ig lambda chain V-II region TOG  IPI00382423.1 0.244 -2.035046947 0.6815 -0.553214438 0.513 -0.962969269 
Isoform 1 of Calcyclin-binding protein  IPI00395627.3 0.187 -2.418889825 0.494 -1.017417053 0.825666667 -0.276368632 
SERPINA3 cDNA FLJ35730 fis, clone 
TESTI2003131, highly similar to ALPHA-1-
ANTICHYMOTRYPSIN  IPI00550991.3 0.303666667 -1.719439542 2.235333333 1.160489982 1.66 0.731183242 
HPR 47 kDa protein  IPI00641737.1 0.276 -1.857259828 3.153666667 1.65703018 1.752333333 0.809277234 
APOB Apolipoprotein B-100  IPI00022229.1 0.390333333 -1.357221425 1.495666667 0.580788683 2.471666667 1.305484192 
HPR Isoform 1 of Haptoglobin-related protein  IPI00477597.1 0.3 -1.736965594 3.102 1.633198686 1.947333333 0.961499857 
C5 Complement C5  IPI00032291.2 0.471 -1.086201035 2.219666667 1.150343039 1.727333333 0.788546515 
SERPINA4 Kallistatin  IPI00328609.3 0.280333333 -1.834784795 1.272666667 0.347854602 1.649666667 0.722174541 
 PGLYRP2 Isoform 1 of N-acetylmuramoyl-L-
alanine amidase  IPI00163207.1 0.414333333 -1.271136204 1.593 0.671746267 2.482 1.311503115 
ITIH4 100 kDa protein  IPI00896413.1 0.357333333 -1.484657595 2.044666667 1.031865666 1.180666667 0.239601711 
THBS1 Thrombospondin-1  IPI00296099.6 0.457666667 -1.127630875 1.717333333 0.780170093 1.446666667 0.532732542 
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PROTEIN IPI 
DUKES A 
(Average) 
DUKES A 
(Log2) DUKES B (Average) 
Dukes B 
(Log2) 
DUKES C 
(Average) 
DUKES C 
(Log2) 
ITIH4 ITIH4 protein  IPI00896419.2 0.357333333 -1.484657595 2.044666667 1.031865666 1.180666667 0.239601711 
ITIH4 Protein  IPI00922043.1 0.445 -1.168122759 2.090333333 1.063733019 1.201666667 0.265036759 
ITIH4 Isoform 1 of Inter-alpha-trypsin inhibitor 
heavy chain H4  IPI00294193.4 0.357333333 -1.484657595 2.044666667 1.031865666 1.180666667 0.239601711 
ITIH4 Isoform 1 of Inter-alpha-trypsin inhibitor 
heavy chain H4  IPI00294193.4 0.357333333 -1.484657595 2.044666667 1.031865666 1.180666667 0.239601711 
ITIH4 cDNA FLJ53871, highly similar to Inter-
alpha-trypsin inhibitor heavy chain H4  IPI00791097.2 0.3345 -1.579921884 2.084 1.059355278 1.117 0.159629186 
APOC1 Apolipoprotein C-I  IPI00021855.1 0.446666667 -1.1627295 1.793333333 0.842643672 2.808666667 1.489885415 
Isoform 5 of Titin  IPI00759613.1 0.483 -1.049904906 1.769666667 0.823477641 2.067333333 1.047771025 
Isoform 3 of Tubulin polyglutamylase TTLL7  IPI00643434.1 0.402 -1.314732593 2.527 1.337425664 1.225 0.292781749 
DMXL2 DMXL2 protein  IPI00152542.2 0.464666667 -1.10573194 1.997333333 0.998075123 
  cDNA FLJ55439, highly similar to TNF receptor-
associated factor 5  IPI00005760.2 0.309 -1.694321257 2.195666667 1.134659049 1.304 0.38294387 
Isoform 1 of R3H domain-containing protein 2  IPI00396041.6 0.27 -1.888968688 4.252333333 2.088254692 1.919333333 0.940605288 
Putative uncharacterized protein CDH26  IPI00853237.1 0.2615 -1.935117148 2.3165 1.211946682 1.2485 0.320195821 
Isoform 1 of Probable G-protein coupled receptor 
116  IPI00437186.1 0.284333333 -1.814344854 2.274 1.185232254 1.324666667 0.405629372 
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Table 26 summarizes (See also Table 25) the total number of proteins deregulated in 
each of the Dukes stages.  It exhibits the total numbers of proteins, which were 
deregulated specifically for a certain stage, and also the numbers that were 
deregulated in more than 1 Dukes stage. 
Table 26: Total numbers of deregulated proteins by Dukes stage 
Dukes stage Total number 
deregulated 
 
Total number 
upregulated 
 
Total number of 
proteins down 
regulated 
A 113 2 (2%) 111 (98%) 
B 87 72 (83%) 15 (17%) 
C 107 73 (68%) 34 (32%) 
 
A larger proportion of proteins were found to be down regulated in Dukes Stage A 
(98%), whilst in Dukes stage B and C proteins were found to be predominantly be up-
regulated, 83% and 68% respectively 
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Table 27: Numbers of deregulated proteins in Dukes Stages A-C identified in iTRAQ 
experiment 
Upregulated Proteins 
Number of 
proteins 
Dukes A only 0 
Dukes B Only 28 
Dukes C Only 28 
Dukes B & C 36 
- Higher Dukes B 17 
- Higher Dukes C 19 
Up-regulated protein in all 3 stages 2 
Down-regulated Proteins  
Dukes A only 68 
Dukes B only 0 
Dukes C only 0 
Dukes A & B 11 
- Higher Dukes A 11 
- Higher Dukes B 0 
Dukes A & C 27 
- Higher Dukes A 27 
- Higher Dukes C 0 
Down regulated proteins in all 3 stages 5 
Number of proteins deregulated (up or down) in all 3 stages  15 
 
As elucidated in Table 27 no proteins were up regulated only in Dukes stage A.  28 
proteins were up-regulated exclusively in Dukes Stage B and C. 68 proteins were 
specifically down regulated in Dukes A, whilst none were uniquely down regulated in 
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Dukes B and C.  Only a small proportion of proteins (15) were deregulated (up or 
down regulated) in all 3 stages.   
For an overview of the deregulated proteins functional analysis was performed using 
Panther and UniProt (See links above).  The proteins that were found to be 
deregulated belonged to the enzyme modulator (12%) and immunity (11%) protein 
classes predominantly (See Figure 24).   
Figure 24: Protein classes of deregulated Dukes Stage proteins 
 
Looking specifically at the molecular and biological functions of the proteins as 
depicted by Figures 29 and 30.   Biological analysis disclosed that the largest % of the 
proteins were involved in cellular processes and immunity (See Figure 25).  Whilst 
functional analysis revealed that the proteins are predominantly involved in cellular 
binding and catalytic activities (See Figure 26). 
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Figure 25: Biological functions of deregulated proteins 
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Figure 26: Molecular functions of deregulated proteins 
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3.9  Results for CRC pool label free analysis 
Table 28: Label free analysis of CRC pool 
 CRC pool experiment 1 CRC pool experiment 2 
No of control replicates 6 6 
No of CRC replicates 6 6 
MS DATA 
Total number of features 13456 5361 
No. of 2+ features 5618 2176 
No. of 3+ features 4398 1678 
No. of 4+ features 3440 1507 
No. of features with at least 2 
isotopes 
6083 5325 
No. of features  up-regulated in 
CRC 
2473 1027 
No. of features with Power > 
0.8 
2336 2100 
No. of features with P value < 
0.05 
3597 1496 
MS/MS DATA 
No. of features selected for 
inclusion with power >0.8, p < 
0.05 & up-regulated in CRC 
1623 1109 
No. of MS/MS spectra 288 133 
No. of proteins identified  10 No hits 
 
Initially the LC-MS runs were aligned (automatically and manually) in the LC 
direction, to correct for the variable elution of the peptides during the 
chromatographic separation (See Figure 27).    
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Figure 27: Alignment of LC-MS data 
 
Following generation of the alignment vectors the data was filtered.  The total number 
of features identified prior to the filtering stage in experiment 1 was 13456, and in 
experiment 2 it was 5361 (See Table 32 and Figures 28 & 29).  This was further 
refined by including only features that were within the retention times, had a charge 
stage of > +2 and had more than 2 isotopes for subsequent analysis.  All other 
features,   which   didn’t   match   the   above   criteria,   were   deleted.      The   numbers   of  
features for each of these entities in both the experiments are detailed in Table 32 and 
are also depicted in Figures 28 & 29.   
 
 
 
 
 189 
Figure 28: Filtering of features experiment 1 
 
Figure 29: Filtering of features experiment 2 
 
The sample data was then grouped to reflect the underlying biological groupings, 
meaning that 2 groups - Control and CRC were formed with 6 replicates in each.  
Following the group set up the statistically ranked list of features were reviewed, 
validated and edited.  The results could be reviewed in 1D, 2D or 3D, displaying the 
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data in multiple views such as described allows comparative exploration of the 
detected features.  Following this stage the features were ranked and filtered by 
selecting those that were up-regulated in CRC, power > 0.8 and p-value < 0.05 (See 
Figure 30).   A total of 2473 and 1027 features were up-regulated in CRC in 
experiments 1 and 2 respectively (See Table 32).  2336 features in experiment 1 and 
2100 features in experiment 2 had power > 0.8, whilst 3597 features in experiment 1 
and 1496 features in experiment 2 had a p < 0.05 (See Table 28).  A total of 1623 
features in experiment 1 and 1109 in experiment 2 had all 3 tags and were included 
for MS/MS analysis (See Table 32).  
Figure 30: Results review 
 
Prior to MS/MS, correlation analysis (PCA, dendograms and power analysis) was  
performed. Principal component analysis (PCA) was used to determine if there were 
any outliers (See Figures 35 - 40).  It appeared that there were no outliers in either 
experiment (See Figures 35 - 40).  The features were grouped according to their 
expression profiles (See Figures 35 - 40) and finally a power calculation was 
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performed (See Figures 31 - 36).  To detect 100% of features with power >0.8, 8 
replicates in experiment 1 and 11 in experiment 2 would be required.  
Figure 31: PCA analysis experiment 1 
 
Figure 32: PCA analysis experiment 2 
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Figure 33: Expression patterns experiment 1 
 
Figure 34: Expression patterns experiment 2 
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Figure 35: Power calculation experiment 1 
 
Figure 36: Power calculation experiment 2 
 
Finally the LC-MS data, which contained MS/MS spectra, was used to produce 
inclusion lists to determine any protein IDs for the selected peaks (See Figure 37).  In 
experiment 1 there were 288 MS/MS spectra, which lead to the identification of 10 
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proteins, whilst in experiment 2 there were 133 MS/MS spectra, which failed to 
derive any hits.   
Figure 37: Inclusion data 
 
The protein identifications generated from the MS/MS data for CRC experiment 1 can 
be found in Table 33.  This label free data was compared to the iTRAQ data generated 
earlier in this research (See Table 23).  The average iTRAQ ratio was calculated for a 
particular protein from all 4 experiments and transformed into log2 ratio.  Table  29 
contains all the proteins detected in the label free experiment, with those in 
highlighted in bold being recognised in the iTRAQ experiment and those in italic not.   
Of the 10 proteins identified in the label free experiment only 4 were documented in 
the iTRAQ experiment as being significant.  The 4 proteins did however have 
completely different fold changes as compared to the iTRAQ ratios, with the label 
free methodology generally reporting lower fold changes (See Table 29).  The 
remaining 6 proteins in this CRC label free experiment were not recognised as being 
significant in the iTRAQ experiment (See Table 29).  
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Table 29:  Label free IDs for CRC experiment 
 
Label Free – CRC iTRAQ 
Description Accession Peptide count Confidence score Anova (p)* Max fold change Average Log2 
Ceruloplasmin IPI00017601.1 4 195.41 8.57E-05 1.869027596 iTRAQ data not good  
Highly similar to ALPHA-1-
ANTICHYMOTRYPSIN IPI00550991.3 1 76.79 0.162877085 1.419919367 2.431125 1.281624074 
Isoform 1 of Alpha-1-antitrypsin IPI00553177.1 1 85.59 0.592178155 1.070675911 3.9806 1.992985906 
Hemoglobin subunit alpha IPI00410714.5 1 52.53 8.50E-06 2.586194399 4.042 2.015069322 
Complement C1s subcomponent IPI00017696.1 1 35.23 0.237979767 1.262483581 iTRAQ data not good  
Inter-alpha-trypsin inhibitor heavy chain H2 IPI00305461.3 1 79.07 0.001775281 1.58133409 iTRAQ data not good  
Vitamin D-binding protein IPI00555812.4 1 84.99 2.00E-05 3.189556575 iTRAQ data not good  
Leucine-rich alpha-2-glycoprotein IPI00022417.4 1 68.29 0.004521553 2.471707524 3.309375 1.726558779 
Serotransferrin IPI00022463.1 1 47.16 0.008871878 2.392256508 iTRAQ data not good  
Apolipoprotein A-IV IPI00304273.2 1 55.62 0.209378108 1.175811581 iTRAQ data not good  
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4.0 Results for Dukes Stage label free analysis 
Table 30: Label free analysis of Dukes samples 
 Dukes experiment 1 Dukes experiment 2 
No of control replicates 6 6 
No of Dukes stage replicates 6 per stage 6 per stage 
MS DATA 
Total number of features 16444 12660 
No. of 2+ features 6701 4138 
No. of 3+ features 5610 4129 
No. of 4+ features 4133 4393 
No. of features up-regulated in 
each Dukes stage  
A – 142 A – 305 
B – 788 B – 650 
C – 394 C – 327 
No. of features with Power > 0.8 8479 6431 
No. of features with P value < 
0.05 
8422 5834 
MS/MS DATA 
No. of features selected for 
inclusion with power >0.8, p < 
0.05 & up-regulated in each 
Dukes stage 
2402 1554 
No. of MS/MS spectra 2554 846 
No. of proteins identified  56 
1 – Dukes stage A, 34 – Dukes 
stage B & 22 – Dukes stage C 
No Hits 
 
The Dukes label free data was firstly aligned to allow for differences in 
chromatographic separation.  This is illustrated in Figure 42. 
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Figure 38: Alignment of LC-MS data 
 
As in the CRC label free data analysis the data was the filtered.  The total number of 
features identified prior to the filtering stage in experiment 1 was 16444, and in 
experiment 2 it was 12660 (See Table 30).  Only features that were upregulated in 
each Dukes stage, were within the retention times, had a charge stage of > +2 and had 
more than 2 isotopes were included in subsequent analysis.  The numbers of features 
for each of these entities in both the experiments are detailed in Table 34 and are also 
depicted in Figures 39 & 40.   
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Figure 39: Filtering of features experiment 1 
 
Figure 40: Filtering of features experiment 2 
 
The samples were categorized to form 2 groups – Dukes and Control, with 6 
replicates for each Dukes stage in the Dukes group and 6 replicates in the control 
group.  Following the group set up the statistically ranked list of features were 
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reviewed, validated and edited.  The features within each biological group were then 
ranked and filtered by selecting those that were up-regulated in each Dukes stage, 
power > 0.8 and p-value < 0.05 (See Figure 41).   A total of 142 and 305 features 
were up-regulated in Dukes stage A, 788 and 650 in Dukes stage B and finally 394 
and 327in Dukes stage C, in experiments 1 and 2 respectively (See Table 34).  8479 
features in experiment 1 and 6341 features in experiment 2 had power > 0.8, whilst 
8422 features in experiment 1 and 5834 features in experiment 2 had a p < 0.05 (See 
Table 30).  A total of 2402 features in experiment 1 and 1554 in experiment 2 had all 
3 tags and were included for MS/MS analysis (See Table 30).  
Figure 41: Results review 
 
Following on from the results editing stage, correlation analysis (PCA, dendograms 
and power analysis) was performed. Principal component analysis (PCA) was used to 
determine if there were any outliers (See Figures 42 - 47).   It can be seen from Figure 
42 that there is an outlier within Dukes A and B groups for experiment 1, and 2 
outliers in in experiment 2 for the Dukes C group as per Figure 43.  The features were 
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also grouped according to their expression profiles (See Figures 42 - 47).  Finally a 
power calculation was performed (See Figures 42 - 47).  It is indicative in experiment 
1 that 20 replicates would detect 100% of features with power >0.8, whilst in 
experiment 2, 8 replicates would give the same result.  
Figure 42: PCA analysis experiment 1 
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Figure 43: PCA analysis experiment 2 
 
Figure 44: Expression patterns experiment 1 
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Figure 45: Expression patterns experiment 2 
 
Figure 46: Power calculation experiment 1 
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Figure 47: Power calculation experiment 2 
 
Finally the LC-MS data, which contained MS/MS spectra, was used to produce 
inclusion lists to determine any protein IDs for the selected peaks (See Figure 48).  In 
experiment 1 there were 2554 MS/MS spectra, which lead to the identification of 1 
protein in Dukes stage A, 34 in Dukes B and 22 in Dukes C.  In experiment 2 there 
were 846 MS/MS spectra, but this did not result in any hits.   
 
 
 
 
 
 
 
 
 
 204 
Figure 48: Inclusion data 
 
The protein identifications generated from the MS/MS data for Dukes experiment 1 
can be found in Table 31.  This label free data was compared to the iTRAQ data 
generated earlier in this research (See Table 25).  Table 31 contains all the proteins 
detected in the Dukes label free experiment, with those in highlighted in bold not 
being recognised in the iTRAQ experiment and those in italic do not have iTRAQ 
data.  Proteins in blue are up-regulated in Dukes A, in red are up regulated in B and in 
black are those proteins up-regulated in Dukes C.   The average iTRAQ ratio was 
calculated for a particular protein from all 3 experiments and transformed into log2 
ratio. Of the 56 proteins identified in the label free experiment 31 were documented in 
the iTRAQ experiment as being significant.  All of these 31 proteins did however 
have completely different fold changes as compared to the iTRAQ ratios, with the 
label free methodology generally reporting, higher fold changes (See Table 31).  Of 
the remaining proteins in this Dukes label free experiment 12 were not recognised as 
being significant in the iTRAQ experiment and 13 had no iTRAQ data.    
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Table 31:  Label free IDs for Dukes experiment 
 
Label Free – Dukes iTRAQ 
Description Accession Peptide 
count 
Confidence 
score 
Anova (p)* Max fold 
change 
Average Log2 
Isoform 1 of Alpha-1-antitrypsin IPI00553177.1 18 1583.32 1.48E-09 6.709470631 2.818 1.494671612 
Hemoglobin subunit alpha IPI00410714.5 2 64.78 2.30E-08 5.808928172 4.008666667 2.003122458 
Apolipoprotein A-IV IPI00304273.2 4 379.86 3.04E-05 6.242199341 1.999333333 0.999519021 
APOA4 apolipoprotein A-IV precursor IPI00847179.1 6 536.76 3.79E-05 6.318994827 1.989 0.992043276 
CLU Clusterin IPI00291262.3 3 209.6 0.01280058 2.545657883 1.401 0.486456956 
CP Ceruloplasmin IPI00017601.1 5 422.34 2.06E-07 5.141080348 2.000333333 1.000240429 
IGL@ IGL@ protein IPI00719373.2 3 156.56 0.001251134 2.426921838 0.582 -0.780908942 
IGL@;IGLC2;IGLC1;IGLV2-14;IGLC3 IGL@ protein IPI00154742.6 2 180.71 0.00153543 2.433576836 0.607 -0.720231578 
Transthyretin IPI00022432.1 2 148.13 0.233194773 1.929751084 No iTRAQ data  
Apolipoprotein A-I IPI00021841.1 5 428.43 0.000779142 2.477428618 0.571333333 -0.807595391 
Alpha-2-macroglobulin IPI00478003.1 8 667.74 2.73E-07 3.117789485 1.691 0.75787666 
Isoform 1 of Inter-alpha-trypsin inhibitor heavy chain H3 IPI00028413.8 2 36.83 2.44E-07 4.123548168 2.555 1.353323291 
C9 Complement component C9 IPI00022395.1 3 127.25 1.97E-05 5.394184279 2.549 1.349931373 
vitamin D-binding protein precursor IPI00742696.2 3 129.67 0.000135497 3.476228843 2.001333333 1.000961476 
Apolipoprotein B-100 IPI00022229.1 10 752.79 2.28E-08 3.825978287 2.471666667 1.305484192 
Isoform 2 of Serum albumin IPI00384697.2 7 471.21 1.55E-07 7.96818137 No iTRAQ data  
Lumican IPI00020986.2 1 94.74 0.024043353 3.837394858 1.467 0.552868871 
Serpin peptidase inhibitor, clade D (Heparin cofactor), member 1 IPI00292950.4 2 185.77 3.76E-09 17.28401788 2.313666667 1.210181028 
highly similar to ALPHA-1-ANTICHYMOTRYPSIN IPI00550991.3 6 376.52 7.67E-07 4.106154248 1.66 0.731183242 
Vitronectin IPI00298971.1 3 117.61 0.000569215 2.623578167 1.471333333 0.557124129 
Isoform 2 of Inter-alpha-trypsin inhibitor heavy chain H4 IPI00218192.2 5 286.6 1.15E-09 5.806236472 2.044666667 1.031865666 
Isoform 2 of Inter-alpha-trypsin inhibitor heavy chain H4 IPI00218192.3 5 329.56 1.15E-09 5.806236472 2.044666667 1.031865666 
Complement C2 (Fragment) IPI00303963.1 2 58.92 0.007094013 3.927877768 1.333666667 0.415398128 
Hemoglobin subunit beta IPI00654755.3 5 440.16 3.11E-15 24.26394864 3.421333333 1.77455867 
IGKV1-5 IGKV1-5 protein IPI00419424.3 3 238.31 3.85E-07 6.002254428 0.627666667 -0.671929501 
Angiotensinogen IPI00032220.3 3 253.95 1.46E-07 15.47725923 2.014333333 1.010302441 
Kallistatin IPI00328609.3 1 53.45 8.54E-05 7.327534971 1.649666667 0.722174541 
Putative uncharacterized protein PRSS1 IPI00164162.6 1 35.61 0.00030176 18.55751179 No iTRAQ data  
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Label Free – Dukes iTRAQ 
Description Accession Peptide 
count 
Confidence 
score 
Anova (p)* Max fold 
change 
Average Log2 
IGHM IGHM protein IPI00472610.2 6 213.85 2.08E-06 6.299372764 0.615666667 -0.699778634 
Hepatitis B virus receptor binding protein (Fragment) IPI00816681.1 6 213.85 2.08E-06 6.299372764 No iTRAQ data  
Complement factor I IPI00291867.3 1 82.6 0.012212645 24.07880753 1.314 0.393965276 
Protein S100-A9 IPI00027462.1 2 130.89 0.004359854 20.51061324 No iTRAQ data  
IGHA2 Putative uncharacterized protein DKFZp686C02220 
(Fragment) 
IPI00423461.3 1 51.08 0.000998287 29.9879557 No iTRAQ data  
Ig kappa chain V-I region AU IPI00003111.6 1 40.56 0.010024445 4.846260056 No iTRAQ data  
Isoform 1 of Gelsolin IPI00026314.1 7 457.76 5.19E-05 3.543319736 1.538666667 0.621680723 
Pigment epithelium-derived factor IPI00006114.4 1 59.48 0.001654999 21.58536382 1.875333333 0.907147052 
Isoform 1 of Protein unc-45 homolog A IPI00072534.2 1 34.63 0.000348735 14.59435354 No iTRAQ data  
Apolipoprotein E IPI00021842.1 1 94.84 0 36.12788376 1.221333333 0.288457003 
Leucine-rich alpha-2-glycoprotein IPI00022417.4 1 82.29 9.89E-12 14.95291968 3.469666667 1.794797069 
highly similar to Alpha-2-HS-glycoprotein IPI00022431.2 2 131.24 5.54E-12 47.0375274 0.989 -0.015957574 
HPR 47 kDa protein IPI00641737.1 5 314.62 4.04E-09 10.73607771 3.153666667 1.65703018 
Alpha-1-acid glycoprotein 2 IPI00020091.1 1 49.36 2.85E-08 316.5104972 No iTRAQ data  
Serum amyloid P-component IPI00022391.1 1 97.29 2.53E-10 7.256198248 1.512666667 0.597094108 
alpha-2-glycoprotein 1, zinc IPI00166729.4 2 199.99 1.31E-05 4.387677142 1.569333333 0.65015182 
Complement component C8 gamma chain IPI00011261.2 1 88.81 2.21E-08 4.484871619 No iTRAQ data  
Retinol-binding protein 4 IPI00022420.3 2 62.72 0.014567439 2.343620467 No iTRAQ data  
55 kDa protein IPI00029863.4 1 67.59 2.19E-06 44.22328668 1.644 0.717210299 
Isoform 1 of N-acetylmuramoyl-L-alanine amidase IPI00163207.1 1 81.94 0.040366187 14.22121153 2.482 1.311503115 
Thymosin beta-4-like protein 3 IPI00180240.2 1 33.75 9.80E-08 8.669846201 0.602333333 -0.731365995 
Isoform 3 of Long-chain-fatty-acid--CoA ligase 6 IPI00296333.5 1 42.89 0.002623774 3.463683085 No iTRAQ data  
Platelet basic protein IPI00022445.1 2 100.69 0.018293233 4.583565094 0.724666667 -0.46461056 
Isoform 1 of UPF0487 protein C17orf71 IPI00328183.2 1 35.03 2.33E-10 58.72972362 No iTRAQ data  
Carboxypeptidase N subunit 2 IPI00479116.1 1 66.82 0.000119268 2.312180121 1.643333333 0.716625146 
Hemopexin IPI00022488.1 1 32.23 5.09E-09 216.5114381 2.367 1.243059706 
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4.1  Ingenuity Pathway Analysis (IPA)  
4.1.1  Core Analysis 
Ingenuity Pathway Analysis (Qiagen) is a web based software application that allows 
users to integrate and analyze genomic or proteomic data.  Searching using this 
software allows a better understanding of the data, which is derived from proteomic 
experiments, and allows the user to ascertain the significance of the results whilst also 
determining any functional relationships between the data points.  I used two 
applications within IPA application, Core and Biomarker analysis. Purposely using 
these 2 applications I was able to identify  
1. The biological pathways the identified proteins participate in,  
2. The proteins interacted with each other directly or through intermediate 
molecules 
3. The processes each of the proteins were involved in  
4. And also elucidate and prioritize potential biomarkers.   
Once the raw data had been processed using the Software packages previously 
described IPA was used to answer the biological questions this project had 
endeavored to uncover.  The raw ratio data was initially transformed by determining 
the average protein abundance for each identified protein and then converting this 
average to logarithmic scale using log 2 transformation, making it easier to compare 
fold changes between up-regulated and down regulated proteins.  The identifiers 
within IPA are either the IPI or UniProt accession number.  Predominantly the latter 
was used as on several occasions IPA failed to recognize the IPI identifier. IPA Core 
analysis was then initially undertaken which essentially delivers an assessment of the 
signalling pathways the proteins participate in, the molecular networks and the 
biological processes that are disrupted in the dataset of interest.  The IPA Biomarker 
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application was used only for the Dukes iTRAQ dataset as the other data sets had too 
few proteins to allow this part of the application to be used productively.  Even 
although all possible biomarkers identified from the raw data were put into IPA, not 
all of them could be computed in IPA, meaning that the identifier  wasn’t  mapped  to  a  
particular protein.  This happened because it may have been an uncharacterized or 
putative protein or simply the databases stored within IPA were not comprehensive 
enough.  Table 32 below summarizes the number of proteins, which unfortunately 
could not be analyzed within IPA.  Although they could not be further evaluated 
within IPA they may be novel CRC biomarkers and therefore should not be fully 
excluded form further downstream analysis. 
Table 32: Summary of the numbers of proteins from each dataset not mapped within 
IPA 
Analysis No of proteins unmapped 
CRC iTRAQ 1 
CRC Label free 1 
Dukes iTRAQ 79 
Dukes Label free 10 
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4.1.1.1 IPA core analysis for CRC proteins identified with iTRAQ 
quantitation  
A total of 10 proteins from the CRC iTRAQ data were mapped within IPA.  Table  33 
details the proteins as well as the fold changes associated with each protein, the 
location and type of protein, and finally any biomarker applications the proteins may 
already have been discovered to possess. The protein with the greatest fold change 
within the data set is Collagen Type I, alpha 2.   All of the proteins are found in the 
extracellular space and they appear to be predominantly involved in transport and 
other functions.  50% of the proteins have been identified as having a potential role as 
biomarker. 
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Table 33: Mapped IDs for CRC iTRAQ 
 
Fold 
Change 
(log2) ID Symbol Entrez Gene Name Location Type(s) Biomarker Application(s) 
0.625 P02743 APCS Amyloid P component, serum Extracellular Space Other Unspecified application 
0.694 P25311 AZGP1 Alpha-2-glycoprotein 1, zinc-binding Extracellular Space Transporter   
1.091 P02748 C9 Complement component 9 Extracellular Space Other   
2.369 P02452 COL1A1 Collagen, type I, alpha 1 Extracellular Space Other Diagnosis 
2.541 P08123 COL1A2 Collagen, type I, alpha 2 Extracellular Space Other   
0.950 P19827 ITIH1 Inter-alpha-trypsin inhibitor heavy chain 1 Extracellular Space Other   
1.319 P02750 LRG1 Leucine-rich alpha-2-glycoprotein 1 Extracellular Space Other   
0.757 P06702 S100A9 S100 calcium binding protein A9 Cytoplasm Other 
Diagnosis, unspecified 
application 
1.797 P01009 SERPINA1 
Serpin peptidase inhibitor, clade A (alpha-1 antiproteinase, 
antitrypsin), member 1 Extracellular Space Other 
Diagnosis, unspecified 
application 
0.951 P01011 SERPINA3 
Serpin peptidase inhibitor, clade A (alpha-1 antiproteinase, 
antitrypsin), member 3 Extracellular Space Other Unspecified application 
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Figure 49:  Canonical pathways enriched in the differentially expressed proteins for 
CRC iTRAQ (Ingenuity Pathway Analysis) 
 
The figure above displays the most significant Canonical Pathways across the entire 
CRC iTRAQ dataset as a bar chart.  The Canonical Pathways involved in this analysis 
are displayed along the y-axis. The x-axis displays the -log of p-value, which is 
calculated by Fisher's exact test.     The orange points represents a ratio which is 
calculated by dividing the number of genes in a given pathway that meet the cutoff 
criteria divided by the total number of genes that make up that pathway.  Taller bars 
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have more genes associated with the Canonical Pathway than shorter bars, with 
largest ratio being presented first.    
Table 34: Top 5 Canonical Pathways for CRC iTRAQ (Ingenuity Pathway Analysis) 
Pathway (-Log (p-value) P-value Ratio 
Acute Phase Response 
signaling Pathway 
5.884 1.31E-06 4/173 (0.023) 
Atherosclerosis 
Signaling 
4.503 3.14E-05 3/131 (0.023) 
Intrinsic Prothrombin 
Activation Pathway 
3.995 1.01E-04 2/32 (0.062) 
LXR/RXR Activation 2.723 1.89E-03 2/126 (0.016) 
Hepatic Fibrosis 2.617 2.42E-03 2/140 (0.014) 
 
As depicted in Figure 49, and Table 34 the acute phase signaling response pathway 
comes up as the top hit (p-value 1.31E-06 (-log (p-value) 5.884)). There are 4 proteins 
present in the differentially expressed proteins out of the 173 proteins in the acute 
phase signaling response pathway, thus the ratio is 0.023.  
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Figure 50: Networks enriched in the differentially expressed proteins CRC iTRAQ 
(Ingenuity Pathway Analysis) 
 
The above network has been generated to determine the regulatory relationships 
between the proteins in the CRC iTRAQ dataset.  A total of 3 networks were merged 
to generate the above network diagram (See Table 39).   The coloured molecule 
shapes are the proteins identified in my protein dataset, with the red indicating they 
are up-regulated.  The intensity of the red indicates the degree of up reglation, with a 
higher intensity of colur indicating a greater degree of up-regulatation.  Uncolured 
shapes are not part of the dataset.  Broken lines betwwen molecules suggest an 
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indirect realtionship, whilst a solid line indicates a direct relationship.  The network 
has the tumour suppressor protein Tp53 at the core of it. 
Table 35 contains a list of the networks in order of significance along with the 
characteristics of each network.  Each network is assigned an ID number which is 
generrated by its significance.  The molecules that compose each network from the 
dataset are also listed.  The score is based on a p-value calculation, which calculates 
the likelihood that the Molecules generated from the dataset are part of the network 
by random chance alone. It is the negative exponent of the right-tailed Fisher's exact 
test result, and is simply a measure of the number of molecules within in a network.  
Thus the greater the number of molecules in a network, the higher the score (lower 
the p-value) will be.  The three most significant functions for each network are listed 
in the table also.  It appears that the proteins within the most significant network 
produced from the CRC iTRAQ experiment are involved in cancer and 
gastrointestinal disease.   
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Table 35:  CRC iTRAQ networks 
Network No. of 
molecules 
Containing molecules Score Functions 
1 7 APCS, AZGP1, COL1A1, 
COL1A2, S100A9, SERPINA1, 
SERPINA3 
17 Cancer, GI 
disease, 
Cellular 
development 
2 1 C9 3 Cancer, Cell 
signalling, 
Inflammation 
3 1 ITIH1 2 Small 
molecule 
biochemistry 
 
4.1.1.2  IPA core analysis CRC label free quantitation  
A total of 9 proteins from the CRC label free data were mapped within IPA.  Table 37 
details the proteins as well as the fold changes associated with each protein, the 
location and type of protein, and finally any biomarker applications the proteins may 
already have been discovered to possess. The protein with the greatest fold change 
within the data set is Vitamin D binding protein, which is corroborated by the CRC 
iTRAQ data.   All of the proteins are found in the extracellular space and they appear 
to be predominantly involved in transport and other functions.  56% of the proteins 
have been identified as having a potential role as biomarker.  Only 3 of the proteins 
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were found in the CRC iTRAQ and Label free groups following IPA analysis 
(Leucine rich alpha-2-glycoprotein, serpin peptidase inhibitor, clade A (alpha-1 
antiproteinase, antitrypsin), member 1 and serpin peptidase inhibitor, clade A (alpha-1 
antiproteinase, antitrypsin), member 3). 
Figure 51:  Canonical pathways enriched in the differentially expressed proteins for 
CRC Label free (Ingenuity Pathway Analysis) 
 
As depicted in Figure 51, and Table 36 the acute phase signaling response pathway 
comes up as the top hit (p-value 4.85E-11 (-log (p-value) 10.314)). There are 6 
proteins present in the differentially expressed proteins out of the 181 proteins in the 
acute phase signaling response pathway, thus the ratio is 0.033.  
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Table 36: Top 5 Canonical Pathways for CRC label free (Ingenuity Pathway 
Analysis) 
Pathway (-Log (p-value) P-value Ratio 
Acute Phase Response 
signaling Pathway 
10.315 4.85E-11 6/181 (0.033) 
LXR/RXR Activation 6.64 2.29E-07 4/139 (0.029) 
Clathrin-mediated 
Endocytosis signaling 
4.08 8.33E-05 3/198 (0.015) 
Atherosclerosis signaling 2.807 1.56E-03 2/139 (0.014) 
IL-12 signaling 2.727 1.88E-03 2/157 (0.013) 
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Table 37: Mapped IDs CRC label free 
 
Fold 
Change ID Symbol Entrez Gene Name Location Type(s) Biomarker Application(s) 
1.176 IPI00304273.2 APOA4 apolipoprotein A-IV 
Extracellular 
Space transporter unspecified application 
1.262 IPI00017696.1 C1S complement component 1, s subcomponent 
Extracellular 
Space Peptidase   
1.869 IPI00017601.1 CP ceruloplasmin (ferroxidase) 
Extracellular 
Space Enzyme Efficacy 
3.190 IPI00555812.4 GC group-specific component (vitamin D binding protein) 
Extracellular 
Space transporter   
1.581 IPI00305461.3 ITIH2 inter-alpha-trypsin inhibitor heavy chain 2 
Extracellular 
Space Other   
2.472 IPI00022417.4 LRG1 leucine-rich alpha-2-glycoprotein 1 
Extracellular 
Space Other   
1.071 IPI00553177.1 
SERPIN
A1 
serpin peptidase inhibitor, clade A (alpha-1 antiproteinase, 
antitrypsin), member 1 
Extracellular 
Space Other 
diagnosis, unspecified 
application 
1.420 IPI00550991.3 
SERPIN
A3 
serpin peptidase inhibitor, clade A (alpha-1 antiproteinase, 
antitrypsin), member 3 
Extracellular 
Space Other unspecified application 
2.392 IPI00022463.1 TF Transferrin 
Extracellular 
Space transporter efficacy, prognosis 
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Figure 52: Networks enriched in the differentially expressed proteins CRC Label free 
(Ingenuity Pathway Analysis) 
 
Only 1 network was produced for the CRC label free as portrayed in the above 
diagram (See Table 38 and Figure 52).   The coloured molecule shapes are the 
proteins identified in my protein dataset, with the red indicating they are up-regulated.  
The intensity of the red indicates the degree of up reglation, with a higher intensity of 
colur indicating a greater degree of up-regulatation.  Uncolured shapes are not part of 
the dataset.  Broken lines betwwen molecules suggest an indirect realtionship, whilst 
a solid line indicates a direct relationship.  Tumour necrosis factor (TNF) is the 
predominant protein at the centre of this network.   
Table 38 lists the characteristics of each network which were described in the CRC 
iTRAQ section. Within a network, the higher the score, the lower the p-value will be.  
The three most significant functions for each network are listed in the table too.  It 
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appears that the proteins within produced from the CRC iTRAQ experiment are 
involved predominantly in small molecule biochemistry. 
Table 38:  CRC Label free networks 
Network No. of 
molecules 
Containing molecules Score Functions 
1 9 GC, LRG1, TF, CP, ITIH2, 
SERPINA1, SERPINA3, C1S, 
APO4 
27 Small 
molecule 
biochemistry 
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4.1.1.3 IPA core analysis for Dukes proteins identified with iTRAQ 
quantitation 
A total of 112 proteins were identified in IPA for Dukes A-C iTRAQ analysis (See 
Table 40).  Biomarker analysis was performed on these within IPA and so this will be 
discussed later. 
4.1.1.3.1  Dukes A iTRAQ IPA analysis 
Figure 53:  Canonical pathways enriched in the differentially expressed proteins for 
Dukes A iTRAQ (Ingenuity Pathway Analysis) 
 
As depicted in Figure 53, and Table 39 the acute phase signaling response pathway 
comes up as the top hit (p-value 8.15E-20 (-log (p-value) 19.089)). There are 18 
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proteins present in the differentially expressed proteins out of the 173 proteins in the 
acute phase signaling response pathway, thus the ratio is 0.104.  
Table 39: Top 5 Canonical Pathways for Dukes A iTRAQ (Ingenuity Pathway 
Analysis) 
Pathway (-Log (p-value) P-value Ratio 
Acute Phase Response 
signaling Pathway 
19.089 8.15E-20 18/173 (0.104) 
LXR/RXR Activation 18.462 3.45E-19 16/126 (0.127) 
Clathrin-mediated 
Endocytosis signaling 
10.208 6.19E-11 12/191 (0.063) 
Atherosclerosis signaling 9.588 2.58E-10 10/131 (0.076) 
Complement system 8.097 7.99E-09 6/33 (0.182) 
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Table 40: Mapped IDs Dukes A iTRAQ 
 
Log 
Ratio ID Symbol Entrez Gene Name Location Type(s) Biomarker Application(s) 
-0.392 P01023 A2M Alpha-2-macroglobulin Extracellular Space Transporter   
-0.719 Q13707 ACTA2 Actin, alpha 2, smooth muscle, aorta Cytoplasm Other Efficacy 
-0.719 P63261 ACTG1 Actin, gamma 1 Cytoplasm Other Unspecified application 
-0.476 P01019 AGT 
Angiotensinogen (serpin peptidase inhibitor, clade A, 
member 8) Extracellular Space 
Growth 
factor Efficacy 
-3.756 P02768 ALB Albumin Extracellular Space Transporter 
Diagnosis, efficacy, prognosis, safety, 
unspecified application 
-0.111 P02743 APCS Amyloid P component, serum Extracellular Space Other Unspecified application 
-2.332 P02652 APOA2 Apolipoprotein A-II Extracellular Space Transporter   
-0.021 P06727 APOA4 Apolipoprotein A-IV Extracellular Space Transporter Unspecified application 
-1.357 P04114 APOB Apolipoprotein B Extracellular Space Transporter Diagnosis, efficacy 
-1.163 P02654 APOC1 Apolipoprotein C-I Extracellular Space Transporter Prognosis, unspecified application 
0.845 P02655 APOC2 Apolipoprotein C-II Extracellular Space Transporter   
0.288 P02649 APOE Apolipoprotein E Extracellular Space Transporter 
Diagnosis, efficacy, prognosis, 
unspecified application 
-0.457 P25311 AZGP1 Alpha-2-glycoprotein 1, zinc-binding Extracellular Space Transporter   
-0.306 P02747 C1QC Complement component 1, q subcomponent, C chain Extracellular Space Other   
0.142 B4DPQ0 C1R Complement component 1, r subcomponent Extracellular Space Peptidase   
-0.088 Q9NZP8 C1RL Complement component 1, r subcomponent-like Extracellular Space Peptidase   
-0.932 P09871 C1S Complement component 1, s subcomponent Extracellular Space Peptidase   
-1.086 P01031 C5 Complement component 5 Extracellular Space Cytokine   
-0.769 P02748 C9 Complement component 9 Extracellular Space Other   
-2.419 Q9HB71 CACYBP Calcyclin binding protein Nucleus Other   
-2.769 Q5VT06 CEP350 Centrosomal protein 350kDa Cytoplasm Other   
-0.647 Q53EZ4 CEP55 Centrosomal protein 55kDa Cytoplasm Other   
-1.079 P05156 CFI Complement factor I Extracellular Space Peptidase   
-1.012 P05452 CLEC3B C-type lectin domain family 3, member B Extracellular Space Other   
-0.674 P10909 CLU Clusterin Cytoplasm Other Efficacy, unspecified application 
0.727 P08123 COL1A2 Collagen, type I, alpha 2 Extracellular Space Other   
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Log 
Ratio ID Symbol Entrez Gene Name Location Type(s) Biomarker Application(s) 
-0.653 P00450 CP Ceruloplasmin (ferroxidase) Extracellular Space Enzyme Efficacy 
-1.106 Q8WTV7 DMXL2 Dmx-like 2 Cytoplasm Other   
-2.769 Q9UFH2 DNAH17 Dynein, axonemal, heavy chain 17 Cytoplasm Other   
-2.769 Q03001 DST Dystonin Plasma Membrane Other Unspecified application 
-2.769 Q92556 ELMO1 Engulfment and cell motility 1 Cytoplasm Other   
-0.383 P00742 F10 Coagulation factor X Extracellular Space Peptidase Efficacy 
-2.629 A3RKG7 F7 
Coagulation factor VII (serum prothrombin conversion 
accelerator) Plasma Membrane Peptidase Unspecified application 
-0.276 P00740 F9 Coagulation factor IX Extracellular Space Peptidase   
-0.592 Q05CP7 FABP1 Fatty acid binding protein 1, liver Cytoplasm Transporter Unspecified application 
-0.421 O75636 FCN3 Ficolin (collagen/fibrinogen domain containing) 3 Extracellular Space Other   
-0.598 P02751 FN1 Fibronectin 1 Extracellular Space Enzyme 
Diagnosis, efficacy, prognosis, 
unspecified application 
-0.517 P02774 GC Group-specific component (vitamin D binding protein) Extracellular Space Transporter   
-1.814 Q8IZF2 GPR116 G protein-coupled receptor 116 Plasma Membrane 
G-protein 
coupled 
receptor   
-0.160 P06396 GSN Gelsolin Extracellular Space Other Disease progression, efficacy 
-0.594 P68871 HBB Haemoglobin, beta Cytoplasm Transporter   
-1.737 P00739 HPR Haptoglobin-related protein Extracellular Space Peptidase   
-3.346 P01859 IGHG2 Immunoglobulin heavy constant gamma 2 (G2m marker) Plasma Membrane Other   
-2.611 P01860 IGHG3 Immunoglobulin heavy constant gamma 3 (G3m marker) Extracellular Space Other   
-1.842 P01871 IGHM Immunoglobulin heavy constant mu Plasma Membrane 
Transmemb
rane 
receptor   
-1.515 P01591 IGJ 
Immunoglobulin J polypeptide, linker protein for 
immunoglobulin alpha and mu polypeptides Extracellular Space Other   
-2.398 P01834 IGKC Immunoglobulin kappa constant Extracellular Space Other Unspecified application 
-1.989 Q5NV69 IGLV1-40 Immunoglobulin lambda variable 1-40 Other Other   
-0.728 P19827 ITIH1 Inter-alpha-trypsin inhibitor heavy chain 1 Extracellular Space Other   
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Log 
Ratio ID Symbol Entrez Gene Name Location Type(s) Biomarker Application(s) 
-0.597 P19823 ITIH2 Inter-alpha-trypsin inhibitor heavy chain 2 Extracellular Space Other   
-0.141 Q06033 ITIH3 Inter-alpha-trypsin inhibitor heavy chain 3 Extracellular Space Other   
-1.168 B7ZKJ8 ITIH4 
Inter-alpha-trypsin inhibitor heavy chain family, member 
4 Extracellular Space Other   
-1.729 Q8IVT5 KSR1 Kinase suppressor of ras 1 Cytoplasm Kinase   
-0.145 P02750 LRG1 Leucine-rich alpha-2-glycoprotein 1 Extracellular Space Other   
-0.825 Q9NR34 MAN1C1 Mannosidase, alpha, class 1C, member 1 Cytoplasm Enzyme   
-2.769 Q9BV36 MLPH Melanophilin Cytoplasm Other   
-0.921 P13591 NCAM1 Neural cell adhesion molecule 1 Plasma Membrane Other Efficacy, prognosis 
-1.271 Q96PD5 PGLYRP2 Peptidoglycan recognition protein 2 Plasma Membrane 
Transmemb
rane 
receptor   
-1.309 Q6NSZ4 PHKG1 Phosphorylase kinase, gamma 1 (muscle) Cytoplasm Kinase   
-0.719 A5A3E0 
POTEE/POT
EF POTE ankyrin domain family, member F Other Other   
-1.336 Q92954 PRG4 Proteoglycan 4 Extracellular Space Other   
-3.063 P07477 PRSS1 Protease, serine, 1 (trypsin 1) Extracellular Space Peptidase   
-1.889 Q15032 R3HDM1 R3H domain containing 1 Other Other   
-0.473 Q15276 RABEP1 Rabaptin, RAB GTPase binding effector protein 1 Cytoplasm Transporter   
-1.105 Q13702 RAPSN Receptor-associated protein of the synapse Plasma Membrane Other   
-1.719 P01009 SERPINA1 
Serpin peptidase inhibitor, clade A (alpha-1 
antiproteinase, antitrypsin), member 1 Extracellular Space Other Diagnosis, unspecified application 
-1.835 P29622 SERPINA4 
Serpin peptidase inhibitor, clade A (alpha-1 
antiproteinase, antitrypsin), member 4 Extracellular Space Other   
-0.562 P08185 SERPINA6 
Serpin peptidase inhibitor, clade A (alpha-1 
antiproteinase, antitrypsin), member 6 Extracellular Space Other   
-0.706 Q8IVC0 SERPIND1 
Serpin peptidase inhibitor, clade D (heparin cofactor), 
member 1 Extracellular Space Other Disease progression 
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Log 
Ratio ID Symbol Entrez Gene Name Location Type(s) Biomarker Application(s) 
-0.081 P36955 SERPINF1 
Serpin peptidase inhibitor, clade F (alpha-2 antiplasmin, 
pigment epithelium derived factor), member 1 Extracellular Space Other   
-0.559 Q14BN4 SLMAP Sarcolemma associated protein Plasma Membrane other   
-0.444 Q9UNH7 SNX6 sorting nexin 6 Cytoplasm transporter   
-2.769 O75410 TACC1 transforming, acidic coiled-coil containing protein 1 Nucleus other   
-1.629 P02787 TF Transferrin Extracellular Space transporter efficacy,prognosis 
-1.128 P07996 THBS1 thrombospondin 1 Extracellular Space other diagnosis,efficacy 
-2.229 P67936 TPM4 tropomyosin 4 Cytoplasm other   
-1.694 B4E0A2 TRAF5 TNF receptor-associated factor 5 Cytoplasm transporter   
-1.315 Q6ZT98 TTLL7 tubulin tyrosine ligase-like family, member 7 Plasma Membrane other   
-1.050 Q8WZ42 TTN Titin Other kinase   
-2.769 Q9HAV4 XPO5 exportin 5 Nucleus transporter   
-0.483 Q14587 ZNF268 zinc finger protein 268 Nucleus other   
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Figure 54: Network 1 enriched in the differentially expressed proteins Dukes A 
iTRAQ (Ingenuity Pathway Analysis).  NF Kappa B is the main protein at the heart of 
this network. 
 
 
 
 
 
 
 228 
Figure 55: Network 2 enriched in the differentially expressed proteins Dukes A 
iTRAQ (Ingenuity Pathway Analysis).  Tp53 and MAP Kinase proteins form the core 
of this network analysis. 
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Figure 56: Network 3 enriched in the differentially expressed proteins Dukes A 
iTRAQ (Ingenuity Pathway Analysis).  Interleukins form a large part of this network. 
 
The top 3 networks for the Dukes A iTRAQ data are shown in Figures 54-56.  They 
havent been merged on this occasion as the detail from the networks was lost in doing 
so.  The coloured molecule shapes are the proteins identied in my protein dataset, 
with the red indicating they are up-regulated, the green demonstrating they are down 
regulated.  The intensity of the colour indicates the degree of up reglation, with a 
higher intensity of colour indicating a greater degree of dysregulatation.  Uncolured 
shapes are not part of the dataset.  Broken lines betwwen molecules suggest an 
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indirect realtionship, whilst a solid line indicates a direct relationship.  Table 41 
contains a list of the networks in order of significance along with the characteristics of 
each network.   It appears that the proteins within the most significant network 
produced from the Dukes A iTRAQ experiment are involved in small molecule 
biochemistry.   
Table 41:  Dukes A iTRAQ networks 
Network No. of 
molecules 
Containing molecules Score Functions 
1 16 A2M, APOA2, APOA4, APOB, 
APOC2 APOE, C5, CLU, F7, 
FIO, FN1, KSR1, NCAM1, 
SERPINA1, THBS1, TRAF5 
27 Small 
molecule 
biochemistry 
2 16 ACTA2, ACTG1, AGT, 
APOC1, C9, C1QC, CEP55, CP, 
DST, ELMO1, GG, PHKG1, 
PRSS1, SNX6, TACC1, XP05 
27 Cancer, GI 
disease 
3 13 AGT, ALB, AZGP1, C1R, C1S, 
F9, HBB, IGHG2, IGHG3, 
PGLYRP2, SLMAP, TF, 
ZNF268 
20 Inflammtory 
disease 
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4.1.1.3.2 Dukes B iTRAQ IPA analysis 
Figure 57:  Canonical pathways enriched in the differentially expressed proteins for 
Dukes B iTRAQ (Ingenuity Pathway Analysis) 
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As depicted in Figure 57, and Table 42 the acute phase signaling response pathway 
comes up as the top hit (p-value 1.66E-23 (-log (p-value) 22.779)). There are 22 
proteins present in the differentially expressed proteins out of the 173 proteins in the 
acute phase signaling response pathway, thus the ratio is 0.127.  
Table 42: Top 5 Canonical Pathways for Dukes B iTRAQ (Ingenuity Pathway 
Analysis) 
Pathway (-Log (p-value) P-value Ratio 
Acute Phase Response 
signaling Pathway 
22.779 1.66E-23 22/173 (0.127) 
LXR/RXR activation 19.649 2.24E-20 18/126 (0.143) 
Complement System 12.681 2.08E-13 9/33 (0.273) 
Atherosclerosis signaling 9.764 1.72E-10 11/131 (0.084) 
Clathrin-mediated 
Endocytosis signaling 
8.927 1.21E-09 12/191 (0.063) 
 
The mapped IDs along as some other information regarding each protein and their 
associated fold change is found in Table 43. 
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Table 43: Mapped IDs Dukes B iTRAQ 
 
Log Ratio ID Symbol Entrez Gene Name Location Type(s) Biomarker Application(s) 
0.758 P01023 A2M Alpha-2-macroglobulin Extracellular Space Transporter   
0.974 Q13707 ACTA2 Actin, alpha 2, smooth muscle, aorta Cytoplasm other Efficacy 
0.974 P63261 ACTG1 actin, gamma 1 Cytoplasm other unspecified application 
0.945 P01019 AGT 
angiotensinogen (serpin peptidase inhibitor, 
clade A, member 8) Extracellular Space growth factor Efficacy 
-1.141 P02768 ALB Albumin Extracellular Space transporter 
diagnosis,efficacy,prognosis,
safety,unspecified 
application 
0.913 P02760 AMBP alpha-1-microglobulin/bikunin precursor Extracellular Space transporter 
safety,unspecified 
application 
0.662 Q9UPS8 ANKRD26 ankyrin repeat domain 26 Nucleus transcription regulator   
0.597 P02743 APCS amyloid P component, serum Extracellular Space other unspecified application 
-0.538 P02652 APOA2 apolipoprotein A-II Extracellular Space transporter   
0.441 P06727 APOA4 apolipoprotein A-IV Extracellular Space transporter unspecified application 
0.581 P04114 APOB apolipoprotein B Extracellular Space transporter diagnosis,efficacy 
0.843 P02654 APOC1 apolipoprotein C-I Extracellular Space transporter 
prognosis,unspecified 
application 
1.376 P02655 APOC2 apolipoprotein C-II Extracellular Space transporter   
1.316 Q6LBZ1 APOE apolipoprotein E Extracellular Space transporter 
diagnosis,efficacy,prognosis,
unspecified application 
0.650 P25311 AZGP1 alpha-2-glycoprotein 1, zinc-binding Extracellular Space transporter   
0.780 P02747 C1QC 
complement component 1, q subcomponent, C 
chain Extracellular Space other   
0.847 B4DPQ0 C1R complement component 1, r subcomponent Extracellular Space peptidase   
0.767 Q9NZP8 C1RL complement component 1, r subcomponent-like Extracellular Space peptidase   
0.736 P09871 C1S complement component 1, s subcomponent Extracellular Space peptidase   
0.415 P06681 C2 complement component 2 Extracellular Space peptidase   
1.150 P01031 C5 complement component 5 Extracellular Space cytokine   
0.534 P07357 C8A complement component 8, alpha polypeptide Extracellular Space other   
1.090 P02748 C9 complement component 9 Extracellular Space other   
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Log Ratio ID Symbol Entrez Gene Name Location Type(s) Biomarker Application(s) 
-1.017 Q9HB71 CACYBP calcyclin binding protein Nucleus other   
-1.113 Q5VT06 CEP350 centrosomal protein 350kDa Cytoplasm other   
0.342 Q53EZ4 CEP55 centrosomal protein 55kDa Cytoplasm other   
0.187 P05156 CFI complement factor I Extracellular Space peptidase   
0.346 P05452 CLEC3B C-type lectin domain family 3, member B Extracellular Space other   
0.486 P10909 CLU Clusterin Cytoplasm other 
efficacy,unspecified 
application 
0.565 J3QQM7 CNDP1 
carnosine dipeptidase 1 (metallopeptidase M20 
family) Cytoplasm peptidase   
1.415 P02452 COL1A1 collagen, type I, alpha 1 Extracellular Space other Diagnosis 
1.531 P08123 COL1A2 collagen, type I, alpha 2 Extracellular Space other   
0.969 P00450 CP ceruloplasmin (ferroxidase) Extracellular Space enzyme Efficacy 
0.717 P22792 CPN2 carboxypeptidase N, polypeptide 2 Extracellular Space peptidase   
0.998 Q8WTV7 DMXL2 Dmx-like 2 Cytoplasm other   
-1.113 Q9UFH2 DNAH17 dynein, axonemal, heavy chain 17 Cytoplasm other   
-1.113 Q03001 DST Dystonin Plasma Membrane other unspecified application 
-1.113 Q92556 ELMO1 engulfment and cell motility 1 Cytoplasm other   
0.863 P00742 F10 coagulation factor X Extracellular Space peptidase Efficacy 
-0.695 A3RKG7 F7 
coagulation factor VII (serum prothrombin 
conversion accelerator) Plasma Membrane peptidase unspecified application 
0.194 P00740 F9 coagulation factor IX Extracellular Space peptidase   
1.342 Q05CP7 FABP1 fatty acid binding protein 1, liver Cytoplasm transporter unspecified application 
0.559 O75636 FCN3 
ficolin (collagen/fibrinogen domain containing) 
3 Extracellular Space other   
1.191 P02751 FN1 fibronectin 1 Extracellular Space enzyme 
diagnosis,efficacy,prognosis,
unspecified application 
1.001 P02774 GC 
group-specific component (vitamin D binding 
protein) Extracellular Space transporter   
1.185 Q8IZF2 GPR116 G protein-coupled receptor 116 Plasma Membrane 
G-protein coupled 
receptor   
0.622 P06396 GSN Gelsolin Extracellular Space other disease progression,efficacy 
1.775 P68871 HBB hemoglobin, beta Cytoplasm transporter   
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Log Ratio ID Symbol Entrez Gene Name Location Type(s) Biomarker Application(s) 
0.662 Q9ULT8 HECTD1 
HECT domain containing E3 ubiquitin protein 
ligase 1 Other enzyme   
1.633 P00739 HPR haptoglobin-related protein Extracellular Space peptidase   
1.243 P02790 HPX Hemopexin Extracellular Space transporter   
-0.727 P01859 IGHG2 
immunoglobulin heavy constant gamma 2 (G2m 
marker) Plasma Membrane other   
-0.652 P01860 IGHG3 
immunoglobulin heavy constant gamma 3 (G3m 
marker) Extracellular Space other   
-0.591 P01871 IGHM immunoglobulin heavy constant mu Plasma Membrane 
transmembrane 
receptor   
-1.783 P01591 IGJ 
immunoglobulin J polypeptide, linker protein 
for immunoglobulin alpha and mu polypeptides Extracellular Space other   
-0.628 P01834 IGKC immunoglobulin kappa constant Extracellular Space other unspecified application 
-0.573 Q5NV69 IGLV1-40 immunoglobulin lambda variable 1-40 Other other   
1.066 P19827 ITIH1 inter-alpha-trypsin inhibitor heavy chain 1 Extracellular Space other   
0.982 P19823 ITIH2 inter-alpha-trypsin inhibitor heavy chain 2 Extracellular Space other   
1.328 B4DPQ4 ITIH3 inter-alpha-trypsin inhibitor heavy chain 3 Extracellular Space other   
1.064 B7ZKJ8 ITIH4 
inter-alpha-trypsin inhibitor heavy chain family, 
member 4 Extracellular Space other   
0.014 Q2UVF0 KIF21B kinesin family member 21B Cytoplasm other   
-1.633 Q8IVT5 KSR1 kinase suppressor of ras 1 Cytoplasm kinase   
1.795 P02750 LRG1 leucine-rich alpha-2-glycoprotein 1 Extracellular Space other   
1.101 Q9NR34 MAN1C1 mannosidase, alpha, class 1C, member 1 Cytoplasm enzyme   
-1.113 Q9BV36 MLPH Melanophilin Cytoplasm other   
1.076 P13591 NCAM1 neural cell adhesion molecule 1 Plasma Membrane other efficacy, prognosis 
0.546 Q7Z628 NET1 neuroepithelial cell transforming 1 Nucleus other   
0.014 Q14980 NUMA1 nuclear mitotic apparatus protein 1 Nucleus other unspecified application 
0.672 Q96PD5 PGLYRP2 peptidoglycan recognition protein 2 Plasma Membrane 
transmembrane 
receptor   
-0.076 Q6NSZ4 PHKG1 phosphorylase kinase, gamma 1 (muscle) Cytoplasm kinase   
0.974 A5A3E0 POTEE/POTEF POTE ankyrin domain family, member F Other other   
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Log Ratio ID Symbol Entrez Gene Name Location Type(s) Biomarker Application(s) 
1.858 O60813 PRAMEF11 PRAME family member 11 Extracellular Space other   
-0.980 Q92954 PRG4 proteoglycan 4 Extracellular Space other   
-0.563 P07477 PRSS1 protease, serine, 1 (trypsin 1) Extracellular Space peptidase   
2.088 Q15032 R3HDM1 R3H domain containing 1 Other other   
0.561 Q15276 RABEP1 
rabaptin, RAB GTPase binding effector protein 
1 Cytoplasm transporter   
0.546 Q9NS91 RAD18 RAD18 homolog (S. cerevisiae) Nucleus other   
0.202 Q13702 RAPSN receptor-associated protein of the synapse Plasma Membrane other   
0.014 O43290 SART1 
squamous cell carcinoma antigen recognized by 
T cells Nucleus other   
0.014 Q15020 SART3 
squamous cell carcinoma antigen recognized by 
T cells 3 Nucleus other   
1.495 P01009 SERPINA1 
serpin peptidase inhibitor, clade A (alpha-1 
antiproteinase, antitrypsin), member 1 Extracellular Space other 
diagnosis, unspecified 
application 
0.348 P29622 SERPINA4 
serpin peptidase inhibitor, clade A (alpha-1 
antiproteinase, antitrypsin), member 4 Extracellular Space other   
0.413 P08185 SERPINA6 
serpin peptidase inhibitor, clade A (alpha-1 
antiproteinase, antitrypsin), member 6 Extracellular Space other   
0.922 P05543 SERPINA7 
serpin peptidase inhibitor, clade A (alpha-1 
antiproteinase, antitrypsin), member 7 Extracellular Space transporter   
0.733 Q8IVC0 SERPIND1 
serpin peptidase inhibitor, clade D (heparin 
cofactor), member 1 Extracellular Space other disease progression 
0.892 P36955 SERPINF1 
serpin peptidase inhibitor, clade F (alpha-2 
antiplasmin, pigment epithelium derived factor), 
member 1 Extracellular Space other   
1.452 B4E1F0 SERPING1 
serpin peptidase inhibitor, clade G (C1 
inhibitor), member 1 Extracellular Space other   
0.151 Q14BN4 SLMAP sarcolemma associated protein Plasma Membrane other   
1.316 Q9UNH7 SNX6 sorting nexin 6 Cytoplasm transporter   
0.662 Q7Z6B7 SRGAP1 SLIT-ROBO Rho GTPase activating protein 1 Cytoplasm other   
0.687 O75044 SRGAP2 SLIT-ROBO Rho GTPase activating protein 2 Cytoplasm other   
0.014 B3KYA7 STK3 serine/threonine kinase 3 Cytoplasm kinase   
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Log Ratio ID Symbol Entrez Gene Name Location Type(s) Biomarker Application(s) 
-1.113 O75410 TACC1 
transforming, acidic coiled-coil containing 
protein 1 Nucleus other   
0.687 Q8NDG6 TDRD9 tudor domain containing 9 Cytoplasm other   
0.002 P02787 TF Transferrin Extracellular Space transporter efficacy, prognosis 
0.780 P07996 THBS1 thrombospondin 1 Extracellular Space other diagnosis,efficacy 
-0.412 P67936 TPM4 tropomyosin 4 Cytoplasm other   
1.135 B4E0A2 TRAF5 TNF receptor-associated factor 5 Cytoplasm transporter   
1.337 Q6ZT98 TTLL7 tubulin tyrosine ligase-like family, member 7 Plasma Membrane other   
0.823 Q8WZ42 TTN Titin Other kinase   
-1.113 Q9HAV4 XPO5 exportin 5 Nucleus transporter   
0.014 P61129 ZC3H6 zinc finger CCCH-type containing 6 Other other   
1.353 Q14587 ZNF268 zinc finger protein 268 Nucleus other   
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Figure 58: Network 1 enriched in the differentially expressed proteins Dukes B 
iTRAQ (Ingenuity Pathway Analysis).  MAP Kinases and NK-Kappa B are at the 
center of this network. 
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Figure 59: Network 2 enriched in the differentially expressed proteins Dukes B 
iTRAQ (Ingenuity Pathway Analysis).  Beta-Catenin is one of the proteins at the core 
of this network. 
 
 
 
 
 
 
 240 
Figure 60: Network 3 enriched in the differentially expressed proteins Dukes B 
iTRAQ (Ingenuity Pathway Analysis).  Transforming GF-β1  and  MAP  Kinase  1  are  
at the center of this network. 
 
 
 
The top 3 networks for the Dukes B iTRAQ data are shown in Figures 58 - 60.  They 
haven’t been merged on this occasion as the detail from the networks was lost in 
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doing so.  The coloured molecule shapes are the proteins identified in my protein 
dataset, with the red indicating they are up-regulated, the green demonstrating they 
are down regulated.  The intensity of the colour indicates the degree of up reglation, 
with a higher intensity of colour indicating a greater degree of dysregulatation.  
Uncoloured shapes are not part of the dataset.  Broken lines between molecules 
suggest an indirect realtionship, whilst a solid line indicates a direct relationship.  
Table 44 contains a list of the networks in order of significance along with the 
characteristics of each network.   It appears that the proteins within the most 
significant network produced from the Dukes B iTRAQ experiment are involved in 
molecular transport.   
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Table 44:  Dukes B iTRAQ networks 
Network No. of 
molecules 
Containing molecules Score Functions 
1 21 A2M, AGT, ALB, APOA2, 
APOA4, APOB, APOC2, 
APOE, C5, CLU, COL1A1, 
COL1A2, F7, F10, FN1, KSR1, 
NCAM1, SERPINA1, STK, 
THBS1, TRAF5. 
37 Molecular 
transport 
2 14 APCS, APOC1, C1QC, 
CACYBP, CP, ELM01, FABP1, 
GC, GSN, ITIH4, SERPINA1, 
SERPINE1, SERPINC1, 
TACC1 
21 Cell signalling 
3 13 ACTA2, ALB, AZGP1, C1R, 
C1S, F9, IGHM, NET1, SART1, 
SART3, SLMAP, TF, XP05 
19 Cell 
morphology 
and 
devlopment 
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4.1.1.3.3 Dukes C iTRAQ IPA analysis 
Figure 61:  Canonical pathways enriched in the differentially expressed proteins for 
Dukes C iTRAQ (Ingenuity Pathway Analysis) 
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As depicted in Figure 61, and Table 45 the acute phase signaling response pathway 
comes up as the top hit (p-value 8.4E-25 (-log (p-value) 24.076)). There are 23 
proteins present in the differentially expressed proteins out of the 173 proteins in the 
acute phase signaling response pathway, thus the ratio is 0.133.  
Table 45: Top 5 Canonical Pathways for Dukes C iTRAQ (Ingenuity Pathway 
Analysis) 
Pathway (-Log (p-value) P-value Ratio 
Acute Phase Response 
signaling Pathway 
24.076 8.4E-25 23/173 (0.133) 
LXR/RXR activation 21.035 9.23E-22 19/126 (0.151) 
Complement System 14.482 3.29E-15 10/33 (0.303) 
Atherosclerosis signaling 10.963 1.09E-11 12/131 (0.092) 
Clathrin-mediated 
Endocytosis signaling 
9.952 1.12E-10 13/191 (0.068) 
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Table 46: Mapped IDs Dukes C iTRAQ 
 
Log 
Ratio ID Symbol Entrez Gene Name Location Type(s) Biomarker Application(s) 
0.371 P01023 A2M alpha-2-macroglobulin Extracellular Space transporter   
0.828 Q13707 ACTA2 actin, alpha 2, smooth muscle, aorta Cytoplasm other efficacy 
0.828 P63261 ACTG1 actin, gamma 1 Cytoplasm other unspecified application 
1.010 P01019 AGT 
angiotensinogen (serpin peptidase inhibitor, clade A, 
member 8) Extracellular Space growth factor efficacy 
-2.165 P02768 ALB Albumin Extracellular Space transporter 
diagnosis,efficacy,prognosis,safety,unspe
cified application 
0.519 P02760 AMBP alpha-1-microglobulin/bikunin precursor Extracellular Space transporter safety,unspecified application 
0.272 Q9UPS8 
ANKRD
26 ankyrin repeat domain 26 Nucleus 
transcription 
regulator   
1.267 P02743 APCS amyloid P component, serum Extracellular Space other unspecified application 
-0.395 P02652 APOA2 apolipoprotein A-II Extracellular Space transporter   
1.000 P06727 APOA4 apolipoprotein A-IV Extracellular Space transporter unspecified application 
1.305 P04114 APOB apolipoprotein B Extracellular Space transporter diagnosis,efficacy 
1.490 P02654 APOC1 apolipoprotein C-I Extracellular Space transporter prognosis,unspecified application 
2.204 P02655 APOC2 apolipoprotein C-II Extracellular Space transporter   
2.177 P02649 APOE apolipoprotein E Extracellular Space transporter 
diagnosis,efficacy,prognosis,unspecified 
application 
0.055 P25311 AZGP1 alpha-2-glycoprotein 1, zinc-binding Extracellular Space transporter   
0.866 P02747 C1QC complement component 1, q subcomponent, C chain Extracellular Space other   
1.341 B4DPQ0 C1R complement component 1, r subcomponent Extracellular Space peptidase   
1.301 Q9NZP8 C1RL complement component 1, r subcomponent-like Extracellular Space peptidase   
0.949 P09871 C1S complement component 1, s subcomponent Extracellular Space peptidase   
0.789 P06681 C2 complement component 2 Extracellular Space peptidase   
0.789 P01031 C5 complement component 5 Extracellular Space cytokine   
0.731 P07357 C8A complement component 8, alpha polypeptide Extracellular Space other   
0.725 P07358 C8B complement component 8, beta polypeptide Extracellular Space other   
1.350 P02748 C9 complement component 9 Extracellular Space other   
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Log 
Ratio ID Symbol Entrez Gene Name Location Type(s) Biomarker Application(s) 
-0.276 Q9HB71 
CACYB
P calcyclin binding protein Nucleus other   
-0.585 Q5VT06 CEP350 centrosomal protein 350kDa Cytoplasm other   
0.717 Q53EZ4 CEP55 centrosomal protein 55kDa Cytoplasm other   
0.394 P05156 CFI complement factor I Extracellular Space peptidase   
0.481 P05452 
CLEC3
B C-type lectin domain family 3, member B Extracellular Space other   
0.773 P10909 CLU Clusterin Cytoplasm other efficacy,unspecified application 
0.948 J3QQM7 CNDP1 
carnosine dipeptidase 1 (metallopeptidase M20 
family) Cytoplasm peptidase   
1.322 P02452 
COL1A
1 collagen, type I, alpha 1 Extracellular Space other diagnosis 
1.269 P08123 
COL1A
2 collagen, type I, alpha 2 Extracellular Space other   
1.000 P00450 CP ceruloplasmin (ferroxidase) Extracellular Space enzyme efficacy 
1.128 P22792 CPN2 carboxypeptidase N, polypeptide 2 Extracellular Space peptidase   
-0.585 Q9UFH2 
DNAH1
7 dynein, axonemal, heavy chain 17 Cytoplasm other   
-0.585 Q03001 DST Dystonin Plasma Membrane other unspecified application 
-0.585 Q92556 ELMO1 engulfment and cell motility 1 Cytoplasm other   
0.865 P00742 F10 coagulation factor X Extracellular Space peptidase efficacy 
-1.909 A3RKG7 F7 
coagulation factor VII (serum prothrombin 
conversion accelerator) Plasma Membrane peptidase unspecified application 
0.698 P00740 F9 coagulation factor IX Extracellular Space peptidase   
0.961 Q05CP7 FABP1 fatty acid binding protein 1, liver Cytoplasm transporter unspecified application 
0.874 O75636 FCN3 ficolin (collagen/fibrinogen domain containing) 3 Extracellular Space other   
1.994 P02751 FN1 fibronectin 1 Extracellular Space enzyme 
diagnosis,efficacy,prognosis,unspecified 
application 
0.826 P02774 GC 
group-specific component (vitamin D binding 
protein) Extracellular Space transporter   
0.406 Q8IZF2 GPR116 G protein-coupled receptor 116 Plasma Membrane 
G-protein coupled 
receptor   
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Log 
Ratio ID Symbol Entrez Gene Name Location Type(s) Biomarker Application(s) 
0.964 P06396 GSN Gelsolin Extracellular Space other disease progression,efficacy 
1.535 P68871 HBB hemoglobin, beta Cytoplasm transporter   
0.272 Q9ULT8 
HECTD
1 
HECT domain containing E3 ubiquitin protein ligase 
1 Other enzyme   
0.961 P00739 HPR haptoglobin-related protein Extracellular Space peptidase   
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Figure 62: Network 1 enriched in the differentially expressed proteins Dukes C 
iTRAQ (Ingenuity Pathway Analysis).  NF-Kappa-β1and   MAP   Kinases   play   a  
predominant role in this network. 
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Figure 63: Network 2 enriched in the differentially expressed proteins Dukes C 
iTRAQ  (Ingenuity  Pathway  Analysis).    β-Catenin is one of the proteins at the core of 
this network analysis. 
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Figure 64: Network 3 enriched in the differentially expressed proteins Dukes C 
iTRAQ (Ingenuity Pathway Analysis).  Interleukins play a front role in this network. 
 
The top 3 networks for the Dukes C iTRAQ data are shown in Figures 62 - 64.  They 
havent been merged on this occasion as the detail from the networks was lost in doing 
so.  The coloured molecule shapes are the proteins identified in my protein dataset, 
with the red indicating they are up-regulated, the green demonstrating they are down 
regulated.  The intensity of the colour indicates the degree of up reglation, with a 
higher intensity of colour indicating a greater degree of dysregulatation.  Uncoloured 
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shapes are not part of the dataset.  Broken lines between molecules suggest an indirect 
relationship, whilst a solid line indicates a direct relationship.  Table 47 contains a list 
of the networks in order of significance along with the characteristics of each 
network.   It appears that the proteins within the most significant network produced 
from the Dukes B iTRAQ experiment are involved in small molecule biochemistry.   
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Table 47:  Dukes C iTRAQ networks 
Network No. of 
molecules 
Containing molecules Score Functions 
1 21 A2M, AGT, ALB, APOA2, 
APOA4, APOB, APOC2, 
APOE, C5, CLU, COL1A1, 
COL1A2, F7, F10, FN1, KSR1, 
NCAM1, SERPINA1, STK3, 
THBS1, TRAF5. 
37 Small 
moelcule 
biochemistry 
2 16 APCS, APOC1, CACYBP, 
ELM01, FABP1, GSN,  HBB, 
ITIH4, RAD18, SERPING1, 
SNX6, TACC1, TMP4, TTN, 
ZNF, Z68 
25 Cellular 
function and 
maintenance, 
tissue 
morphology 
3 13 ACTA2,  AGT, ALB, C1QC, 
C1RL, CP, GC, NET1, ORM1, 
SERPINA7, SERPIND1, TF, 
XP05 
19 Cell signalling 
and immunity 
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4.1.1.4  IPA for Dukes proteins identified with label free quantitation 
A total of 46 proteins from the Dukes Label free data were mapped within IPA.  Table 
49 details the proteins as well as the fold changes associated with each protein, the 
location and type of protein, and finally any biomarker applications the proteins may 
already have been discovered to possess. The protein with the greatest fold change 
within the data set is orosomucoid 2.   The majority of the proteins are found in the 
extracellular space (85%), with the remainder in the cytoplasm (13%) and plasma 
membrane (2%) and they appear to be predominantly involved in transport and other 
functions.  37% of the proteins have been identified as having a potential role as 
biomarker. 
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Figure 65:  Canonical pathways enriched in the differentially expressed proteins for 
Dukes Label free (Ingenuity Pathway Analysis)  
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Table 48: Top 5 Canonical Pathways for Dukes Label free (Ingenuity Pathway 
Analysis) 
Pathway (-Log (p-value) P-value Ratio 
Acute Phase Response 
signaling Pathway 
28.369 4.28E-29 10/173 (0.116) 
LXR/RXR Activation 27.203 6.27E-28 18/126 (0.143) 
Atherosclerosis 
Signaling 
10.678 2.1E-11 9/131 (0.069) 
IL-12 signaling 10.333 4.64E-11 9/137 (0.066) 
Production of NOx and 
ROS 
9.119 7.61E-10 9/186 (0.048) 
 
As depicted in Figure 65, and Table 48 the acute phase signaling response pathway 
comes up as the top hit (p-value 4.29E-29 (-log (p-value) 28.369)). There are 10 
proteins present in the differentially expressed proteins out of the 173 proteins in the 
acute phase signaling response pathway, thus the ratio is 0.116.  
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Table 49: Mapped IDs Dukes Label free 
 
Fold 
Change ID Symbol Entrez Gene Name Location Type(s) Biomarker Application(s) 
3.118 IPI00478003.1 A2M alpha-2-macroglobulin Extracellular Space transporter   
3.464 IPI00296333.5 ACSL6 
acyl-CoA synthetase long-chain family 
member 6 Cytoplasm enzyme   
15.477 IPI00032220.3 AGT 
angiotensinogen (serpin peptidase inhibitor, 
clade A, member 8) Extracellular Space growth factor Efficacy 
47.038 IPI00022431.2 AHSG alpha-2-HS-glycoprotein Extracellular Space other unspecified application 
7.968 IPI00384697.2 ALB albumin Extracellular Space transporter 
diagnosis,efficacy,prognosis,safety,unspecified 
application 
7.256 IPI00022391.1 APCS amyloid P component, serum Extracellular Space other unspecified application 
2.477 IPI00021841.1 APOA1 apolipoprotein A-I Extracellular Space transporter diagnosis,efficacy,unspecified application 
6.319 IPI00847179.1 APOA4 apolipoprotein A-IV Extracellular Space transporter unspecified application 
3.826 IPI00022229.1 APOB apolipoprotein B Extracellular Space transporter diagnosis,efficacy 
36.128 IPI00021842.1 APOE apolipoprotein E Extracellular Space Transporter 
diagnosis,efficacy,prognosis,unspecified 
application 
4.388 IPI00166729.4 AZGP1 alpha-2-glycoprotein 1, zinc-binding Extracellular Space Transporter   
3.928 IPI00303963.1 C2 complement component 2 Extracellular Space Peptidase   
3.998 IPI00032291.2 C5 complement component 5 Extracellular Space Cytokine   
4.485 IPI00011261.2 C8G 
complement component 8, gamma 
polypeptide Extracellular Space Transporter   
5.394 IPI00022395.1 C9 complement component 9 Extracellular Space Other   
24.079 IPI00291867.3 CFI complement factor I Extracellular Space Peptidase   
2.546 IPI00291262.3 CLU clusterin Cytoplasm Other efficacy,unspecified application 
5.141 IPI00017601.1 CP ceruloplasmin (ferroxidase) Extracellular Space Enzyme Efficacy 
2.312 IPI00479116.1 CPN2 carboxypeptidase N, polypeptide 2 Extracellular Space Peptidase   
3.476 IPI00742696.2 GC 
group-specific component (vitamin D 
binding protein) Extracellular Space Transporter   
3.543 IPI00026314.1 GSN gelsolin Extracellular Space Other disease progression,efficacy 
24.264 IPI00654755.3 HBB hemoglobin, beta Cytoplasm Transporter   
216.511 IPI00022488.1 HPX hemopexin Extracellular Space Transporter   
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Fold 
Change ID Symbol Entrez Gene Name Location Type(s) Biomarker Application(s) 
29.988 IPI00423461.3 IGHA2 
immunoglobulin heavy constant alpha 2 
(A2m marker) Extracellular Space Other   
2.427 IPI00719373.2 IGLC1 
immunoglobulin lambda constant 1 (Mcg 
marker) Cytoplasm Other   
4.124 IPI00028413.8 ITIH3 inter-alpha-trypsin inhibitor heavy chain 3 Extracellular Space Other   
5.806 IPI00218192.3 ITIH4 
inter-alpha-trypsin inhibitor heavy chain 
family, member 4 Extracellular Space Other   
14.953 IPI00022417.4 LRG1 leucine-rich alpha-2-glycoprotein 1 Extracellular Space Other   
3.837 IPI00020986.2 LUM lumican Extracellular Space Other   
316.510 IPI00020091.1 ORM2 orosomucoid 2 Extracellular Space Other   
14.221 IPI00163207.1 PGLYRP2 peptidoglycan recognition protein 2 Plasma Membrane 
transmembrane 
receptor   
4.584 IPI00022445.1 PPBP 
pro-platelet basic protein (chemokine (C-X-
C motif) ligand 7) Extracellular Space Cytokine   
18.558 IPI00164162.6 PRSS1 protease, serine, 1 (trypsin 1) Extracellular Space Peptidase   
2.344 IPI00022420.3 RBP4 retinol binding protein 4, plasma Extracellular Space Transporter unspecified application 
20.511 IPI00027462.1 S100A9 S100 calcium binding protein A9 Cytoplasm Other diagnosis, unspecified application 
6.709 IPI00553177.1 SERPINA1 
serpin peptidase inhibitor, clade A (alpha-1 
antiproteinase, antitrypsin), member 1 Extracellular Space Other diagnosis, unspecified application 
4.106 IPI00550991.3 SERPINA3 
serpin peptidase inhibitor, clade A (alpha-1 
antiproteinase, antitrypsin), member 3 Extracellular Space Other unspecified application 
7.328 IPI00328609.3 SERPINA4 
serpin peptidase inhibitor, clade A (alpha-1 
antiproteinase, antitrypsin), member 4 Extracellular Space Other   
17.284 IPI00292950.4 SERPIND1 
serpin peptidase inhibitor, clade D (heparin 
cofactor), member 1 Extracellular Space Other disease progression 
21.585 IPI00006114.4 SERPINF1 
serpin peptidase inhibitor, clade F (alpha-2 
antiplasmin, pigment epithelium derived 
factor), member 1 Extracellular Space Other   
58.730 IPI00328183.2 SMG8 
SMG8 nonsense mediated mRNA decay 
factor Cytoplasm Enzyme   
1.930 IPI00022432.1 TTR transthyretin Extracellular Space Transporter 
diagnosis,efficacy,prognosis,unspecified 
application 
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Fold 
Change ID Symbol Entrez Gene Name Location Type(s) Biomarker Application(s) 
14.594 IPI00072534.2 UNC45A unc-45 homolog A (C. elegans) Plasma Membrane Other   
2.624 IPI00298971.1 VTN vitronectin Extracellular Space Other   
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Figure 66: Network 1 enriched in the differentially expressed proteins Dukes Label 
free (Ingenuity Pathway Analysis).  The MAP Kinase proteins have an important part 
to play in this network. 
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Figure 67: Network 2 enriched in the differentially expressed proteins Dukes Label 
free (Ingenuity Pathway Analysis).  Cyclin dependent kinases and apoptosis related 
cysteine peptidases are at the central to this network. 
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Figure 68: Network 3 enriched in the differentially expressed proteins Dukes Label 
free (Ingenuity Pathway Analysis).  HNF homeobox proteins are integral to this 
network. 
 
The top 3 networks for the Dukes Lable free data are shown in Figures 66 - 68.  They 
havent been merged on this occasion as the detail from the networks was lost in doing 
so.  The coloured molecule shapes are the proteins identied in my protein dataset, 
with the red indicating they are up-regulated.  The intensity of the red indicates the 
degree of up reglation, with a higher intensity of colour indicating a greater degree of 
 262 
up-regulatation.  Uncoloured shapes are not part of the dataset.  Broken lines between 
molecules suggest an indirect realtionship, whilst a solid line indicates a direct 
relationship.  Table 50 contains a list of the networks in order of significance along 
with the characteristics of each network.   It appears that the proteins within the most 
significant network produced from the Dukes Label free experiment are involved in 
small molecule biochemistry.   
Table 50:  Dukes Lable Free networks 
Network No. of 
molecules 
Containing molecules Score Functions 
1 14 A2M, APOA1, APOA4, APOB, 
APOE, C5, CLU, HPX, RBP4, 
SERPINA1, SERPINA3, 
SERPINF1, TTR, VTN 
27 Small 
molecule 
biochemistry 
2 9 AZGP1, CPP, GC, GSJ, HBB, 
IGLC1, LUM, PRSS1, S100A9 
15 Cancer, Cell 
death and 
survival, 
cellular 
development 
3 10 AGT, AHSG, ALB, APCS, 
ITIH4 
10 Metabolic and 
Endocrine 
disease 
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4.1.2  IPA Biomarker Analysis 
As previously mentioned in section 4.1.1 biomarker analysis was performed on the 
Dukes iTRAQ study as it generated the largest number of candidate proteins with 
more than 1 per Dukes stage as compared to the Dukes Label free experiment.  A total 
of 192 proteins were identified for Dukes stage A-C using iTRAQ, of which 112 only 
could be analysed in IPA for reasons outlined previously.  IPA biomarkers capability 
means that likely and relevant biomarkers for the disease in question can be sought.  
Within the software the biomarkers are classified according to their biological 
characteristics, mechanisms are elucidated, as well as the generation of a list of 
candidate biomarkers, which are either unique or common across the various groups 
being characterised.   Initially each Dukes dataset were filtered using the following 
settings 
1. Species – Human 
2. Tissues and Cell lines – Blood, Plasma, serum and Colorectal cancer cell lines 
and tissues. 
3. All molecule types 
4. Diseases – Cancer and Gastrointestinal disease 
5. All biomarkers 
4.2.2.1  Dukes A Biomarker analysis (See Table 51) 
A total of 23 proteins from the original mapped proteins were deemed as eligible 
Biomarkers.  These proteins are presented in Table 51.  16 are found in the 
extracellular space, 4 in the cytoplasm and 3 in the plasma membrane.  11 proteins 
were reported as having other functions, 7 were described as transporters, 2 as 
peptidases and 1 as a growth factor.  All of the proteins were down regulated as seen 
by the negative Log 2 ratios.  All are found in blood.  15 were not identified to be 
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associated with the large intestine and 8 were not connected colorectal cell lines.  The 
biomarkers applications were diverse and indicated potential roles in diagnosis, 
efficacy, disease progression and prognosis.  All 23-protein biomarkers were also 
reported in the Dukes B and C biomarker filter results. 
4.1.2.2  Dukes B Biomarker analysis (See Table 52) 
26 proteins were delineated from the biomarker filter of the Dukes B dataset.  13 of 
the proteins had other functions, 8 have a primary transporter role, 2 are peptidases, 
and 1 is a growth factor and 1 an enzyme.  3 of the proteins are down regulated the 
remainder are up regulated.  All of the proteins are present in blood, but only 9 are 
allied to the large intestine and 16 with colorectal cell lines.  Similar biomarker roles 
were identified as per the Dukes A analysis.  3 of the proteins (alpha-1-microglobulin, 
collagen, type I, alpha and nuclear mitotic apparatus protein 1) were not identified in 
the Dukes analyses but were in the Dukes C. 
4.1.2.3  Dukes C Biomarker analysis (See Table 53) 
27 proteins were identified as potential biomarkers for identifying patients with Dukes 
C CRC.  19 of the proteins are present in the extracellular space, 4 within the 
cytoplasm, 3 in the plasma membrane and 1 in the nucleus.  5 of the proteins were 
down regulated the remainder being up regulated.  All are found in blood, but only 9 
are associated with the large intestine and 15 with colonic cell lines.  Similar 
biomarker applications were identified as per the other 2 Dukes analysis.  Only 1 
protein was unique to the Dukes C analysis – Orsomucoid 1. 
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4.1.2.4  Combined Dukes A-C biomarker comparison (See Table 54) 
All of the proteins iTRAQ Dukes A-C proteins derived from the IPA analysis were 
combined and compared and used to generate a list of proteins that could be used to 
identify any of the Dukes stages.  The stages could be distinguished from each other 
by having different cut off values, as each protein has a different degree of up or 
down regulation, which is directly related to Dukes Stage.  Table 54 contains a list of 
23 such proteins, which are associated with each Dukes stage and thus could be used 
as potential biomarkers.  16 of the proteins are found in the extracellular space, 4 in 
the cytoplasm and 3 in the plasma membrane.  10 proteins have other biological 
functions, 7 are transporters, 2 are enzymes, 2 are peptidases and 1 is a growth factor.  
All are found in humans and blood.  15 are not associated with the large intestine and 
10 are not correlated with colorectal cancer cell lines.  Multifarious biomarker 
applications for the identified proteins have been postulated, ranging from diagnosis, 
to efficacy and prognosis.  7 proteins have an unspecified application 
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Table 51: IPA Biomarkers Dukes A 
 
Symbol 
Entrez 
Gene Name Location Family UniProt 
Log 
Ratio Human Blood 
Plasma/
Serum 
Large 
Intestine 
COLO 
205 
HCC
-2998 
HCT 
-116 
HCT 
-15 
HT 
29 
KM-
12 
Biomarker 
Application(s) 
ACTA2 
actin, alpha 
2, smooth 
muscle, 
aorta Cytoplasm Other Q13707 -0.719 x x   X       X     Efficacy 
ACTG1 
actin, 
gamma 1 Cytoplasm Other P63261 -0.719 x x   X X X x X x x 
unspecified 
application 
AGT 
angiotensino
gen (serpin 
peptidase 
inhibitor, 
clade A, 
member 8) 
Extracellular 
Space 
growth 
factor P01019 -0.476 x x x   X           Efficacy 
ALB Albumin 
Extracellular 
Space Transporter P02768 -3.756 x x x               
diagnosis,efficacy
,prognosis,safety,
unspecified 
application 
APCS 
amyloid P 
component, 
serum 
Extracellular 
Space Other P02743 -0.111 x x x               
unspecified 
application 
APOA4 
apolipoprote
in A-IV 
Extracellular 
Space Transporter P06727 -0.021 x x x               
unspecified 
application 
APOB apo B 
Extracellular 
Space Transporter P04114 -1.357 x x x               diagnosis,efficacy 
APOC1 apo C-I 
Extracellular 
Space transporter P02654 -1.163 x x x     x         
prognosis, 
unspecified 
application 
APOE apoE 
Extracellular 
Space transporter Q6LBZ1 0.342 x x x X             
diagnosis,efficacy
,prognosis, 
unspecified 
application 
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Symbol 
Entrez 
Gene Name Location Family UniProt 
Log 
Ratio Human Blood 
Plasma/
Serum 
Large 
Intestine 
COLO 
205 
HCC
-2998 
HCT 
-116 
HCT 
-15 
HT 
29 
KM-
12 
Biomarker 
Application(s) 
CLU Clusterin Cytoplasm Other P10909 -0.674 X x x X X x x X x x 
efficacy, 
unspecified 
application 
CP 
CP 
(ferroxidase) 
Extracellular 
Space Enzyme P00450 -0.653 X x x       x       Efficacy 
DST Dystonin 
Plasma 
Membrane Other Q03001 -2.769 X x x   X x x X x x 
unspecified 
application 
F7 
coagulation 
factor VII 
(serum 
prothrombin 
conversion 
accelerator) 
Plasma 
Membrane Peptidase A3RKG7 -2.629 X x x               
unspecified 
application 
F10 
coagulation 
factor X 
Extracellular 
Space Peptidase P00742 -0.383 X x x               Efficacy 
FABP1 
fatty acid 
binding 
protein 1, 
liver Cytoplasm transporter Q05CP7 -0.592 X x x X X x         
unspecified 
application 
FN1 fibronectin 1 
Extracellular 
Space Enzyme P02751 -0.598 X x x X         x   
diagnosis,efficacy
,prognosis, 
unspecified 
application 
GSN Gelsolin 
Extracellular 
Space Other P06396 -0.160 X x x X X x x X x x 
disease 
progression, 
efficacy 
IGKC 
immunoglob
ulin kappa 
constant 
Extracellular 
Space Other P01834 -2.398 x x x               
unspecified 
application 
NCAM1 
neural cell 
adhesion 
molecule 1 
Plasma 
Membrane Other P13591 -0.921 x x x             x 
efficacy, 
prognosis 
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Symbol 
Entrez 
Gene Name Location Family UniProt 
Log 
Ratio Human Blood 
Plasma/
Serum 
Large 
Intestine 
COLO 
205 
HCC
-2998 
HCT 
-116 
HCT 
-15 
HT 
29 
KM-
12 
Biomarker 
Application(s) 
SERPIN
A1 
serpin 
peptidase 
inhibitor, 
clade A (), 
member 1 
Extracellular 
Space Other P01009 -1.719 x x x           x   
Diagnosis 
,unspecified 
application 
SERPIN
D1 
serpin 
peptidase 
inhibitor, 
clade D  
Extracellular 
Space Other Q8IVC0 -0.706 x x x               
disease 
progression 
TF Transferrin 
Extracellular 
Space transporter P02787 -1.629 x x x               
efficacy, 
prognosis 
THBS1 
thrombospon
din 1 
Extracellular 
Space Other P07996 -1.128 x x x X X x x   x   diagnosis,efficacy 
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Table 52: IPA Biomarkers Dukes B 
 
Symbol 
Entrez 
Gene Name Location Family UniProt 
Log 
Ratio Human Blood 
Plasma/
Serum 
Large 
Intestine 
COLO
205 
HCC
-2998 
HCT
-116 
HCT
-15 
HT
29 
KM-
12 
Other Colon 
Cancer Cell 
Lines 
ACTA2 
actin, alpha 
2, smooth 
muscle, 
aorta Cytoplasm Other Q13707 0.974 x x   X     x       efficacy 
ACTG1 
actin, 
gamma 1 Cytoplasm Other P63261 0.974 x x   X X x x X x   
unspecified 
application 
AGT 
angiotensino
gen (serpin 
peptidase 
inhibitor, 
clade A, 
member 8) 
Extracellular 
Space 
growth 
factor P01019 0.945 x x X             x efficacy 
ALB Albumin 
Extracellular 
Space transporter P02768 -1.141 x x X               
diagnosis,efficacy
,prognosis,safety,
unspecified 
application 
AMBP 
alpha-1-
microglobuli
n/bikunin 
precursor 
Extracellular 
Space transporter P02760 0.913 x x X               
safety,unspecified 
application 
APCS 
amyloid P 
component, 
serum 
Extracellular 
Space Other P02743 0.597 x x X               
unspecified 
application 
APOA4 apo A-IV 
Extracellular 
Space transporter P06727 0.441 x x X               
unspecified 
application 
APOB apo B 
Extracellular 
Space transporter P04114 0.581 x x X             x diagnosis,efficacy 
APOC1 apo C-I 
Extracellular 
Space transporter P02654 0.843 x x X   X           
prognosis,unspeci
fied application 
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Symbol 
Entrez 
Gene Name Location Family UniProt 
Log 
Ratio Human Blood 
Plasma/
Serum 
Large 
Intestine 
COLO
205 
HCC
-2998 
HCT
-116 
HCT
-15 
HT
29 
KM-
12 
Other Colon 
Cancer Cell 
Lines 
APOE apo E 
Extracellular 
Space transporter Q6LBZ1 1.316 x x x X           x 
diagnosis,efficacy
,prognosis,unspec
ified application 
CLU Clusterin Cytoplasm Other P10909 0.486 x x x X X x x X x   
efficacy,unspecifi
ed application 
COL1A1 
collagen, 
type I, alpha 
1 
Extracellular 
Space Other P02452 1.415 x x x               diagnosis 
CP 
ceruloplasmi
n 
(ferroxidase) 
Extracellular 
Space Enzyme P00450 0.969 x x x     x         efficacy 
DST Dystonin 
Plasma 
Membrane Other Q03001 -1.113 x x x   X x x X x   
unspecified 
application 
F7 
coagulation 
factor VII 
(serum 
prothrombin 
conversion 
accelerator) 
Plasma 
Membrane Peptidase A3RKG7 -0.695 x x x               
unspecified 
application 
F10 
coagulation 
factor X 
Extracellular 
Space Peptidase P00742 0.863 x x x               efficacy 
FABP1 
fatty acid 
binding 
protein 1, 
liver Cytoplasm transporter Q05CP7 1.342 x x x X X         x 
unspecified 
application 
FN1 fibronectin 1 
Extracellular 
Space Enzyme P02751 1.191 x x x X       X     
diagnosis,efficacy
,prognosis,unspec
ified application 
GSN Gelsolin 
Extracellular 
Space Other P06396 0.622 x x x X X x x X x x 
disease 
progression,effica
cy 
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Symbol 
Entrez 
Gene Name Location Family UniProt 
Log 
Ratio Human Blood 
Plasma/
Serum 
Large 
Intestine 
COLO
205 
HCC
-2998 
HCT
-116 
HCT
-15 
HT
29 
KM-
12 
Other Colon 
Cancer Cell 
Lines 
IGKC 
Ig kappa 
constant 
Extracellular 
Space Other P01834 -0.628 x x x               
unspecified 
application 
NCAM1 
neural cell 
adhesion 
molecule 1 
Plasma 
Membrane Other P13591 1.076 x x x           x   
efficacy, 
prognosis 
NUMA1 
nuclear 
mitotic 
apparatus 
protein 1 Nucleus Other Q14980 0.014 x x x X X x x X x   
unspecified 
application 
SERPIN
A1 
serpin 
peptidase 
inhibitor, 
clade A 
(alpha-1 
antiproteinas
e, 
antitrypsin), 
member 1 
Extracellular 
Space Other P01009 1.495 x x x         X   x 
diagnosis, 
unspecified 
application 
SERPIN
D1 
serpin 
peptidase 
inhibitor, 
clade D 
(heparin 
cofactor), 
member 1 
Extracellular 
Space Other Q8IVC0 0.733 x x x               
disease 
progression 
TF Transferrin 
Extracellular 
Space transporter P02787 0.002 x x x               
efficacy, 
prognosis 
THBS1 
thrombospon
din 1 
Extracellular 
Space Other P07996 0.780 x x x X X x   X   x diagnosis,efficacy 
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Table 53: IPA Biomarkers Dukes C 
 
Symbol 
Entrez 
Gene Name Location Family UniProt 
Log 
Ratio Human Blood 
Plasma/
Serum 
Large 
Intestine 
COLO
205 
HCC
-2998 
HCT
-116 
HCT
-15 
HT
29 
KM-
12 
Biomarker 
Application(s) 
ACTA2 
actin, alpha 
2, smooth 
muscle, 
aorta Cytoplasm Other Q13707 0.828 x x   
X 
      X     Efficacy 
ACTG1 
actin, 
gamma 1 Cytoplasm Other P63261 0.828 x x   
X 
X x x X x x 
unspecified 
application 
AGT 
angiotensino
gen (serpin 
peptidase 
inhibitor, 
clade A, 
member 8) 
Extracellular 
Space 
growth 
factor P01019 1.010 x x x 
 
X           Efficacy 
ALB Albumin 
Extracellular 
Space Transporter P02768 -2.165 x x x 
 
            
diagnosis,efficacy
,prognosis,safety,
unspecified 
application 
AMBP 
alpha-1-
microglobuli
n/bikunin 
precursor 
Extracellular 
Space Transporter P02760 0.519 x x x 
 
            
safety,unspecified 
application 
APCS 
amyloid P 
component, 
serum 
Extracellular 
Space Other P02743 1.267 x x x 
 
            
unspecified 
application 
APOA4 Apo A-IV 
Extracellular 
Space Transporter P06727 1.000 x x x 
 
            
unspecified 
application 
APOB Apo B 
Extracellular 
Space Transporter P04114 1.305 x x x 
 
            diagnosis,efficacy 
APOC1 Apo C-I 
Extracellular 
Space Transporter P02654 1.490 x x x 
 
  x         
prognosis,unspeci
fied application 
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Symbol 
Entrez 
Gene Name Location Family UniProt 
Log 
Ratio Human Blood 
Plasma/
Serum 
Large 
Intestine 
COLO
205 
HCC
-2998 
HCT
-116 
HCT
-15 
HT
29 
KM-
12 
Biomarker 
Application(s) 
APOE Apo E 
Extracellular 
Space Transporter P02649 2.177 x x x 
X 
            
diagnosis,efficacy
,prognosis,unspec
ified application 
CLU Clusterin Cytoplasm Other P10909 0.773 x x x 
X 
X x x X x x 
efficacy,unspecifi
ed application 
COL1A1 
collagen, 
type I, alpha 
1 
Extracellular 
Space Other P02452 1.322 x x x 
 
            Diagnosis 
CP 
CP 
(ferroxidase) 
Extracellular 
Space Enzyme P00450 1.000 x x x 
 
    x       Efficacy 
DST Dystonin 
Plasma 
Membrane Other Q03001 -0.585 x x x 
 
X x x X x x 
unspecified 
application 
F7 
coagulation 
factor VII 
(serum 
prothrombin 
conversion 
accelerator) 
Plasma 
Membrane Peptidase A3RKG7 -1.909 x x x 
 
            
unspecified 
application 
F10 
coagulation 
factor X 
Extracellular 
Space Peptidase P00742 0.865 x x x 
 
            Efficacy 
FABP1 
fatty acid 
binding 
protein 1, 
liver Cytoplasm transporter Q05CP7 0.961 x x x 
X 
X x         
unspecified 
application 
FN1 fibronectin 1 
Extracellular 
Space Enzyme P02751 1.994 x x x 
X 
        x   
diagnosis,efficacy
,prognosis,unspec
ified application 
GSN Gelsolin 
Extracellular 
Space Other P06396 0.964 x x x 
X 
X x x X x x 
disease 
progression,effica
cy 
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Symbol 
Entrez 
Gene Name Location Family UniProt 
Log 
Ratio Human Blood 
Plasma/
Serum 
Large 
Intestine 
COLO
205 
HCC
-2998 
HCT
-116 
HCT
-15 
HT
29 
KM-
12 
Biomarker 
Application(s) 
IGKC 
Ig kappa 
constant 
Extracellular 
Space Other P01834 -1.753 x x x 
 
            
unspecified 
application 
NCAM1 
neural cell 
adhesion 
molecule 1 
Plasma 
Membrane Other P13591 0.431 x x x 
 
          x 
efficacy, 
prognosis 
NUMA1 
nuclear 
mitotic 
apparatus 
protein 1 Nucleus Other Q14980 0.822 x x x 
X 
X x x X x x 
unspecified 
application 
ORM1 
orosomucoid 
1 
Extracellular 
Space Other P02763 0.786 x x x 
 
            
unspecified 
application 
SERPIN
A1 
serpin 
peptidase 
inhibitor, 
clade A 
(alpha-1 
antiproteinas
e, 
antitrypsin), 
member 1 
Extracellular 
Space Other P01009 0.731 x x x 
 
        x   
diagnosis, 
unspecified 
application 
SERPIN
D1 
serpin 
peptidase 
inhibitor, 
clade D 
(heparin 
cofactor), 
member 1 
Extracellular 
Space Other Q8IVC0 1.210 x x x 
 
            
disease 
progression 
TF Transferrin 
Extracellular 
Space transporter P02787 -0.043 x x x 
 
            
efficacy, 
prognosis 
THBS1 
thrombospon
din 1 
Extracellular 
Space Other P07996 0.533 x x x 
X 
X x x   x   diagnosis,efficacy 
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Table 54: Common Dukes iTRAQ Biomarkers 
Symbol Entrez Gene Name 
UniProt/Swiss-Prot 
Accession Log Ratio Dukes A Log Ratio Dukes B Log Ratio Dukes C 
ACTA2 actin, alpha 2, smooth muscle, aorta Q13707 -0.719 0.974 0.828 
ACTG1 actin, gamma 1 P63261 -0.719 0.974 0.828 
AGT angiotensinogen (serpin peptidase inhibitor, clade A, member 8) P01019 -0.476 0.945 1.010 
ALB Albumin P02768 -3.756 -1.141 -2.165 
APCS amyloid P component, serum P02743 -0.111 0.597 1.267 
APOA4 apolipoprotein A-IV P06727 -0.021 0.441 1.000 
APOB apolipoprotein B P04114 -1.357 0.581 1.305 
APOC1 apolipoprotein C-I P02654 -1.163 0.843 1.490 
APOE apolipoprotein E Q6LBZ1 0.342 1.316 2.177 
CLU Clusterin P10909 -0.674 0.486 0.773 
CP ceruloplasmin (ferroxidase) P00450 -0.653 0.969 1.000 
DST Dystonin Q03001 -2.769 -1.113 -0.585 
F7 coagulation factor VII (serum prothrombin conversion accelerator) A3RKG7 -2.629 -0.695 -1.909 
F10 coagulation factor X P00742 -0.383 0.863 0.865 
FABP1 fatty acid binding protein 1, liver Q05CP7 -0.592 1.342 0.961 
FN1 fibronectin 1 P02751 -0.598 1.191 1.994 
GSN Gelsolin P06396 -0.160 0.622 0.964 
IGKC immunoglobulin kappa constant P01834 -2.398 -0.628 -1.753 
NCAM1 neural cell adhesion molecule 1 P13591 -0.921 1.076 0.431 
SERPINA1 
serpin peptidase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), 
member 1 P01009 -1.719 1.495 0.731 
SERPIND1 serpin peptidase inhibitor, clade D (heparin cofactor), member 1 Q8IVC0 -0.706 0.733 1.210 
TF Transferrin P02787 -1.629 0.002 -0.043 
THBS1 thrombospondin 1 P07996 -1.128 0.780 0.533 
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4.2  ID PAGE analysis of Control and CRC depleted serum 
Figure 69: 1D gel analysis of pooled CRC serum 
 
Serum proteins from matched IgY immuno-affinity depleted CRC and control 
samples were resolved by 1D gel electrophoresis.  All the gel spots in Figure 69 were 
subsequently excised and analysed by MS.  This comparative image analysis 
demonstrates that there are clearly proteins, which are differentially expressed in both 
the serum of patients with CRC and those who do not.  Visual inspection of the gel 
shows that not only are there differences in expression but also intensity. Analysis of 
the excised bands generated a total of 162 proteins from the CRC subjects and 137 
proteins from the controls, which were above the significance threshold. Comparing 
the protein profiles generated from both gels identified 118 unique proteins in the 
CRC CRC CRC CON CON 
1μg protein 3μg protein 5μg protein 
CON 
 
 
D10-6 
 
 
C10-5 
 
 
 
C10-4 
 
 
 
C10-2 
 
 
 
D10-3 
 
 
 
D10-1 
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CRC group and 106 proteins from the control cohort.  This was however only an 
evaluation of expression patterns rather than a quantitative comparison.  
Any observed differences in band expression or intensity between the 2 sample 
groups (as depicted by the red and blue coloured text boxes on the gel in Figure 73) 
were also analysed separately and are detailed below.  As illustrated on the gel 3 
bands were excised from both the CRC and control sections.  The proteins identified 
from each section are shown in the tables below.  A total of 30 proteins were 
identified from all 3 sections of the CRC section, whilst a total of 56 were identified 
from the control sector. 14 proteins were unique to the CRC group and 15 were 
exclusive to the control group.  There were 17 crossover proteins between the 2 
groups.  A number of different forms of Keratin were found various sections of the 
gel and are likely to represent contaminants.  The last 2 columns in each table defines 
the molecular and biological functions of the proteins excised. 
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Table 55: Proteins identified from CRC bands excised at D10-1, with their molecular 
and biological functions  
Protein IPI Molecular function 
Biological 
function 
Serotransferrin precursor  IPI00022463 Iron binding Transport 
Isoform 1 of Gelsolin precursor  IPI00026314 Calcium binding Cellular processes 
Afamin precursor  IPI00019943 Vit. E binding Transport 
Insulin-like growth factor-binding protein complex 
acid labile chain precursor  IPI00020996 Growth factor 
Growth 
promotion 
ALB protein  IPI00216773 - - 
IGHM protein  IPI00477090  Immunity 
Ceruloplasmin precursor  IPI00017601 Copper ion binding Copper transport 
Ig mu heavy chain disease protein  IPI00385264 Antigen binding Immunity 
Keratin, type II cytoskeletal 1  IPI00220327 - - 
Putative uncharacterized protein 
DKFZp686N02209  IPI00384938 - - 
Hyaluronan-binding protein 2 precursor  IPI00746623 - Coagulation 
SERPINA1 PRO2275  IPI00305457 - - 
Vitamin D-binding protein precursor  IPI00555812 Transporter Vitamin D binding 
Complement C1s subcomponent precursor  IPI00017696 MAC complex Immunity 
IGKV1-5 IGKV1-5 protein  IPI00419424 - Immunity 
 
From D10-1 band excision 15 protein IDs were attained.  A number of the proteins 
are involved in immunity, the remainder in cellular processes such as growth and 
transport. 
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Table 56: Proteins identified from CRC bands excised at D10-3, with their molecular 
and biological functions  
Protein IPI Molecular function 
Biological 
function 
Isoform 1 of Serum albumin precursor  IPI00745872 Molecule binding Transport 
Complement component C9 precursor  IPI00022395 MAC constiuent Immunity 
Isoform 1 of N-acetylmuramoyl-L-alanine amidase 
precursor  IPI00163207 
Metal ion 
binding/ 
receptor activity 
Immunity 
Heparin cofactor 2 precursor  IPI00879573 Heparin binding Coagulation 
Complement C2 precursor (Fragment)  IPI00303963 Serine Protease Immunity 
Alpha-1-antichymotrypsin precursor  IPI00550991 Protease Immunity 
CP 97 kDa protein  IPI00794184 - Cell organisation 
Protein chibby homolog 3  IPI00740400 Beta-Catenin binding Differentiation 
 
Following excision of D10-3 band the gel as depicted in Figure 73, 8 proteins were 
identified.  Again a number of the proteins (50%) in this section are involved in 
immunity. 
Table 57: Proteins identified from CRC bands excised at D10-6, with their molecular 
and biological functions  
Protein IPI Molecular function 
Biological 
function 
Haptoglobin precursor  IPI00641737 Catalytic activity Immunity 
Haptoglobin isoform 2 preproprotein  IPI00478493 Catalytic activity Immunity 
Keratin, type II cytoskeletal 1  IPI00220327 - - 
Transthyretin precursor  IPI00022432 Hormone Transport 
Isoform 3 of Keratin, type II cytoskeletal 80  IPI00375843 - - 
Keratin, type II cytoskeletal 6B  IPI00293665 - - 
Trypsin-1 precursor  IPI00011694 Protease Digestion 
20 kDa protein  IPI00793108 - - 
Keratin, type II cytoskeletal 79  IPI00241841 - - 
Hemoglobin subunit epsilon  IPI00217471 Heme, Iron ion binding Oxygen transport 
 
Following excision of the D10-6 section of gel as depicted in Figure 73, 10 proteins 
were identified.  There are a number of keratin proteins in this part of the gel. 
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Table 58: Proteins identified from control bands excised at C10-2, with their 
molecular and biological functions  
Protein IPI Molecular function 
Biological 
function 
Prothrombin precursor (Fragment)  IPI00019568 Protease Coagulation 
Isoform 1 of Gelsolin precursor  IPI00026314 Actin capping Biogenesis 
Keratin, type II cytoskeletal 1  IPI00220327 - - 
Afamin precursor  IPI00019943 Vit E binding Transport 
Insulin-like growth factor-binding protein complex 
acid labile chain precursor  IPI00020996 - Cell growth 
Complement C1s subcomponent precursor  IPI00017696 Protease Immunity 
Apolipoprotein A-IV precursor  IPI00304273 Binding Lipid transport 
Keratin, type I cytoskeletal 9  IPI00019359 - - 
Vitamin K-dependent protein S precursor  IPI00294004 Endopeptidase activity Blood coagulation 
Vitamin D-binding protein precursor  IPI00555812 Transporter Vitamin D binding 
26 kDa protein  IPI00796888 - - 
Keratin, type I cytoskeletal 10  IPI00009865 - - 
Ceruloplasmin precursor  IPI00017601 Copper ion binding Copper transport 
SERPINF2 protein  IPI00029863 Protease inhibitor Acute phase 
Dopamine beta-hydroxylase  IPI00171678 Binding Catecholamine biosynthesis 
Keratin 77  IPI00376379 - - 
Isoform 1 of Peptidase inhibitor 16 precursor  IPI00301143 Peptidase inhibitor activity - 
Hyaluronan-binding protein 2 precursor  IPI00746623 Glycosamino-glycan binding Cell adhesion 
Keratin, type II cytoskeletal 3  IPI00290857 - - 
Transthyretin precursor  IPI00022432 Thyroid hormone Transport 
 
Following excision of the D10-2 section of the gel as depicted in Figure 73, 20 
proteins were identified.  There are a number of different molecular and biological 
processes that the proteins are involved in, in this section of the gel. 
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Table 59: Proteins identified from control bands excised at C10-4, 
Protein IPI Molecular function 
Biological 
function 
Ceruloplasmin precursor  IPI00017601   
Isoform 1 of Serum albumin precursor  IPI00745872   
Keratin, type II cytoskeletal 1  IPI00220327 - - 
Isoform 1 of N-acetylmuramoyl-L-alanine amidase 
precursor  IPI00163207 Hydrolase Immunity 
Complement C2 precursor (Fragment)  IPI00303963 MAC complex Immunity 
Extracellular matrix protein 1 precursor  IPI00003351 Integrin & Heparin binding 
Cell-matrix 
adhesion 
Keratin, type I cytoskeletal 10  IPI00009865 - - 
Vitamin D-binding protein precursor  IPI00555812 Transporter Vitamin D binding 
Transthyretin precursor  IPI00022432 Thyroid hormone Transport 
Serpin peptidase inhibitor, clade D (Heparin 
cofactor), member 1  IPI00292950 
Serine-type 
endopeptidase 
inhibitor activity 
Blood 
coagulation, 
cheomtaxis 
Keratin, type II cytoskeletal 2 epidermal  IPI00021304 - - 
Alpha-1-antichymotrypsin precursor  IPI00550991 Protease inhibitor Acute phase 
Complement component C9 precursor  IPI00022395 MAC complex Immunity 
Keratin, type II cytoskeletal 8  IPI00554648 - - 
Keratin 77  IPI00376379 - - 
SERPINF2 protein  IPI00029863 Protease inhibitor Acute phase 
Complement component C8 beta chain precursor  IPI00294395 MAC complex Complement activation 
Keratin, type II cytoskeletal 6A  IPI00300725 - - 
23 kDa protein  IPI00794403 - - 
Trypsin-1 precursor  IPI00011694 Protease Digestion 
Keratin, type II cytoskeletal 79  IPI00241841 - - 
Complement component C8 alpha chain precursor  IPI00011252 MAC complex Complement activation 
Protein chibby homolog 3  IPI00740400 
Chromatin 
regulator, 
repressor 
Transcription 
Transforming growth factor, beta-induced, 68kDa 
variant (Fragment)  IPI00556324 Integrin binding 
Cell adhesion and 
proliferation 
 
Following excision of the C10-4 section of the gel as depicted in Figure 73, 24 
proteins were identified.   
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Table 60: Proteins identified from control bands excised at C10-5, with their 
molecular and biological functions  
Protein IPI Molecular function 
Biological 
function 
Transthyretin precursor  IPI00022432 Thyroid hormone Transport 
AMBP protein precursor  IPI00022426 Serine protease inhibitor 
Host-virus 
interaction 
C2 protein  IPI00514968 Hydrolase, protease Immunity 
Isoform 1 of N-acetylmuramoyl-L-alanine amidase 
precursor  IPI00163207 Hydrolase Immunity 
Keratin, type II cytoskeletal 1  IPI00220327 - - 
Hepatocyte growth factor activator precursor  IPI00029193 Hydrolase Endopeptidase activity 
Vitamin D-binding protein precursor  IPI00555812 Transporter Vitamin D binding 
Apolipoprotein A-IV precursor  IPI00304273 
Antioxidant 
activity, 
cholesterol 
transporter 
activity 
Cholesterol 
homeostasis 
Clusterin precursor  IPI00291262 Chaperone Cell death 
Pigment epithelium-derived factor precursor  IPI00006114 
Serine-type 
endopeptidase 
inhibitor activity 
Cell proliferation 
Serpin peptidase inhibitor, clade D (Heparin 
cofactor), member 1  IPI00292950 
Serine-type 
endopeptidase 
inhibitor activity 
Blood 
coagulation, 
cheomtaxis 
Isoform 1 of Ficolin-3 precursor  IPI00293925 Carbohydrate binding 
Complement 
activation, lectin 
pathway 
 
Following excision of the C10-5 section of the gel as depicted in Figure 73, 12 
proteins were identified.   
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4.3 Comparison of iTRAQ, Label free quantitation and 1D 
Gel analysis 
I have used 3 different proteomic platforms to investigate CRC serum within this 
research project.  All can 3 methods can be quantitative, but in the case of the Gel in 
this   research   project   it   wasn’t.      The   results   from   the   3   profiling   approaches   were  
compared with reference to the sample amount required, preparation time, 
instrumental time and the biological results (See Table 61).  Certainly the 1D Gel 
performs favorably in the majority of the measured categories.  The iTRAQ approach 
generally requires larger sample amounts and longer preparation and instrumental 
times, but the number of identified proteins is greater.  For some reason the label free 
approach within the constraints of this study performed relatively poorly.  This may 
be in part attributable to it having been a relatively new technology within the 
department I undertook my MD, or because of problems with the samples or 
instruments.  Similar samples and mass spectrometers were however utilized for the 
iTRAQ experiments, which yielded good results.   A larger number of these proteins 
are of low abundance also.  Patel et al (290) specifically compared the 3 proteomic 
approaches adopted in this research and found good agreement between all 3 at the 
profiling level, but the label free approach gave better information if more than one 
peptide or better sequence coverage was required.   
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Table 61:  Comparison of ID-Gel, iTRAQ and Label free proteomics 
 
 1D-Gel iTRAQ Label Free 
Amount of protein required for experiment 10μg 50μg 50μg 
Preparation time including overnight steps 3 Days 1 week 1 week 
Number of samples to analyze 
1 per condition; 
2 in total 50 – 60 fractions 
3 technical replicates per condition; 
6 for CRC and 12 for Dukes experiment 
Time for LC-MS 1 day 2 – 3 days 2 days 
Total analysis time 1 week 2 - 3 weeks 2 – 3 weeks 
Number of proteins identified in CRC 
experiment 162 251 10 
Number of proteins identified in Dukes 
experiment    
A N/A 460 1 
B N/A 463 34 
C N/A 462 22 
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4.4 Results for serum glycosylation analysis using lectin affinity 
chromatography 
Table 62: Lectin analysis of pooled CRC serum 
 Lectin analysis of CRC serum 
WGA Jac Con A 
No. of proteins above the 
significance threshold 
64 37 21 
No. of  high abundant 
proteins (%) 
2 (3%) 2 (5%) 2 (10%) 
No. of medium abundant 
proteins (%) 
22 (34%) 20 (54%) 7 (33%) 
No. of low abundant proteins 
(%) 
40 (63%) 15 (41%) 12 (57%) 
No. of unique proteins (%) 36 (56%) 6 (16%) 4 (19%) 
No. of cross over proteins 
(%) 
28 (44%) 31 (84%) 17 (81%) 
 
The lectin analysis was performed towards the end of my MD and hence the Lectin 
analysis   wasn’t   used   to   compare   control   and   colorectal   cancer   samples   fully.  
Utilising quantitative proteomics in conjunction with this sub proteome analysis along 
with a similar evaluation of control serum, would have more likely yielded more 
meaningful results.  Using pooled depleted CRC serum and the lectins detailed above 
I did however identify a number of proteins using the multi-lectin affinity column.  A 
number of conclusions can be inferred from the above analysis despite the apparent 
deficiencies. (see tables 62 - 65).  The most identifications (See Table 62 & Table 64) 
were achieved using the WGA lectin.  The number of high abundance proteins using 
this proteomic platform was low for all 3 lectin affinity columns.  The % of low 
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abundance proteins ranged from 41% to 63%, with the WGA column attaining the 
highest %.   There was a large % of cross over proteins for the Con A (81%) and the 
Jac (84%) Lectin columns.  The WGA column resulted in the largest % of unique 
proteins (56%) as measured against the Jac and Con A lectin columns.  Overall it 
suggests that sub proteome analysis in CRC biomarker studies is feasible and would 
be best conducted using the WGA lectin column.   
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Table 63:  Jac CRC results 
 
Description Accession 
Alpha-2-HS-glycoprotein IPI00022431 
Angiotensinogen IPI00032220 
Isoform 1 of Serum albumin IPI00745872 
Highly similar to ALPHA-1-ANTICHYMOTRYPSIN IPI00550991 
Keratin, type II cytoskeletal 1 IPI00220327 
Vitamin D-binding protein IPI00555812 
Ceruloplasmin IPI00017601 
Alpha-2-macroglobulin IPI00478003 
Inter-alpha-trypsin inhibitor heavy chain H1 IPI00292530 
IGHV3OR16-13;IGHA1 IGHA1 protein IPI00166866 
AMBP protein IPI00022426 
Prothrombin (Fragment) IPI00019568 
Keratin, type II cytoskeletal 2 epidermal IPI00021304 
Apolipoprotein A-I IPI00021841 
Afamin IPI00019943 
Putative uncharacterized protein DKFZp686H17246 IPI00792115 
Keratin, type II cytoskeletal 6A IPI00300725 
Coagulation factor X IPI00019576 
Complement component C9 IPI00022395 
IGKV1-5 IGKV1-5 protein IPI00419424 
Serum amyloid P-component IPI00022391 
Complement C1s subcomponent IPI00017696 
Transthyretin IPI00022432 
Ferritin IPI00009865 
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Keratin, type I cytoskeletal 10 IPI00019359 
Keratin, type I cytoskeletal 9 IPI00292950 
Serpin peptidase inhibitor, clade D (Heparin cofactor), member 1 IPI00375843 
Isoform 3 of Keratin, type II cytoskeletal 80 IPI00328609 
Kallistatin IPI00304273 
Apolipoprotein A-IV IPI00023019 
Isoform 1 of Sex hormone-binding globulin IPI00305457 
SERPINA1 PRO2275 IPI00006114 
Pigment epithelium-derived factor IPI00020019 
Adiponectin IPI00022445 
Platelet basic protein IPI00292946 
Thyroxine-binding globulin IPI00291867 
Complement factor I IPI00305461 
Inter-alpha-trypsin inhibitor heavy chain H2 IPI00022431 
 
 
 
 
 
 
 
 
 289 
Table 64:  WGA CRC results 
 
Description Accession 
Alpha-2-macroglobulin  IPI00478003 
Highly similar to ALPHA-1-ANTICHYMOTRYPSIN  IPI00550991 
Ceruloplasmin  IPI00017601 
Insulin-like growth factor-binding protein complex acid labile chain  IPI00020996 
Alpha-2-HS-glycoprotein  IPI00022431 
LUM 23 kDa protein  IPI00794403 
Inter-alpha-trypsin inhibitor heavy chain H1  IPI00292530 
Angiotensinogen  IPI00032220 
Isoform 1 of N-acetylmuramoyl-L-alanine amidase  IPI00163207 
Complement factor I  IPI00291867 
ALB protein  IPI00216773 
Apolipoprotein A-IV  IPI00304273 
Isoform 1 of Sex hormone-binding globulin  IPI00023019 
Complement component 2  IPI00643506 
Carboxypeptidase N subunit 2  IPI00479116 
Clusterin  IPI00291262 
AMBP protein  IPI00022426 
Kallistatin  IPI00328609 
Keratin, type II cytoskeletal 1  IPI00220327 
Beta-Ala-His dipeptidase  IPI00064667 
Coagulation factor X  IPI00019576 
Prothrombin (Fragment)  IPI00019568 
Gelsolin  IPI00377087 
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Description Accession 
Isoform 1 of Carboxypeptidase B2  IPI00329775 
Afamin  IPI00019943 
Isoform 1 of Alpha-1-antitrypsin  IPI00553177 
Pigment epithelium-derived factor  IPI00006114 
Transthyretin  IPI00022432 
Vitamin D-binding protein  IPI00555812 
Endothelial protein C receptor precursor  IPI00009276 
Complement component C9  IPI00022395 
Dopamine beta-hydroxylase precursor  IPI00871997 
mannan-binding lectin serine protease 1 isoform 2 precursor  IPI00290283 
Isoform 1 of CD166 antigen  IPI00015102 
Serum amyloid P-component  IPI00022391 
Complement C1r subcomponent-like protein  IPI00009793 
von Willebrand factor  IPI00023014 
Isoform 3 of Keratin, type II cytoskeletal 80  IPI00375843 
Isoform 2 of Attractin  IPI00162735 
SERPINF2 protein  IPI00029863 
Thyroxine-binding globulin  IPI00292946 
platelet glycoprotein Ib alpha polypeptide precursor  IPI00748955 
IGL@ IGL@ protein  IPI00154742 
IGHV3OR16-13;IGHA1 IGHA1 protein  IPI00061977 
Intercellular adhesion molecule 2  IPI00009477 
L-selectin  IPI00218795 
Isoform 12 of CD44 antigen  IPI00297160 
Extracellular matrix protein 1  IPI00003351 
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Description Accession 
Coagulation factor IX  IPI00296176 
Isoform 1 of Ficolin-3  IPI00293925 
Isoform 2 of Multiple inositol polyphosphate phosphatase 1  IPI00028553 
similar to Fc fragment of IgG, low affinity IIIa, receptor  IPI00738873 
Isoform 1 of Cell surface glycoprotein MUC18  IPI00016334 
Inter-alpha-trypsin inhibitor heavy chain H2  IPI00305461 
Apolipoprotein A-I  IPI00021841 
IGKV1-5 IGKV1-5 protein  IPI00419424 
Isoform 1 of Dipeptidase 2  IPI00007127 
Macrophage colony-stimulating factor 1 receptor  IPI00011218 
Carboxypeptidase N, polypeptide 1  IPI00641144 
 Protein chibby homolog 3  IPI00740400 
Galectin-3-binding protein  IPI00023673 
Serpin peptidase inhibitor, clade D (Heparin cofactor), member 1  IPI00292950 
Leucine-rich alpha-2-glycoprotein  IPI00022417 
Monocyte differentiation antigen CD14  IPI00029260 
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Table 65:  Con A CRC results 
 
Description Accession 
Angiotensinogen IPI00032220 
Alpha-2-macroglobulin IPI00478003 
Ceruloplasmin IPI00017601 
ALB protein IPI00216773 
Alpha-2-HS-glycoprotein IPI00022431 
Highly similar to ALPHA-1-ANTICHYMOTRYPSIN IPI00550991 
Keratin, type II cytoskeletal 1 IPI00220327 
Prothrombin (Fragment) IPI00019568 
AMBP protein IPI00022426 
Dopamine beta-hydroxylase precursor IPI00871997 
Complement component 2 IPI00643506 
Thyroxine-binding globulin IPI00292946 
SERPINA1 PRO2275 IPI00305457 
Complement factor I IPI00291867 
IGL@ IGL@ protein IPI00154742 
Vitamin D-binding protein IPI00555812 
Kallistatin IPI00328609 
Probable G-protein coupled receptor 115 IPI00217512 
Keratin, type II cytoskeletal 3 IPI00290857 
Isoform 1 of Attractin IPI00027235 
IGHV3OR16-13;IGHA1 IGHA1 protein IPI00061977 
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DISCUSSION 
5.1  Overview of Proteomics 
The proteome encompasses all proteins within an organism in their unmodified or 
modified state.   The word proteome is a combination of the words protein and 
genome, and was first described by M. Wilkins, a PhD student in 1994 (273).  The 
study of proteins, Proteomics, is a relatively new advancement and was first modelled 
in 1997 following the maturation of the Human Genome Project.  The proteome is the 
final biological system that can be assayed in an organism after the genome and 
transcriptome.  It is however the most complex to scrutinize due to the fact it can 
differ markedly not only between cells but also with changes in the hosts 
physiological environment.  Additionally the translation of mRNA is inconstant, and 
in some instances does not always transmute into a protein.  Moreover the amount of 
protein produced is also dependent on the transcription of mRNA, which is under 
both genetic control and directly related to the hosts biological composition.  The 
translation of mRNA is not the only confounding factor.  Proteins are subjected to a 
variety of post-translational modifications, which are critical to their function.  The 
existence of such adds a further dimension of complexity when trying to identify 
proteins in composite mixtures.  Perhaps the biggest theoretical challenge in studying 
proteomics, however, is firstly the wide dynamic range of proteins and secondly the 
total number of proteins in the human body.  The concentration of albumin is more 
than a billion times that of Interleukin-6 (274), making the detection of low 
abundance proteins such as interleukins, which are of biological interest, extremely 
difficult.  The human genome contains approximately 21,000 genes, each of which 
can encode for more than 1 protein, the total number of proteins within the human 
body has been estimated to be between 250,000 to 1 million (274, 275).  This 
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difference in protein diversity is believed to be related to, post translational 
modifications and splicing.  Proteomics studies do however give a different 
understanding of disease mechanisms compared to genomic inquiries.  Genes dictate 
the expression of proteins, but proteins functionally direct normal and disease 
physiology, thus their detection and measurement will undoubtedly augment the 
understanding of aberrant cellular processes. In essence the genetic potential of a cell 
is determined by protein expression as proteins direct almost all cellular functions. 
The origin of modern proteomic technologies stems from the methodology described 
by Wilkins et al (273).  They described the identification of unknown proteins 
through either amino acid composition or peptide mass fingerprinting and matching 
these entities against theoretical proteins within computational databases. These 
principles form the basis of many contemporary proteomics studies, which initially 
involve the processing and separation of samples followed by the acquisition and 
analysis of the sample data.  There are a number of different technologies that can be 
exploited to achieve these objectives and these have been discussed in this thesis 
within the introduction.  I specifically looked at Mass Spectrometry Quantitative 
(iTRAQ and Label Free) based proteomic techniques for reasons outlined in the 
introduction.  From the literature, and from my research, it does however appear that 
there is no single proteomic platform that will mollify all proteomic measures and that 
new technologies will have to emerge to allow for the sampling of lower abundance 
proteins 
Undoubtedly the application of proteomic tools to molecular and cellular biology has 
lead to an expansion in the knowledge and understanding of many complex disease 
processes. More recently, however, its application has been extended to biomarker 
discovery.  The development of such a technology has meant that biomarkers for 
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early disease detection, the monitoring of disease and the response of disease to 
specific treatments has been isolated, and has therefore meant risk and treatment 
stratification can ensue.  The application of proteomics to the field of biomarker 
discovery has however presented a variety of difficulties to overcome apart from 
those detailed above.  Both pre-analytical (sample) and analytical variability can 
impose systematic biases and adversely affect biomarker discovery projects.  
Measures to lessen the influence of possible biases need to be introduced which may 
include the examination of a clearly defined sample population with a common 
disease for which non-invasive samples can be obtained and processed with relative 
ease.  The collection of samples and the subsequent analytical techniques employed 
should also be stringently standardized for each of the sample groups to ensure that 
any heterogeneity is due to biological differences rather than external factors.  These 
have been discussed in detail in the Introduction.  Within this piece of research I 
minimized these factors by collecting the majority of the samples prospectively, with 
the controls and CRC samples being collected in a similar environment.  They were 
aliquoted out to prevent repeated freeze-thaw cycles and the control and CRC samples 
were then processed for each experiment in tandem using a standardized protocol that 
I developed. 
Another confounding factor in any biomarker discovery study is reproducibility.  
Within the literature others have not readily replicated the biomarker discovery results 
of   another   research’s   group.      This   is   highlighted   by   2   parallel   studies   utilizing  MS  
based proteomics for large-scale protein analysis in yeast.  Peng et al (276) identified 
1504 yeast proteins in a proteomics experiment, but Washburn et al (277) discovered 
only 858 of these proteins in a similar study.  Furthermore, the study by Washburn et 
al identified 607 proteins that were not found by Peng et al.  
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Adjusting for such confounding factors is impossible in biomarker discovery studies 
unlike in traditional proteomic strategies.  It is therefore important that any biomarker 
discovery study is designed and conducted aptly in order to minimize any peripheral 
variants, which could ultimately complicate the study outcomes. 
5.2  Study Population 
The patients recruited to this study were selected following a positive guaiac and 
immunochemical FOBT.  The CRC patients were chosen based on, firstly the 
identification of a colorectal carcinoma at colonoscopy, and secondly following full 
radiological and pathological staging to categorize them as Dukes Stage A – C.  
Dukes Stage D tumours were not included in this analysis.  The controls were 
identified following a negative colonoscopy.   The blood samples were taken prior to 
the colonoscopy and underwent stringent processing as described in the materials and 
methods section.  The majority of the blood samples were collected prospectively but 
some were collected retrospectively.  The use of archived samples may have imposed 
some pre-analytical variability into the research due to the fact that the samples may 
have been handled and processed differently.  The cancer and control samples were 
however collected under similar conditions, thus  any  differences  couldn’t  have  been  
exclusively due to sample ascertainment.   In quantitative terms, previous research has 
indicated that tourniquet application time, exercise, and whether the sample is 
obtained while the subject is sitting or recumbent can each individually induce a 
change in total protein concentrations by 10% (278, 279).  Thus even minor 
differences that may have not been considered can have major implications for down 
stream analysis.  Sample quality is also imperative to ensure both molecular features 
and any intra sample homogeneity are preserved.   
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The mean age of the CRC cohort was 72yrs, whilst that of the controls was 67yrs.  
We analyzed 53 CRC patients, which comprised of 16 Dukes A, 14 Dukes B and 23 
Dukes C, whilst only 17 controls were utilized in this study.   Although I have clearly 
documented  the  age,  gender  and  underlying  disease  process,  I  haven’t  accounted  for  
phenotypic responses or variations between the sample populations such as could be 
induced by smoking, diet or other underlying medical conditions.  These parameters 
could account for some of the perceived differences between the sample groups rather 
than it being disease specific.   
I particularly choose to study serum as a potential source of protein biomarkers for 
CRC because of the general ease of accessibility, patient acceptability and relative 
ease of handling.  I used serum rather than plasma due to the loss of coagulation 
factors, which for this particular study have no biological relevance and their presence 
may have even disadvantaged the discovery of lower abundance proteins.  A proximal 
fluid such as faeces may have more readily identified meaningful biomarkers but it is 
a much harder medium to analyze using proteomic technologies and lacks both the 
scientific and patient permissibility that perhaps a media such as serum does. 
5.3  Method Development of quantitative proteomic platform 
This thesis was based around the principles of MS based quantitative proteomics.  
iTRAQ and label free technologies were predominantly exploited within this 
stratagem to try and disclose protein biomarkers for detecting CRC in asymptomatic 
individuals within serum.  Using two quantitative MS methods meant that I could 
directly compare both methodologies to determine which method was superior but 
also substantiate any potential biomarkers, which would have been identified and 
verified through 2 different approaches. Although both the methods I utilized within 
this thesis are well described, the complexities of biomarker discovery are well 
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documented, and I therefore thought it was imperative to look at all aspects of this 
process and develop a strategic proteomic platform that could then be applied to 
identify markers of early disease.  As previously alluded to, serum possesses a vast 
dynamic range of proteins, with those proteins of biological interest being present in 
the lowest concentrations.  To enable these proteins to be assayed antibody depletion 
methodologies to remove high abundance proteins, which are of little biological 
significance, are routinely employed in serum protein biomarker studies to augment 
the identification of such.  There are a number of commercially available columns for 
this purpose as previously highlighted in the earlier sections of this thesis, but I 
specifically looked at and contrasted the Agilent MARS Hu6 and Hu14 columns as 
well as the GenWay IgY/Supermix LC system.  Analyzing the depleted sample using 
mass spectrometry directly following the above process would be extremely 
ineffective.  Complex samples contain a large number of proteolytic peptides, but 
only a small subset of these can be assayed in a single MS run, which therefore limits 
the number of eventual identifications (See Figure 70).  Modern mass spectrometers 
are extremely sensitive but the their ability to detect peptides is obstructed by sample 
complexities but also because of time constraints that are imposed on the instruments.  
The reduced duty cycle also means that under-sampling can occur because of an 
imposed limitation on peptide collision rates.  Identification and quantification rates 
are directly proportional to sampling rates therefore every effort should be exploited 
to further reduce complexities and improve the sensitivity and scope of proteomic 
analysis.   
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Figure 70: Proportion of proteins quantitated versus protein abundance 
 
Reproduced from Bantscheff M. et al.  Quantitative mass spectrometry in proteomics: 
A critical review. Anal Bioanal Chem 2007;389, 1017-31. 
Strategies to circumvent these issues typically include a pre-fractionation step prior to 
any mass spectrometry exploration.  There are several methods that can be applied to 
a proteomics study but generally they all involve separating peptides by a certain 
physical or chemical property they possess, and thus proteins are sequenced across 
multiple fractionated samples.    I specifically looked at and compared 3 such 
methods, which have been alluded to within the introduction.    Included within the 
methodology development phase, I also looked at different protein concentration 
assays, optimization of mass spectrometer parameters and assessing the iTRAQ 
labelling error associated with my experiments.  The steps described above are used 
for the both the iTRAQ and label free protocols in this research and, thus the method 
development, which will be discussed in further detail below, is applicable to both 
approaches.  
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5.3.1  Quantitative Proteomics 
The development of diverse MS analytical methods has provided extensive qualitative 
knowledge regarding both protein structure and function.  The information generated 
is however static and specifically only indicates the presence or absence of proteins, 
and  doesn’t  elucidate  distinctions  in  protein  expression  between  disease states.  Mass 
spectrometry   isn’t   inherently   quantitative   firstly   because   proteolytic   peptides   have  
different physiochemical properties that result in inconsistent mass spectrometric 
responses between runs, and secondly, only a small percentage of the total peptides in 
a sample are actually evaluated at any particular time.  To quantitate proteins within 
complex biological samples requires adopting a relative or absolute quantitative MS 
platform.  Fundamental to either quantitative approach is the ionization and sampling 
of peptides initially during MS1 to produce a precursor ion scan, which is 
representative of all the ionized peptides within the sample.  Subsequently during 
MS2 the precursor ions are fragmented to generate a fragment ion scan for each 
precursor ion, which is then compared to peptide databases and computationally 
organized into protein sequences.  Relative MS quantitation strategies generally 
equate the levels of the same individual peptides between biologically different 
samples and express differences in terms of a fold change.  This may involve 
independently assaying and then analyzing disease and control samples and then 
comparing the MS spectra to determine peptide abundance relative to each.   There 
are generally 2 approaches within the domain of relative quantitation – isotopic labels 
and label free strategies.  I adopted both paradigms in this research to not only assess 
both approaches but also to substantiate any biomarkers identified.  Of the isotopic 
strategies I chose to employ iTRAQ as the sample medium I was using meant that  
other metabolic technologies were not compatible, and compared to other chemical 
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labelling technologies such as ICAT, iTRAQ is associated with significantly 
increased peptide coverage.  Compared to relative quantitation, absolute quantitation 
determines any difference in peptide and thus protein concentration between diverse 
samples as an exact amount or concentration.  It entails spiking known concentrations 
of synthetic heavy target peptides into an experimental sample and then performing 
LC-MS/MS.  Peptides will co-elute and be analyzed concurrently if they are of 
similar chemistry.  In contrast to relative quantitation, however, the abundance of the 
experimental sample is compared with the spiked target peptide to quantitate the 
absolute concentration using a pre-determined standard curve.  Generally this 
approach is used following the discovery step, when target proteins have been 
identified and require to be verified. 
5.3.1.1  iTRAQ 
Isobaric Tagging for Relative Quantitation (iTRAQ) is a non-gel based protein 
quantitative technology that was developed by Ross et al in 2004 (280).  It is based on 
the covalent labelling of amine reactive tags to the to the N-terminus and lysine side 
chains of peptides.  The tags will label all tryptic peptides within a sample.  There are 
2 commercially available sets of reagents from Applied Biosystems that involve either 
4 or 8 tags (4-plex or 8-plex experiment), allowing for the labelling and simultaneous 
comparison of 4-8 samples by mass spectrometry.    When the peptides with the 
attached tag are fragmented, the tag generates a reporter ion within the low molecular 
mass range.  The signals of the reporter ions for each MS2 spectrum will then 
establish the relative abundance ratio of the peptide.  The combined ratios for every 
peptide will then give the protein abundance.  The application of iTRAQ to biomarker 
studies is superlative as it allows quantitation and multiplexing in a single experiment 
and can be applied to the analysis of a number of diverse clinical samples. The ability 
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of iTRAQ to also differentiate between disease and control samples by either over or 
under expression of proteins will allow molecular characterization of patients by 
stage, intervention or even prognosis etc.  Although in principle ITRAQ appears to 
confer many advantages it does have a number of drawbacks.  Both mass 
spectrometer testing and subsequent data analysis is time consuming and complicated, 
and more importantly the whole workflow has to be rigorously standardized and 
adhered to.  Even although strict guidelines are implemented there are several studies 
that suggest iTRAQ ratio data can exhibit heterogeneity of variance, and often this 
variance is higher for low intensity signals.  This can be problematic in ITRAQ 
directed biomarker discovery studies for 2 reasons, firstly low intensity signals 
govern, and secondly a large number of proteins are identified with small numbers of 
peptides.   Other studies have also demonstrated that iTRAQ under estimates ratios, 
commonly referred to as ratio compression.  This can occur because of background 
interference or isotopic contamination (281-283).  The former is perhaps the harder to 
control, but it has been suggested it can be resolved using high-resolution sample 
fractionation (283).  Often two peptides with similar m/z will be difficult to resolve 
and thus the resultant product ion scan will contain fragment data from both peptides.  
Only 1 of the peptides will be subsequently classified, but its ratio data will be diluted 
by the presence of the other peptides information.  The changes in the differential 
expression (i.e. whether up or down regulated) of proteins were generally the same for 
iTRAQ and label free methods in my experiments.  The degree of fold change was 
however different for the label free and the iTRAQ.   Trinh et al (284) did however 
demonstrate with western blot analysis that the label free ratios were closer to the 
absolute ratio.  The literature on the application of ITRAQ to CRC is not extensive, 
especially in the search for serum biomarkers for CRC screening.  Zhang at al 
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identified 75 proteins with 95% confidence using iTRAQ in 10 patients with CRC and 
10 control patients, 9 of which were up regulated and 4 down regulated in the CRC 
group (285).  Fan et al (286) identified 802 dys-regulated proteins in CRC patients, 82 
of which were determined to be cancer specific. In the same study they identified that 
the complete absence or under expression of Gelsolin in CRC patients had a 
sensitivity of 86.89% and a specificity of 100%.  (286) 
5.3.1.2  Label free 
Although isotopic labelling for protein quantitation is reliable and has a proven 
profile, it is expensive, time consuming, involves extra pre-analytical steps to 
introduce it and results in the generation of large complicated data sets.  Li et al (287) 
showed that Label free quantitation surpassed chemical labelling in terms of the depth 
of proteome coverage and precision, and using a high-performance hybrid mass 
spectrometer such as the Orbitrap is better.  The quantification performance and 
reproducibility of iTRAQ was however proven superior to label free quantitation in 
the same paper.  Trinh et al (284) determined that Label free quantitation produced 
better and more accurate quantitation.  Ghaemmaghami et al (288) showed that 
spectra counting correlated notably with estimates of protein numbers in yeast, 
meaning that assessments of relative abundance are accurate using label free 
proteomics. Wang et al (289) established that both methodologies (iTRAQ and Label 
free) were comparable and the selection of the quantitation tool should be based on 
the hypothesis and experimental design.  Patel et al (290) corroborated the results 
from Wang et al (289), showing that there is good conformity between the 
methodologies but if more than 1 peptide is required for protein identification the 
Label free approach prevails.  Their overall conclusion was that to obtain both 
qualitative and quantitative information in any proteomics experiment a number of 
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issues such as sample size, sample preparation, cost, sequence coverage etc. require to 
be contemplated prior to adopting one of the described quantitative platforms.  There 
are 2 general approaches to determine protein abundance using label free quantitation: 
spectral counting and peak intensity to determine protein abundance.  The former uses 
MS2 data to directly measure the protein abundance, whilst the latter uses MS1 data.   
Both methods have been used to quantify protein expression in complex protein 
mixtures within the literature, specifically relating to spectral counting (291-296), and 
to ion intensity (289, 297-300).  The construction of such studies suggests that label 
free analysis is feasible to assess for changes in protein abundance in clinical samples.  
The majority of the studies did however fail to report false positive rates, error 
calculations and validation mechanisms.  Protein abundance has been found to 
correlate well with ion intensity and spectral counting in simple biological systems 
(289, 301).  Old et al (294) substantiated the results of the aforementioned studies in a 
more complex mammalian system. 
Progenesis LC-MS (Nonlinear dynamics) determines peptide abundance from the 
summation of all the peak intensities within the isotope boundaries. Protein 
abundance is derived from the sum of peptide abundances from one particular protein.   
Profile MS data is transformed into peak lists initially with the m/z values, 
abundances and intensities.  The next step in the Progenesis workflow is the 
generation of automatic and manual vectors, to match and normalize all the 
experimental runs to a reference run, normally one of the control biological replicates.  
The reference runs retention times are used for alignment.   After normalization the 
biological replicates are grouped and statistical analysis is performed using one way 
analysis of variance (ANOVA) calculations of all the detected features.  Peak lists are 
exported in the mgf format and a Mascot search is undertaken, the results of which 
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and are later imported back into Progenesis.  An inclusion list is thus generated 
following further statistical analysis and used to generate MS2 spectra, the results of 
which are imported back into Progenesis.  Protein abundance is determined and each 
protein is assigned a p-value.   By using this label-free quantification method 
numerous proteins can be identified and quantified within one experiment from 
several biological and technical replicates, providing mass spectrometric information 
on the differences in the protein compositions of the compared samples.  Weisser et al 
(302) compared Progenesis with 2 other label free software packages, MaxQuant and 
OpenMs, and disclosed that all were capable of processing large data sets with 
comparable quantitation results.  The use of label free quantitation for global 
proteomic profiling in CRC patients especially using plasma or serum as the media is 
not wide-ranging. Xue et al (303) compared the secretome of a primary colorectal 
cancer cell line and a metastatic lymph node cell line using label free proteomics.  910 
proteins were identified, 6 of which were validated by western blot.  2 of the proteins 
were then analyzed in serum in a cohort of patients with CRC, and found to be up 
regulated, suggesting a potential role for the proteins for predicting the presence of 
lymph node metastasis.  Matsubara et al (294, 304) proposed adipophilin as a 
potential biomarker for the detection of early-stage CRC using label free proteomics. 
Another label-free quantitative MS approach (305) identified 45 serum-based proteins 
with altered expression levels in pre- versus post celecoxib treatment in patients with 
FAP. Therapeutic targeting of the cyclooxegenase-2 (Cox-2) enzyme has been a 
successful strategy in reducing the polyp burden. The serum-based study used a 
baseline measurement prior to treatment, and serum taken from the same patients 
following 6 months of celecoxib treatment. Nine proteins increased in expression, and 
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36 decreased upon celecoxib treatment. The expression levels of Apo A-IV, Apo A-II, 
CD72, and Prx-3 were shown by western blot to be reduced following treatment. 
5.3.2  Depletion Methods 
Protein depletion is normally the first step in any orthogonal proteomics strategy.  
There are many commercially available kits to accomplish this, with the primary aim 
of each to separate the high and sometimes medium abundance proteins from those 
proteins of lower concentration and of potential interest.  Although high abundance 
proteins are generally thought to be of little diagnostic importance in biomarker 
studies, recent literature has suggested proteins which might be pertinent, can be lost 
through the depletion process because of non-specific binding to the larger carrier 
proteins such as albumin (306-309).  This is potentially a drawback of such 
methodology as it maybe that valuable markers are being discarded in the depleted 
bound fraction.  The validity of this approach in biomarker discovery projects may 
therefore be questioned due to the fact that only part of the proteome is being assayed.  
A useful approach that I could have undertaken in my study may have been to also 
analyze the unbound fraction from each of the depletion methods to ensure that 
valuable proteins were not being inadvertently omitted.  The problem is, however, 
that more than 80% of human serum is composed of albumin and immunoglobulins.  
Along with albumin and immunoglobulins there are 20 other proteins that are 
responsible for 99% of the total protein content in human plasma, meaning that there 
are 1000s of proteins contained within 1% of the remaining total protein mass (310). 
Without the removal of these high abundance proteins the analysis of low abundance 
proteins would not be possible.  Even if more than 99% of albumin is removed, it is 
still present at concentrations that are 50,000 times more than that of tumour makers 
such as PSA (311, 312). The removal of as many high abundance proteins as possible 
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has shown to enhance the discovery of low abundance proteins.  For example the 
removal of the top 7 or 14 as done by the MARS columns has shown to improve the 
detection of non-targeted plasma proteins by an average of 4-fold, as assessed by 
MS/MS. Using either top 7 or top 14 immunodepletion resulted in a 25% increase in 
identified proteins compared to unfractionated plasma, 5-6% of which were 
considered to be low abundant (313).  Data from the HUPO Plasma Proteome Project 
also demonstrated that whether depletion of albumin only, albumin and 
immunoglobulin’s or the six most abundant proteins was undertaken, low abundant 
protein detection increased (314).  To achieve greater orders of depletion, systems 
that deplete more than 12 of the top high abundant proteins and/or moderately 
abundant proteins are being exploited.   In one such study 695 plasma proteins were 
confidently identified by LC-MS/MS using the IgY12/Supermix system, including 42 
proteins with reported normal concentrations of ~100 pg./ml to 100 ng/ml, which 
were confirmed by ELISA (315).  In the same study they reported that this 
multicomponent immunoaffinity separation system was also effective, reproducible 
and that the extent of non-specific binding was minimal (315).  There is however 
limited published studies comparing the different depletion systems, in the few 
comparisons that are available, the literature suggests the methods are generally 
complementary.  In one such study by Roche (316) they actually observed that 
increasing the number of depleted proteins from 12 to 20 had little beneficial effect.   
Tu et al (317) compared the MARS 6 and 14 systems, and they also concluded that 
the depletion of 7 or more high abundant proteins had no considerable advantage.  
The literature therefore appears to support the utilization of depletion systems in 
general, but there appears to be a lack of consensus about the number of proteins that 
should be eliminated and if it bestows any gain to increase the numbers of such.  I 
 308 
therefore choose to look at and contrast 3 depletion systems – MARS 6, MARS 14 
and the IgY/Supermix system, which deplete 6, 14 and 12 of the most abundant 
proteins as well as the supermix system which depletes 50 of the top moderately 
abundant serum proteins. 
A number of conclusions can be drawn from the data I generated from testing 3 of the 
aforementioned antibody depletion columns 
1. The results for all of the parameters investigated to determine the overall 
performance of each column were not reproducible between testing on the 
QSTAR mass spectrometer and the Orbitrap mass spectrometer.  This maybe 
attributable to the efficacy of the instrument as generally the Orbitrap 
performed superiorly in all areas, or it maybe the result of the low 
reproducibility of the columns.  The former is perhaps more likely as the 
conclusion is applicable to all 3 columns rather than just 1 or 2. 
2. The binding specificity of all 3 columns for high abundance proteins is lower 
than the literature suggests.  For the MARS 6 67%-84%, MARS 14 76%-89% 
and lastly for the IgY/Supermix it was 89%-93%.  In the literature it is 
suggested that the MARS 6 and 14 depletion columns will retain 95%-99% of 
the proteins it is intended to, and the IgY/Supermix >99%. 
3. Use of the IgY/Supermix system lead to a larger number of proteins being 
identified, of which a larger % were of low abundance compared to both 
MARS systems.  Between 20-40% more low abundance proteins were 
identified using the IgY/Supermix system. 
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5.3.3  Peptide separation methods 
Traditionally proteins have been separated using gel based separation techniques but 
this has been largely superseded (for reasons outlined in my introduction) by 
chromatographic separation techniques.   Multidimensional chromatography also 
known as MUDPIT, involves separating peptides in 2 dimensions according to 
specific physiochemical properties that the peptide possess.  Traditionally a 
combination of Strong Cation exchange (SCX) was used in the first dimension 
followed by a Reverse Phase (RP-HPLC) mode of separation in the second 
dimension.  Regardless of which method of first dimension separation is employed it 
must possess high separation efficiency and be compatible with downstream systems.  
SCX has good orthogonality but its separation efficiency is inferior to RP, but RP 
lacks orthogonality.  The use of high salt concentrations required for peptide elution 
in SCX also makes down stream analysis problematic.  RP conventionally used low 
pH buffers, which results in poor orthogonality and MS spectra.  The development of 
high pH RP separation has however meant that SCX is being supplanted.  Gilar et al 
demonstrated that high-pH peptide separation is sufficiently orthogonal to standard 
low pH, that in combination with its superior separation efficiency, has meant that it 
may succeed SCX as the first-dimension fractionation technique of choice (318).  
Moreover by combining high-pH–low-pH RP fractions means that they can be further 
concentrated in the first dimension, improving both orthogonality and second 
dimension separation (319).   On the basis of the above I decided to assess 4 different 
separation methods: 1 was a non-LC method using C18 zip tips, the other 3 were LC 
based methods: SCX using 2 different columns (ThermoBasic and Poly A), the other 
a High-pH RP column.  Each system was studied using a control iTRAQ 4-plex 
experiment as outlined in the materials and methods section.  The loading capacity of 
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serum  for  all  the  methods  was  200μg.        8  fractions  were  collected  for  the  C18  zip tips, 
whilst 50-60 fractions (where each comprised of 3-4 combined fractions) were 
collected for the LC columns based on the appearance of the chromatograms at 
215nm.   
A number of conclusions can be inferred from my analysis 
1. The total number of protein identifications (96) was greatest for the 
PolySulfoethyl A SCX column  
2. The lowest number of high abundance proteins and the highest number of low 
abundance proteins was achieved by PolySulfoethyl A SCX column. 
3. As expected the C18 performed poorest in all of the parameters, which were 
appraised. 
4. The C18 generated the largest number of unique proteins but this was 
predominantly because a higher percentage of high and medium abundance 
proteins were identified following their use 
5. The LC columns engendered a similar % of both unique and cross over 
proteins.  
For the reasons stipulated above the PolySulfoethyl A SCX column was implemented 
for analysis of downstream CRC and Dukes samples. 
5.3.4  Optimization of mass spectrometry parameters 
The accurate characterization and quantification of proteins in a complex biological 
mixture is fundamental to any biomarker discovery study.  This has been achieved 
due to advances in both the hardware and software within the field.  Modern mass 
spectrometers can now achieve accurate mass measurements of < 5ppm on both 
precursor and product ion scans.  There are many different types of mass 
spectrometers each with unique capabilities but also negatives.  The Orbitrap mass 
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spectrometer is one of the most powerful and sensitive instruments.  It also has been 
demonstrated to have unprecedented accuracy and hence its general employment and 
applicability for the majority of proteomics experiments in the current literature.  
Viner et al (320) compared the Orbitrap-XL with a QSTAR elite and identified that 
the Orbitrap-XL 
1. Uncovered 2.5 times more proteins in a complex E.coli lysate compared to the 
QSTAR mass spectrometer 
2.  Had unrivalled sensitivity.  The Orbitrap mass spectrometer managed to 
identify more proteins from 100ng of protein compared to the analysis of 
500ng of protein by the QSTAR 
3. Parallel data acquisition can be accomplished in the Orbitrap.  MS2 analysis 
can be performed in the ion trap whilst the Orbitrap can perform accurate mass 
measurements simultaneously. 
4. Experimental mass accuracy was 2-3ppm compared to 25-30ppm for the 
QSTAR in this paper 
5. Orbitrap data could be analyzed with much narrower precursor ion mass 
tolerances, resulting in more confident peptide identification assignments 
6. Orbitrap data had higher ion scores because of the dominance of both b- and 
y- series of ions in the resultant spectra, compared to the prevalence of y-ions 
in the QSTAR spectra. 
High mass accuracy, resolution and accurate quantitation that the Orbitrap mass 
spectrometer possesses are ideal for quantitative proteomics.  An added quandary in 
chemical labelling strategies such as iTRAQ is the detection of the reporter ions. 
iTRAQ quantitation under standard CID fragmentation conditions, as commonly used 
in ion traps, or hybrid ion traps such as the Orbitrap, is not possible.  This is because 
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CID fragmentation cannot compute the low mass range, which covers the iTRAQ 
reporter ions.  The introduction of Pulsed Q Dissociation (PQD) and Higher energy 
C-trap dissociation (HCD) does however now allow the analysis of the low m/z 
region and therefore iTRAQ reporter ions.  The combination of CID in the linear ion 
trap, with HCD in the collision cell enhances the analytical capability.  Zhang et al 
(321) demonstrated that  
1. To generate the optimal HCD fragmentation conditions 40% normalized 
collision energy (NCE) should be exploited. 40% NCE provided the most 
intense iTRAQ ratios along with the best protein coverage. 
2. Using HCD for iTRAQ experiments can achieve a mass accuracy of < 3ppm 
3. Nine proteins were measured with relative errors and standard deviations of < 
7% using HCD 
4. The LTQ Orbitrap identified and quantified more peptides based on HCD 
scans 
5. At the protein level the relative error was 7% for the Orbitrap and 24% for the 
QSTAR.  Whilst at the peptide level it was 9% for the Orbitrap compared to 
21% for the QSTAR.  The relative error was 10% for the Orbitrap compared 
to 26% for the QSTAR.  Bache et al (322) demonstrated precision at the 
peptide level of better than 4% for HCD. 
Kocher et al (323) compared HCD and PQD for iTRAQ quantitation for both a simple 
and a complex protein mixture.    They demonstrated that HCD in combination with 
CID outperformed PQD and HCD, which was most evident in the analysis of the 
complex protein sample.  The CID-HCD approach identified and quantified 3 times 
more peptides, and subsequently twice as many proteins in the complex sample.  
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Furthermore accurate analysis and quantitation of low abundant species was 
augmented using this combined approach.   
Bantscheff et al (324) established that the use of PQD fragmentation in iTRAQ 
experiments was better than HCD fragmentation as it provided better sensitivity, mass 
accuracy and more accurate quantitation. 
A number of inferences can be made from the data generated from my research 
1. In the initial method development phase, it became apparent that the Orbitrap 
mass spectrometer generated both a larger number of identified proteins and 
also a greater % percentage of lower abundance proteins (See Results section 
3.1) 
2. In the iTRAQ experiments, the Orbitrap mass spectrometer generated better 
data in terms of the numbers of proteins identified, and the % of low 
abundance proteins 
3. A 180 minute HPLC gradient generated a greater number of peptides for 
analysis  although  it  didn’t  lead  to  the  identification  of  any  significant  proteins 
4. With respect to Orbitrap optimization a NCE of 45% gave both reasonable 
ms/ms fragments and ITRAQ reporter ion intensities. PQD fragmentation 
generated good reporter ion data, but the ms/ms data was very poor 
5. With regard to the QSTAR optimisation a 2 second EPI scan gave more 
peptide identifications and thus protein identifications, as well as better 
ITRAQ quantitation. 
5.3.5  iTRAQ labelling error 
Precision and accuracy are both inherent and desirable characteristics of any 
quantitation method.  Random errors affect precision, whilst systematic biases such as 
inefficient labelling and digestion can affect the accuracy.   To achieve both precision 
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and accuracy, reproducible and exact results require to be obtained from the 
experiment.  Assessing the labelling error associated with any iTRAQ experiment is 
therefore imperative in order to assign confidence to the final result.  The labelling 
error was assessed using control serum with the multi-dimensional methodology 
detailed in the materials and methods section.  A total of 96 unique proteins were 
identified from 2 replicate experiments to assess the labelling error, compared to 251 
(across 4 experiments) in the final CRC experiment, and 446 from the final Dukes 
experiment.  Despite implementing similar experimental conditions the yield from all 
3 experiments differs significantly when equivalence would have been expected.  
Possible explanations for this may relate to user, biological or instrumental variance. 
Of the labelled proteins the error range was estimated to be 0.94 (+/- 0.07) – 0.98 (+/- 
0.08).  From this it could therefore be inferred that any fold change outwith this range 
would be regarded as a tangible deviation between the 2 biological samples.  The 
false discovery rate is within the acceptable limit of 5% reported in the literature 
(325). 
The labelling efficiency in all 3 experiments appears to be sub standard.   Possible 
reasons include incomplete iTRAQ data may have been incomplete labelling in the 
initial steps because of the presence of contaminants such as amines, hydrolysis of the 
iTRAQ reagent, or problems with alkylation and reduction.  To ensure labelling pre 
MS/MS, the raw MS data was examined and it was identified that approximately 90% 
of peptides had labels attached.  The data processing step was also studied.  Reporter 
ions  cannot  be  processed   in  a  similar  manner   to  peptides  as   they  don’t  have  normal  
isotope distributions, and therefore require to be interpreted as single peaks in the low 
m/z range, Mascot was however set to prevent this occurring. 
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5.4  CRC biomarkers  
5.4.1  CRC iTRAQ and Label free biomarkers 
Current and potential CRC biomarkers have been discussed within the introduction of 
this thesis.  The aim of this thesis was to determine diagnostic biomarkers within the 
serum of patients with CRC using proteomic technologies.  I used 2 proteomic 
technologies to mine the serum of patients with CRC to determine if any biomarkers 
could be used to distinguish the presence of disease in normal and affected 
individuals.  Using 2 platforms I had hoped to compare both methodologies but also 
validate the results generated from each.  Overall the biomarker yield from both 
platforms was small compared to published literature.  However the harvest from 4 
and 6 technical replicates in the CRC and Dukes experiment, run on different 
occasions was similar, suggesting that the workflow may not have been the causative 
factor.  From the experiments, 12 proteins from the iTRAQ and 10 from the label free 
pathways were identified as possible biomarkers.  Interestingly, however, only 4 
proteins (alpha-1-antichymotrypsin, isoform 1 of alpha-1-antittrypsin, hemoglobin 
subunit alpha and Leucine-rich alpha-2-glycoprotein) were common to both groups, 
and generally the iTRAQ methodology reported higher ratios compared to label free.   
This highlights some of the main difficulties encountered in proteomics studies of 
which reproducibility is foremost.  The fact that many proteins were deregulated 
within both sample suggests that a panel of biomarkers are likely to be required to 
supply the sensitivity and specificity that single markers lack.  Each of the identified 
proteins function, its involvement in CRC carcinogenesis and lastly its use as a 
biomarker (potential or known) in CRC or other diseases will be discussed.   This was 
achieved using Ingenuity Pathway Analysis (IPA) and PubMed. 
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Collagen Type 1 (COL1A2 and COL1A1) (Identified in iTRAQ experiment): 
The most abundant molecule within the collagen family is Collagen Type I.  It 
consists of a heterotrimer with two  α-1  chains  and  one  α-2 chain, which are made-up 
of repeated glycine-X-Y motifs (X and Y being any of the 20 amino acids of which 
proline and lysine form post-translational modifications by hydroxylation) 
(326).  This form of collagen represents the major fibrillar component of the stroma in 
most solid malignancies, such as colorectal, hepatocellular, and breast carcinomas 
(327, 328). The correct extracellular matrix in stroma is necessary for the growth of 
tumours. These matrix components, in particular collagen type I, can be produced by 
either the tumour cells or the stromal fibroblast cells.  Carcinoma cells including 
colorectal cancer cells, that produce type I collagen, tend to have reduced tumorigenic 
potential (329-332). COL1A2 was found to be methylated in 80% of melanomas 
(333), and is also found to be frequently hypermethylated in several other 
malignancies. Expression of COL1A2, in a tumorigenic cell line, led to increased 
adhesion, slower growth, and reduced colony formation in soft agar; features that are 
suggestive of a tumour-suppressive role for COL1A2 (328, 333). Mori et al (327) 
showed CpG hypermethylation of the promoter region of the COL1A2 gene, which 
led its down-regulation in bladder cancer cell lines. They also showed restored 
COL1A2 expression in the transfectant decreased cell growth and migration activity 
that supports the tumour suppressive role of COL1A2.  In more aggressive tumours, 
collagen type I is over-expressed and the stromal fibroblasts or myofibroblasts 
produce the collagen stroma and thus plays a role in tumour development (327, 328). 
Thus the controversial role of collagen type I in carcinoma may be explained by the 
evidence that metastatic tumour cells produce factors that stimulate collagen synthesis 
by the stromal fibroblasts, and the carcinoma cells produce little or no collagen (328).  
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Yu et al (334) reported overexpression of COL1A2 in medulloblastoma and linked it 
to angiogenesis as the receptor for this gene- ITGB1, which was also found to be 
overexpressed.  Yang et al (335) 2007 showed overexpression of COL1A2 in gastric 
cancer tissues and performed pathway analysis using the differentially expressed 
genes. Their analysis suggests the involvement of COL1A2 in deregulation of TGF-
beta signaling (THBS2, MAPK1 and INHBA) pathway in gastric cancer and also in 
colorectal cancer.  Smith et al (336) 2009 reported overexpression of COL1A2 in 
colorectal cancer stroma. 
Leucine-rich alpha-2-glycoprotein: 
A literature search within PubMed and within IPA shows leucine-rich   α-2-
glycoprotein-1 (LRG1) is a candidate biomarker for pancreatic cancer, ovarian 
cancer, stomach cancer, hepatocellular carcinoma and non-small cell lung cancer, 
suggesting it may possibly be involved in cancer in general. 
LRG1 is a serum glycoprotein, which has a normal plasma concentration of 21-50 
μg/ml.  The   function  of  LRG1 remains unknown, although it has been postulated to 
play a part in role in cell adhesion, granulocytic differentiation due to its expression in 
neutrophil lineage experiments, and cell migration due to its overexpression in high-
endothelial venules and tendency to bind extracellular matrix proteins (337). LRG1 
has been implicated as a protein involved upstream of the TGF-βR   II   pathway,  
suggesting it may play a role in signaling because of its involvement in the TGF-βR  II  
pathway.   It has also been proposed to play a potential role in cell survival and 
apoptosis (337).  Andersen et al. (337) reported a nearly 3-fold up-regulation of LRG1 
protein in ovarian cancer serum and suggested its use as a potential biomarker for 
diagnosis of ovarian cancer.   This was corroborated by Boylan et al. (338) who also 
reported over 3 fold up-regulation of LRG1 in pooled depleted serum samples from 
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ovarian cancer patients using iTRAQ(R) proteomic method.   Using ICAT/MS/MS 
analysis, Lin et al. (339) reported over expression of LRG1 protein in the depleted 
serum of ovarian cancer patients and included it in their candidate diagnostic 
biomarkers.  Sandanayake et al. (340) reported increased LRG1, CA19-9 and IL-6 
levels in serum from patients with biliary tract cancer compared with benign disease 
and healthy controls using two-dimensional difference gel electrophoresis and tandem 
mass spectrometry approach to profile immunodepleted serum samples with further 
confirmation by ELISA.  Li et al. (341) reported higher levels of LRG1 protein in 
urinary exosomes and lung tissue of non-small cell lung cancer (NSCLC) patients 
using nano-HPLC-chip-MS/MS approach and suggested that LRG1 may be a 
candidate biomarker for diagnosis of NSCLC in urine.   Nyberg et al.  (342) 
constructed a multivariate biomarker model that included LRG1 to diagnose 
Interstitial Lung Disease (ILD) events in Japanese non-small-cell lung cancer 
(NSCLC) patients. Tatsuhiko, et al. (343) reported up-regulation of leucine-rich 
alpha-2-glycoprotein in plasma samples of pancreatic cancer patients using 
proteomics approach and validation of their observation using western blotting.  
Bones, et al. (344), reported leucine-rich alpha-2-glycoprotein being differentially 
expressed in depleted serum of gastric cancer patients compared to healthy controls 
by 2D-DIGE method.  Chaerkady, et al. (345) reported over expression of leucine-
rich alpha-2-glycoprotein in hepatocellular carcinoma cells using 18O labelled lectin 
affinity enrichment LC-MS/MS quantitation method.  Ladd et al (346) demonstrated a 
predictive value in diagnosing CRC in women using a panel consisting of CEA, 
MAPRE1, IGFBP2, and LRG1 proteins with a specificity of 95% and sensitivity of 
41%.  Serada et al (347) demonstrated a potential biomarker role for serum LRG1 in 
determining disease activity in ulcerative colitis suggesting that its ability to 
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differentiate between inflammatory and malignant diseases of the colon maybe 
limited. 
Isoform 1 of Alpha-1-antitrypsin: 
Alpha-1 antitrypsin (AAT) is the most prominent protease inhibitor in human serum.  
It is a glycoprotein, which belongs to the Serpin (SERine Proteinase Inhibitors) family 
of proteins.  Apart from being synthesized by some white blood cells and hepatocytes, 
it is also produced by tumor cells.  Its predominant role is in the protection of tissues 
from proteolytic degradation and also in the regulation of proteolytic processes.  It 
also plays a central role in coagulation, cell death and complement activation.  Altered 
expression of alpha-1-antitrypsin has been demonstrated in a number of different 
malignancies including breast cancer (348) and colorectal cancer (349).  Xie et al 
(349) demonstrated that alpha-1-antitrypsin in combination with cathepsin D has 
100% sensitivity and 99.7% sensitivity in predicting early stage CRC.  Alpha-1-
antitrypsin is however altered in conditions involving inflammation thus suggesting it 
may not be suitable as a biomarker for detecting CRC.   
Alpha-2-HS-glycoprotein: 
Alpha-2-HS-glycoprotein (AHSG) also known as Feutin-A belongs to the feutin class 
of plasma proteins, which are a large family of carrier proteins.  AHSG is a 
glycoprotein synthesized by hepatocytes and found at high levels in serum, urine, 
saliva, cerebrospinal fluid, and bone (350).  AHSG has recently been associated with 
tumor progression and resistance to chemotherapy by mediating its effects through 
Transforming Growth Factor-H1 (351).  Yi et al identified AHSG with a sensitivity of 
79% in breast cancer patients before surgery (352).  Petrik et al (353) showed that 
serum levels of AHSG predict survival in patients with glioblastoma when combined 
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with age and other prognostic scoring systems.  Fan et al (354) established that AHSG 
along with Tubulin could detect CRC in nearly 100% of cases. 
Serotransferrin: 
Serotransferrin belongs to the transferrin group of proteins, which are essentially 
glycoproteins that control the levels of iron within tissues.  It is predominantly a 
plasma protein, which is primarily synthesized in the liver.  Its main role is to deliver 
iron from the duodenum and macrophages to various tissues.  Its role in 
tumourigenesis is to reduce the levels of circulating tumour cells by using its receptor 
to attract antibodies (355).  Using 2D gel electrophoresis Ryu et al (356) showed that 
serotransferrin amongst other proteins is under expressed in gastric cancer.   Lin et al 
(357) reported serotransferrin using 2D gel electrophoresis and MALDI, as a putative 
marker of uterine leiomyoma.  With reference to CRC Alwari et al (358) showed that 
various proteomic markers are altered within the aberrant crypt foci (ACF), which 
included serotransferrin.  The ACF is the possibly the earliest identifiable 
pathological lesion within the colorectal carcinogenesis model.  
S100A9 protein: 
S100-A9 protein also known as migration inhibitory factor-related protein 14 (MRP-
14) is a member of the S100 family of proteins located within the cytoplasm and 
nucleus.  Their principal role is in the regulation of the cell cycle and cellular 
differentiation.  The S100A9 protein has been implicated in malignancy by promoting 
abnormal differentiation of cells within the stroma (359).   It has been suggested in 
some studies to have a tumour suppressor role but a tumour promoter role in others.  
Goncalves et al (360) showed that S100A9 could be used to differentiate between 
different subtypes of  breast  cancer,  and  that  it’s dysregulation was associated with a 
poorer grade.  Kim et al (361) showed that the S100A9 protein is significantly 
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elevated in the plasma of patients with CRC and that the changes occur early in 
colorectal carcinogenesis.  Stulik et al (362) showed that the expression of the 
S100A9 protein along with S100A8 protein was significantly increased in colorectal 
cancer tissue. 
Ceruloplasmin: 
Ceruloplasmin is predominantly synthesized in the liver as an enzyme.  Its main role 
is to transport Copper, of which it carries more than 95% of the total copper 
concentration.  It does in addition play a role in iron metabolism also.  Several groups 
have evaluated its function as a possible cancer biomarker.  Lokamani et al (363) 
using 2DIGE demonstrated that Ceruloplasmin might serve as a predictive marker for 
the progression of high-grade cervical lesions.  They also showed that Ceruloplasmin 
closely interacts with the oncogene NF-κb.    Also  using  gel  electrophoresis  Hanas  et  al  
(364) found that Ceruloplasmin along with alpha-2 macroglobulin and complement 
3C were significantly elevated in the sera of patients with pancreatic cancer compared 
to controls.  With regard to the identification of Ceruloplasmin as a CRC biomarker 
Putzki et al (365) showed that compared with controls the levels of haptoglobin and 
ceruloplasmin were significantly elevated, but retinol binding is decreased. 
Apoliporptein A-IV: 
Apolipoprotein A-IV (APO-IV) is a plasma protein, which is produced in the colon.  
It is released into the circulation via chylomicrons.  APO-IV synthesis and secretion is 
increased by the presence of intestinal fat.  The physiological role of APO-IV appears 
to be in lipid absorption, transport and metabolism.  Dowling et al (366) reported 
increased levels of APO-IV in the sera of patients with squamous cell carcinoma of 
the lung thus suggesting it may have a role as a protein biomarker in the disease.  
Ueda et al (367) also established a potential role for APO-IV as a clinically useful 
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biomarker for both the early detection and tumour staging of lung cancer.  
Overexpression of APO-IV has also been documented in patients with neuroblastoma 
by Sandoveal et al (368).  Broedl et al (369) conveyed that high levels of APO-IV 
correlated with worse disease activity in colonic crohns, thus suggesting that its role 
as a biomarker in CRC may be limited.   
Complement component C9: 
Complement component C9 is a protein involved in immunity and is a major 
constituent of the membrane attack complex.  It therefore plays a key role in both 
innate and adaptive immunity by forming pores in the plasma membrane of target 
cells.  Chong et al (370) showed that C9 overexpression was detected in a panel of 
gastric cancer cell lines compared with normal cells. A subsequent study on plasma 
samples showed that the sensitivity of C9 approached 90% and specificity 74% for 
the recognition of gastric cancer, suggesting a potential role of C9 as a biomarker for 
gastric cancer.  C9 has also been projected as a credible biomarker for distinguishing 
patients with squamous cell lung cancer.  Ahn et al (371) analyzed sera from patients 
with squamous cell lung cancer and using glycoproteomics they showed elevated 
serum levels of C9 compared to healthy controls with a specificity of 89% and 
sensitivity of 53%.  Murakoshi et al (372) described appreciably elevated levels of C9 
in patients with early CRC, suggesting a potential role of C9 as an early diagnosis 
biomarker in CRC.   
Haemoglobin subunit alpha: 
Haemoglobin alpha 1 (HBA1) comprises 97% of total haemoglobin.  HBA1 is 
composed of two alpha and 2 beta chains.  It is specifically involved in the 
transportation of oxygen throughout the tissues.  HBA1 has been identified as a 
potential serum biomarker for patients with ovarian cancer.  Woong-Shick et al (371) 
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illustrated that HBA1 was significantly differentially expressed in the sera of patients 
with ovarian cancer, and had a sensitivity of 77%.  Chaterji et al (374) looked at 
HBA1 levels in lung cancer bearing mice, and demonstrated deregulation of HBA1 
and thus postulated a potential role of the protein as a novel biomarker. Rho et al 
(375) undertook proteomic analysis of colorectal cancer tissue and amongst four other 
proteins demonstrated differential expression of HBA1 in such a medium.  
Gelosolin: 
Gelosolin is a multifunctional actin regulatory protein, which is essential for 
integrating membrane and intracellular functions. Its predominant role is in 
cytoskeletal remodelling but it does also appear to inhibit apoptosis.  The expression 
of gelosolin was found to be an independent predictor of progressive or recurrent 
urothelial tumours by Rao et al (376).  Yang et al (377) revealed that high levels of 
Gelosolin was associated with an overall poorer prognosis for non-small cell lung 
cancer suggesting a role for Gelosolin as a biomarker for predicting tumour 
progression.  Ohnishi et al (378) defined a role for Gelosolin as a prognostic marker 
in astrocytoma patients.  Tsai et al (379) validated that Gelosolin is over expressed in 
plasma in patients with Stage IV CRC compared to normal and stage I-III CRC, 
intimating a role for the protein as plasma biomarker for metastatic CRC.  Gay et al 
(380) showed that Gelsolin is under expressed early in CRC and is associated with the 
transition of adenoma to CRC.   Lastly Fan et al (381) using iTRAQ on CRC tissue 
established that Gelosolin was under expressed in CRC with a sensitivity of 86.89% 
and specificity of 100%, and may therefore have utility as biomarker in patients with 
CRC. 
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Vitamin D binding protein: 
Vitamin D binding protein, also known as gc-globulin is a multifunctional plasma 
protein, which belongs to the albumin family.  It binds vitamin D and its metabolites 
and transports them to various tissues.  It also prevents polymerization of actin and 
associates with membrane bound immunoglobulin on B-cells and IgG.  Pawlik et al 
(382) studied protein expression in nipple aspirates of patients with early stage breast 
cancer using ICAT and found that Vitamin D binding protein was over expressed.  Li 
et al (383) identified Vitamin D binding protein as a potential novel urinary biomarker 
for the early detection and surveillance of bladder cancer.  Depending on the levels of 
Vitamin D binding protein, bladder cancer could be predicted with 82-92% sensitivity 
and 83-88% specificity using urinary Vitamin D binding protein. Yamamoto et al 
(384) illustrated that immunotherapy with Vitamin D protein in patients with 
metastatic CRC, eradicated some metastatic tumour cells.  Jenab et al (385) portrayed 
an inverse relationship between pre-diagnostic levels of Vitamin D and CRC; this 
augments the use of Vitamin D protein as a potential CRC biomarker.  This is 
supported by the work Ma et al (386) who validated a potential role for Vitamin D 
binding protein as a diagnostic biomarker for CRC. 
5.5  Dukes biomarkers 
5.5.1  Dukes iTRAQ and label free biomarkers 
There are very few protein profiling studies that have been published on the 
identification of protein biomarkers by clinical or pathological stage of CRC.  This 
appears to be the first study that has specifically looked at the detection of diagnostic 
protein biomarkers by Dukes Stage.  Using a combination of 2 proteomic platforms 
namely iTRAQ and label free proteomics we have reported a number of proteins that 
are up or down regulated in the sera of patients with Dukes Stage A-C CRC.  From 
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both studies it appears that a panel of biomarkers rather than a single biomarker will 
have to be developed, as there  wasn’t  a  solitary  protein  that  consistently  deviated  in  
all the samples tested.  191 proteins were identified to be significantly transformed in 
the Dukes iTRAQ analysis.  113 proteins were found to be altered in Dukes A, 87 in 
Dukes B and 107 in Dukes C.  Of the 191 proteins initially reported, 112 were 
analyzed in   IPA.      79   proteins   couldn’t   be   analyzed as they were either 
uncharacterized or putative proteins  or  they  didn’t  have  a  Uniprot  accession  identifier, 
which was facilely presented in the IPA database.  By undertaking such analysis I 
have introduced some element of selection bias into my data analysis.  The 79 
proteins,  which  couldn’t  be   scrutinized, further may in fact be important diagnostic 
CRC biomarkers and should perhaps be considered when the validation phase of the 
work is undertaken.  Of the 112 proteins evaluated during IPA core analysis, 23 were 
deemed in IPA to be possible biomarkers for elucidating Dukes stage using the 
Biomarkers software package within IPA.  The proteins identified all had different 
values of up or down regulation and thus cut off values for each protein could 
potentially be used to discriminate between the 3 stages of CRC.  In comparison, only 
56 proteins were acknowledged as being deregulated in the Label free Dukes 
experiment.  When input into IPA 46 proteins were identified and evaluated using 
IPA core analysis.  Due to there being only one protein detected as being altered in 
Dukes A using this methodology IPA Biomarker analysis could not be undertaken.  
Comparing the sets of proteins 13 (angiotensinogen, albumin, amyloid P, APO-IV, 
APO-IV precursor, APO B, APO E, clusterin, ceruloplasmin, gelsolin, Ig constant, 
serpin peptidase inhibitor, clade A, serpin peptidase inhibitor, clade D) were constant, 
identified in being present in both the Dukes ITRAQ biomarker IPA analysis and the 
Dukes Label free IPA analysis.  As previously mentioned within literature the label 
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free platform appears to over express the ratios.  This is in accordance with the CRC 
experiments within this thesis, where the label free methodology over reported the 
ratios.  Whilst in the Dukes experiment it under reported them.   It therefore remains 
unclear as to which method is befitting for a quantitative proteomics study.  To 
ascertain which method is superior for quantitation, spiked-in standards should have 
been used to determine the relationship between expected and observed ratios for both 
methods.  Wang et al (387) compared both methods extensively and found that label 
free quantitation was more accurate, as generally the ratio data more closely 
replicated the known spiked ratios.   They also established that the majority of 
significantly regulated proteins showed slightly higher changes using label free 
quantitation as compared to iTRAQ (387).  The probability of any of the proteins 
identified in this research project being a unique biomarker signature for identifying 
Dukes stage at diagnosis would have to be investigated in a cohort of patients.  The 
majority of the proteins listed are either high or medium abundance proteins and thus 
unlikely to be exclusive to CRC, but perhaps a multi panel approach would yield the 
sensitivity and specificity that is required.  Certainly all of the proposed proteins are 
present in blood and 65% are linked with the large intestine or colorectal cancer cell 
lines (IPA).  70% of the proteins already have a recognized biomarker profile, which 
suggests a potential role as a diagnostic biomarker in CRC, but also may suggest that 
the deregulation of such proteins is common to several diseases.  Immunity and 
inflammation are mechanisms certainly interrelated to most pathological processes, 
and there is certainly a body of evidence to demonstrate that adaptive immunity plays 
an integral role in the development of colorectal carcinogenesis (388).   This could be 
supported by the Dukes biomarker data that is provided in this thesis, in that the 
majority of acute phase or immune proteins are down regulated in Dukes A CRC 
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patients, but are increasingly expressed in those patients with Dukes B and C CRC 
suggesting that they may play a protective part. 
5.6  Gel 
Gel electrophoresis is the most common technology employed in proteomic studies 
for monitoring changes in differential expression in complex protein samples.  
Although  it  will  allow  for  the  identification  of  proteins  it  doesn’t  quantify  the  proteins  
of interest.  The proteins of interest are excised individually from the gel, digested and 
analyzed via MS.   Although generally considered the most applicable, cheapest and 
simplistic proteomic method there are issues with its reproducibility and also the 
difficulty with detecting hydrophobic, membranous, high molecular weight or high pI 
proteins.  A few CRC biomarkers have been identified using 2DIGE.  Roessler et al 
(389) compared matched CRC and control tissue and resolved them by gel 
electrophoresis.  Gel spots were excised and the deregulated proteins identified by 
MS.  From previous studies they had identified 5 proteins strongly deregulated in 
CRC but in this study they identified a further protein, proteasome activator complex 
subunit 3 (PSME3), which was clearly up regulated.  Friedman et al (390) compared 6 
patients with different stages of colon cancer with matched controls to investigate 
tumour specific changes in the proteomes using 2DIGE.  1500 features were analyzed 
in each paired comparison, 52 of these proteins were considered to be unique to CRC.  
Ma et al (391) identified 42 different proteins by 2DIGE in CRC tissues.  Of these 
Desmin and zinc finger 829 protein were found to be significantly elevated in CRC.   
The gel analysis performed for this research was a further way of identifying proteins 
that maybe considered as potential biomarkers for CRC.  Visual inspection of the gel 
clearly demonstrates that there are differences between the sera of patients with 
colorectal cancer and controls.  Analysis of the whole gel delineated 118 proteins that 
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were differentially expressed in the CRC cohort and 106 unique to the control group.   
Sections of the gel were analyzed individually, where there were differences in the 
intensity of the band compared to the control section, or if a band was present or 
missing at a specific level parallel to the control as described in the results chapter.  I 
specifically only looked at the 3 CRC sections, and 32 proteins were subsequently 
identified.  6 of the proteins were keratin and therefore likely contaminants and 14 
were unclassified.  Of the remainder, 9 of the proteins are involved in immunity, 6 in 
cellular transport, 3 in other cellular processes such as growth, differentiation and 
apoptosis and 2 are involved in the coagulation pathways.  Of the 32 proteins, 12 were 
considered to be high abundance proteins and 20 proteins were considered to be low 
abundance proteins.  I specifically looked at the low abundance proteins in more 
detail to determine any association they have with CRC by performing a literature 
search in PubMed.  The following proteins were found to be associated with CRC or 
another form of cancer. 
1. Insulin like growth factors – Insulin like growth factors (IGFs) play a 
fundamental role in cell differentiation, proliferation and apoptosis.  These 
effects are mediated through the IGF-I receptor, which can itself induce cell 
transformation.  The actions of IGFs can be augmented or inhibited by one of 
6 IGF-binding proteins (IGFBPs).  Many epidemiological studies have clearly 
defined the role of IGFs, with increased levels of IGF-I and IGFBP-3 being 
identified in CRC (392) 
2. Hylauronan (HA) – Is a polysaccharide expressed in epithelial cells.  Elevated 
levels of HA are associated with increased cellular proliferation.  Elevated 
levels of HA in CRC tumour cells is associated with increased stage and 
grade, and is a predictor for both disease recurrence and poor survival (393).  
 329 
The binding of cells to HA is mediated through a number of receptors of 
which CD44 is the most plentiful.  Up regulation of CD44 is also seen in CRC 
and is associated with a poorer prognosis.   
3. Chibby – β-Catenin is a canonical transcriptional activator of the Wnt 
pathway, and is nominally destroyed by the APC proteins.  The deregulation 
of  this  pathway  and  accumulation  of  β-Catenin plays a pivotal role early in the 
development of sporadic CRC.  Chibby is a protein that can prevent the 
activation   of   β-Catenin by competing with Lef-1, suggesting a role as a 
potential tumour suppressor protein.  Interestingly Chibby is located on chr 22, 
a region that is frequently lost in colorectal cancer.  Recently Mo et al (394) 
investigated the role of Chibby in CRC development,   they   didn’t   however  
identify mutated Chibby in any of the 36 colorectal tumours they investigated, 
suggesting that its role in colorectal carcinogenesis is imperceptible.   
4. Vitamin D binding protein – Serum Vitamin-D binding protein (Gc protein) is 
a precursor for Macrophage Activating Factor (MAF), which has been shown 
to be a potential immunotherapy in breast, prostate and colorectal cancer 
(395).  The role of Gc protein in colorectal carcinogenesis is further supported 
by the fact the precursor activity of Gc protein for MAF is reduced or even 
lost, leading to immunosuppression.  One paper by Yamamoto et al (396), 
showed that the treatment of 8 patients following a colorectal resection with 
purified Gc protein, lead to a reduction in Nagalase activity and thus the 
eradication of residual tumour cells.  Nagalase deglycosylates Gc protein 
which means it cannot be converted into MAF. 
5. Gelosolin – Gelosolin is a cytoskeletal protein which promotes cell motility.  
Its role in tumour biology is complex, and its expression correlates with a 
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poorer prognosis and treatment resistance.  It has been linked to many cancers 
including breast and lung, with its initial role assuming a suppressor role but 
with advancing stage it accelerates oncogenesis (397).  It has been found to 
expressed in low concentrations in primary colorectal tumour cells but is over 
expressed in liver metastasis associated with CRC (398). 
6. Afamin – Is a vitamin E binding protein.  It has been identified using 
proteomic techniques to be decreased in patients with ovarian cancer (399).  A 
larger  case  control  study  was  however  conducted  and  concluded  that’s  its  use  
as a sole biomarker in ovarian cancer would not be viable.  Using iTRAQ 
Rehman et al (399) identified Afamin to be up regulated in patients with 
prostatic cancer.  There are no documented studies within the current literature 
of Afamin as a potential biomarker for CRC. 
5.7  Sub-proteome analysis – Glycosylation 
Following protein translation, proteins can undergo further transformation to extend 
their role and function.  Such post- translational modifications of proteins, is achieved 
through the attachment of functional groups to certain amino acids.  One of the 
commonest post-translational modifications is glycosylation, which acts to confer 
both protein stability and configuration, as well as providing stable cell-to-cell 
adhesion via the attachment of lectins.  Aberrant glycosylation is strongly linked to 
oncogenesis and differentiation, meaning that the altered glycosylation patterns in 
tumor cells may serve as early sentinel biomarkers. Sub proteome analysis is gaining 
popularity as it way of potentially reducing the complexities associated with 
proteomics.  Glycoproteomics is however a difficult area to investigate due to 
glycan’s high structural complexity and also the low mass sensitivity of 
glycopeptides.  The detection of alterations in glycosylation patterns at the cytological 
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level can be achieved through the use of lectins or antibodies.  Lectins recognize 
carbohydrate epitopes from specific glycoforms.  The use of lectins in cancer 
glycobiology has already been established in the literature.  The lectin HPA has been 
used to assess both breast and gastric cancer biopsy specimens (400-402).  The 
expression of HPA in both these sample sets was found to parallel with lymph node 
metastasis and decreased survival (400-402). Other lectins with different glycan-
specific bindings have been used to demonstrate different signal patterns related to 
cancers of the prostate, ovary and colon (403-405).   One study found that the 10% of 
proteins which attached to HPA and LEL lectin were increased in abundance at least 
3 fold in breast cancer patients (400).  Using the AAL lectin, Comunale et al (406) 
Identified 50 proteins in patients with hepatocellular carcinoma, of which 
Haemopexin emerged as a potential biomarker with a specificity and sensitivity of 
92%.  There is however very little in the current literature using Lectins to identify 
potential serum biomarkers for CRC.  Yao et al (407) identified EFEMP2 as a 
potential serum biomarker in CRC patients using such technology.  Qiu et al (408) 
determined that N-linked glycan patterns could be used to distinguish between 
different colorectal pathologies. 
Within the remit of this study we aimed to assess the extent of the CRC serum 
glycoproteome and also to monitor any changes in serum of CRC patients.  The 
selection of lectins was based on the already known N- and O-linked glycan structures 
that are commonly found in human serum.  82 out of 100 most abundant proteins in 
serum are glycoproteins and therefore prior to using the lectin affinity columns we 
depleted serum using the IgY/Supermix system to enable better coverage of the lower 
abundance proteome.  Using the lectin columns we captured 122 proteins in the CRC 
cohort, compared with the iTRAQ workflow, which classified 154 proteins.  95% of 
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the proteins recognized were however medium (MAP) (40%) or low (LAP) (55%) 
abundance proteins, compared to 92% (40% MAP & 52% LAP) from the iTRAQ 
study.  This is supported by other studies, which found that sub proteome analysis 
identifies fewer proteins than in depth protein analysis.  The potential gain is however 
that a larger % of proteins captured by lectin affinity are deemed to be low abundance 
proteins.    Unfortunately  this  isn’t  either  a  quantitative  or  comparative  experiment,  and  
I have merely demonstrated that lectin analysis of CRC serum is both feasible, and 
can lead to the identification of a larger % of low abundance proteins compared to 
general proteomic platforms. 
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6.0  CONCLUSIONS AND FUTURE WORK 
The work presented here has been split into 2 main areas 
- Proteomic method development for biomarker discovery in serum 
- The identification of potential protein biomarkers in serum for the diagnosis of 
early stage CRC using such technology 
As previously highlighted CRC is a common and curable disease if diagnosed and 
treated early.  To aid early diagnosis screening of asymptomatic individuals using 
FOBT is currently advocated.  The benefit of FOBT has been confirmed in several 
RCTs, and although it may seem like a simple and safe test, it can lead to false 
positive outcomes exposing patients to the potential complications associated with 
having a colonoscopy.  As a result several research groups are attempting to define 
panels of biomarkers that are likely to yield higher sensitivity and specificity by 
providing a unique signature for the disease.  Research relating to biomarker 
discovery has been greatly augmented by the development of proteomic platforms.  
Proteomics is however a complex and challenging area to scrutinize, which has been 
highlighted in this thesis.  Every step within a proteomics study has to be closely 
regulated to exclude imposing heterogeneity other than the biological variation that 
truly exists between sample groups.  Strict controls and meticulous experimental 
design is therefore paramount.  The major limitation of the work presented here 
directly relates to these matters.  Phenotypic variations between samples were not 
accounted for.   These can arise because of the presence of other medical conditions, 
medicines, smoking, diet and many other biological co-founders.  These factors are 
very difficult to control thus sample attainment, preparation and subsequent analysis 
were rigorously controlled throughout this period of research to ensure no further bias 
was introduced.  A major element of this thesis was therefore to design and apply 
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current proteomic technologies to investigate the serum of patients with CRC.  
Development of a suitable workflow was initially undertaken using control serum to 
determine which individual technologies would yield the best results.  Serum is a 
difficult medium to analyze because of its composition and in particular its high 
dynamic range.  Different types of sample depletion and enrichment were therefore 
considered and examined.  The efficiency of 3 different depletion columns was 
evaluated, and it was discovered that the Genway antibody depletion column would 
be most appropriate for mining the low dynamic protein range.   The main problem of 
employing this type of sample preparation is the possibility of losing proteins of 
biological relevance, as they maybe transported by larger proteins that are not of 
relevance and thus removed during this process.  I perhaps could have tested this 
postulation by analyzing the bound fraction of the depletion procedure.  Other 
elements of the proteomics pathway such as fractionation, mass spectrometry and 
both label and label free quantitative utilities were also considered.  These have all 
been validated and reviewed within the discussion.  The use of 2 quantitative 
platforms was undertaken to corroborate any potential proteins identified but also to 
determine their performance.  In contrary to other groups findings I discovered that 
iTRAQ lead to the identification of more proteins and proteins that are of lower 
abundance.  One of the most testing areas of proteomics is the analysis and 
interpretation of the eventual datasets.  Often a large volume of data is generated and 
attempting to identify changes within serum that are pertinent is both difficult and 
time consuming.   Several hundred proteins were identified across the 4 main 
experiments I conducted, very few of which were consistently transformed in each of 
the experiments.  Identifying those, which might have been relevant, was therefore 
arduous.  The use of statistical software such as IPA augmented this process but this 
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was still less than ideal as it failed to process nearly 40% of the identified proteins 
because they were putative or uncharacterized proteins, or they were not readily 
identified within the uniprot or IPA database.  To reduce the complexities associated 
with large proteomic studies I also explored sub-proteome analysis and in particular 
glycosylation.  Unfortunately due to problems with samples and mass spectrometry, 
full analysis could not be undertaken, but it highlighted that such analysis would be 
both feasible, it would reduce some of attached difficulties and also be beneficial in 
CRC biomarker discovery.  Upon completion of the method development phase, 
serum from CRC patients and controls was researched as a whole and also by stage 
using the verified pathway and 2 proteomic technologies – iTRAQ and label free 
proteomics.  The eventual outcome of this work was that several features were found 
to be differentially dysregulated between patients with CRC and controls, and that the 
level of expression of some of the proteins is related to stage.  These were 
subsequently identified and ranked.  A total of 20 proteins were identified in the 
pooled CRC experiment and 42 in the Dukes experiments.  This highlights that a 
single biomarker for CRC detection is unlikely to be useful and that development of a 
multi protein biomarker panel will yield the required sensitivity and specificity.  Stage 
analysis would also be feasible through the use of different cut off values for each 
protein. Both the biological significance and current clinical utilities of some of these 
proteins has been discussed earlier in this thesis.  Continuing on from these results 
would be to eventually develop a protein biomarker panel that could be use to screen 
for CRC. The proteins detected within this study would firstly require to be validated 
within a large cohort of patients using ELISA or MRMs, to determine the biological 
accuracy and reproducibility of each at predicting the likehood of a patient having 
CRC.   Further work could also be undertaken to determine protein biomarkers of 
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precursor lesions, adenomas, by firstly looking at protein markers within the 
adenomatous tissue, and then translating such into a panel of serum biomarkers.     
Ultimately this project has explored and perfected a workflow for proteomic 
biomarker discovery in serum.  The application of this methodology to CRC has lead 
to the identification of a number of aberrantly expressed proteins that may have a 
potential clinical application as diagnostic biomarkers within a screening population.  
As previously highlighted there are major limitations fo such a study mostly relating 
to phenotypic variations between samples.  The pooling of serum may have 
potentially reduced such co founders but it could be possible that the results I have 
identified maybe the result of variations in sample procurement rather than biological 
variations secondary to the presence or absence of colorectal cancer.    If nothing else 
it has highlighted the complexities of proteomics studies and emphasized that 
stringency is paramount. 
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Appendix 
Table 66: Dysregulated proteins CRC iTRAQ 
 
PROTEIN IPI 
CRC 
(1) 
CRC 
(1) CONTROL 
CRC 
(2) 
CRC 
(2) CONTROL 
CRC 
(3) 
CRC 
(3) CONTROL 
CRC 
(4) 
CRC 
(4) CONTROL 
APOA4 Apolipoprotein A-IV  IPI00304273 1.258 --- 1.376 1.427 --- 1.262 1.737 1.447 1.447 1.053 1.029 1.001 
APOA4 apolipoprotein A-IV 
precursor  IPI00847179 
   
1.402 --- 1.257 1.741 1.471 1.449 
   TTR Transthyretin  IPI00022432 1.299 --- 1.073 1.121 --- 1.028 
   
2.023 1.498 1.023 
Platelet basic protein  IPI00022445 0.873 --- 0.746 0.937 --- 0.872 1.025 1.183 0.947 4.504 3.053 1.558 
Isoform 1 of Alpha-1-
antitrypsin  IPI00553177 5.72 5.117 0.929 4.984 4.64 1.009 6.416 6.064 1.221 3.706 1.423 0.464 
Ceruloplasmin  IPI00017601 1.668 --- 1.128 1.888 1.379 1.266 2.095 1.996 1.784 0.614 1.047 1.065 
Vitamin D-binding protein  IPI00555812 --- 57.543 --- 1.613 --- 1.446 1.94 1.614 1.422 4.026 5.182 2.975 
 vitamin D-binding protein 
precursor  IPI00742696 
   
1.582 --- 1.446 2.057 1.717 1.553 
   SERPINA3 cDNA FLJ35730 
fis, clone TESTI2003131, 
highly similar to ALPHA-1-
ANTICHYMOTRYPSIN  IPI00550991 2.352 3.073 1.127 2.356 3.134 1.222 2.617 3.568 1.401 1.063 0.623 0.664 
A2M Alpha-2-macroglobulin  IPI00478003 1.484 --- 1.153 1.393 0.771 0.962 1.303 1.296 1.064 2.264 2.353 2.508 
AHSG Alpha-2-HS-
glycoprotein  IPI00022431 1.046 --- 1.116 1.473 --- 1.203 
   
2.22 2.088 1.872 
Isoform 1 of Gelsolin  IPI00026314 1.711 --- 1.218 1.8 --- 1.351 1.679 2.115 1.655 1.864 0.955 0.821 
Isoform 1 of Fibrinogen alpha 
chain  IPI00021885 0.772 0.666 0.482 0.776 0.622 0.484 0.843 0.779 0.603 
   Prothrombin (Fragment)  IPI00019568 --- 57.838 --- 0.895 0.027 0.556 1.114 1.18 0.931 2.053 1.588 1.294 
Inter-alpha-trypsin inhibitor 
heavy chain H2  IPI00305461 --- --- --- 2.244 --- 1.173 1.332 1.265 1.183 3.252 1.973 1.812 
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cDNA FLJ35478 fis, clone 
SMINT2007796, highly similar 
to Gelsolin  IPI00513782 
   
1.738 --- 1.264 
      Leucine-rich alpha-2-
glycoprotein  IPI00022417 3.688 3.54 1.238 3.924 3.92 1.088 4.76 4.317 1.1 0.977 0.775 0.609 
Serum amyloid P-component  IPI00022391 1.738 2.024 1.027 1.738 --- 1.027 1.897 1.926 1.513 1.766 1.501 0.805 
Pigment epithelium-derived 
factor  IPI00006114 --- 58 --- 1.808 --- 1.033 2.042 1.738 1.581 1.367 1.303 0.959 
Serpin peptidase inhibitor, clade 
D (Heparin cofactor), member 1  IPI00292950 1.289 --- 1.205 1.479 0.673 1.245 1.812 1.447 1.305 1.236 1.64 1.102 
Gelsolin  IPI00796316 
   
2.402 --- 1.597 
      
Clusterin  IPI00291262 --- 57.659 --- 1.298 
138.20
6 1.477 0.83 0.768 0.752 
   COL1A1 Collagen alpha-1(I) 
chain  IPI00297646 8.299 8.243 2.557 6.35 6.266 2.436 --- --- 2.008 
   Thymosin beta-4-like protein 3  IPI00180240 0.739 0.84 0.559 0.804 0.82 0.581 0.806 0.849 0.804 
   Thymosin beta-4-like protein 1  IPI00816288 
   
0.843 0.753 0.537 
      COL1A2 Collagen alpha-2(I) 
chain  IPI00304962 12.949 8.243 2.557 4.99 6.827 0.514 --- 4.659 --- 
   LUM 23 kDa protein  IPI00794403 
   
--- 57.576 --- 
      HBA2;HBA1 Hemoglobin 
subunit alpha  IPI00410714 5.725 3.33 1.974 5.894 3.287 1.945 --- --- --- 
   HPR 47 kDa protein  IPI00641737 7.613 6.202 0.886 6.575 5.746 0.893 --- --- --- 
   Inter-alpha-trypsin inhibitor 
heavy chain H1  IPI00292530 2.787 --- --- 2.997 --- 1.144 1.244 1.171 1.193 3.309 2.003 1.542 
C2 Complement C2 (Fragment)  IPI00303963 --- 57.589 --- 1.187 --- 0.892 1.338 1.498 1.598 1.431 1.59 1.097 
Complement factor I  IPI00291867 --- 57.374 --- 1.406 1.844 1.125 1.755 1.534 1.465 3.428 4.477 2.525 
SERPINF2 SERPINF2 protein  IPI00029863 --- --- --- 1.358 1.246 1.162 
      AGT Angiotensinogen  IPI00032220 --- --- --- 1.653 0.271 1.183 1.989 2.207 1.704 0.826 1.029 0.934 
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 Tax_IGFBP3 Insulin-like 
growth factor-binding protein 3  IPI00018305 1.345 1.151 0.626 1.345 --- 0.626 --- --- --- 
   IGHV3OR16-13;IGHA1 
IGHA1 protein  IPI00430842 
   
0.497 0.412 1.326 1.162 1.209 1.427 
   IGHV3OR16-13;IGHA1 
Putative uncharacterized protein 
DKFZp686J11235 (Fragment)  IPI00426060 
   
0.497 0.412 1.326 
      IGL@ IGL@ protein  IPI00658130 
   
0.453 0.462 1.264 
      Lambda-chain  IPI00827875 
   
0.453 0.462 1.265 
       TaxActin, aortic smooth muscle  IPI00008603 --- 1.756 --- --- 1.71 --- 
      IGL@ IGL@ protein  IPI00829877 
   
0.45 0.472 1.261 0.413 0.411 1.289 
   APOB Apolipoprotein B-100  IPI00022229 --- 58.217 --- 1.707 1.433 0.946 
   
--- --- --- 
AMBP AMBP protein  IPI00022426 
   
1.384 1.664 1.185 
   
1.035 1.08 0.765 
F13A1 Coagulation factor XIII, 
A1 polypeptide  IPI00855773 --- 1.163 0.778 --- 1.147 0.78 --- --- --- 1.356 0.957 0.734 
SERPINA7 Thyroxine-binding 
globulin  IPI00292946 --- 1.533 --- 1.542 1.506 1.18 
      LOC653269 similar to protein 
expressed in prostate, ovary, 
testis, and placenta 2 isoform 2  IPI00740545 
   
--- 1.71 --- 
      APOA1 Apolipoprotein A-I  IPI00021841 --- 0.406 --- 1.603 1.473 1.061 
   
4.792 3.448 1.512 
C1S Complement C1s 
subcomponent  IPI00017696 --- --- --- --- 57.773 --- 1.995 1.702 1.521 
   PROS1 Vitamin K-dependent 
protein S  IPI00294004 0.266 --- --- 0.251 --- --- 
      ITIH3 Isoform 1 of Inter-alpha-
trypsin inhibitor heavy chain H3  IPI00028413 --- 58.717 --- 1.487 1.1 --- 
   
--- --- --- 
 Tax_Id=9606 
Gene_Symbol=AFM Afamin  IPI00019943 --- 57.476 --- --- 57.467 --- 1.317 1.43 1.947 2.819 1.348 2.305 
C4A Complement C4-A  IPI00032258 --- --- --- 0.797 1.108 --- --- --- --- 
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Ig lambda chain V-II region 
TRO  IPI00382426 
   
--- --- 0.59 
      PGLYRP2 Isoform 1 of N-
acetylmuramoyl-L-alanine 
amidase  IPI00163207 --- 0.667 --- --- 58.169 0.667 
   
2.626 2.414 1.794 
S100A9 Protein S100-A9  IPI00027462 1.972 1.827 1.201 1.925 1.834 1.179 1.943 2.073 1.253 
   C9 Complement component 
C9  IPI00022395 2.232 2.571 1.23 2.306 2.574 1.229 2.595 2.863 1.567 --- --- --- 
TMPRSS13 Isoform 1 of 
Transmembrane protease, serine 
13  IPI00000848 
   
0.994 1.659 0.672 0.994 1.869 0.718 1.724 1.237 0.969 
BTD biotinidase precursor  IPI00218413 --- --- --- --- 1.13 0.992 
      IGKV2-24 IGKV2-24 protein  IPI00440577 
   
1.151 --- 1.025 
      VTN Vitronectin  IPI00298971 --- 0.835 --- --- 0.755 --- --- --- --- 
   HSPC159 Galectin-related 
protein  IPI00023549 4.887 1.582 1.537 2.658 1.717 1.225 
      B2M B2M protein  IPI00796379 
   
1.772 --- 1.306 
      CFL1 Cofilin-1  IPI00012011 --- 59.988 --- --- 59.988 --- --- --- --- 
   C1R Complement C1r 
subcomponent  IPI00296165 
   
--- --- --- 
   
1.412 1.433 1.042 
ATRN Isoform 2 of Attractin  IPI00162735 --- --- --- --- 57.635 --- 
      SDPR Serum deprivation-
response protein  IPI00005809 0.538 --- --- 0.563 0.638 0.674 
      APOC2 Apolipoprotein C-II  IPI00021856 1.892 1.843 0.725 1.902 1.771 0.721 --- --- --- 
   ARHGDIB Rho GDP-
dissociation inhibitor 2  IPI00003817 --- 1.505 --- --- 1.505 --- 
      IGL@ IGL@ protein  IPI00745660 
   
0.473 0.583 1.433 
      AZGP1 alpha-2-glycoprotein 
1, zinc  IPI00166729 2.007 2.234 0.978 1.923 2.222 1.028 2.081 2.526 1.214 1.269 1.167 0.761 
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F7 Factor VII active site mutant 
immunoconjugate  IPI00382606 
   
1.394 1.86 1.12 
       PRG4 Isoform E of 
Proteoglycan-4  IPI00656111 --- 0.941 --- 0.844 0.983 0.614 
      Lumican IPI00020986 
 
57.584 
    
1.525 1.57 1.823 1.878 1.729 1.301 
IGHV3OR16-13;IGHA1 cDNA 
FLJ14473 fis, clone MAMMA 
1001080 IPI00386879 0.489 0.403 1.302 
         Putative uncharacterised protein IPI00807428 0.449 0.468 1.258 
         IGL@ IGL@ protein IPI00154742 0.433 0.468 1.259 
   
--- --- --- 
   IGKV1-5 IGKV1-5 protein IPI00419424 1.151 --- 1.025 
         Ig lambda chain V-II region 
BUR IPI00003947 --- --- 0.761 
         IGL@ IGL@ protein IPI00719373 0.469 0.536 1.45 
         IGHMFLJ00385 protein 
(Fragment) IPI00168728 --- --- --- 
         Highly similar to clusterin IPI00795633 
         
1.682 1.627 1.53 
DMXL2 Protein IPI00896496 
         
9.004 11.53 2.975 
55KDa protein IPI00029863 
      
1.596 1.769 1.327 1.376 1.46 0.954 
Highly similar to AMBP protein IPI00922298 
      
1.338 1.27 1.814 1.038 1.08 0.765 
IGFBP3 15KDa protein IPI00926261 
         
5.204 2.744 2.757 
Highly similar to ceruloplasmin IPI00794184 
      
2.127 1.994 1.797 
   Highly similar to alpha-2-HS-
glycoprotein IPI00022431 
      
2.243 1.764 1.317 
   Isoform 1 of N-
acetylmuramoyl-L-alanine 
amidase IPI00394992 
      
20 56 --- 
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TMSB4X TMSB4X protein 
(fragment) IPI00815642 
      
0.787 0.849 0.845 
   Coagulation factor X  IPI00019576 --- --- --- --- 57.84 --- 
   
1.847 1.8 1.768 
Kallistatin  IPI00328609 --- --- --- --- 57.709 --- --- --- --- 1.264 1.489 1.11 
Carboxypeptidase N catalytic 
chain  IPI00010295 
   
--- 57.903 --- 
   
2.036 1.321 1.067 
Apolipoprotein A-II  IPI00021854 --- --- --- --- 57.097 --- 
   
--- --- --- 
Selenoprotein P  IPI00029061 --- --- --- --- 57.501 --- 
      Corticosteroid-binding globulin  IPI00027482 --- --- --- --- --- --- 
   
1.121 0.781 0.749 
dedicator of cytokinesis 10  IPI00333770 
   
2.319 2.679 1.257 
      Apolipoprotein C-I  IPI00021855 --- --- --- 1.574 1.874 0.545 --- --- --- 
   peroxiredoxin 2 isoform c  IPI00375401 
   
--- 58.083 --- 
      Apolipoprotein C-III  IPI00021857 --- --- --- --- --- --- --- --- --- 
   Isoform 1 of Pregnancy zone 
protein  IPI00025426 
   
1.183 1.373 0.961 
      Cystatin-C  IPI00032293 
   
--- --- --- 
      ALB ALB protein  IPI00216773 --- --- --- --- --- --- --- --- --- 1.356 0.957 0.734 
Isoform 1 of Peptidase inhibitor 
16  IPI00301143 
   
--- 58.168 --- 
      Superoxide dismutase [Cu-Zn]  IPI00218733 
   
--- --- --- 
   
--- --- --- 
cDNA FLJ78387  IPI00876888 
   
0.227 0.251 0.703 
      IGHV4-31 IGHV4-31 protein  IPI00784810 
   
0.227 0.251 0.703 
      ELK2P1 ELK2, member of ETS 
oncogene family, pseudogene 1  IPI00736860 
   
0.182 0.203 0.964 
      IGHM IGHM protein  IPI00477090 
   
0.616 0.505 1.083 
      SELL L-selectin  IPI00218795 --- --- --- --- 57.442 --- 1.378 1.253 1.732 1.587 3.157 0.83 
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Cytoskeleton-associated protein 
5  IPI00028275 
   
--- 57.785 --- 
      hypothetical protein 
LOC441239  IPI00464965 
   
--- 57.785 --- 
      hypothetical protein 
LOC158358  IPI00216990 
   
--- 57.785 --- 
      Isoform 1 of Cartilage acidic 
protein 1  IPI00451624 --- --- --- --- --- --- 
      Obscurin-like 1 isoform A  IPI00893234 
   
--- 57.556 --- 
      immunoglobulin J chain  IPI00178926 
   
--- 0.136 --- 
      hypothetical protein LOC80164  IPI00887824 
   
--- 57.651 --- 
      similar to hCG22561  IPI00888405 
   
--- 57.651 --- 
      Thrombospondin-1  IPI00296099 
   
--- --- --- --- --- --- 
    THIST1H1B Histone H1.5  IPI00217468 --- --- --- --- --- --- 
       Conserved hypothetical protein  IPI00443486 
   
--- 57.759 --- 
      Tetranectin  IPI00009028 
   
--- 57.592 --- 
      MASP1 92 kDa protein  IPI00871139 
   
--- 57.67 --- 
      Alpha-tocopherol transfer 
protein-like  IPI00013624 
   
--- --- --- 
      ZMYND8 RACK7 isoform e  IPI00418316 
   
--- --- --- 
      COL3A1 Isoform 1 of Collagen 
alpha-1(III) chain  IPI00021033 
   
--- --- 1.919 --- --- --- 
   MBD4 Isoform 1 of Methyl-
CpG-binding domain protein 4  IPI00426727 
   
--- 57.3 --- 
      SNX6 sorting nexin 6 isoform b  IPI00298111 
   
--- --- --- 
      FLNA filamin A, alpha isoform 
1  IPI00302592 
   
--- --- --- 
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Isoform 1 of EGF-containing 
fibulin-like extracellular matrix 
protein 1  IPI00029658 
   
--- --- --- 
      Isoform 1 of E3 ubiquitin-
protein ligase rififylin  IPI00103867 
   
--- --- --- 
      Isoform 1 of Rab GTPase-
binding effector protein 1  IPI00293009 
   
--- --- --- 
   
--- --- --- 
ACSL6 ACSL6 protein  IPI00384110 
   
--- --- --- 
      Histidine-rich glycoprotein  IPI00022371 
   
--- 57.332 --- 
      Beta-Ala-His dipeptidase  IPI00064667 
   
--- 57.515 --- 
      Intercellular adhesion molecule 
2  IPI00009477 
   
--- 57.474 --- 
      CDH13 Cadherin-13  IPI00024046 
   
--- --- --- 
      FETUB GUGU beta form  IPI00552199 
   
--- --- --- --- --- --- 
   GOLGA3 Isoform 1 of Golgin 
subfamily A member 3  IPI00305267 
   
--- --- --- 
      C6orf167 Isoform 1 of 
Uncharacterized protein 
C6orf167  IPI00394816 
   
--- --- --- 
      MLL4 Isoform 1 of Histone-
lysine N-methyltransferase 
MLL4  IPI00218823 
   
--- --- --- 
      RUNDC3A Similar to RaP2 
interacting protein 8  IPI00298817 
   
--- --- --- 
       Ubiquitin carboxyl-terminal 
hydrolase 38  IPI00168084 
   
--- --- --- 
      Caspase 7, apoptosis-related 
cysteine peptidase  IPI00647486 
   
--- --- --- 
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Isoform 3 of Chitinase domain-
containing protein 1  IPI00045536 
   
--- --- --- 
      LAT Isoform Long of Linker 
for activation of T-cells family 
member 1  IPI00012888 
   
--- --- --- 
      TF Serotransferrin  IPI00022463 
   
--- --- --- 
      C3 Complement C3 (Fragment)  IPI00783987 
   
0.282 --- --- 
      ALDOA Fructose-bisphosphate 
aldolase A  IPI00465439 
   
--- --- --- 
       Isoform 1 of Vascular cell 
adhesion protein 1  IPI00018136 
   
--- --- --- 
      WNK2 Antigen NY-CO-43  IPI00384826 
   
--- 0.258 --- 
      Isoform 2 of Cytoplasmic 
dynein 2 heavy chain 1  IPI00171494 
   
--- 57.935 --- 
      SEMG1 Isoform 1 of 
Semenogelin-1  IPI00023020 
   
--- 57.935 --- 
      Isoform 1 of Rootletin  IPI00456492 
   
--- 57.651 --- 
      Isoform 1 of Golgin subfamily 
A member 4  IPI00013272 
   
0.745 1.197 0.551 
      Isoform 2 of Structural 
maintenance of chromosomes 
protein 4  IPI00328298 
   
0.745 1.197 0.551 
      39 kDa protein  IPI00871408 
   
0.134 --- --- 
      MAP3K4 Isoform B of 
Mitogen-activated protein 
kinase kinase kinase 4  IPI00186536 
   
0.134 --- --- 
      Complement component C8 
alpha chain  IPI00011252 
   
--- --- --- 
      Isoform LMW of Kininogen-1  IPI00215894 
   
--- --- --- 
   
--- --- --- 
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Isoform 1 of Urea transporter, 
kidney  IPI00177820 
   
--- --- --- 
      Isoform 2A of Desmocollin-2  IPI00025846 
   
--- --- --- 
      Putative zinc-alpha-2-
glycoprotein-like 1 IPI00871622 
   
--- --- --- 
      Isoform 1 of tropomyosin alpha-
4 chain IPI00010779 
      
1.532 1.249 1.245 
   KIF21B Protein IPI00657775 
      
2.015 1.745 1.467 1.908 1.241 1.062 
ARHGDIB IPI00792537 
      
--- --- --- 
   Serum depravation response 
protein IPI00005809 
      
0.514 0.561 0.67 
   IGHA1;IGHV3OR16-13 cDNA 
FLJ14473 fis, clone 
MAMA1001080, highly similar 
to homo sapiens IPI00386879 
      
0.68 0.742 1.631 
   IGHA1;IGHV3OR16-13 
putative uncharacterised protein 
DFKZp686K04218 (fragment) IPI00426060 
      
0.68 0.742 1.631 
   Adenylate cyclase associated 
protein IPI00514858 
      
--- --- --- 
   Thyroxine binding globulin IPI00292946 
      
2.094 2.069 1.765 0.874 1.041 0.874 
F5 252KDa protein IPI00022937 
      
1.566 1.305 1.199 
   CA2 Carbonic anhydrase IPI00218414 
      
1.688 1.412 1.394 
   CA2 11KDa protein IPI00790885 
      
1.668 1.412 1.394 
   ACTA 1 Actin alpha 1 
skeletalmuscle protein IPI00218795 
      
--- --- --- 
   
IGJ Immunoglobulin J Chain IPI00178926 
      
--- --- --- 
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JMJD1A Jmjc domian-
containing histone 
demethylation protein 2A IPI00479545 
      
1.466 1.498 2.207 
   
Isoform 6 of obscurin IPI00854629 
      
13.26
2 20.837 1.044 
   Prostaglandin D2 synthase 
21KDa IPI00513767 
      
--- --- --- 
   Inter-alpha-trypsin inhibitor 
heavy chain H3 IPI00028413 
      
1.538 1.423 1.342 
   Isoform 1 of U5 small nuclear 
ribonucleoprotein 200KDa 
heliase IPI00420014 
      
--- --- --- 
   LOC652147 hypothetical 
protein, partial IPI00740142 
      
--- --- --- 
   FLJ44048 Isoform 1 of 
uncharacterised protein 
FLJ440448 IPI00410549 
      
1.565 2.248 1.3 
   Beta 2 microglobulin IPI00004656 
      
--- --- --- 
   Conserved hypothetical protein IPI00019566 
      
1.48 1.895 1.22 
   VCAM1 Isoform 1 of vascular 
cell adhesion protein 1 IPI00018136 
      
--- --- --- 
   DDX1 ATP-dependent RNA 
helicase DDX1 IPI00293655 
      
--- --- --- 
   EFEMP1 Isoform 1 of EGF-
containing fibulin like 
extracellualr matrix protein 1 IPI00029658 
      
--- --- --- 
   Isoform 2 of tropomyosin alpha-
4 chain IPI00216975 
      
1.293 1.271 1.563 
   Isoform 2 of tropomyosin alpha-
3 chain IPI00218320 
      
1.293 1.271 1.563 
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Tropomysosin 1 aplpha variant 
6 IPI00384369 
      
1.293 1.271 1.563 
   Serpin A13 precursor IPI00410448 
      
2.394 3.731 1.495 
   Cholinesterase precursor IPI00025864 
      
--- --- --- 
   Isoform 1 of vinculin IPI00291175 
      
--- --- --- 
   Insulin like growth factor 
binding protein, acid labile 
subunit isoform 1 precursor IPI00925635 
         
2.531 2.308 3.693 
SEPP1 selenoprotein P isoform 
2 IPI00847381 
         
4.159 1.754 2.192 
IGL@ IGL@ protein IPI00784935 
         
10.514 1.96 1.302 
GOG6 cDNA FLJ56431, highly 
similar to conserved oligomeric 
Golgi complex component IPI00642611 
         
3.903 5.136 2.843 
Isoform 1 of Ras-related GTP 
binding protein B IPI00010317 
         
3.903 5.136 2.843 
Importin 8 IPI00007401 
         
1.733 0.598 0.738 
Insulin like growth factor 
binding protein 6 IPI00029235 
         
4.553 3.19 1.422 
Glutathione peroxidase 3 IPI00026199 
         
4.432 3.425 2.257 
IGHA1;IGHV3OR16-13 
putative uncharacterised protein 
DFKZp686G21220 (fragment) IPI00423460 
         
14.458 4.051 2.922 
IGHA2;IGHV3OR16-13 
putative uncharacterised protein 
DFKZp686O16217 (fragment) IPI00894384 
         
14.458 4.051 2.922 
IGHA2;IGHV3OR16-13 
putative uncharacterised protein 
DFKZp686C02220 (fragment) IPI00423461 
         
14.458 4.051 2.922 
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IGHA1 cDNA FLJ90170 fis, 
clone MAMA1000370, highly 
similar to Ig alpha-1 chain IPI00449920 
         
14.458 4.051 2.922 
Highly similar to complement 
C1r subcomponent IPI00296165 
         
2.305 1.987 1.842 
Isoform 2 of uncharacterised 
protein C20orf117 IPI00797771 
         
1.908 1.241 1.062 
NUMA1 isoform 2 of nuclear 
mitotis apparatus protein IPI00006196 
         
1.908 1.241 1.062 
SART1 U4/U6.U5 tri-snRNP-
associated protein IPI00021417 
         
1.908 1.241 1.062 
GCC2 Isoform 2 of GRIP and 
colied-coil domain containing 
protein 2 IPI00333197 
         
1.908 1.241 1.062 
DUOX1 Isoform 1 of Dual 
oxidase 1 IPI00185038 
         
1.908 1.241 1.062 
STK3 cDNA FLJ16404 fis, 
clone UTERU2008019 IPI00411984 
         
1.908 1.241 1.062 
Isoform A of Proteoglycan 4 IPI00024825 
         
--- --- --- 
Monocyte differentiation 
antigen CD14 IPI00029260 
         
2.481 2.256 2.404 
FAM48B1 Protein FAM48B1 IPI00083000 
         
1.084 1.077 0.977 
CLEC3B Putataive 
uncharacterised protein 
DKFZp686H17246 IPI00792115 
         
2.298 --- 0.269 
Isoform 1 of Ficolin-3 IPI00293925 
         
4.097 3.316 2.717 
ADNP Activity-dependent 
neuroprotector homeobox 
protein IPI00022215 
         
1.003 0.625 0.584 
Hyaluronan-binding protein 2 IPI00746623 
         
22.147 14.469 9.802 
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PROTEIN IPI 
CRC 
(1) 
CRC 
(1) CONTROL 
CRC 
(2) 
CRC 
(2) CONTROL 
CRC 
(3) 
CRC 
(3) CONTROL 
CRC 
(4) 
CRC 
(4) CONTROL 
Putative uncharacterised protein 
C1S IPI00749179 
         
5.204 3.421 2.513 
FLJ22184 hypothetical protein 
LOC80164 IPI00887824 
         
1.114 0.991 0.957 
FLJ22184 similar to hCG22561 IPI00888405 
         
1.114 0.991 0.957 
MAN1C1 Mannosyl-
oligosaccharide 1,2-alpha-
mannosidase IC IPI00745251 
         
1.795 2.739 1.549 
ECM1 Isoform1 of Extracellular 
matrix protein 1 IPI00003351 
         
3.153 0.955 0.385 
Zince finger SWIM domain 
containing protein IPI00303331 
         
3.71 3.185 2.47 
Isoform Beta of poliovirus 
receptor IPI00219425 
         
--- --- --- 
Isoform 1 of Optineurin IPI00304189 
         
2.275 1.291 0.905 
C2orf77 hypothetical protein 
LOC129881 IPI00739770 
         
--- --- --- 
HEG1 Isoform 1 of Protein 
HEG homolog 1 IPI00297263 
         
--- --- --- 
HEG1 Isoform 2 of Protein 
HEG homolog 1 IPI00795307 
         
--- --- --- 
C19orf61 59 kDa protein  IPI00005181 
         
1.838 1.542 1.12 
ADIPOQ Adiponectin  IPI00020019 
         
1.384 1.322 1.085 
 Enolase  IPI00328587 
         
--- --- --- 
GOLGA3 Isoform 2 of Golgin 
subfamily A member 3  IPI00333419 
         
--- --- --- 
FMN2 Formin-2  IPI00742944 
         
--- --- --- 
MLL4 Isoform 1 of Histone-
lysine N-methyltransferase 
MLL4  IPI00218823 
         
--- --- --- 
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PROTEIN IPI CRC (1) CRC (1) CONTROL CRC (2) CRC (2) CONTROL CRC (3) CRC (3) CONTROL CRC (4) CRC (4) CONTROL 
C6orf167 Isoform 1 of 
Uncharacterized protein 
C6orf167  IPI00394816 
         
--- --- --- 
CHD1L Isoform 1 of 
Chromodomain-helicase-DNA-
binding protein 1-like  IPI00329088 
         
--- --- --- 
EIF4G2 eukaryotic translation 
initiation factor 4 gamma, 2 
isoform 2  IPI00782985 
         
--- --- --- 
JAK1 Tyrosine-protein kinase 
JAK1  IPI00784013 
         
--- --- --- 
CHD1L Isoform 2 of 
Chromodomain-helicase-DNA-
binding protein 1-like  IPI00890729 
         
--- --- --- 
CASP7 Isoform Alpha' of 
Caspase-7  IPI00216675 
         
--- --- --- 
RUNDC3A Isoform 3 of RUN 
domain-containing protein 3A  IPI00298817 
         
--- --- --- 
CNOT6LP1 hypothetical 
protein, partial  IPI00455253 
         
--- --- --- 
USP38 Ubiquitin carboxyl-
terminal hydrolase 38  IPI00168084 
         
--- --- --- 
Isoform 3 of Zinc transporter 
ZIP12  IPI00043756 
         
--- --- --- 
FYVE finger-containing 
phosphoinositide kinase  IPI00396145 
         
1.431 1.403 1.778 
FER1L5 Isoform 1 of Fer-1-like 
protein 5  IPI00883989 
         
--- --- --- 
BBS4 Isoform 2 of Bardet-Biedl 
syndrome 4 protein  IPI00290189 
         
--- --- --- 
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Table 67: Dukes iTRAQ 
PROTEIN IPI 
DUKES 
A (1) 
DUKES 
A(2) 
DUKES 
A (3) 
DUKES 
B (1) 
DUKES 
B (2) 
DUKES 
B (3) 
DUKES 
C (1) 
DUKES 
C (2) 
DUKES 
C (3) 
DUKES 
A (Av.) 
DUKES 
A 
(Log2) 
DUKES 
B (Av) 
DUKES
B 
(Log2) 
DUKES 
C (Av.) 
DUKES 
C 
(Log2) 
Isoform 1 of Alpha-
1-antitrypsin  IPI00553177.1 0.487 0.643 0.587 2.8 2.843 2.811 1.332 1.667 1.377 0.572 -0.805 2.818 1.495 1.459 0.545 
APOA4 
Apolipoprotein A-
IV  IPI00304273.2 0.868 1.062 1.027 1.295 1.399 1.379 1.906 2.055 2.037 0.986 -0.021 1.358 0.441 1.999 1.000 
APOA4 
apolipoprotein A-
IV precursor  IPI00847179.1 0.868 1.067 1.035 1.276 1.391 1.373 1.891 2.045 2.031 0.990 -0.014 1.347 0.429 1.989 0.992 
A2M Alpha-2-
macroglobulin  IPI00478003.1 0.651 0.797 0.838 1.948 1.934 1.191 1.183 1.407 1.291 0.762 -0.392 1.691 0.758 1.294 0.371 
SERPINA3 cDNA 
FLJ35730 fis, clone 
TESTI2003131, 
highly similar to 
ALPHA-1-
ANTICHYMOTRY
PSIN  IPI00550991.3 0.307 0.334 0.27 2.283 2.149 2.274 1.572 1.821 1.587 0.304 -1.719 2.235 1.160 1.660 0.731 
CP Ceruloplasmin  IPI00017601.1 0.521 0.723 0.664 2.009 1.913 1.95 1.859 2.127 2.015 0.636 -0.653 1.957 0.969 2.000 1.000 
APOA1 
Apolipoprotein A-I  IPI00021841.1 0.507 0.408 0.4 0.608 0.56 0.546 0.905 0.885 0.887 0.438 -1.190 0.571 -0.808 0.892 -0.164 
IGKV1-5 IGKV1-5 
protein  IPI00419424.3 0.15 0.174 0.14 0.807 0.535 0.541 0.05 0.33 0.311 0.155 -2.693 0.628 -0.672 0.230 -2.118 
Putative 
uncharacterized 
protein  IPI00550731.2 0.161   0.159 1.285 
 
0.542 0.05   0.339 0.160 -2.644 0.914 -0.131 0.195 -2.362 
IGKC IGKC 
protein  IPI00472961.2 0.182 0.205 0.182 0.854 0.539 0.548 0.113 0.394 0.383 0.190 -2.398 0.647 -0.628 0.297 -1.753 
IGKV2-24 IGKV2-
24 protein  IPI00440577.3 0.184 0.212 0.17 1.417 0.535 0.54 0.05 0.344 0.342 0.189 -2.406 0.831 -0.268 0.245 -2.027 
 353 
PROTEIN IPI DUKES A (1) DUKES A(2) DUKES A (3) DUKES B (1) DUKES B (2) DUKES B (3) DUKES C (1) DUKES C (2) DUKES C (3) DUKES A (Av.) DUKES A (Log2) DUKES B (Av) DUKESB (Log2) DUKES C (Av.) DUKES C (Log2) 
IGK@ IGK@ 
protein  IPI00784865.1 0.184 0.212 0.17 1.417 0.535 0.54 0.05 0.344 0.342 0.189 -2.406 0.831 -0.268 0.245 -2.027 
IGKV3-20 IGK@ 
protein  IPI00889156.1 0.184 0.212 0.17 1.417 0.535 0.54 0.05 0.344 0.342 0.189 -2.406 0.831 -0.268 0.245 -2.027 
ALB Isoform 1 of 
Serum albumin  IPI00745872.2 0.097 0.065 0.06 0.509 0.428 0.423 0.238 0.235 0.196 0.074 -3.756 0.453 -1.141 0.223 -2.165 
ALB Putative 
uncharacterized 
protein ALB  IPI00022434.4 0.097 0.065 0.06 0.506 0.428 0.423 0.239 0.235 0.196 0.074 -3.756 0.452 -1.145 0.223 -2.163 
IGKC IGKC 
protein  IPI00845354.1 0.184 0.212 0.17 1.562 0.538 0.541 0.05 0.377 0.342 0.189 -2.406 0.880 -0.184 0.256 -1.964 
GSN Isoform 1 of 
Gelsolin  IPI00026314.1 1.025 0.864 0.797 1.576 1.529 1.511 2.12 1.892 1.839 0.895 -0.160 1.539 0.622 1.950 0.964 
AHSG cDNA 
FLJ55606, highly 
similar to Alpha-2-
HS-glycoprotein  IPI00022431.2 0.384 0.35 0.333 1.052 0.969 1.001 0.934 1.036 0.997 0.356 -1.491 1.007 0.011 0.989 -0.016 
HPR 47 kDa 
protein  IPI00641737.1 0.269 0.282 0.277 2.8 3.257 3.404 1.454 2.056 1.747 0.276 -1.857 3.154 1.657 1.752 0.809 
APOB 
Apolipoprotein B-
100  IPI00022229.1 0.423 0.42 0.328 1.556 1.399 1.532 2.592 2.31 2.513 0.390 -1.357 1.496 0.581 2.472 1.305 
PPBP Platelet basic 
protein  IPI00022445.1 0.305 0.349 0.31 0.708 0.715 0.743 0.681 0.771 0.722 0.321 -1.638 0.722 -0.470 0.725 -0.465 
Lambda-chain  IPI00827875.1 0.254 0.23 0.213 0.632 0.6 0.616 0.533 0.562 0.51 0.232 -2.106 0.616 -0.699 0.535 -0.902 
IGL@ IGL@ 
protein  IPI00154742.6 0.265 0.22 0.205 0.625 0.589 0.607 0.538 0.563 0.51 0.230 -2.120 0.607 -0.720 0.537 -0.897 
IGL@ IGL@ 
protein  IPI00658130.1 0.254 0.245 0.213 0.647 0.599 0.619 0.533 0.562 0.512 0.237 -2.075 0.622 -0.686 0.536 -0.901 
 354 
PROTEIN IPI DUKES A (1) DUKES A(2) DUKES A (3) DUKES B (1) DUKES B (2) DUKES B (3) DUKES C (1) DUKES C (2) DUKES C (3) DUKES A (Av.) DUKES A (Log2) DUKES B (Av) DUKESB (Log2) DUKES C (Av.) DUKES C (Log2) 
IGLV2-
14;IGLC2;IGLC1;I
GLC3 IGLV2-14 
protein  IPI00816555.1 0.254 0.23 0.213 0.632 0.6 0.616 0.533 0.562 0.51 0.232 -2.106 0.616 -0.699 0.535 -0.902 
IGL@ IGL@ 
protein  IPI00744476.6 0.254 0.23 0.213 0.632 0.6 0.616 0.533 0.562 0.51 0.232 -2.106 0.616 -0.699 0.535 -0.902 
Putative 
uncharacterized 
protein  IPI00807428.1 0.196 0.194 0.181 0.638 0.598 0.62 0.525 0.565 0.506 0.190 -2.393 0.619 -0.693 0.532 -0.911 
IGL@ IGL@ 
protein  IPI00555945.1 0.213 0.198 0.184 0.638 0.601 0.622 0.521 0.551 0.496 0.198 -2.334 0.620 -0.689 0.523 -0.936 
ITIH2 Inter-
alpha-trypsin 
inhibitor heavy 
chain H2  IPI00305461.2 0.643 0.703 0.637 2.05 1.914 1.96 1.541 1.819 1.567 0.661 -0.597 1.975 0.982 1.642 0.716 
 IGLV4-3 IGLV4-3 
protein  IPI00382938.3 0.195 0.18 0.171 0.625 0.603 0.628 0.522 0.555 0.494 0.182 -2.458 0.619 -0.693 0.524 -0.933 
TTR Transthyretin  IPI00022432.1 --- 0.634 --- --- 
 
--- 2.3 0.736 0.681 
      IGHM IGHM 
protein  IPI00472610.2 0.191 0.15 0.139 0.647 0.603 0.597 0.276 0.276 0.233 0.160 -2.644 0.616 -0.700 0.262 -1.934 
HRG Histidine-rich 
glycoprotein  IPI00022371.1 0.567 0.582 0.575 0.97 0.983 0.989 0.952 0.997 0.978 
      IGHV4-31 
Immunoglobulin 
heavy variable 4-31  IPI00785084.1 0.196 0.15 0.139 0.642 0.602 0.595 0.276 0.275 0.232 0.162 -2.629 0.613 -0.706 0.261 -1.938 
IGHG1 IGHG1 
protein  IPI00448938.1 0.196 0.15 0.139 0.642 0.603 0.595 0.282 0.278 0.235 0.162 -2.629 0.613 -0.705 0.265 -1.916 
HPR Isoform 1 of 
Haptoglobin-related 
protein  IPI00477597.1 0.327 0.274 0.299 2.8 3.151 3.355 1.53 2.292 2.02 0.300 -1.737 3.102 1.633 1.947 0.961 
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PROTEIN IPI DUKES A (1) DUKES A(2) DUKES A (3) DUKES B (1) DUKES B (2) DUKES B (3) DUKES C (1) DUKES C (2) DUKES C (3) DUKES A (Av.) DUKES A (Log2) DUKES B (Av) DUKESB (Log2) DUKES C (Av.) DUKES C (Log2) 
cDNA FLJ78387  IPI00876888.1 0.196 0.15 0.139 0.642 0.602 0.595 0.276 0.276 0.232 0.162 -2.629 0.613 -0.706 0.261 -1.936 
IGHG1 Putative 
uncharacterized 
protein 
DKFZp686O01196  IPI00423463.1 0.196 0.15 0.139 0.642 0.602 0.595 0.276 0.275 0.232 0.162 -2.629 0.613 -0.706 0.261 -1.938 
IGHG1 Putative 
uncharacterized 
protein 
DKFZp686K03196  IPI00423464.1 0.196 0.15 0.139 0.647 0.603 0.596 0.289 0.279 0.235 0.162 -2.629 0.615 -0.701 0.268 -1.901 
IGHV3OR16-
13;IGHA1 IGHA1 
protein  IPI00430842.3 0.234 0.183 0.186 0.621 0.552 0.573 0.745 0.69 0.653 0.201 -2.315 0.582 -0.781 0.696 -0.523 
IGHV3OR16-
13;IGHA1 IGHA1 
protein  IPI00719233.1 0.234 0.183 0.186 0.621 0.552 0.573 0.745 0.69 0.653 0.201 -2.315 0.582 -0.781 0.696 -0.523 
F7 Factor VII 
active site mutant 
immunoconjugate  IPI00382606.1 0.196 0.15 0.139 0.653 0.603 0.597 0.289 0.276 0.234 0.162 -2.629 0.618 -0.695 0.266 -1.909 
IGHV3OR16-
13;IGHA1 Putative 
uncharacterized 
protein 
DKFZp686K18196 
(Fragment)  IPI00423462.5 0.234   0.186 0.621 
 
0.569 0.657 
 
0.635 0.210 -2.252 0.595 -0.749 0.646 -0.630 
 HCG2010697  IPI00642632.1 0.167 0.174 0.157 0.59 0.551 0.564 0.442 0.443 0.393 0.166 -2.591 0.568 -0.815 0.426 -1.231 
IGHV3OR16-
13;IGHA1 SNC66 
protein  IPI00383164.1 0.089 0.119 0.137 0.681 0.569 0.597 0.602 0.629 0.58 0.115 -3.120 0.616 -0.700 0.604 -0.728 
GC vitamin D-
binding protein 
precursor  IPI00742696.2 0.734 0.722 0.641 2.075 1.936 1.993 1.736 1.895 1.687 0.699 -0.517 2.001 1.001 1.773 0.826 
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PROTEIN IPI DUKES A (1) DUKES A(2) DUKES A (3) DUKES B (1) DUKES B (2) DUKES B (3) DUKES C (1) DUKES C (2) DUKES C (3) DUKES A (Av.) DUKES A (Log2) DUKES B (Av) DUKESB (Log2) DUKES C (Av.) DUKES C (Log2) 
IGL@ IGL@ 
protein  IPI00745660.2 0.212 0.294 0.233 0.677 0.63 0.632 0.507 0.544 0.494 0.246 -2.021 0.646 -0.630 0.515 -0.957 
HBB Hemoglobin 
subunit beta  IPI00654755.3 0.671 0.647 0.669 3.494 3.197 3.573 2.653 3.171 2.87 0.662 -0.594 3.421 1.775 2.898 1.535 
GC Vitamin D-
binding protein  IPI00555812.4 0.712 0.725 0.652 1.885 1.901 1.954 1.675 1.886 1.68 0.696 -0.522 1.913 0.936 1.747 0.805 
IGLV3-21 IGLV3-
21 protein  IPI00815938.1 0.167   0.157 0.59 
 
0.559 0.442   0.406 0.162 -2.626 0.575 -0.800 0.424 -1.238 
HBA2;HBA1 
Hemoglobin 
subunit alpha  IPI00410714.5 0.918 0.708 0.698 3.732 4.064 4.23 3.108 3.954 3.492 0.775 -0.368 4.009 2.003 3.518 1.815 
ITIH1 Inter-alpha-
trypsin inhibitor 
heavy chain H1  IPI00292530.1 0.559 0.671 0.581 2.048 2.099 2.132 1.57 1.999 1.713 0.604 -0.728 2.093 1.066 1.761 0.816 
LOC100126583 
cDNA FLJ41981 
fis, clone 
SMINT2011888, 
highly similar to 
Protein Tro alpha1 
H,myeloma  IPI00784830.1 0.089 0.119 0.137 0.661 0.566 0.595 0.566 0.618 0.569 0.115 -3.120 0.607 -0.719 0.584 -0.775 
IGHA2 IGHA2 
protein  IPI00783993.1 0.089 0.119 0.137 0.661 0.566 0.595 0.566 0.618 0.569 0.115 -3.120 0.607 -0.719 0.584 -0.775 
SERPINF1 
Pigment 
epithelium-derived 
factor  IPI00006114.4 0.927 0.973 0.936 1.92 1.792 1.855 1.853 1.961 1.812 0.945 -0.081 1.856 0.892 1.875 0.907 
IGL@ IGL@ 
protein  IPI00829877.1 0.196 0.193 0.181 0.651 0.59 0.613 0.514 0.56 0.506 0.190 -2.396 0.618 -0.694 0.527 -0.925 
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PROTEIN IPI DUKES A (1) DUKES A(2) DUKES A (3) DUKES B (1) DUKES B (2) DUKES B (3) DUKES C (1) DUKES C (2) DUKES C (3) DUKES A (Av.) DUKES A (Log2) DUKES B (Av) DUKESB (Log2) DUKES C (Av.) DUKES C (Log2) 
Putative 
uncharacterized 
protein 
ENSP00000374988 
(Fragment)  IPI00736860.3 0.134 0.103 0.096 0.64 0.574 0.566 0.24 0.245 0.194 0.111 -3.171 0.593 -0.753 0.226 -2.143 
CLU Clusterin  IPI00291262.3 0.541 0.699 0.64 1.52 1.31 1.373 1.722 1.691 1.713 0.627 -0.674 1.401 0.486 1.709 0.773 
C9 Complement 
component C9  IPI00022395.1 0.525 0.693 0.543 2.217 2.035 2.135 2.59 2.503 2.554 0.587 -0.769 2.129 1.090 2.549 1.350 
AGT 
Angiotensinogen  IPI00032220.3 0.708 0.769 0.68 1.797 2.01 1.968 1.505 2.289 2.249 0.719 -0.476 1.925 0.945 2.014 1.010 
IGHM Putative 
uncharacterized 
protein 
DKFZp686I15212  IPI00418153.1 0.202 0.15 0.139 0.695 0.612 0.607 0.303 0.281 0.239 0.164 -2.611 0.638 -0.648 0.274 -1.866 
IGHG3 IGHG3 
protein  IPI00472345.1 0.202 0.15 0.139 0.692 0.611 0.606 0.301 0.278 0.236 0.164 -2.611 0.636 -0.652 0.272 -1.880 
IGHM FLJ00385 
protein (Fragment) IPI001687282 
 
0.15 
  
0.611 
  
0.278 
       LRG1 Leucine-
rich alpha-2-
glycoprotein  IPI00022417.4 0.996 0.889 0.828 3.256 3.579 3.574 2.579 3.465 3.015 0.904 -0.145 3.470 1.795 3.020 1.594 
PRSS1 Trypsin-1  IPI00011694.1 0.115 0.127 0.117 0.689 0.667 0.674 1.114 1.058 1.065 0.120 -3.063 0.677 -0.563 1.079 0.110 
F2 Prothrombin 
(Fragment)  IPI00019568.1 0.652 0.68 0.669 0.833 0.829 0.81 1.167 0.99 1.02 0.667 -0.584 0.824 -0.279 1.059 0.083 
IGHM IGHM 
protein  IPI00477090.6 0.314 0.264 0.259 0.724 0.619 0.649 0.642 0.637 0.581 0.279 -1.842 0.664 -0.591 0.620 -0.690 
IGHM IGHM 
protein  IPI00479708.5 0.314 0.264 0.259 0.74 0.621 0.652 0.649 0.636 0.58 0.279 -1.842 0.671 -0.576 0.622 -0.686 
 358 
PROTEIN IPI DUKES A (1) DUKES A(2) DUKES A (3) DUKES B (1) DUKES B (2) DUKES B (3) DUKES C (1) DUKES C (2) DUKES C (3) DUKES A (Av.) DUKES A (Log2) DUKES B (Av) DUKESB (Log2) DUKES C (Av.) DUKES C (Log2) 
Serpin peptidase 
inhibitor, clade D 
(Heparin cofactor), 
member 1  IPI00292950.4 0.587 0.667 0.585 1.693 1.651 1.641 2.25 2.364 2.327 0.613 -0.706 1.662 0.733 2.314 1.210 
Putative 
uncharacterised 
protein APOB IPI00894122.2 
 
0.504 
  
1.332 
  
2.243 
       Putative 
uncharacterized 
protein 
DKFZp686C15213  IPI00426051.3 0.134 0.082 0.079 0.671 0.574 0.568 0.265 0.233 0.181 0.098 -3.346 0.604 -0.727 0.226 -2.143 
APOE 
Apolipoprotein E  IPI00021842.1 1.18 1.249 1.235 2.565 2.387 2.371 4.433 4.566 4.572 1.221 0.288 2.441 1.287 4.524 2.177 
COL1A1 Collagen 
alpha-1(I) chain  IPI00297646.4 --- --- --- 2.8 3.17 2.028 2.61 2.516 2.374 
  
2.666 1.415 2.500 1.322 
FGA Isoform 2 of 
Fibrinogen alpha 
chain  IPI00029717.1 0.659 0.647 0.606 1.263 1.076 1.075 1.233 1.245 1.233 0.637 -0.650 1.138 0.187 1.237 0.307 
55 kDa protein  IPI00029863.4 0.594 0.699 0.623 1.264 1.275 1.264 1.484 1.709 1.739 0.639 -0.647 1.268 0.342 1.644 0.717 
Serum amyloid P-
component  IPI00022391.1 1.137 0.816 0.825 1.554 1.485 1.499 2.563 2.326 2.333 0.926 -0.111 1.513 0.597 2.407 1.267 
C4A Complement 
C4-A  IPI00032258.4 --- --- --- 2.011 1.867 2.019 1.657 1.713 1.621 
  
1.966 0.975 1.664 0.734 
IGHG2 Protein  IPI00829767.1 0.134 0.082 0.079 0.671 0.574 0.568 0.265 0.233 0.181 0.098 -3.346 0.604 -0.727 0.226 -2.143 
APOE MRNA for 
apolipoprotein E  IPI00878953.1 1.219 
 
1.316 2.607   2.374 4.433   4.548 1.268 0.342 2.491 1.316 4.491 2.167 
C5 Complement C5  IPI00032291.2 0.489 0.435 0.489 2.37 2.12 2.169 1.812 1.789 1.581 0.471 -1.086 2.220 1.150 1.727 0.789 
VTN Vitronectin  IPI00298971.1 --- 0.372 --- 1.534 1.421 1.459 0.927 1.097 0.941 
  
1.471 0.557 0.988 -0.017 
TF Serotransferrin  IPI00022463.1 0.433 0.265 0.272 1.044 0.962 0.999 0.852 1.04 1.02 0.323 -1.629 1.002 0.002 0.971 -0.043 
 359 
PROTEIN IPI DUKES A (1) DUKES A(2) DUKES A (3) DUKES B (1) DUKES B (2) DUKES B (3) DUKES C (1) DUKES C (2) DUKES C (3) DUKES A (Av.) DUKES A (Log2) DUKES B (Av) DUKESB (Log2) DUKES C (Av.) DUKES C (Log2) 
LUM Lumican  IPI00020986.2 --- --- --- 1.892 1.235 1.274 1.597 1.629 1.705 
  
1.467 0.553 1.209 0.273 
 Ig kappa chain V-
IV region Len  IPI00387120.1 --- 0.96 --- --- --- --- --- 1.118 --- 
      ORM1 Alpha-1-
acid glycoprotein 1  IPI00022429.3 --- --- --- --- 2.531 --- 1.441 1.956 1.777 
    
1.725 0.786 
ITIH3 Isoform 1 
of Inter-alpha-
trypsin inhibitor 
heavy chain H3  IPI00028413.8 0.921 0.942 0.857 2.415 2.533 2.524 2.571 2.705 2.389 0.907 -0.141 2.491 1.317 2.555 1.353 
AZGP1 alpha-2-
glycoprotein 1, zinc  IPI00166729.4 0.737 0.782 0.666 1.66 1.542 1.506 0.979 1.132 1.005 0.728 -0.457 1.569 0.650 1.039 0.055 
IGHG4 Putative 
uncharacterized 
protein IGHG4 
(Fragment)  IPI00830132.1 0.162 0.09 0.087 0.647 0.565 0.559 0.274 0.239 0.19 0.113 -3.146 0.590 -0.760 0.234 -2.093 
IGFALS insulin-
like growth factor 
binding protein, 
acid labile subunit 
isoform 1 precursor  IPI00925635.1 --- --- --- 1.39 2.748 1.439 1.931 2.464 2.3 
    
2.232 1.158 
cDNA FLJ60769, 
highly similar to 
Inter-alpha-trypsin 
inhibitor heavy 
chain H3  IPI00909807.1 1.064 0.946 0.863 2.443 2.546 2.541 2.629 2.721 2.398 0.958 -0.062 2.510 1.328 2.583 1.369 
SERPINA4 
Kallistatin  IPI00328609.3 0.256 0.333 0.252 1.069 1.357 1.392 1.611 1.666 1.672 0.280 -1.835 1.273 0.348 1.650 0.722 
 360 
PROTEIN IPI DUKES A (1) DUKES A(2) DUKES A (3) DUKES B (1) DUKES B (2) DUKES B (3) DUKES C (1) DUKES C (2) DUKES C (3) DUKES A (Av.) DUKES A (Log2) DUKES B (Av) DUKESB (Log2) DUKES C (Av.) DUKES C (Log2) 
IGHA2 Putative 
uncharacterized 
protein 
DKFZp686O16217 
(Fragment)  IPI00894384.1 0.098   0.113 0.697 
 
0.603 0.619 
 
0.588 0.106 -3.245 0.650 -0.621 0.604 -0.729 
FN1 Isoform 1 of 
Fibronectin  IPI00022418.1 0.615 0.767 0.6 2.383 2.254 2 3.913 4.064 3.975 0.661 -0.598 2.283 1.191 3.984 1.994 
COL1A2 Collagen 
alpha-2(I) chain  IPI00304962.3 1.963 1.506 1.497 3.182 2.712 2.773 2.195 2.701 2.336 1.655 0.727 2.889 1.531 2.411 1.269 
IGHA2 protein IPI00893853.2 
 
0.123 
  
0.584 
  
0.639 
       AFM Afamin  IPI00019943.1 --- 0.264 --- 1.41 1.172 1.177 0.957 0.974 0.846 
      Isoform 1 of 
pregnancy zone 
protein IPI00025426.2 
 
0.507 
  
1.77 
  
1.126 
       cDNA FLJ55673, 
highly similar to 
Complement factor 
B  IPI00019591.2 --- --- --- --- --- --- --- --- --- 
      C2 Complement C2 
(Fragment)  IPI00303963.1 --- --- --- 1.336 1.31 1.355 1.633 1.757 1.793 
  
1.334 0.415 1.728 0.789 
 S100A9 Protein 
S100-A9  IPI00027462.1 --- --- --- --- --- --- --- --- --- 
      Putative 
uncharacterized 
protein PZP  IPI00748437.2 0.688 
 
0.592 1.631 
 
1.79 0.997 
 
0.976 0.640 -0.644 1.711 0.774 0.987 -0.020 
 PGLYRP2 
Isoform 1 of N-
acetylmuramoyl-
L-alanine amidase  IPI00163207.1 0.418 0.455 0.37 1.681 1.549 1.549 2.377 2.462 2.607 0.414 -1.271 1.593 0.672 2.482 1.312 
 361 
PROTEIN IPI DUKES A (1) DUKES A(2) DUKES A (3) DUKES B (1) DUKES B (2) DUKES B (3) DUKES C (1) DUKES C (2) DUKES C (3) DUKES A (Av.) DUKES A (Log2) DUKES B (Av) DUKESB (Log2) DUKES C (Av.) DUKES C (Log2) 
Ig kappa chain V-
III region WOL  IPI00387118.1 0.197 0.205 0.185 0.59 0.542 0.551 0.401 0.421 0.394 0.196 -2.354 0.561 -0.834 0.405 -1.303 
ITIH4 100 kDa 
protein  IPI00896413.1 0.363 0.403 0.306 2.113 1.966 2.055 1.114 1.308 1.12 0.357 -1.485 2.045 1.032 1.181 0.240 
APOA2 
Apolipoprotein A-II  IPI00021854.1 0.225 0.188 0.183 0.808 0.62 0.638 0.964 0.675 0.643 0.199 -2.332 0.689 -0.538 0.761 -0.395 
THBS1 
Thrombospondin-1  IPI00296099.6 0.419 0.519 0.435 1.714 1.696 1.742 1.357 1.564 1.419 0.458 -1.128 1.717 0.780 1.447 0.533 
ITIH4 ITIH4 
protein  IPI00896419.2 0.363 0.403 0.306 2.113 1.966 2.055 1.114 1.308 1.12 0.357 -1.485 2.045 1.032 1.181 0.240 
HBG2 Hemoglobin 
gamma-G 
(Fragment)  IPI00816618.1 --- --- --- --- --- --- --- --- --- 
      Apolipoprotein C-
III variant 1  IPI00657670.1 --- --- --- --- --- --- --- --- --- 
      C1RL Complement 
C1r subcomponent-
like protein  IPI00009793.4 1.072 0.882 0.869 1.684 1.674 1.748 2.388 2.491 2.512 0.941 -0.088 1.702 0.767 2.464 1.301 
ACTG1 Actin, 
cytoplasmic 2  IPI00021440.1 0.565 0.672 0.586 1.995 1.944 1.952 1.755 1.93 1.641 0.608 -0.719 1.964 0.974 1.775 0.828 
SERPINA7 
Thyroxine-binding 
globulin  IPI00292946.1 --- --- --- 2.2 1.741 1.743 1.694 2.243 2.11 
  
1.895 0.922 2.016 1.011 
SERPING1 cDNA 
FLJ58826, highly 
similar to Plasma 
protease C1 
inhibitor  IPI00879931.1 --- 0.367 --- 2.776 2.718 2.715 1.312 1.519 1.261 
  
2.736 1.452 1.364 0.448 
CNDP1 Beta-Ala-
His dipeptidase  IPI00064667.4 --- --- --- 1.501 1.458 1.48 1.955 1.893 1.938 
  
1.480 0.565 1.929 0.948 
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PROTEIN IPI DUKES A (1) DUKES A(2) DUKES A (3) DUKES B (1) DUKES B (2) DUKES B (3) DUKES C (1) DUKES C (2) DUKES C (3) DUKES A (Av.) DUKES A (Log2) DUKES B (Av) DUKESB (Log2) DUKES C (Av.) DUKES C (Log2) 
ITIH4 Protein  IPI00922043.1 0.398 0.525 0.412 2.197 2.007 2.067 1.118 1.336 1.151 0.445 -1.168 2.090 1.064 1.202 0.265 
ACTG1 22KDa 
protein IPI00790339.2 
 
0.672 
  
1.944 
  
1.93 
 
0.672 -0.573 
    APOC2 
Apolipoprotein C-
II  IPI00021856.3 1.863 1.771 1.756 2.8 2.482 2.505 4.494 4.668 4.657 1.797 0.845 2.596 1.376 4.606 2.204 
ITIH4 Isoform 1 of 
Inter-alpha-trypsin 
inhibitor heavy 
chain H4  IPI00294193.4 0.363 0.403 0.306 2.113 1.966 2.055 1.114 1.308 1.12 0.357 -1.485 2.045 1.032 1.181 0.240 
Ig Kappa chain V-
III B6 IPI00387113.1 
 
0.951 
  
0.551 
  
--- 
 
0.951 -0.072 0.551 -0.860 
  ITIH4 Isoform 1 of 
Inter-alpha-trypsin 
inhibitor heavy 
chain H4  IPI00294193.4 0.363 0.403 0.306 2.113 1.966 2.055 1.114 1.308 1.12 0.357 -1.485 2.045 1.032 1.181 0.240 
ITIH1 PRO2769  IPI00383338.1 --- 
 
--- --- 
 
--- --- 
 
--- 
      C8A Complement 
component C8 
alpha chain  IPI00011252.1 --- --- --- 1.42 1.434 1.49 1.626 1.703 1.652 
  
1.448 0.534 1.660 0.731 
ORM2 Alpha-1-
acid glycoprotein 2  IPI00020091.1 --- --- --- --- --- --- --- --- --- 
      CST3 Cystatin-C  IPI00032293.1 --- --- --- --- --- --- --- --- --- 
      C1R cDNA 
FLJ54471, highly 
similar to 
Complement C1r 
subcomponent  IPI00296165.6 1.101 1.117 1.093 1.684 1.869 1.845 2.388 2.661 2.551 1.104 0.142 1.799 0.847 2.533 1.341 
C1S Complement 
C1s subcomponent  IPI00017696.1 0.487 0.587 0.498 1.621 1.702 1.675 1.761 2.04 1.991 0.524 -0.932 1.666 0.736 1.931 0.949 
 363 
PROTEIN IPI DUKES A (1) DUKES A(2) DUKES A (3) DUKES B (1) DUKES B (2) DUKES B (3) DUKES C (1) DUKES C (2) DUKES C (3) DUKES A (Av.) DUKES A (Log2) DUKES B (Av) DUKESB (Log2) DUKES C (Av.) DUKES C (Log2) 
Ig kappa chain V-I 
region DEE  IPI00387025.1 --- --- --- --- --- --- --- --- --- 
      AMBP Protein 
AMBP  IPI00022426.1 --- --- --- 1.975 1.841 1.833 1.313 1.556 1.431 
  
1.883 0.913 1.433 0.519 
IGJ 
immunoglobulin J 
chain  IPI00178926.2 0.344 0.342 0.364 0.265 0.318 0.289 0.491 0.486 0.484 0.350 -1.515 0.291 -1.783 0.487 -1.038 
Rheumatoid factor 
D5 light chain 
(Fragment)  IPI00816799.1 --- --- --- 0.742 0.664 0.651 0.282 0.39 0.314 
  
0.686 -0.544 0.329 -1.605 
ACTA2 ACTA2 
protein (Fragment)  IPI00927545.1 0.565 0.672 0.586 1.995 1.944 1.952 1.755 1.93 1.641 0.608 -0.719 1.964 0.974 1.775 0.828 
CFI Complement 
factor I  IPI00291867.3 0.459 0.49 0.471 1.177 1.114 1.123 1.336 1.309 1.297 0.473 -1.079 1.138 0.187 1.314 0.394 
CFI 43 kDa protein  IPI00795153.2 0.459   0.471 1.177 
 
1.123 1.336 
 
1.297 0.465 -1.105 1.150 0.202 1.317 0.397 
TMSL3 Thymosin 
beta-4-like protein 
3  IPI00180240.2 0.074 0.093 0.081 0.536 0.52 0.526 0.599 0.615 0.593 0.083 -3.597 0.527 -0.923 0.602 -0.731 
C1RL 48 kDa 
protein  IPI00872573.1 1.072 0.878 0.869 1.684 1.736 1.748 2.511 2.491 2.511 0.940 -0.090 1.723 0.785 2.504 1.324 
ITIH4 cDNA 
FLJ53871, highly 
similar to Inter-
alpha-trypsin 
inhibitor heavy 
chain H4  IPI00791097.2 0.363   0.306 2.113   2.055 1.114 
 
1.12 0.335 -1.580 2.084 1.059 1.117 0.160 
V1-17 protein  IPI00887169.1 0.245 0.268 0.243 0.704 0.653 0.659 0.519 0.562 0.507 0.252 -1.989 0.672 -0.573 0.529 -0.918 
C8G Complement 
component C8 
gamma chain  IPI00011261.2 --- --- --- --- --- --- --- --- --- 
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PROTEIN IPI DUKES A (1) DUKES A(2) DUKES A (3) DUKES B (1) DUKES B (2) DUKES B (3) DUKES C (1) DUKES C (2) DUKES C (3) DUKES A (Av.) DUKES A (Log2) DUKES B (Av) DUKESB (Log2) DUKES C (Av.) DUKES C (Log2) 
Myosin-reactive 
immunoglobulin 
kappa chain 
variable region 
(Fragment)  IPI00384401.1 0.126 0.132 0.12 0.683 0.67 0.664 0.337 0.423 0.342 0.126 -2.989 0.672 -0.573 0.367 -1.445 
HPX Hemopexin  IPI00022488.1 --- --- --- 2.271 2.44 2.39 --- 0.909 --- 
  
2.367 1.243 0.909 -0.138 
Single-chain Fv 
(Fragment)  IPI00470652.1 0.11 0.121 0.109 0.482 0.466 0.481 0.354 0.396 0.351 0.113 -3.141 0.476 -1.070 0.367 -1.446 
Ig lambda chain V-I 
region HA  IPI00382420.1 0.245 0.342 0.243 0.845 0.64 0.672 0.521 0.559 0.523 0.277 -1.854 0.719 -0.476 0.534 -0.904 
Ig heavy chain V-I 
region EU IPI00382455.2 
 
0.121 
  
0.466 
  
0.396 
       Isoform 1 of Ras-
related GTP 
binding protein B IPI00010317.4 
 
0.816 
  
2.148 
  
1.954 
       TPM4 Isoform 1 of 
Tropomyosin 
alpha-4 chain  IPI00010779.4 0.27 0.19 0.18 0.863 0.701 0.691 0.885 0.891 0.914 0.213 -2.229 0.752 -0.412 0.897 -0.157 
PROC cDNA 
FLJ51925, highly 
similar to Vitamin 
K-dependent 
protein C  IPI00908685.1 --- --- --- --- --- --- --- --- --- 
      POTEF 
ANKRD26-like 
family C member 
1B  IPI00739539.6 0.565 0.672 0.586 1.995 1.944 1.952 1.755 1.93 1.641 0.608 -0.719 1.964 0.974 1.775 0.828 
Ig heavy chain V-
III region TEI  IPI00382494.1 --- --- --- --- --- --- --- --- --- 
      
 365 
PROTEIN IPI DUKES A (1) DUKES A(2) DUKES A (3) DUKES B (1) DUKES B (2) DUKES B (3) DUKES C (1) DUKES C (2) DUKES C (3) DUKES A (Av.) DUKES A (Log2) DUKES B (Av) DUKESB (Log2) DUKES C (Av.) DUKES C (Log2) 
Myosin-reactive 
immunoglobulin 
heavy chain 
variable region 
(Fragment)  IPI00384392.1 --- --- --- --- --- --- --- --- --- 
      VWF cDNA 
FLJ59036, highly 
similar to von 
Willebrand factor  IPI00788786.1 --- --- --- --- --- --- --- --- --- 
      Von Willebrand 
factor IPI00023014.2 
 
--- 
  
--- 
  
--- 
       CPN2 
Carboxypeptidase 
N subunit 2  IPI00479116.1 --- --- --- 1.659 1.612 1.659 2.224 2.107 2.227 
  
1.643 0.717 2.186 1.128 
Coagulation factor 
V  IPI00478809.3 --- --- --- --- --- --- --- --- --- 
       252 kDa protein  IPI00022937.4 --- --- --- --- --- --- --- --- --- 
      Amyloid lambda 6 
light chain variable 
region SAR 
(Fragment)  IPI00386839.1 0.277 0.303 0.278 0.621 0.597 0.6 0.572 0.59 0.544 0.286 -1.806 0.606 -0.723 0.569 -0.814 
Similar to lectin, 
galactoside-
binding, soluble, 3 
binding protein IPI00887555.2 
 
--- 
  
--- 
  
--- 
       BTD cDNA 
FLJ51892, highly 
similar to 
Biotinidase  IPI00927683.1 --- --- --- --- --- --- --- --- --- 
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PROTEIN IPI DUKES A (1) DUKES A(2) DUKES A (3) DUKES B (1) DUKES B (2) DUKES B (3) DUKES C (1) DUKES C (2) DUKES C (3) DUKES A (Av.) DUKES A (Log2) DUKES B (Av) DUKESB (Log2) DUKES C (Av.) DUKES C (Log2) 
TPM3 tropomyosin 
3 isoform 5  IPI00477649.1 --- --- --- --- --- --- 0.885 0.88 0.879 
      Isoform 2 of 
tropmyosin alpha-4 
chain IPI00216975.2 
 
0.19 
  
0.69 
  
0.915 
       LGALS3BP 
Galectin-3-binding 
protein  IPI00023673.1 --- 
 
--- --- 
 
--- --- 
 
--- 
      APOC1 
Apolipoprotein C-I  IPI00021855.1 0.418 0.504 0.418 1.792 1.796 1.792 2.777 2.847 2.802 0.447 -1.163 1.793 0.843 2.809 1.490 
APOC1 
Apolipoprotein C-I  IPI00021855.1 0.418 0.504 0.418 1.792 1.796 1.792 2.777 2.847 2.802 0.447 -1.163 1.793 0.843 2.809 1.490 
CDNA FLJ58124, 
highly similar to 
Complement factor 
I IPI00796990.3 
 
0.485 
  
1.114 
  
1.308 
        Isoform 2 of 
Tropomyosin beta 
chain  IPI00220709.3 --- 
 
--- --- 
 
--- 0.882 
 
0.879 
       Isoform 1 of 
Tropomyosin beta 
chain IPI00013991.3 
 
--- 
  
--- 
  
0.88 
        Isoform 3 of 
Tropomyosin beta 
chain IPI00218820.3 
 
--- 
  
--- 
  
0.88 
       APOL1 Isoform 1 
of Apolipoprotein 
L1  IPI00514475.5 --- --- --- --- --- --- --- --- --- 
      IGKV2-40 Ig kappa 
chain V-II region 
Cum  IPI00387107.3 0.134 0.145 0.124 0.57 0.534 0.543 0.293 0.302 0.277 0.134 -2.896 0.549 -0.865 0.291 -1.783 
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PROTEIN IPI DUKES A (1) DUKES A(2) DUKES A (3) DUKES B (1) DUKES B (2) DUKES B (3) DUKES C (1) DUKES C (2) DUKES C (3) DUKES A (Av.) DUKES A (Log2) DUKES B (Av) DUKESB (Log2) DUKES C (Av.) DUKES C (Log2) 
Putative 
uncharacterized 
protein 
ENSP00000374799 
(Fragment)  IPI00854709.1 0.134 0.145 0.124 0.57 0.534 0.543 0.293 0.302 0.277 0.134 -2.896 0.549 -0.865 0.291 -1.783 
LOC440786 Ig 
kappa chain V-II 
region TEW  IPI00736885.1 0.134 0.145 0.124 0.57 0.534 0.543 0.293 0.302 0.277 0.134 -2.896 0.549 -0.865 0.291 -1.783 
GPX3 Glutathione 
peroxidase 3  IPI00026199.2 --- --- --- --- --- --- --- --- 
       ADIPOQ 
Adiponectin  IPI00020019.1 --- --- --- --- --- --- --- --- 
       SEPP1 
selenoprotein P 
isoform 2  IPI00847381.1 --- --- --- 0.956 0.898 0.925 1.888 1.016 1.082 
      Cadherin-5 IPI00012792.3 
 
--- 
  
--- 
  
--- 
       cDNA FLJ51093, 
highly similar to 
Cadherin-5  IPI00910166.1 --- 
 
--- --- 
 
--- --- 
 
--- 
      FETUB Fetuin-B  IPI00743766.2 --- --- --- --- --- --- --- --- --- 
      C4B Complement 
protein C4B 
frameshift mutant 
(Fragment)  IPI00922744.1 --- 
 
--- --- 
 
--- --- 
 
--- 
      IGFBP3 Insulin-
like growth factor-
binding protein 3  IPI00018305.4 0.503 0.552 0.516 0.714 0.774 0.777 1.15 1.131 1.09 
      Putative alpha-1-
antitrypsin-related 
protein IPI00736763.2 
 
1.852 
  
4.257 
  
2.609 
        Tetranectin  IPI00009028.1 0.48 0.542 0.466 1.324 1.238 1.252 1.3 1.451 1.437 0.496 -1.012 1.271 0.346 1.396 0.481 
 368 
PROTEIN IPI DUKES A (1) DUKES A(2) DUKES A (3) DUKES B (1) DUKES B (2) DUKES B (3) DUKES C (1) DUKES C (2) DUKES C (3) DUKES A (Av.) DUKES A (Log2) DUKES B (Av) DUKESB (Log2) DUKES C (Av.) DUKES C (Log2) 
Ig kappa chain V-I 
region Ni  IPI00387106.1 --- --- --- --- --- --- --- --- --- 
      SLFN11 Schlafen 
family member 11 IPI00171044.8 
 
0.485 
  
2.614 
  
1.554 
       SLC16A8 
Monocarboxylate 
transporter 3 IPI00296004.3 
 
0.485 
  
2.614 
  
1.554 
       Coagulation factor 
IX  IPI00296176.2 0.775 0.903 0.799 1.183 1.145 1.104 1.717 1.614 1.535 0.826 -0.276 1.144 0.194 1.622 0.698 
 cDNA FLJ45630 
fis, clone 
CHONS2001287, 
moderately similar 
to INSULIN-LIKE 
GROWTH 
FACTOR 
BINDING 
PROTEIN 3  IPI00444386.3 0.503 0.552 0.516 0.714 0.774 0.777 1.15 1.131 1.09 
       cDNA FLJ35128 
fis, clone 
PLACE6008768, 
moderately similar 
to INSULIN-LIKE 
GROWTH 
FACTOR 
BINDING 
PROTEIN 3 IPI00902471.3 
 
0.552 
  
0.774 
  
1.131 
       dedicator of 
cytokinesis 10  IPI00333770.6 --- --- --- --- --- --- --- --- --- 
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PROTEIN IPI DUKES A (1) DUKES A(2) DUKES A (3) DUKES B (1) DUKES B (2) DUKES B (3) DUKES C (1) DUKES C (2) DUKES C (3) DUKES A (Av.) DUKES A (Log2) DUKES B (Av) DUKESB (Log2) DUKES C (Av.) DUKES C (Log2) 
Isoform 2 of 
Dedicator of 
cytokinesis protein 
10  IPI00375113.2 --- --- --- --- --- --- --- --- --- 
      Complement C1q 
subcomponent 
subunit C  IPI00022394.2 --- 0.809 --- 1.709 1.75 1.693 1.798 1.885 1.786 0.809 -0.306 1.717 0.780 1.823 0.866 
CD44 Isoform 
CD44 of CD44 
antigen  IPI00305064.1 --- --- --- --- --- --- --- --- --- 
      CD44 Isoform 14 
of CD44 antigen IPI00827937.2 
 
--- 
  
--- 
  
--- 
        cDNA FLJ57891, 
highly similar to 
Tropomyosin beta 
chain  IPI00909308.1 --- --- --- --- --- --- 0.882 0.88 0.879 
      ACTBL2 Beta-
actin-like protein 2  IPI00003269.1 --- 
 
--- --- 
 
--- --- 
 
--- 
      KIAA0182 Isoform 
1 of Genetic 
suppressor element 
1  IPI00215963.5 --- --- --- --- --- --- --- --- --- 
      CPN1 
Carboxypeptidase 
N catalytic chain  IPI00010295.1 --- --- --- --- --- --- --- --- --- 
      CA1 Carbonic 
anhydrase 1  IPI00215983.3 --- --- --- --- --- --- --- --- --- 
      
 370 
PROTEIN IPI DUKES A (1) DUKES A(2) DUKES A (3) DUKES B (1) DUKES B (2) DUKES B (3) DUKES C (1) DUKES C (2) DUKES C (3) DUKES A (Av.) DUKES A (Log2) DUKES B (Av) DUKESB (Log2) DUKES C (Av.) DUKES C (Log2) 
Cryocrystalglobulin 
CC2 lambda light 
chain variable 
region (Fragment)  IPI00890733.1 0.245 0.268 0.243 0.704 0.653 0.659 0.519 0.562 0.507 0.252 -1.989 0.672 -0.573 0.529 -0.918 
Myosin-reactive 
immunoglobulin 
heavy chain 
variable region 
(Fragment)  IPI00783024.1 --- --- --- --- --- --- --- --- --- 
      Anti-folate binding 
protein (Fragment)  IPI00915820.1 --- --- --- --- --- --- --- --- --- 
      ARHGDIB Rho 
GDP-dissociation 
inhibitor 2  IPI00003817.3 --- --- --- --- --- --- --- --- --- 
      C1QB complement 
component 1, q 
subcomponent, B 
chain precursor  IPI00477992.1 --- --- --- --- --- --- --- --- --- 
      PRDX2 
Peroxiredoxin-2  IPI00027350.3 --- --- --- --- --- --- --- --- --- 
      Ig lambda chain V-I 
region NEW  IPI00382421.1 --- --- --- --- --- --- --- --- --- 
      CA2 Carbonic 
anhydrase 2  IPI00218414.5 --- --- --- --- --- --- --- --- --- 
       Tax_Id=9606 
Gene_Symbol=PR
G4 Isoform A of 
Proteoglycan 4  IPI00024825.2 0.526 0.324 0.338 0.498 0.519 0.504 0.719 0.681 0.684 0.396 -1.336 0.507 -0.980 0.695 -0.526 
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PROTEIN IPI DUKES A (1) DUKES A(2) DUKES A (3) DUKES B (1) DUKES B (2) DUKES B (3) DUKES C (1) DUKES C (2) DUKES C (3) DUKES A (Av.) DUKES A (Log2) DUKES B (Av) DUKESB (Log2) DUKES C (Av.) DUKES C (Log2) 
ECM1 Isoform 3 of 
Extracellular matrix 
protein 1  IPI00909747.1 --- --- --- --- --- --- --- --- --- 
      Coagulation factor 
X  IPI00019576.1 0.722 0.855 0.723 1.803 1.839 1.814 1.764 1.944 1.755 0.767 -0.383 1.819 0.863 1.821 0.865 
CA2 11KDa protein IPI00790885.2 
 
--- 
  
--- 
  
--- 
       PROS1 80 kDa 
protein  IPI00873445.1 --- --- --- --- --- --- --- --- --- 
      Anti-(ED-B) scFV 
(Fragment)  IPI00916434.1 --- --- --- --- --- --- --- --- --- 
      Isoform 1 of 
Mannan-binding 
lectin serine 
protease 2  IPI00294713.4 --- --- --- --- --- --- --- --- --- 
      Isoform 1 of 
Sulfhydryl oxidase 
1  IPI00003590.2 --- --- --- --- --- --- --- --- --- 
      Serum 
paraoxonase/arylest
erase 1  IPI00218732.3 --- --- --- --- --- --- --- --- --- 
      SPARC SPARC  IPI00014572.1 --- --- --- --- --- --- --- --- --- 
      Ig heavy chain V-
III region WAS  IPI00382493.1 --- 
 
--- --- 
 
--- --- 
 
--- 
      Ig heavy chain V-
III region POM  IPI00382491.1 --- --- --- --- --- --- --- --- --- 
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PROTEIN IPI DUKES A (1) DUKES A(2) DUKES A (3) DUKES B (1) DUKES B (2) DUKES B (3) DUKES C (1) DUKES C (2) DUKES C (3) DUKES A (Av.) DUKES A (Log2) DUKES B (Av) DUKESB (Log2) DUKES C (Av.) DUKES C (Log2) 
Isoform 1 of 
Phosphatidylinosito
l-glycan-specific 
phospholipase D  IPI00299503.2 --- --- --- --- --- --- --- --- --- 
      Putative 
uncharacterized 
protein 
DKFZp686H17246  IPI00792115.1 --- --- --- --- --- --- --- --- --- 
      Serum amyloid A-4 
protein  IPI00019399.1 --- --- --- --- --- --- --- --- --- 
      Isoform 1 of Sex 
hormone-binding 
globulin  IPI00023019.1 --- --- --- --- --- --- --- --- --- 
      Protein S100-A8  IPI00007047.1 --- --- --- --- --- --- --- --- --- 
      Isoform 1 of C-
reactive protein  IPI00022389.1 --- --- --- --- --- --- --- --- --- 
      Corticosteroid-
binding globulin  IPI00027482.1 0.63 0.741 0.661 1.321 1.325 1.349 1.733 1.536 1.378 0.677 -0.562 1.332 0.413 1.549 0.631 
Apolipoprotein C-
IV  IPI00022731.1 --- --- --- --- --- --- --- --- --- 
      Complement 
component C8 beta 
chain  IPI00294395.1 --- --- --- --- 1.888 --- 1.155 2.015 1.787 
    
1.652 0.725 
similar to actin 
alpha 1 skeletal 
muscle protein  IPI00886911.1 --- 
 
--- --- 
 
--- --- 
 
--- 
      
                 Ig lambda chain V-
III region LOI  IPI00385985.1 --- --- --- --- --- --- --- --- --- 
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PROTEIN IPI DUKES A (1) DUKES A(2) DUKES A (3) DUKES B (1) DUKES B (2) DUKES B (3) DUKES C (1) DUKES C (2) DUKES C (3) DUKES A (Av.) DUKES A (Log2) DUKES B (Av) DUKESB (Log2) DUKES C (Av.) DUKES C (Log2) 
LPA 
Apolipoprotein(a)  IPI00029168.1 --- --- --- --- --- --- --- --- --- 
      LOC653781 similar 
to protein expressed 
in prostate, ovary, 
testis, and placenta 
2 isoform 2 IPI00738655.2 
 
0.342 
  
0.64 
  
0.559 
       Similar to 
Lipoprotein Lp IPI00889177.2 
 
--- 
  
--- 
  
--- 
       Ig heavy chain V-
III region POM  IPI00387097.1 --- 
  
--- 
  
--- 
        Ig kappa chain V-I 
region VH IPI00829834.2 
 
--- --- 
 
--- --- 
 
--- --- 
      Insulin-like growth 
factor-binding 
protein 6  IPI00029235.1 --- --- --- --- --- --- --- --- --- 
      
                 highly similar to 
Homo sapiens 
tropomyosin 2 
(beta) (TPM2), 
transcript variant 2, 
mRNA  IPI00910712.1 --- 
 
--- --- 
 
--- --- 
 
--- 
      macrophage 
stimulating 1  IPI00925540.1 --- --- --- --- --- --- --- --- --- 
      Cholinesterase 
precursor  IPI00025864.5 --- --- --- --- --- --- --- --- --- 
      Ig Lambda chain V-
II region WIN IPI00382434.2 
 
0.342 
  
0.64 
  
0.559 
       16 kDa protein  IPI00788926.1 --- 
 
--- --- 
 
--- --- 
 
--- 
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PROTEIN IPI DUKES A (1) DUKES A(2) DUKES A (3) DUKES B (1) DUKES B (2) DUKES B (3) DUKES C (1) DUKES C (2) DUKES C (3) DUKES A (Av.) DUKES A (Log2) DUKES B (Av) DUKESB (Log2) DUKES C (Av.) DUKES C (Log2) 
Ig lambda chain V-
IV region Hil  IPI00382440.1 --- --- --- --- --- --- --- --- --- 
      Putative 
uncharacterized 
protein 
ENSP00000374805  IPI00854644.1 --- --- --- --- --- --- --- --- --- 
      Isoform 2 of 
Attractin  IPI00162735.3 --- --- --- --- --- --- --- --- --- 
      Isoform 1 of Cell 
surface 
glycoprotein 
MUC18  IPI00016334.2 --- --- --- --- --- --- --- --- --- 
      Cofilin-1  IPI00012011.6 --- --- --- --- --- --- --- --- --- 
      Putative 
uncharacterized 
protein TTN  IPI00412307.8 0.806 
 
0.699 2.166   1.877 1.719   1.498 0.753 -0.410 2.022 1.015 
  platelet 
glycoprotein Ib 
alpha polypeptide 
precursor  IPI00748955.2 --- --- --- --- --- --- --- --- --- 
      Isoform 1 of 
Ficolin-3  IPI00293925.2 0.732 0.799 0.709 1.499 1.471 1.451 1.941 1.772 1.785 0.747 -0.421 1.474 0.559 1.833 0.874 
Myosin-reactive 
immunoglobulin 
heavy chain 
variable region 
(Fragment)  IPI00384393.1 --- --- --- --- --- --- --- --- --- 
      IGLV4-69 V5-6 
protein  IPI00478997.3 0.29 0.259 0.25 0.84 0.785 0.798 0.601 0.634 0.54 0.266 -1.909 0.808 -0.308 0.592 -0.757 
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PROTEIN IPI DUKES A (1) DUKES A(2) DUKES A (3) DUKES B (1) DUKES B (2) DUKES B (3) DUKES C (1) DUKES C (2) DUKES C (3) DUKES A (Av.) DUKES A (Log2) DUKES B (Av) DUKESB (Log2) DUKES C (Av.) DUKES C (Log2) 
IGLV1-36 V1-11 
protein  IPI00552943.3 0.245 0.268 0.243 0.704 0.653 0.659 0.519 0.562 0.507 0.252 -1.989 0.672 -0.573 0.529 -0.918 
Isoform 1 of 
Ficolin-2  IPI00017530.2 --- --- --- --- --- --- --- --- --- 
      Isoform 5 of Titin  IPI00759613.1 0.574 0.457 0.418 1.758 1.768 1.783 2.098 2.056 2.048 0.483 -1.050 1.770 0.823 2.067 1.048 
Isoform 1 of 
Carboxypeptidase 
B2  IPI00329775.7 --- --- --- --- --- --- --- --- --- 
      Isoform 1 of Urea 
transporter, kidney  IPI00177820.3 --- --- --- --- --- --- --- --- --- 
      Vasorin  IPI00395488.2 --- --- --- --- --- --- --- --- --- 
      CALM2;CALM3;C
ALM1 Calmodulin 
 IPI00075248.1
1 --- --- --- --- --- --- --- --- --- 
      CFD Complement 
factor D 
preproprotein  IPI00165972.3 --- --- --- --- --- --- --- --- --- 
      Isoform 1 of 
Optineurin  IPI00304189.5 --- --- --- --- --- --- --- --- --- 
      Transforming 
growth factor-beta-
induced, 68KDa, 
isoform CRA IPI00236901.6 
 
--- 
  
--- 
  
--- 
       Transforming 
growth factor-beta-
induced protein ig-
h3  IPI00018219.1 --- 
 
--- --- 
 
--- --- 
 
--- 
      Isoform 1 of 
Ubiquitin carboxyl-
terminal hydrolase 
33  IPI00236901.6 --- --- --- --- --- --- --- --- --- 
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PROTEIN IPI DUKES A (1) DUKES A(2) DUKES A (3) DUKES B (1) DUKES B (2) DUKES B (3) DUKES C (1) DUKES C (2) DUKES C (3) DUKES A (Av.) DUKES A (Log2) DUKES B (Av) DUKESB (Log2) DUKES C (Av.) DUKES C (Log2) 
Mannosyl-
oligosaccharide 1,2-
alpha-mannosidase 
IC  IPI00745251.2 0.499 0.64 0.555 2.193 2.121 2.122 1.855 2.057 1.739 0.565 -0.825 2.145 1.101 1.884 0.914 
SART1 U4/U6.U5 
tri-snRNP-
associated protein 1  IPI00021417.3 --- --- --- 1.031 0.994 1.004 1.838 1.711 1.756 
  
1.010 0.014 1.768 0.822 
CD14 Monocyte 
differentiation 
antigen CD14  IPI00029260.2 --- --- --- --- --- --- --- --- --- 
      Serglycin  IPI00019372.1 --- --- --- --- --- --- --- --- --- 
      Kinesin-like protein 
KIF21B variant  IPI00397809.4 --- --- --- 1.031 0.994 1.004 1.838 1.711 1.756 
  
1.010 0.014 1.768 0.822 
Hyaluronan-binding 
protein 2  IPI00746623.2 --- --- --- --- --- --- --- --- --- 
      peroxiredoxin 2 
isoform c  IPI00375401.1 --- 
 
--- --- 
 
--- --- 
 
--- 
      Isoform 1 of Dual 
oxidase 1  IPI00185038.3 --- --- --- 0.926 0.886 0.892 1.417 1.453 1.481 
      Isoform 2 of 
Uncharacterized 
protein C20orf117  IPI00797771.1 --- --- --- 1.031 0.994 1.004 1.838 1.711 1.756 
  
1.010 0.014 1.768 0.822 
Isoform 2 of 
Nuclear mitotic 
apparatus protein 1  IPI00006196.3 --- --- --- 1.031 0.994 1.004 1.838 1.711 1.756 
  
1.010 0.014 1.768 0.822 
Isoform 1 of 
Squamous cell 
carcinoma antigen 
recognized by T-
cells 3  IPI00006025.1 --- --- --- 1.031 0.994 1.004 1.838 1.711 1.756 
  
1.010 0.014 1.768 0.822 
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PROTEIN IPI DUKES A (1) DUKES A(2) DUKES A (3) DUKES B (1) DUKES B (2) DUKES B (3) DUKES C (1) DUKES C (2) DUKES C (3) DUKES A (Av.) DUKES A (Log2) DUKES B (Av) DUKESB (Log2) DUKES C (Av.) DUKES C (Log2) 
Zinc finger CCCH 
domain-containing 
protein 6  IPI00410656.1 --- --- --- 1.031 0.994 1.004 1.838 1.711 1.756 
  
1.010 0.014 1.768 0.822 
cDNA FLJ16404 
fis, clone 
UTERU2008019, 
highly similar to 
Serine/threonine-
protein kinase 3  IPI00411984.5 --- --- --- 1.031 0.994 1.004 1.838 1.711 1.756 
  
1.010 0.014 1.768 0.822 
 Phosphatidylcholin
e-sterol 
acyltransferase  IPI00022331.1 --- --- --- --- --- --- --- --- --- 
      Protein Z-
dependent protease 
inhibitor  IPI00007199.4 --- --- --- --- --- --- --- --- --- 
      C19orf61 59 kDa 
protein  IPI00005189.1 0.577 0.748 0.554 1.21 1.136 1.123 1.513 1.708 1.722 0.626 -0.675 1.156 0.210 1.648 0.720 
Isoform 3 of 
Tubulin 
polyglutamylase 
TTLL7  IPI00643434.1 0.39 --- 0.414 2.467 --- 2.587 1.205 --- 1.245 0.402 -1.315 2.527 1.337 1.225 0.293 
PHKG1 PHKG1 
protein 
 IPI00220396.1
9 0.385 --- 0.422 0.943 --- 0.954 1.168 --- 1.193 0.404 -1.309 0.949 -0.076 1.181 0.239 
Lipopolysaccharide
-binding protein  IPI00032311.4 --- --- --- --- --- --- --- --- --- 
      SERPINA5 Plasma 
serine protease 
inhibitor  IPI00007221.1 --- --- --- --- --- --- --- --- --- 
      IGHD FLJ00382 
protein (Fragment)  IPI00829636.1 --- --- --- --- --- --- --- --- --- 
      Isoform 2 of 
Nidogen-1  IPI00384542.3 --- --- --- --- --- --- --- --- --- 
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PROTEIN IPI DUKES A (1) DUKES A(2) DUKES A (3) DUKES B (1) DUKES B (2) DUKES B (3) DUKES C (1) DUKES C (2) DUKES C (3) DUKES A (Av.) DUKES A (Log2) DUKES B (Av) DUKESB (Log2) DUKES C (Av.) DUKES C (Log2) 
Vh1-D-J3-region 
(Fragment)  IPI00827627.1 --- --- --- --- --- --- --- --- --- 
      Retinol binding 
protein 4, plasma  IPI00480192.1 --- --- --- --- --- --- --- --- --- 
      DMXL2 DMXL2 
protein  IPI00152542.2 0.403 0.529 0.462 1.865 2.017 2.11 1.463 1.815 1.545 0.465 -1.106 1.997 0.998 
  Low affinity 
immunoglobulin 
gamma Fc region 
receptor III-A  IPI00218834.9 --- 
 
--- --- 
 
--- --- 
 
--- 
      similar to RIKEN 
cDNA 
C230030N03  IPI00887150.1 --- --- --- --- --- --- --- --- --- 
      Cartilage 
oligomeric matrix 
protein  IPI00028030.4 --- --- --- --- --- --- --- --- --- 
      Thrombospondin-2  IPI00018769.4 --- --- --- --- --- --- --- --- --- 
      Keratin, type I 
cytoskeletal 10  IPI00009865.2 --- --- --- --- --- --- --- --- --- 
      Kelch-like protein 
34  IPI00166264.3 --- --- --- --- --- --- --- --- --- 
      Serum deprivation-
response protein  IPI00005809.7 --- --- --- --- --- --- --- --- --- 
      Beta-2-
microglobulin  IPI00004656.3 --- --- --- --- --- --- --- --- --- 
      Isoform 2 of Neural 
cell adhesion 
molecule L1-like 
protein  IPI00299059.5 --- --- --- --- --- --- --- --- --- 
      Peptidyl-prolyl cis-
trans isomerase A  IPI00419585.9 --- --- --- --- --- --- --- --- --- 
      
 379 
PROTEIN IPI DUKES A (1) DUKES A(2) DUKES A (3) DUKES B (1) DUKES B (2) DUKES B (3) DUKES C (1) DUKES C (2) DUKES C (3) DUKES A (Av.) DUKES A (Log2) DUKES B (Av) DUKESB (Log2) DUKES C (Av.) DUKES C (Log2) 
Isoform 1 of Trem-
like transcript 1 
protein  IPI00410333.2 --- --- --- --- --- --- --- --- --- 
      Extracellular 
superoxide 
dismutase [Cu-Zn]  IPI00027827.2 --- --- --- --- --- --- --- --- --- 
      cDNA FLJ56657 IPI00908408.3 
 
--- 
  
--- 
  
--- 
       Fc fragment of IgG, 
low affinity IIIa, 
receptor (CD 16a) 
isoform d precursor IPI00895917.2 
 
--- 
  
--- 
  
--- 
       highly similar to 
150 kDa oxygen-
regulated protein  IPI00922838.1 --- --- --- --- --- --- --- --- --- 
      Isoform 2 of 
Protein HEG 
homolog 1  IPI00795307.2 --- --- --- --- --- --- --- --- --- 
      Isoform A of Zinc 
finger protein 268  IPI00031595.1 0.633 0.82 0.694 2.503 2.591 2.568 1.91 2.483 1.982 0.716 -0.483 2.554 1.353 2.125 1.087 
FABP1 protein 
(Fragment)  IPI00010290.2 0.633 
 
0.694 2.503   2.568 1.91   1.982 0.664 -0.592 2.536 1.342 1.946 0.961 
Myosin-reactive 
immunoglobulin 
light chain variable 
region (Fragment)  IPI00384399.1 --- 
 
--- --- 
 
--- --- 
 
--- 
      IGLV1-40 V1-13 
protein (Fragment)  IPI00789259.1 0.245 0.268 0.243 0.704 0.653 0.659 0.519 0.562 0.507 0.252 -1.989 0.672 -0.573 0.529 -0.918 
Ig lambda chain V-
II region BUR  IPI00003947.1 0.245 0.268 0.243 0.704 0.653 0.659 0.519 0.562 0.507 0.252 -1.989 0.672 -0.573 0.529 -0.918 
IGLV2-18 V1-5 
protein  IPI00553215.3 0.245   0.243 0.704 
 
0.659 0.519 
 
0.507 0.244 -2.035 0.682 -0.553 0.513 -0.963 
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PROTEIN IPI DUKES A (1) DUKES A(2) DUKES A (3) DUKES B (1) DUKES B (2) DUKES B (3) DUKES C (1) DUKES C (2) DUKES C (3) DUKES A (Av.) DUKES A (Log2) DUKES B (Av) DUKESB (Log2) DUKES C (Av.) DUKES C (Log2) 
PRAME family 
member 11  IPI00867556.2 --- 0.202 --- 3.58 3.593 3.701 1.41 1.815 1.468 
  
3.625 1.858 1.564 0.646 
Isoform 1 of Rab 
GTPase-binding 
effector protein 1  IPI00293009.4 0.732 
 
0.709 1.499 
 
1.451 1.941   1.785 0.721 -0.473 1.475 0.561 1.863 0.898 
Isoform 2 of Rab 
GTPase-binding 
effector protein IPI00412712.2 
 
0.799 
  
1.471 
  
1.772 
       39S ribosomal 
protein L19, 
mitochondrial  IPI00027096.2 0.732 0.799 0.709 1.499 1.471 1.451 1.941 1.772 1.785 
      Ig gamma lambda 
chain V-II region 
DOT  IPI00385686.1 0.245 0.268 0.243 0.704 0.653 0.659 0.519 0.562 0.507 0.252 -1.989 0.672 -0.573 0.529 -0.918 
SH3 domain 
binding glutamic 
acid-rich protein 
like 3  IPI00514669.1 --- 
 
--- --- 
 
--- --- 
 
--- 
      SH3BGRL3 
Putative 
uncharacterized 
protein  IPI00010402.2 --- 
 
--- --- 
 
--- --- 
 
--- 
      Ig lambda chain V-
II region NEI  IPI00382424.1 0.245 0.268 0.243 0.704 0.653 0.659 0.519 0.562 0.507 0.252 -1.989 0.672 -0.573 0.529 -0.918 
LOC651536 similar 
to hCG96018  IPI00742233.2 0.245   0.243 0.704 
 
0.659 0.519 
 
0.507 0.244 -2.035 0.682 -0.553 0.513 -0.963 
Ig lambda chain V-
II region VIL  IPI00382433.1 0.245 0.268 0.243 0.704 0.653 0.659 0.519 0.562 0.507 0.252 -1.989 0.672 -0.573 0.529 -0.918 
Ig lambda chain V-
II region TOG  IPI00382423.1 0.245   0.243 0.704 
 
0.659 0.519 
 
0.507 0.244 -2.035 0.682 -0.553 0.513 -0.963 
Ig heavy chain V-
III region CAM  IPI00382482.1 --- --- --- --- --- --- --- --- --- 
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PROTEIN IPI DUKES A (1) DUKES A(2) DUKES A (3) DUKES B (1) DUKES B (2) DUKES B (3) DUKES C (1) DUKES C (2) DUKES C (3) DUKES A (Av.) DUKES A (Log2) DUKES B (Av) DUKESB (Log2) DUKES C (Av.) DUKES C (Log2) 
Immunglobulin 
heavy chain 
variable region 
(Fragment)  IPI00783818.1 --- 
 
--- --- 
 
--- --- 
 
--- 
      OBSL1 Obscurin-
like 1 isoform A  IPI00893234.1 --- --- --- --- --- --- --- --- --- 
      Isoform 1 of Ras-
GEF domain-
containing family 
member 1A  IPI00396081.6 --- --- --- --- --- --- --- --- --- 
      Isoform 1 of 
Sarcolemmal 
membrane-
associated protein  IPI00791574.1 --- 0.679 --- 1.127 1.105 1.1 1.471 1.533 1.515 0.679 -0.559 1.111 0.151 1.506 0.591 
Isoform 7 of 
Sarcolemmal 
membrane-
associated protein  IPI00432472.2 --- 0.679 --- 1.127 1.105 1.1 1.471 1.533 1.515 0.679 -0.559 1.111 0.151 1.506 0.591 
SLMAP 15 kDa 
protein  IPI00792689.1 --- 
 
--- 1.127 
 
1.1 1.471 
 
1.515 
      Isoform Beta of 
Poliovirus receptor  IPI00219425.3 --- --- --- --- --- --- --- --- --- 
      cDNA FLJ55439, 
highly similar to 
TNF receptor-
associated factor 5  IPI00005760.2 0.315 0.34 0.272 2.288 2.116 2.183 1.249 1.407 1.256 0.309 -1.694 2.196 1.135 1.304 0.383 
ASCC3 cDNA 
FLJ56882, highly 
similar to 
Activating signal 
cointegrator 1 
complex subunit 3  IPI00787562.3 0.105 0.072 0.071 0.656 0.519 0.511 0.233 0.217 0.167 0.083 -3.597 0.562 -0.831 0.206 -2.282 
 382 
PROTEIN IPI DUKES A (1) DUKES A(2) DUKES A (3) DUKES B (1) DUKES B (2) DUKES B (3) DUKES C (1) DUKES C (2) DUKES C (3) DUKES A (Av.) DUKES A (Log2) DUKES B (Av) DUKESB (Log2) DUKES C (Av.) DUKES C (Log2) 
INPP5F Isoform 1 
of 
Phosphatidylinositi
de phosphatase 
SAC2  IPI00480159.1 --- --- --- --- --- --- --- --- --- 
      Isoform 1 of 
Tripartite motif-
containing protein 
42  IPI00217444.1 --- --- --- --- --- --- --- --- --- 
      Hepatocyte growth 
factor activator  IPI00029193.1 --- --- --- --- --- --- --- --- --- 
      FLJ22184 similar to 
hCG22561  IPI00888405.1 --- --- --- --- --- --- --- --- --- 
      FLJ22184 
hypothetical protein 
LOC80164  IPI00887824.1 --- --- --- --- --- --- --- --- --- 
      Isoform 1 of 
Calcyclin-binding 
protein  IPI00395627.3 0.19 0.189 0.182 0.511 0.483 0.488 0.838 0.823 0.816 0.187 -2.419 0.494 -1.017 0.826 -0.276 
Isoform 1 of 
Phosphatase and 
actin regulator 1  IPI00028318.7 --- 
 
--- --- 
 
--- --- 
 
--- 
      Metal transporter 
CNNM4  IPI00418426.6 --- 
 
--- --- 
 
--- --- 
 
--- 
      Isoform 1 of Metal 
transporter CNNM2  IPI00006084.4 --- --- --- --- --- --- --- --- --- 
      Complement C1q 
subcomponent 
subunit A  IPI00022392.1 --- --- --- --- --- --- --- --- --- 
      Cytoplasmic dynein 
1 heavy chain 1  IPI00456969.1 --- --- --- --- --- --- --- --- --- 
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PROTEIN IPI DUKES A (1) DUKES A(2) DUKES A (3) DUKES B (1) DUKES B (2) DUKES B (3) DUKES C (1) DUKES C (2) DUKES C (3) DUKES A (Av.) DUKES A (Log2) DUKES B (Av) DUKESB (Log2) DUKES C (Av.) DUKES C (Log2) 
similar to 
chaperonin 
containing t-
complex 
polypeptide 1, eta 
subunit; CCT-eta  IPI00887484.1 --- --- --- --- --- --- --- --- --- 
      Isoform 1 of 
Ryanodine receptor 
3  IPI00329784.1 --- 
 
--- --- 
 
--- --- 
 
--- 
      Putative 
uncharacterized 
protein CYP4F2  IPI00873788.1 --- --- --- --- --- --- --- --- --- 
      Neural cell 
adhesion molecule 
2  IPI00376427.4 0.522 0.567 0.495 2.175 2.071 2.077 1.285 1.507 1.253 0.528 -0.921 2.108 1.076 1.348 0.431 
Isoform 1 of 
Uncharacterized 
protein C6orf170  IPI00253835.7 --- --- --- --- --- --- --- --- --- 
      Isoform 1 of 
Interleukin-12 
receptor beta-2 
chain  IPI00438855.1 --- --- --- --- --- --- --- --- --- 
      Putative 
uncharacterized 
protein ANKRD44 
(Fragment)  IPI00926170.1 --- --- --- --- --- --- --- --- --- 
      SFRS2IP SFRS2-
interacting protein  IPI00181359.5 --- 
 
--- --- 
 
--- --- 
 
--- 
      splicing factor, 
arginine/serine-rich 
2, interacting 
protein  IPI00746412.2 --- 
 
--- --- 
 
--- --- 
 
--- 
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PROTEIN IPI DUKES A (1) DUKES A(2) DUKES A (3) DUKES B (1) DUKES B (2) DUKES B (3) DUKES C (1) DUKES C (2) DUKES C (3) DUKES A (Av.) DUKES A (Log2) DUKES B (Av) DUKESB (Log2) DUKES C (Av.) DUKES C (Log2) 
Cytochrome b5 
domain-containing 
protein 2  IPI00102928.2 --- 
 
--- --- 
 
--- --- 
 
--- 
      Procollagen C-
endopeptidase 
enhancer 1  IPI00299738.1 --- --- --- --- --- --- --- --- --- 
      Isoform 1 of Kinase 
suppressor of Ras 2  IPI00414043.2 0.305 0.305 0.295 0.279 0.353 0.335 0.491 0.503 0.497 0.302 -1.729 0.322 -1.633 0.497 -1.009 
Insulin-like growth 
factor-binding 
protein 4  IPI00305380.3 --- --- --- --- --- --- --- --- --- 
      CDH13 cDNA 
FLJ52398, highly 
similar to Cadherin-
13  IPI00024046.2 --- --- --- --- --- --- --- --- --- 
      CDKL1 
Serine/threonine 
protein kinase 
kkialre-like 1  IPI00791940.1 --- --- --- --- --- --- --- --- --- 
      PIP5K3 FYVE 
finger-containing 
phosphoinositide 
kinase  IPI00396145.1 --- --- --- --- --- --- --- --- --- 
      Isoform LMW of 
Kininogen-1  IPI00215894.1 --- --- --- --- --- --- --- --- --- 
      Isoform 1 of 
Protocadherin Fat 3  IPI00847978.2 --- 0.358 --- --- 2.079 --- --- 1.126 --- 
      Keratin, type I 
cytoskeletal 18  IPI00554788.5 --- 0.358 --- --- 2.079 --- --- 1.126 --- 
      DDX24 protein  IPI00923556.1 --- --- --- --- --- --- --- --- --- 
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PROTEIN IPI DUKES A (1) DUKES A(2) DUKES A (3) DUKES B (1) DUKES B (2) DUKES B (3) DUKES C (1) DUKES C (2) DUKES C (3) DUKES A (Av.) DUKES A (Log2) DUKES B (Av) DUKESB (Log2) DUKES C (Av.) DUKES C (Log2) 
Isoform 1 of 
Dynein heavy chain 
10, axonemal  IPI00784869.4 --- --- --- --- --- --- --- --- --- 
      331 kDa protein  IPI00020356.4 --- 
 
--- --- 
 
--- --- 
 
--- 
      Isoform 2 of 
Transmembrane 
protein 20  IPI00414020.3 --- --- --- --- --- --- --- --- --- 
      similar to 
hCG1812074  IPI00886909.1 --- --- --- --- --- --- --- --- --- 
      Isoform 1 of R3H 
domain-containing 
protein 2  IPI00396041.6 0.247 0.318 0.245 3.586 4.583 4.588 1.642 2.292 1.824 0.270 -1.889 4.252 2.088 1.919 0.941 
sorting nexin 6 
isoform b  IPI00298111.7 0.7 0.807 0.698 2.446 2.454 2.569 2.015 2.45 2.177 0.735 -0.444 2.490 1.316 2.214 1.147 
Isoform HMW of 
Kininogen-1  IPI00032328.2 --- 
 
--- --- 
 
--- --- 
 
--- 
      Putative 
uncharacterized 
protein 
ENSP00000386242  IPI00917248.1 --- 
 
--- --- 
 
--- --- 
 
--- 
      8 kDa protein  IPI00916507.1 --- --- --- --- --- --- --- --- --- 
      Mannosidase, 
alpha, class 1A, 
member 1, isoform 
CRA_a  IPI00439446.2 --- --- --- --- --- --- --- --- --- 
      Isoform 2 of 
Uncharacterized 
protein C15orf41  IPI00796879.2 --- 
 
--- --- 
 
--- --- 
 
--- 
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PROTEIN IPI DUKES A (1) DUKES A(2) DUKES A (3) DUKES B (1) DUKES B (2) DUKES B (3) DUKES C (1) DUKES C (2) DUKES C (3) DUKES A (Av.) DUKES A (Log2) DUKES B (Av) DUKESB (Log2) DUKES C (Av.) DUKES C (Log2) 
similar to 
hCG1812074  IPI00887332.1 --- 
 
--- --- 
 
--- --- 
 
--- 
      Pantetheinase  IPI00030871.2 --- --- --- --- --- --- --- --- --- 
      Leucine-rich repeat 
transmembrane 
neuronal protein 2  IPI00023576.3 --- --- --- --- --- --- --- --- --- 
      Activity-dependent 
neuroprotector 
homeobox protein  IPI00022215.1 --- --- --- --- --- --- --- --- --- 
      Melanoma-
associated antigen 
E1  IPI00015306.4 --- --- --- --- --- --- --- --- --- 
      Serine/threonine-
protein kinase N2  IPI00002804.1 --- --- --- --- --- --- --- --- --- 
      PRO2042  IPI00005990.1 --- --- --- --- --- --- --- --- --- 
      Transmembrane 
protein C9orf144B  IPI00445371.6 --- --- --- --- --- --- --- --- --- 
      Olfactory receptor 
1K1  IPI00169096.1 --- --- --- --- --- --- --- --- --- 
      Putative 
uncharacterized 
protein CDH26  IPI00853237.1 0.26   0.263 2.312   2.321 1.25 
 
1.247 0.262 -1.935 2.317 1.212 1.249 0.320 
Isoform 1 of 
Probable G-protein 
coupled receptor 
116  IPI00437186.1 0.26 0.33 0.263 2.312 2.189 2.321 1.25 1.477 1.247 0.284 -1.814 2.274 1.185 1.325 0.406 
Olfactory receptor 
52I1  IPI00166004.3 --- --- --- --- --- --- --- --- --- 
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PROTEIN IPI DUKES A (1) DUKES A(2) DUKES A (3) DUKES B (1) DUKES B (2) DUKES B (3) DUKES C (1) DUKES C (2) DUKES C (3) DUKES A (Av.) DUKES A (Log2) DUKES B (Av) DUKESB (Log2) DUKES C (Av.) DUKES C (Log2) 
Probable E3 
ubiquitin-protein 
ligase HERC2  IPI00005826.1 --- --- --- 1.6 1.526 1.62 1.143 1.311 1.168 
  
1.582 0.662 1.207 0.272 
Isoform 3 of 
Ankyrin repeat 
domain-containing 
protein 26  IPI00793360.1 --- --- --- 1.6 1.526 1.62 1.143 1.311 1.168 
  
1.582 0.662 1.207 0.272 
tudor domain 
containing 9  IPI00384419.4 --- 
 
--- 1.6   1.62 1.143 
 
1.168 
  
1.610 0.687 1.156 0.209 
SRGAP1 Isoform 2 
of SLIT-ROBO 
Rho GTPase-
activating protein 1  IPI00414827.1 --- --- --- 1.6 1.526 1.62 1.143 1.311 1.168 
  
1.582 0.662 1.207 0.272 
SLIT-ROBO Rho 
GTPase-activating 
protein 2  IPI00479125.3 --- 
 
--- 1.6   1.62 1.143 
 
1.168 
  
1.610 0.687 1.156 0.209 
Putative 
uncharacterized 
protein 
ENSP00000373129  IPI00642121.2 --- 
 
--- 1.6   1.62 1.143 
 
1.168 
  
1.610 0.687 1.156 0.209 
Isoform 1 of OTU 
domain-containing 
protein 7A  IPI00152625.1 --- --- --- --- --- --- --- --- --- 
      HSPA5 protein  IPI00003362.2 --- --- --- --- --- --- --- --- --- 
      Isoform 1 of P2Y 
purinoceptor 13  IPI00789314.2 --- --- --- --- --- --- --- --- --- 
      Isoform 2 of P2Y 
purinoceptor 13  IPI00216851.3 --- --- --- --- --- --- --- --- --- 
      Isoform 1 of 
Calpain-15  IPI00024190.3 --- --- --- --- --- --- --- --- --- 
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PROTEIN IPI DUKES A (1) DUKES A(2) DUKES A (3) DUKES B (1) DUKES B (2) DUKES B (3) DUKES C (1) DUKES C (2) DUKES C (3) DUKES A (Av.) DUKES A (Log2) DUKES B (Av) DUKESB (Log2) DUKES C (Av.) DUKES C (Log2) 
Isoform 1 of 
Peroxisomal 
proliferator-
activated receptor 
A-interacting 
complex 285 kDa 
protein  IPI00249304.3 --- --- --- --- --- --- --- --- --- 
      Isoform 2 of 
Peroxisomal 
proliferator-
activated receptor 
A-interacting 
complex 285 kDa 
protein  IPI00249305.4 --- --- --- --- --- --- --- --- --- 
      Isoform 1 of 
Peptidase inhibitor 
16  IPI00301143.5 --- --- --- --- --- --- --- --- --- 
      COL3A1 Isoform 1 
of Collagen alpha-
1(III) chain  IPI00021033.2 --- --- --- --- --- --- --- --- --- 
      Protease serine 4 
isoform B  IPI00385250.1 --- 
 
--- --- 
 
--- --- 
 
--- 
      Isoform A of 
Trypsin-3  IPI00015614.4 --- 
 
--- --- 
 
--- --- 
 
--- 
      E3 ubiquitin-
protein ligase 
RAD18  IPI00024579.1 --- 0.337 --- 1.542 1.404 1.433 1.93 1.809 1.84 
  
1.460 0.546 1.860 0.895 
Isoform 2 of 
Neuroepithelial 
cell-transforming 
gene 1 protein  IPI00180559.3 --- 0.337 --- 1.542 1.404 1.433 1.93 1.809 1.84 
  
1.460 0.546 1.860 0.895 
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PROTEIN IPI DUKES A (1) DUKES A(2) DUKES A (3) DUKES B (1) DUKES B (2) DUKES B (3) DUKES C (1) DUKES C (2) DUKES C (3) DUKES A (Av.) DUKES A (Log2) DUKES B (Av) DUKESB (Log2) DUKES C (Av.) DUKES C (Log2) 
Isoform 1 of 
Progesterone-
induced-blocking 
factor 1  IPI00328765.3 --- --- --- --- --- --- --- --- --- 
      similar to MCM3 
minichromosome 
maintenance 
deficient 3  IPI00887843.1 --- --- --- --- --- --- --- --- --- 
      piccolo isoform 2  IPI00789624.2 --- --- --- --- --- --- --- --- --- 
      Titin (Fragment)  IPI00436021.3 --- --- --- --- --- --- --- --- --- 
      60S ribosomal 
protein L5  IPI00000494.6 --- --- --- --- --- --- --- --- --- 
      Zinc finger CCCH 
domain-containing 
protein 4  IPI00187011.4 --- --- --- --- --- --- --- --- --- 
      Dystonin  IPI00642259.2 0.147 0.15 0.143 0.473 0.457 0.457 0.706 0.65 0.644 0.147 -2.769 0.462 -1.113 0.667 -0.585 
dystonin isoform 3  IPI00008756.7 0.147 0.15 0.143 0.473 0.457 0.457 0.706 0.65 0.644 0.147 -2.769 0.462 -1.113 0.667 -0.585 
Isoform 1 of 
Dynein heavy chain 
17, axonemal  IPI00888430.1 0.147 0.15 0.143 0.473 0.457 0.457 0.706 0.65 0.644 0.147 -2.769 0.462 -1.113 0.667 -0.585 
Centrosome-
associated protein 
350  IPI00103595.2 0.147 0.15 0.143 0.473 0.457 0.457 0.706 0.65 0.644 0.147 -2.769 0.462 -1.113 0.667 -0.585 
Isoform 4 of 
Transforming 
acidic coiled-coil-
containing protein 2  IPI00643465.2 0.147 0.15 0.143 0.473 0.457 0.457 0.706 0.65 0.644 0.147 -2.769 0.462 -1.113 0.667 -0.585 
Isoform 1 of 
Melanophilin  IPI00012201.1 0.147 0.15 0.143 0.473 0.457 0.457 0.706 0.65 0.644 0.147 -2.769 0.462 -1.113 0.667 -0.585 
Isoform 1 of 
Exportin-5  IPI00640703.3 0.147 0.15 0.143 0.473 0.457 0.457 0.706 0.65 0.644 0.147 -2.769 0.462 -1.113 0.667 -0.585 
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PROTEIN IPI DUKES A (1) DUKES A(2) DUKES A (3) DUKES B (1) DUKES B (2) DUKES B (3) DUKES C (1) DUKES C (2) DUKES C (3) DUKES A (Av.) DUKES A (Log2) DUKES B (Av) DUKESB (Log2) DUKES C (Av.) DUKES C (Log2) 
Isoform A of 
Uncharacterized 
protein C21orf70  IPI00027898.3 0.147 0.15 0.143 0.473 0.457 0.457 0.706 0.65 0.644 0.147 -2.769 0.462 -1.113 0.667 -0.585 
Isoform 1 of 
Engulfment and cell 
motility protein 1  IPI00219532.1 0.147 0.15 0.143 0.473 0.457 0.457 0.706 0.65 0.644 0.147 -2.769 0.462 -1.113 0.667 -0.585 
Putative 
uncharacterized 
protein C14orf53  IPI00924472.1 0.147 0.15 0.143 0.473 0.457 0.457 0.706 0.65 0.644 0.147 -2.769 0.462 -1.113 0.667 -0.585 
Isoform 1 of T-cell 
activation Rho 
CTPase-activating 
protein IPI00166033.2 
 
0.15 
  
0.457 
  
0.65 
       COPS4 COP9 
signalsome 
complex subunit 4 IPI00171184.2 
 
0.15 
  
0.457 
  
0.65 
       Growth/Differentiat
ion factor 8 IPI00023751.1 
 
0.15 
  
0.457 
  
0.65 
       11KDa protein IPI00790528.3 
 
0.15 
  
0.457 
  
0.65 
       Isoform 1 of EGF-
containing fibulin-
like extracellular 
matrix protein 1  IPI00029658.1 --- 
 
--- --- 
 
--- --- 
 
--- 
      Cellular titin 
isoform PEVK 
variant 2  IPI00829745.1 --- 
 
--- --- 
 
--- --- 
 
--- 
      Superkiller 
viralicidic activity 
2-like 2  IPI00647217.2 --- --- --- --- --- --- --- --- --- 
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PROTEIN IPI DUKES A (1) DUKES A(2) DUKES A (3) DUKES B (1) DUKES B (2) DUKES B (3) DUKES C (1) DUKES C (2) DUKES C (3) DUKES A (Av.) DUKES A (Log2) DUKES B (Av) DUKESB (Log2) DUKES C (Av.) DUKES C (Log2) 
cDNA FLJ58573, 
highly similar to 
Exonuclease 3'-5' 
domain-like-
containing protein 2  IPI00465113.2 --- 
 
--- --- 
 
--- --- 
 
--- 
      similar to Annexin 
A8 (Annexin-8) 
(Annexin VIII) 
(Vascular 
anticoagulant-beta) 
(VAC-beta), partial  IPI00888302.1 --- --- --- --- --- --- --- --- --- 
      Zinc finger SWIM 
domain-containing 
protein 4  IPI00303331.3 --- --- --- --- --- --- --- --- --- 
      Isoform Long of 
Myosin-IXb  IPI00336047.5 --- --- --- --- --- --- --- --- --- 
      serum amyloid A2 
isoform a  IPI00006146.4 --- 
 
--- --- 
 
--- --- 
 
--- 
      Isoform 1 of 
Probable 
carboxypeptidase 
X1  IPI00304721.6 --- --- --- --- --- --- --- --- --- 
      Isoform 1 of 
Kynurenine--
oxoglutarate 
transaminase 3  IPI00465373.2 --- --- --- --- --- --- --- --- --- 
      Isoform 2 of 
Kynurenine--
oxoglutarate 
transaminase 3  IPI00465006.2 --- 
 
--- --- 
 
--- --- 
 
--- 
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PROTEIN IPI DUKES A (1) DUKES A(2) DUKES A (3) DUKES B (1) DUKES B (2) DUKES B (3) DUKES C (1) DUKES C (2) DUKES C (3) DUKES A (Av.) DUKES A (Log2) DUKES B (Av) DUKESB (Log2) DUKES C (Av.) DUKES C (Log2) 
BRCA1 Isoform 2 
of Breast cancer 
type 1 susceptibility 
protein  IPI00375507.3 --- --- --- --- --- --- --- --- --- 
      Isoform 1 of E3 
ubiquitin-protein 
ligase LRSAM1  IPI00300805.4 --- --- --- --- --- --- --- --- --- 
       Isoform 1 of 
Aldehyde 
dehydrogenase 
family 3 member 
B1  IPI00018031.1 --- --- --- --- --- --- --- --- --- 
      Aldehyde 
dehydrogenase 
family 3 member 
B2  IPI00009744.2 --- --- --- --- --- --- --- --- --- 
      FIC domain-
containing protein  IPI00026635.3 --- --- --- --- --- --- --- --- --- 
      52 kDa protein  IPI00795769.1 --- --- --- --- --- --- --- --- --- 
      Isoform 1 of 
MICAL-like 
protein 2  IPI00217622.1 --- --- --- --- --- --- --- --- --- 
       Dual specificity 
protein phosphatase 
16  IPI00028428.2 --- --- --- --- --- --- --- --- --- 
      ETV2 ets variant 
gene 2  IPI00893164.1 --- --- --- --- --- --- --- --- --- 
      106 kDa protein  IPI00927752.1 --- --- --- --- --- --- --- --- --- 
      Isoform 2 of 
UPF0577 protein 
KIAA1324-like  IPI00873129.1 --- --- --- --- --- --- --- --- --- 
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PROTEIN IPI DUKES A (1) DUKES A(2) DUKES A (3) DUKES B (1) DUKES B (2) DUKES B (3) DUKES C (1) DUKES C (2) DUKES C (3) DUKES A (Av.) DUKES A (Log2) DUKES B (Av) DUKESB (Log2) DUKES C (Av.) DUKES C (Log2) 
ATP-binding 
cassette, sub-family 
A, member 2 
isoform a  IPI00307592.6 --- --- --- --- --- --- --- --- --- 
      118 kDa protein  IPI00083235.7 --- --- --- --- --- --- --- --- --- 
      Putative 
uncharacterized 
protein LAMA2  IPI00479834.3 --- 
 
--- --- 
 
--- --- 
 
--- 
      67 kDa protein  IPI00020513.2 --- 
 
--- --- 
 
--- --- 
 
--- 
      hypothetical protein 
LOC120406  IPI00783563.2 --- 
 
--- --- 
 
--- --- 
 
--- 
      ZMYND8 cDNA 
FLJ56888, highly 
similar to Protein 
kinase C-binding 
protein 1  IPI00741204.2 --- 
 
--- --- 
 
--- --- 
 
--- 
      Isoform 2 of 
Membrane-
associated 
phosphatidylinosito
l transfer protein 2  IPI00155134.3 --- 
 
--- --- 
 
--- --- 
 
--- 
      LOC100127987 
similar to 
hCG1645807  IPI00887853.1 --- 
 
--- --- 
 
--- --- 
 
--- 
      Serine/threonine-
protein kinase 38-
like  IPI00237011.5 --- 
 
--- --- 
 
--- --- 
 
--- 
      Isoform 1 of 
Symplekin  IPI00023344.2 --- 
 
--- --- 
 
--- --- 
 
--- 
      Growth-inhibiting 
protein 12  IPI00298860.5 --- 
 
--- --- 
 
--- --- 
 
--- 
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PROTEIN IPI DUKES A (1) DUKES A(2) DUKES A (3) DUKES B (1) DUKES B (2) DUKES B (3) DUKES C (1) DUKES C (2) DUKES C (3) DUKES A (Av.) DUKES A (Log2) DUKES B (Av) DUKESB (Log2) DUKES C (Av.) DUKES C (Log2) 
cDNA FLJ58679, 
highly similar to 
Lactotransferrin  IPI00789477.1 --- 
 
--- --- 
 
--- --- 
 
--- 
      Isoform 1 of 
Melanotransferrin  IPI00029275.1 --- 
 
--- --- 
 
--- --- 
 
--- 
      Rho GTPase-
activating protein 
15  IPI00182116.4 --- 
 
--- --- 
 
--- --- 
 
--- 
       T-complex protein 
1 subunit alpha  IPI00290566.1 --- 
 
--- --- 
 
--- --- 
 
--- 
      Similar to t-
complex 1  IPI00844203.1 --- 
 
--- --- 
 
--- --- 
 
--- 
      CHMP4A 
Chromatic 
modifying protein IPI00794397.2 
 
--- 
  
--- 
  
--- 
       PHACTR1 RPEL 
repeat containing 1 IPI00514862.2 
 
--- 
  
--- 
  
--- 
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